<?xml version='1.0' encoding='utf-8' standalone='yes'?>
<collection>
  <source></source>
  <date>2021-07-14</date>
  <key></key>
  <document>
    <id>23063874</id>
    <passage>
      <offset>0</offset>
      <text>NCTC 2544 and IL-18 production: a tool for the identification of contact allergens.	Progress in understanding the mechanisms of skin sensitization, provides us with the opportunity to develop in vitro tests as an alternative to in vivo sensitization testing. Keratinocytes play a key role in all phases of skin sensitization. We have recently identified interleukin-18 (IL-18) production in keratinocyte as a potentially useful endpoint for determination of contact sensitization potential of low molecular weight chemicals. The aim of the present article is to further exploit the performance of the NCTC 2544 assay. NCTC 2544 is a commercially available skin epithelial-like cell line originating from normal human skin, which posses a good expression of cytochrome P450-dependent enzymatic activities. Cells were exposed to contact allergens (2-bromo-2-bromomethyl glutaronitrile, cinnamaldehyde, citral, diethylmaleate, dinitrochlorobenzene, glyoxal, 2-mercaptobenzothiazole, nickel sulfate, 4-nitrobenzylbromide, oxazolone, penicillin G, resorcinol, tetramethylthiuram disulfide), to pre- pro-haptens (cinnamyl alcohol, eugenol, isoeugenol, p-phenylediamine), to respiratory allergens (ammonium hexachloroplatinate, diphenylmethane diisocyanate, glutaraldehyde, hexamethylenediisocyanate, maleic anhydride, trimellitic anhydride) and to irritants (benzaldehyde, cholorobenzene, diethylphtalate, hydrobenzoic acid, lactic acid, octanoic acid, phenol, salicylic acid, sodium lauryl sulphate, sulfamic acid). Cell associated IL-18 was evaluated 24 later by ELISA. At not-cytotoxic concentrations (cell viability higher of 80%, as assessed by MTT reduction assay), all contact sensitizers, including pre-pro-haptens, induced a dose-related increase in IL-18, whereas both irritants, with the exception of sulfamic acid, and respiratory allergens failed. A total of 33 chemicals were tested, with an overall accuracy of 97%. Overall, results obtained indicated that cell-associated IL-18 might provide an in vitro tool for identification and discrimination of contact vs. respiratory allergens and/or irritants.</text>
      <sentence>
        <offset>0</offset>
        <text>NCTC 2544 and IL-18 production: a tool for the identification of contact allergens.</text>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="14" length="5"/>
          <text>IL-18</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>84</offset>
        <text>Progress in understanding the mechanisms of skin sensitization, provides us with the opportunity to develop in vitro tests as an alternative to in vivo sensitization testing.</text>
      </sentence>
      <sentence>
        <offset>259</offset>
        <text>Keratinocytes play a key role in all phases of skin sensitization.</text>
      </sentence>
      <sentence>
        <offset>326</offset>
        <text>We have recently identified interleukin-18 (IL-18) production in keratinocyte as a potentially useful endpoint for determination of contact sensitization potential of low molecular weight chemicals.</text>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin-18</infon>
          <location offset="354" length="14"/>
          <text>interleukin-18</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="370" length="5"/>
          <text>IL-18</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>525</offset>
        <text>The aim of the present article is to further exploit the performance of the NCTC 2544 assay.</text>
      </sentence>
      <sentence>
        <offset>618</offset>
        <text>NCTC 2544 is a commercially available skin epithelial-like cell line originating from normal human skin, which posses a good expression of cytochrome P450-dependent enzymatic activities.</text>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="757" length="15"/>
          <text>cytochrome P450</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>805</offset>
        <text>Cells were exposed to contact allergens (2-bromo-2-bromomethyl glutaronitrile, cinnamaldehyde, citral, diethylmaleate, dinitrochlorobenzene, glyoxal, 2-mercaptobenzothiazole, nickel sulfate, 4-nitrobenzylbromide, oxazolone, penicillin G, resorcinol, tetramethylthiuram disulfide), to pre- pro-haptens (cinnamyl alcohol, eugenol, isoeugenol, p-phenylediamine), to respiratory allergens (ammonium hexachloroplatinate, diphenylmethane diisocyanate, glutaraldehyde, hexamethylenediisocyanate, maleic anhydride, trimellitic anhydride) and to irritants (benzaldehyde, cholorobenzene, diethylphtalate, hydrobenzoic acid, lactic acid, octanoic acid, phenol, salicylic acid, sodium lauryl sulphate, sulfamic acid).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cinnamyl alcohol</infon>
          <location offset="1107" length="16"/>
          <text>cinnamyl alcohol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">eugenol</infon>
          <location offset="1125" length="7"/>
          <text>eugenol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoeugenol</infon>
          <location offset="1134" length="10"/>
          <text>isoeugenol</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">p-phenylediamine</infon>
          <location offset="1146" length="16"/>
          <text>p-phenylediamine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ammonium hexachloroplatinate</infon>
          <location offset="1191" length="28"/>
          <text>ammonium hexachloroplatinate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diphenylmethane diisocyanate</infon>
          <location offset="1221" length="28"/>
          <text>diphenylmethane diisocyanate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutaraldehyde</infon>
          <location offset="1251" length="14"/>
          <text>glutaraldehyde</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hexamethylenediisocyanate</infon>
          <location offset="1267" length="25"/>
          <text>hexamethylenediisocyanate</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">maleic anhydride</infon>
          <location offset="1294" length="16"/>
          <text>maleic anhydride</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trimellitic anhydride</infon>
          <location offset="1312" length="21"/>
          <text>trimellitic anhydride</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzaldehyde</infon>
          <location offset="1353" length="12"/>
          <text>benzaldehyde</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholorobenzene</infon>
          <location offset="1367" length="14"/>
          <text>cholorobenzene</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diethylphtalate</infon>
          <location offset="1383" length="15"/>
          <text>diethylphtalate</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrobenzoic acid</infon>
          <location offset="1400" length="17"/>
          <text>hydrobenzoic acid</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactic acid</infon>
          <location offset="1419" length="11"/>
          <text>lactic acid</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">octanoic acid</infon>
          <location offset="1432" length="13"/>
          <text>octanoic acid</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenol</infon>
          <location offset="1447" length="6"/>
          <text>phenol</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylic acid</infon>
          <location offset="1455" length="14"/>
          <text>salicylic acid</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium lauryl sulphate</infon>
          <location offset="1471" length="22"/>
          <text>sodium lauryl sulphate</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfamic acid</infon>
          <location offset="1495" length="13"/>
          <text>sulfamic acid</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-bromo-2-bromomethyl glutaronitrile</infon>
          <location offset="846" length="36"/>
          <text>2-bromo-2-bromomethyl glutaronitrile</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cinnamaldehyde</infon>
          <location offset="884" length="14"/>
          <text>cinnamaldehyde</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">citral</infon>
          <location offset="900" length="6"/>
          <text>citral</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diethylmaleate</infon>
          <location offset="908" length="14"/>
          <text>diethylmaleate</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dinitrochlorobenzene</infon>
          <location offset="924" length="20"/>
          <text>dinitrochlorobenzene</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glyoxal</infon>
          <location offset="946" length="7"/>
          <text>glyoxal</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-mercaptobenzothiazole</infon>
          <location offset="955" length="23"/>
          <text>2-mercaptobenzothiazole</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nickel sulfate</infon>
          <location offset="980" length="14"/>
          <text>nickel sulfate</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-nitrobenzylbromide</infon>
          <location offset="996" length="20"/>
          <text>4-nitrobenzylbromide</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxazolone</infon>
          <location offset="1018" length="9"/>
          <text>oxazolone</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">penicillin g</infon>
          <location offset="1029" length="12"/>
          <text>penicillin G</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">resorcinol</infon>
          <location offset="1043" length="10"/>
          <text>resorcinol</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetramethylthiuram disulfide</infon>
          <location offset="1055" length="28"/>
          <text>tetramethylthiuram disulfide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1511</offset>
        <text>Cell associated IL-18 was evaluated 24 later by ELISA.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="1527" length="5"/>
          <text>IL-18</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1566</offset>
        <text>At not-cytotoxic concentrations (cell viability higher of 80%, as assessed by MTT reduction assay), all contact sensitizers, including pre-pro-haptens, induced a dose-related increase in IL-18, whereas both irritants, with the exception of sulfamic acid, and respiratory allergens failed.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="1644" length="3"/>
          <text>MTT</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulfamic acid</infon>
          <location offset="1806" length="13"/>
          <text>sulfamic acid</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="1753" length="5"/>
          <text>IL-18</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1855</offset>
        <text>A total of 33 chemicals were tested, with an overall accuracy of 97%.</text>
      </sentence>
      <sentence>
        <offset>1925</offset>
        <text>Overall, results obtained indicated that cell-associated IL-18 might provide an in vitro tool for identification and discrimination of contact vs. respiratory allergens and/or irritants.</text>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-18</infon>
          <location offset="1982" length="5"/>
          <text>IL-18</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17664022</id>
    <passage>
      <offset>0</offset>
      <text>Pre- and postsynaptic mechanisms in the clonidine- and oxymetazoline-induced inhibition of gastric motility in the rat.	The inhibitory effect of clonidine (non-selective alpha2-adrenoceptor agonist) and oxymetazoline (alpha2A-adrenoceptor selective agonist) was compared on basal and stimulated gastric motor activity (gastric tone and contractions) using the balloon method in the rat. It was shown that oxymetazoline (0.2-1.7 micromol/kg, i.v.) decreased the basal motility, while clonidine (1.9-3.8 micromol/kg, i.v.) failed to affect it. When motility was stimulated centrally by insulin (5 IU/rat, i.v.), both clonidine (1.9-3.8 micromol/kg, i.v.) and oxymetazoline (0.1-3.4 micromol/kg, i.v.) inhibited the gastric motor activity. However, while the effect of clonidine was antagonized by the non-selective alpha2-adrenoceptor antagonist yohimbine (5 micromol/kg, i.v.) and the alpha2A-adrenoceptor selective antagonist BRL 44408 (3 micromol/kg, i.v.), the effect of oxymetazoline was only partially affected. Prazosin (alpha1- and alpha2B-adrenoceptor antagonist, 0.07-0.28 micromol/kg, i.v.) also failed to reverse the effect of oxymetazoline. Furthermore, when gastric motility was stimulated peripherally by activation of postsynaptic cholinergic muscarinic receptors by the combination of carbachol (0.14 micromol/kg, i.v.) and hexamethonium (37 micromol/kg, i.v.), clonidine (3.8 micromol/kg, i.v.) failed to affect the increased motor activity, however, oxymetazoline (0.8-3.4 micromol/kg, i.v.) exerted a pronounced inhibition. These results suggest that different mechanisms may be involved in the inhibitory effect of clonidine and oxymetazoline; while clonidine reduces the gastric motility by activation of presynaptic alpha2-adrenoceptors, postsynaptic component in the effect of oxymetazoline has also been raised.</text>
      <sentence>
        <offset>0</offset>
        <text>Pre- and postsynaptic mechanisms in the clonidine- and oxymetazoline-induced inhibition of gastric motility in the rat.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonidine</infon>
          <location offset="40" length="9"/>
          <text>clonidine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymetazoline</infon>
          <location offset="55" length="13"/>
          <text>oxymetazoline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>120</offset>
        <text>The inhibitory effect of clonidine (non-selective alpha2-adrenoceptor agonist) and oxymetazoline (alpha2A-adrenoceptor selective agonist) was compared on basal and stimulated gastric motor activity (gastric tone and contractions) using the balloon method in the rat.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonidine</infon>
          <location offset="145" length="9"/>
          <text>clonidine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymetazoline</infon>
          <location offset="203" length="13"/>
          <text>oxymetazoline</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha2-adrenoceptor</infon>
          <location offset="170" length="19"/>
          <text>alpha2-adrenoceptor</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha2a-adrenoceptor</infon>
          <location offset="218" length="20"/>
          <text>alpha2A-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T10" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T18" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>387</offset>
        <text>It was shown that oxymetazoline (0.2-1.7 micromol/kg, i.v.) decreased the basal motility, while clonidine (1.9-3.8 micromol/kg, i.v.) failed to affect it.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymetazoline</infon>
          <location offset="405" length="13"/>
          <text>oxymetazoline</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonidine</infon>
          <location offset="483" length="9"/>
          <text>clonidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>542</offset>
        <text>When motility was stimulated centrally by insulin (5 IU/rat, i.v.), both clonidine (1.9-3.8 micromol/kg, i.v.) and oxymetazoline (0.1-3.4 micromol/kg, i.v.) inhibited the gastric motor activity.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonidine</infon>
          <location offset="615" length="9"/>
          <text>clonidine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymetazoline</infon>
          <location offset="657" length="13"/>
          <text>oxymetazoline</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="584" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>737</offset>
        <text>However, while the effect of clonidine was antagonized by the non-selective alpha2-adrenoceptor antagonist yohimbine (5 micromol/kg, i.v.) and the alpha2A-adrenoceptor selective antagonist BRL 44408 (3 micromol/kg, i.v.), the effect of oxymetazoline was only partially affected.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonidine</infon>
          <location offset="766" length="9"/>
          <text>clonidine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">yohimbine</infon>
          <location offset="844" length="9"/>
          <text>yohimbine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">brl 44408</infon>
          <location offset="926" length="9"/>
          <text>BRL 44408</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymetazoline</infon>
          <location offset="973" length="13"/>
          <text>oxymetazoline</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha2-adrenoceptor</infon>
          <location offset="813" length="19"/>
          <text>alpha2-adrenoceptor</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">alpha2a-adrenoceptor</infon>
          <location offset="884" length="20"/>
          <text>alpha2A-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T19" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T17" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T16" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T15" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1016</offset>
        <text>Prazosin (alpha1- and alpha2B-adrenoceptor antagonist, 0.07-0.28 micromol/kg, i.v.) also failed to reverse the effect of oxymetazoline.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymetazoline</infon>
          <location offset="1137" length="13"/>
          <text>oxymetazoline</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prazosin</infon>
          <location offset="1016" length="8"/>
          <text>Prazosin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha1- and alpha2b-adrenoceptor</infon>
          <location offset="1026" length="32"/>
          <text>alpha1- and alpha2B-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1152</offset>
        <text>Furthermore, when gastric motility was stimulated peripherally by activation of postsynaptic cholinergic muscarinic receptors by the combination of carbachol (0.14 micromol/kg, i.v.) and hexamethonium (37 micromol/kg, i.v.), clonidine (3.8 micromol/kg, i.v.) failed to affect the increased motor activity, however, oxymetazoline (0.8-3.4 micromol/kg, i.v.) exerted a pronounced inhibition.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbachol</infon>
          <location offset="1300" length="9"/>
          <text>carbachol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hexamethonium</infon>
          <location offset="1339" length="13"/>
          <text>hexamethonium</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonidine</infon>
          <location offset="1377" length="9"/>
          <text>clonidine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymetazoline</infon>
          <location offset="1467" length="13"/>
          <text>oxymetazoline</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">muscarinic receptors</infon>
          <location offset="1257" length="20"/>
          <text>muscarinic receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1542</offset>
        <text>These results suggest that different mechanisms may be involved in the inhibitory effect of clonidine and oxymetazoline; while clonidine reduces the gastric motility by activation of presynaptic alpha2-adrenoceptors, postsynaptic component in the effect of oxymetazoline has also been raised.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonidine</infon>
          <location offset="1634" length="9"/>
          <text>clonidine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymetazoline</infon>
          <location offset="1648" length="13"/>
          <text>oxymetazoline</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonidine</infon>
          <location offset="1669" length="9"/>
          <text>clonidine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxymetazoline</infon>
          <location offset="1799" length="13"/>
          <text>oxymetazoline</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha2-adrenoceptors</infon>
          <location offset="1737" length="20"/>
          <text>alpha2-adrenoceptors</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23214926</id>
    <passage>
      <offset>0</offset>
      <text>Total synthesis of AMF-26, an antitumor agent for inhibition of the Golgi system, targeting ADP-ribosylation factor 1.	An effective method for the total synthesis of 1 (AMF-26), a potentially promising new anticancer drug that disrupts the Golgi system by inhibiting the ADP-ribosylation factor 1 (Arf1) activation, has been developed for the first time. The construction of the chiral linear precursor (a key to the synthesis) was achieved by the asymmetric aldol reaction followed by the computer-assisted predictive stereoselective intramolecular Diels-Alder reaction. The global antitumor activity of the totally synthetic 1 against a variety of human cancer cells was assessed using a panel of 39 human cancer cell lines (JFCR39), and it was shown that the synthetic 1 strongly inhibited the growth of several cancer cell lines at concentrations of less than 0.04 μM. Biological assays of novel derivatives, 26 and 31, which have different side-chains at the C-4 positions in the Δ¹,²-octalin backbone, disclosed the importance of the suitable structure of the side-chain containing conjugated multidouble bonds.</text>
      <sentence>
        <offset>0</offset>
        <text>Total synthesis of AMF-26, an antitumor agent for inhibition of the Golgi system, targeting ADP-ribosylation factor 1.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amf-26</infon>
          <location offset="19" length="6"/>
          <text>AMF-26</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adp</infon>
          <location offset="92" length="3"/>
          <text>ADP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adp-ribosylation factor 1</infon>
          <location offset="92" length="25"/>
          <text>ADP-ribosylation factor 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>119</offset>
        <text>An effective method for the total synthesis of 1 (AMF-26), a potentially promising new anticancer drug that disrupts the Golgi system by inhibiting the ADP-ribosylation factor 1 (Arf1) activation, has been developed for the first time.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adp</infon>
          <location offset="271" length="3"/>
          <text>ADP</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amf-26</infon>
          <location offset="169" length="6"/>
          <text>AMF-26</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adp-ribosylation factor 1</infon>
          <location offset="271" length="25"/>
          <text>ADP-ribosylation factor 1</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">arf1</infon>
          <location offset="298" length="4"/>
          <text>Arf1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T6" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>355</offset>
        <text>The construction of the chiral linear precursor (a key to the synthesis) was achieved by the asymmetric aldol reaction followed by the computer-assisted predictive stereoselective intramolecular Diels-Alder reaction.</text>
      </sentence>
      <sentence>
        <offset>572</offset>
        <text>The global antitumor activity of the totally synthetic 1 against a variety of human cancer cells was assessed using a panel of 39 human cancer cell lines (JFCR39), and it was shown that the synthetic 1 strongly inhibited the growth of several cancer cell lines at concentrations of less than 0.04 μM.</text>
      </sentence>
      <sentence>
        <offset>873</offset>
        <text>Biological assays of novel derivatives, 26 and 31, which have different side-chains at the C-4 positions in the Δ¹,²-octalin backbone, disclosed the importance of the suitable structure of the side-chain containing conjugated multidouble bonds.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">δ¹,²-octalin</infon>
          <location offset="985" length="12"/>
          <text>Δ¹,²-octalin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>20371872</id>
    <passage>
      <offset>0</offset>
      <text>A dilated cardiomyopathy troponin C mutation lowers contractile force by reducing strong myosin-actin binding.	In this study we explore the mechanisms by which a double mutation (E59D/D75Y) in cardiac troponin C (CTnC) associated with dilated cardiomyopathy reduces the Ca(2+)-activated maximal tension of cardiac muscle. Studying the single mutants (i.e. E59D or D75Y) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of CTnC in troponin complex, regulated thin filaments (RTF), and the Ca(2+) sensitivity of contraction and ATPase in cardiac muscle preparations. However, both D75Y and E59D are required to reduce the actomyosin ATPase activity and maximal force in muscle fibers, indicating that E59D enhances the effects of D75Y. Part of the reduction in force/ATPase may be due to a defect in the interactions between CTnC and cardiac troponin T, which are known to be necessary for ATPase activation. An additional mechanism for the reduction in force/ATPase comes from measurements of the binding stoichiometry of myosin subfragment-1 (S-1) to the RTF. Using wild type RTFs, 4.8 mol S-1 was bound per mol filament (seven actins), whereas with E59D/D75Y RTFs, the number of binding sites was reduced by approximately 23% to 3.7. Altogether, these results suggest that the reduction in force and ATPase activation is possibly due to a thin filament conformation that promotes fewer accessible S-1-binding sites. In the absence of any family segregation data, the functional results presented here support the concept that this is likely a dilated cardiomyopathy-causing mutation.</text>
      <sentence>
        <offset>0</offset>
        <text>A dilated cardiomyopathy troponin C mutation lowers contractile force by reducing strong myosin-actin binding.</text>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">troponin c</infon>
          <location offset="25" length="10"/>
          <text>troponin C</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">myosin</infon>
          <location offset="89" length="6"/>
          <text>myosin</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">actin</infon>
          <location offset="96" length="5"/>
          <text>actin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>111</offset>
        <text>In this study we explore the mechanisms by which a double mutation (E59D/D75Y) in cardiac troponin C (CTnC) associated with dilated cardiomyopathy reduces the Ca(2+)-activated maximal tension of cardiac muscle.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="270" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ctnc</infon>
          <location offset="213" length="4"/>
          <text>CTnC</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">e59d</infon>
          <location offset="179" length="4"/>
          <text>E59D</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d75y</infon>
          <location offset="184" length="4"/>
          <text>D75Y</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cardiac troponin c</infon>
          <location offset="193" length="18"/>
          <text>cardiac troponin C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>322</offset>
        <text>Studying the single mutants (i.e. E59D or D75Y) indicates that D75Y, but not E59D, causes a reduction in the calcium affinity of CTnC in troponin complex, regulated thin filaments (RTF), and the Ca(2+) sensitivity of contraction and ATPase in cardiac muscle preparations.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ca(2+)</infon>
          <location offset="517" length="6"/>
          <text>Ca(2+)</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">e59d</infon>
          <location offset="356" length="4"/>
          <text>E59D</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d75y</infon>
          <location offset="364" length="4"/>
          <text>D75Y</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d75y</infon>
          <location offset="385" length="4"/>
          <text>D75Y</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">e59d</infon>
          <location offset="399" length="4"/>
          <text>E59D</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ctnc</infon>
          <location offset="451" length="4"/>
          <text>CTnC</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">troponin</infon>
          <location offset="459" length="8"/>
          <text>troponin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">regulated thin filaments</infon>
          <location offset="477" length="24"/>
          <text>regulated thin filaments</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rtf</infon>
          <location offset="503" length="3"/>
          <text>RTF</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atpase</infon>
          <location offset="555" length="6"/>
          <text>ATPase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>594</offset>
        <text>However, both D75Y and E59D are required to reduce the actomyosin ATPase activity and maximal force in muscle fibers, indicating that E59D enhances the effects of D75Y.</text>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d75y</infon>
          <location offset="608" length="4"/>
          <text>D75Y</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">e59d</infon>
          <location offset="617" length="4"/>
          <text>E59D</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">actomyosin</infon>
          <location offset="649" length="10"/>
          <text>actomyosin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atpase</infon>
          <location offset="660" length="6"/>
          <text>ATPase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">e59d</infon>
          <location offset="728" length="4"/>
          <text>E59D</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d75y</infon>
          <location offset="757" length="4"/>
          <text>D75Y</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>763</offset>
        <text>Part of the reduction in force/ATPase may be due to a defect in the interactions between CTnC and cardiac troponin T, which are known to be necessary for ATPase activation.</text>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atpase</infon>
          <location offset="794" length="6"/>
          <text>ATPase</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ctnc</infon>
          <location offset="852" length="4"/>
          <text>CTnC</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cardiac troponin t</infon>
          <location offset="861" length="18"/>
          <text>cardiac troponin T</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atpase</infon>
          <location offset="917" length="6"/>
          <text>ATPase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>936</offset>
        <text>An additional mechanism for the reduction in force/ATPase comes from measurements of the binding stoichiometry of myosin subfragment-1 (S-1) to the RTF.</text>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atpase</infon>
          <location offset="987" length="6"/>
          <text>ATPase</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">myosin subfragment-1</infon>
          <location offset="1050" length="20"/>
          <text>myosin subfragment-1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">s-1</infon>
          <location offset="1072" length="3"/>
          <text>S-1</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rtf</infon>
          <location offset="1084" length="3"/>
          <text>RTF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1089</offset>
        <text>Using wild type RTFs, 4.8 mol S-1 was bound per mol filament (seven actins), whereas with E59D/D75Y RTFs, the number of binding sites was reduced by approximately 23% to 3.7.</text>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">s-1</infon>
          <location offset="1119" length="3"/>
          <text>S-1</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">e59d</infon>
          <location offset="1179" length="4"/>
          <text>E59D</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">d75y</infon>
          <location offset="1184" length="4"/>
          <text>D75Y</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rtfs</infon>
          <location offset="1189" length="4"/>
          <text>RTFs</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">rtfs</infon>
          <location offset="1105" length="4"/>
          <text>RTFs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1264</offset>
        <text>Altogether, these results suggest that the reduction in force and ATPase activation is possibly due to a thin filament conformation that promotes fewer accessible S-1-binding sites.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atpase</infon>
          <location offset="1330" length="6"/>
          <text>ATPase</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">s-1-binding sites</infon>
          <location offset="1427" length="17"/>
          <text>S-1-binding sites</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1446</offset>
        <text>In the absence of any family segregation data, the functional results presented here support the concept that this is likely a dilated cardiomyopathy-causing mutation.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>3143355</id>
    <passage>
      <offset>0</offset>
      <text>Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase.	High-molecular-mass proteins from pea (Pisum sativum) mitochondrial matrix retained on an XM-300 Diaflo membrane ('matrix extract') exhibited high rates of glycine oxidation in the presence of NAD+ and tetrahydropteroyl-L-glutamic acid (H4 folate) as long as the medium exhibited a low ionic strength. Serine hydroxymethyltransferase (SHMT) (4 x 53 kDa) and the four proteins of the glycine-cleavage system, including a pyridoxal phosphate-containing enzyme ('P-protein'; 2 x 97 kDa), a carrier protein containing covalently bound lipoic acid ('H-protein'; 15.5 kDa), a protein exhibiting lipoamide dehydrogenase activity ('L-protein'; 2 x 61 kDa) and an H4 folate-dependent enzyme ('T-protein'; 45 kDa) have been purified to apparent homogeneity from the matrix extract by using gel filtration, ion-exchange and phenyl-Superose fast protein liquid chromatography. Gel filtration on Sephacryl S-300 in the presence of 50 mM-KCl proved to be the key step in disrupting this complex. During the course of glycine oxidation catalysed by the matrix extract a steady-state equilibrium in the production and utilization of 5,10-methylene-H4 folate was reached, suggesting that glycine cleavage and SHMT are linked together via a soluble pool of H4 folate. The rate of glycine oxidation catalysed by the matrix extract was sensitive to the NADH/NAD+ molar ratios, because NADH competitively inhibited the reaction catalysed by lipoamide dehydrogenase.</text>
      <sentence>
        <offset>0</offset>
        <text>Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="39" length="7"/>
          <text>glycine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>91</offset>
        <text>Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="139" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="165" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glycine decarboxylase</infon>
          <location offset="139" length="21"/>
          <text>glycine decarboxylase</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serine hydroxymethyltransferase</infon>
          <location offset="165" length="31"/>
          <text>serine hydroxymethyltransferase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>198</offset>
        <text>High-molecular-mass proteins from pea (Pisum sativum) mitochondrial matrix retained on an XM-300 Diaflo membrane ('matrix extract') exhibited high rates of glycine oxidation in the presence of NAD+ and tetrahydropteroyl-L-glutamic acid (H4 folate) as long as the medium exhibited a low ionic strength.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="354" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad+</infon>
          <location offset="391" length="4"/>
          <text>NAD+</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetrahydropteroyl-l-glutamic acid</infon>
          <location offset="400" length="33"/>
          <text>tetrahydropteroyl-L-glutamic acid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h4 folate</infon>
          <location offset="435" length="9"/>
          <text>H4 folate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>500</offset>
        <text>Serine hydroxymethyltransferase (SHMT) (4 x 53 kDa) and the four proteins of the glycine-cleavage system, including a pyridoxal phosphate-containing enzyme ('P-protein'; 2 x 97 kDa), a carrier protein containing covalently bound lipoic acid ('H-protein'; 15.5 kDa), a protein exhibiting lipoamide dehydrogenase activity ('L-protein'; 2 x 61 kDa) and an H4 folate-dependent enzyme ('T-protein'; 45 kDa) have been purified to apparent homogeneity from the matrix extract by using gel filtration, ion-exchange and phenyl-Superose fast protein liquid chromatography.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="500" length="6"/>
          <text>Serine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="581" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyridoxal phosphate</infon>
          <location offset="618" length="19"/>
          <text>pyridoxal phosphate</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h4 folate</infon>
          <location offset="853" length="9"/>
          <text>H4 folate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenyl</infon>
          <location offset="1011" length="6"/>
          <text>phenyl</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serine hydroxymethyltransferase</infon>
          <location offset="500" length="31"/>
          <text>Serine hydroxymethyltransferase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">shmt</infon>
          <location offset="533" length="4"/>
          <text>SHMT</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p-protein</infon>
          <location offset="658" length="9"/>
          <text>P-protein</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">h-protein</infon>
          <location offset="743" length="9"/>
          <text>H-protein</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lipoamide dehydrogenase</infon>
          <location offset="787" length="23"/>
          <text>lipoamide dehydrogenase</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">l-protein</infon>
          <location offset="822" length="9"/>
          <text>L-protein</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">t-protein</infon>
          <location offset="882" length="9"/>
          <text>T-protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1063</offset>
        <text>Gel filtration on Sephacryl S-300 in the presence of 50 mM-KCl proved to be the key step in disrupting this complex.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sephacryl s-300</infon>
          <location offset="1081" length="15"/>
          <text>Sephacryl S-300</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">kcl</infon>
          <location offset="1122" length="3"/>
          <text>KCl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1180</offset>
        <text>During the course of glycine oxidation catalysed by the matrix extract a steady-state equilibrium in the production and utilization of 5,10-methylene-H4 folate was reached, suggesting that glycine cleavage and SHMT are linked together via a soluble pool of H4 folate.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="1201" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5,10-methylene-h4 folate</infon>
          <location offset="1315" length="24"/>
          <text>5,10-methylene-H4 folate</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="1369" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h4 folate</infon>
          <location offset="1437" length="9"/>
          <text>H4 folate</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">shmt</infon>
          <location offset="1390" length="4"/>
          <text>SHMT</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1448</offset>
        <text>The rate of glycine oxidation catalysed by the matrix extract was sensitive to the NADH/NAD+ molar ratios, because NADH competitively inhibited the reaction catalysed by lipoamide dehydrogenase.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycine</infon>
          <location offset="1460" length="7"/>
          <text>glycine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadh</infon>
          <location offset="1531" length="4"/>
          <text>NADH</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nad+</infon>
          <location offset="1536" length="4"/>
          <text>NAD+</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadh</infon>
          <location offset="1563" length="4"/>
          <text>NADH</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">lipoamide dehydrogenase</infon>
          <location offset="1618" length="23"/>
          <text>lipoamide dehydrogenase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1400062</id>
    <passage>
      <offset>0</offset>
      <text>Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4 in the rat lung.	Platelet-activating factor (PAF) and leukotrienes (LTs) are potent pulmonary hypertensive and inflammatory mediators produced by the lung. Previously we showed that a rapid injection of PAF into the pulmonary artery of an isolated rat lung produced an extended elevation in mean pulmonary arterial pressure (PAP). The objective of the present study was to determine whether the extended pressor response induced by PAF was caused by prolonged activation of the 5-lipoxygenase pathway or slow clearance of LTs from the lung parenchyma. Rat lungs were perfused with a nonrecirculating physiological salt solution that contained indomethacin and albumin. Five minutes after a rapid injection of PAF into the pulmonary artery catheter, the following elevations (mean % above baseline) were observed: PAP (83%), LTB4 (3,260%), LTC4 (1,490%), LTD4 (970%), and LTE4 (1,500%). At 20 min these levels declined but were still significantly elevated above baseline. The 5-lipoxygenase inhibitor diethylcarbamazine (DEC), administered before the PAF injection, inhibited the elevations of PAP and all LTs. DEC administration that began 5 min after PAF reduced PAP and only LTC4 levels at 20 min in comparison to lungs with no DEC. The 5-lipoxygenase-activating protein inhibitor MK886, administered orally 2-6 h before perfusion, also inhibited the pressor response to PAF as well as LT production, as did DEC. We conclude that 1) the extended pulmonary hypertension induced by PAF was caused mainly by prolonged activation of 5-lipoxygenase with LTC4 production, 2) the relative overall lung clearance of LTB4, LTD4, and LTE4 was slower than that of LTC4, and 3) LTB4, LTD4, and LTE4 had no appreciable pressor effect.</text>
      <sentence>
        <offset>0</offset>
        <text>Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4 in the rat lung.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leukotriene c4</infon>
          <location offset="74" length="14"/>
          <text>leukotriene C4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>106</offset>
        <text>Platelet-activating factor (PAF) and leukotrienes (LTs) are potent pulmonary hypertensive and inflammatory mediators produced by the lung.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leukotrienes</infon>
          <location offset="143" length="12"/>
          <text>leukotrienes</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lts</infon>
          <location offset="157" length="3"/>
          <text>LTs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>245</offset>
        <text>Previously we showed that a rapid injection of PAF into the pulmonary artery of an isolated rat lung produced an extended elevation in mean pulmonary arterial pressure (PAP).</text>
      </sentence>
      <sentence>
        <offset>420</offset>
        <text>The objective of the present study was to determine whether the extended pressor response induced by PAF was caused by prolonged activation of the 5-lipoxygenase pathway or slow clearance of LTs from the lung parenchyma.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lts</infon>
          <location offset="611" length="3"/>
          <text>LTs</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-lipoxygenase</infon>
          <location offset="567" length="14"/>
          <text>5-lipoxygenase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>641</offset>
        <text>Rat lungs were perfused with a nonrecirculating physiological salt solution that contained indomethacin and albumin.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="732" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">albumin</infon>
          <location offset="749" length="7"/>
          <text>albumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>758</offset>
        <text>Five minutes after a rapid injection of PAF into the pulmonary artery catheter, the following elevations (mean % above baseline) were observed: PAP (83%), LTB4 (3,260%), LTC4 (1,490%), LTD4 (970%), and LTE4 (1,500%).</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb4</infon>
          <location offset="913" length="4"/>
          <text>LTB4</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltc4</infon>
          <location offset="928" length="4"/>
          <text>LTC4</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltd4</infon>
          <location offset="943" length="4"/>
          <text>LTD4</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lte4</infon>
          <location offset="960" length="4"/>
          <text>LTE4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>975</offset>
        <text>At 20 min these levels declined but were still significantly elevated above baseline.</text>
      </sentence>
      <sentence>
        <offset>1061</offset>
        <text>The 5-lipoxygenase inhibitor diethylcarbamazine (DEC), administered before the PAF injection, inhibited the elevations of PAP and all LTs.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dec</infon>
          <location offset="1110" length="3"/>
          <text>DEC</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lts</infon>
          <location offset="1195" length="3"/>
          <text>LTs</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diethylcarbamazine</infon>
          <location offset="1090" length="18"/>
          <text>diethylcarbamazine</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-lipoxygenase</infon>
          <location offset="1065" length="14"/>
          <text>5-lipoxygenase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T25" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1200</offset>
        <text>DEC administration that began 5 min after PAF reduced PAP and only LTC4 levels at 20 min in comparison to lungs with no DEC.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dec</infon>
          <location offset="1200" length="3"/>
          <text>DEC</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltc4</infon>
          <location offset="1267" length="4"/>
          <text>LTC4</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dec</infon>
          <location offset="1320" length="3"/>
          <text>DEC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1325</offset>
        <text>The 5-lipoxygenase-activating protein inhibitor MK886, administered orally 2-6 h before perfusion, also inhibited the pressor response to PAF as well as LT production, as did DEC.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mk886</infon>
          <location offset="1373" length="5"/>
          <text>MK886</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lt</infon>
          <location offset="1478" length="2"/>
          <text>LT</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dec</infon>
          <location offset="1500" length="3"/>
          <text>DEC</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-lipoxygenase-activating protein</infon>
          <location offset="1329" length="33"/>
          <text>5-lipoxygenase-activating protein</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1505</offset>
        <text>We conclude that 1) the extended pulmonary hypertension induced by PAF was caused mainly by prolonged activation of 5-lipoxygenase with LTC4 production, 2) the relative overall lung clearance of LTB4, LTD4, and LTE4 was slower than that of LTC4, and 3) LTB4, LTD4, and LTE4 had no appreciable pressor effect.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltc4</infon>
          <location offset="1641" length="4"/>
          <text>LTC4</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb4</infon>
          <location offset="1700" length="4"/>
          <text>LTB4</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltd4</infon>
          <location offset="1706" length="4"/>
          <text>LTD4</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lte4</infon>
          <location offset="1716" length="4"/>
          <text>LTE4</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltc4</infon>
          <location offset="1745" length="4"/>
          <text>LTC4</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltb4</infon>
          <location offset="1758" length="4"/>
          <text>LTB4</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ltd4</infon>
          <location offset="1764" length="4"/>
          <text>LTD4</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lte4</infon>
          <location offset="1774" length="4"/>
          <text>LTE4</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-lipoxygenase</infon>
          <location offset="1621" length="14"/>
          <text>5-lipoxygenase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T9" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23612710</id>
    <passage>
      <offset>0</offset>
      <text>Comparative phosphoproteomic analysis of checkpoint recovery identifies new regulators of the DNA damage response.	How cells recover from a DNA damage-induced arrest is currently poorly understood. We performed large-scale quantitative phosphoproteomics to identify changes in protein phosphorylation that occurred during recovery from arrest in the G2 phase of the cell cycle caused by DNA damage. We identified 154 proteins that were differentially phosphorylated, and systematic depletion of each of these differentially phosphorylated proteins by small interfering RNA (siRNA) identified at least 10 potential regulators of recovery. Astrin, a protein associated with the mitotic spindle, was among the potential regulators of recovery. We found that astrin controlled the abundance of the cell cycle regulator p53 during DNA damage-induced arrest. Cells in which astrin was depleted had decreased murine double minute 2 (MDM2) abundance and increased p53 at the later stages of the DNA damage response. Astrin was required for continued expression of genes encoding proteins that promote cell cycle progression in arrested cells. Thus, by controlling p53 abundance in cells recovering from DNA damage, astrin maintains the cells in a state competent to resume the cell cycle.</text>
      <sentence>
        <offset>0</offset>
        <text>Comparative phosphoproteomic analysis of checkpoint recovery identifies new regulators of the DNA damage response.</text>
      </sentence>
      <sentence>
        <offset>115</offset>
        <text>How cells recover from a DNA damage-induced arrest is currently poorly understood.</text>
      </sentence>
      <sentence>
        <offset>198</offset>
        <text>We performed large-scale quantitative phosphoproteomics to identify changes in protein phosphorylation that occurred during recovery from arrest in the G2 phase of the cell cycle caused by DNA damage.</text>
      </sentence>
      <sentence>
        <offset>399</offset>
        <text>We identified 154 proteins that were differentially phosphorylated, and systematic depletion of each of these differentially phosphorylated proteins by small interfering RNA (siRNA) identified at least 10 potential regulators of recovery.</text>
      </sentence>
      <sentence>
        <offset>638</offset>
        <text>Astrin, a protein associated with the mitotic spindle, was among the potential regulators of recovery.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astrin</infon>
          <location offset="638" length="6"/>
          <text>Astrin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">astrin</infon>
          <location offset="638" length="6"/>
          <text>Astrin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>741</offset>
        <text>We found that astrin controlled the abundance of the cell cycle regulator p53 during DNA damage-induced arrest.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">astrin</infon>
          <location offset="755" length="6"/>
          <text>astrin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="815" length="3"/>
          <text>p53</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>853</offset>
        <text>Cells in which astrin was depleted had decreased murine double minute 2 (MDM2) abundance and increased p53 at the later stages of the DNA damage response.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astrin</infon>
          <location offset="868" length="6"/>
          <text>astrin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">astrin</infon>
          <location offset="868" length="6"/>
          <text>astrin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">murine double minute 2</infon>
          <location offset="902" length="22"/>
          <text>murine double minute 2</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdm2</infon>
          <location offset="926" length="4"/>
          <text>MDM2</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="956" length="3"/>
          <text>p53</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1008</offset>
        <text>Astrin was required for continued expression of genes encoding proteins that promote cell cycle progression in arrested cells.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astrin</infon>
          <location offset="1008" length="6"/>
          <text>Astrin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">astrin</infon>
          <location offset="1008" length="6"/>
          <text>Astrin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1135</offset>
        <text>Thus, by controlling p53 abundance in cells recovering from DNA damage, astrin maintains the cells in a state competent to resume the cell cycle.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="1156" length="3"/>
          <text>p53</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">astrin</infon>
          <location offset="1207" length="6"/>
          <text>astrin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23639249</id>
    <passage>
      <offset>0</offset>
      <text>Indoxyl 3-sulfate stimulates Th17 differentiation enhancing phosphorylation of c-Src and STAT3 to worsen experimental autoimmune encephalomyelitis.	Although AhR activation regulates CD4T cell differentiation, how it works has yet to be elucidated. In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms. I3S increased expression of RORγt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand. Activation of STAT3, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and TCDD. Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation. Finally, we found that I3S worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of IL-17-producing cells in draining lymph nodes.</text>
      <sentence>
        <offset>0</offset>
        <text>Indoxyl 3-sulfate stimulates Th17 differentiation enhancing phosphorylation of c-Src and STAT3 to worsen experimental autoimmune encephalomyelitis.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indoxyl 3-sulfate</infon>
          <location offset="0" length="17"/>
          <text>Indoxyl 3-sulfate</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-src</infon>
          <location offset="79" length="5"/>
          <text>c-Src</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">stat3</infon>
          <location offset="89" length="5"/>
          <text>STAT3</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>148</offset>
        <text>Although AhR activation regulates CD4T cell differentiation, how it works has yet to be elucidated.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="157" length="3"/>
          <text>AhR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>248</offset>
        <text>In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indoxyl 3-sulfate</infon>
          <location offset="354" length="17"/>
          <text>indoxyl 3-sulfate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">i3s</infon>
          <location offset="373" length="3"/>
          <text>I3S</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="336" length="3"/>
          <text>AhR</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>459</offset>
        <text>I3S increased expression of RORγt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">i3s</infon>
          <location offset="459" length="3"/>
          <text>I3S</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2,3,7,8-tetrachlorodibenzo-p-dioxin</infon>
          <location offset="616" length="35"/>
          <text>2,3,7,8-tetrachlorodibenzo-p-dioxin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcdd</infon>
          <location offset="653" length="4"/>
          <text>TCDD</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rorγt</infon>
          <location offset="487" length="5"/>
          <text>RORγt</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="675" length="3"/>
          <text>AhR</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>687</offset>
        <text>Activation of STAT3, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and TCDD.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">i3s</infon>
          <location offset="838" length="3"/>
          <text>I3S</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcdd</infon>
          <location offset="846" length="4"/>
          <text>TCDD</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">stat3</infon>
          <location offset="701" length="5"/>
          <text>STAT3</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-6</infon>
          <location offset="739" length="4"/>
          <text>IL-6</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>852</offset>
        <text>Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">i3s</infon>
          <location offset="1171" length="3"/>
          <text>I3S</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcdd</infon>
          <location offset="1179" length="4"/>
          <text>TCDD</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">i3s</infon>
          <location offset="948" length="3"/>
          <text>I3S</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tcdd</infon>
          <location offset="956" length="4"/>
          <text>TCDD</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine</infon>
          <location offset="996" length="64"/>
          <text>4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-src</infon>
          <location offset="1258" length="5"/>
          <text>c-Src</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">stat3</infon>
          <location offset="1290" length="5"/>
          <text>STAT3</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-src</infon>
          <location offset="871" length="5"/>
          <text>c-Src</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ahr</infon>
          <location offset="913" length="3"/>
          <text>AhR</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-src</infon>
          <location offset="978" length="5"/>
          <text>c-Src</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-src</infon>
          <location offset="1101" length="5"/>
          <text>c-Src</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">stat3</infon>
          <location offset="1111" length="5"/>
          <text>STAT3</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1308</offset>
        <text>Finally, we found that I3S worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of IL-17-producing cells in draining lymph nodes.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">i3s</infon>
          <location offset="1331" length="3"/>
          <text>I3S</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-17</infon>
          <location offset="1463" length="5"/>
          <text>IL-17</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15347780</id>
    <passage>
      <offset>0</offset>
      <text>Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins and serum volatile organic compound measures.	BACKGROUND: Multiple chemical sensitivity (MCS), although poorly understood, is associated with considerable morbidity. AIM: To investigate potential biological mechanisms underlying MCS in a case-control study. METHODS: Two hundred and twenty-three MCS cases and 194 controls (urban females, aged 30-64 years) fulfilled reproducible eligibility criteria with discriminant validity. Routine laboratory results and serum levels of volatile organic compounds (VOCs) were compared. Dose-response relationships, a criterion for causality, were examined linking exposures to likelihood of case status. RESULTS: Routine laboratory investigations revealed clinically unimportant case-control differences in means. Confounder-adjusted odds ratios (OR) showed MCS was negatively associated with lymphocyte count and total plasma homocysteine, positively associated with mean cell haemoglobin concentration, alanine aminotransferase and serum vitamin B6, and not associated with thyroid stimulating hormone, folate or serum vitamin B12. More cases than controls had detectable serum chloroform (P = 0.001) with the OR for detectability 2.78 (95% confidence interval = 1.73-4.48, P &lt; 0.001). Chloroform levels were higher in cases. However, cases had significantly lower means of detectable serum levels of ethylbenzene, m&amp;p-xylene, 3-methylpentane and hexane, and means of all serum levels of 1,3,5- and 1,2,3-trimethylbenzene, 2- and 3-methylpentane, and m&amp;p-xylene. CONCLUSIONS: Our findings are inconsistent with proposals that MCS is associated with vitamin deficiency or thyroid dysfunction, but the association of lower lymphocyte counts with an increased likelihood of MCS is consistent with theories of immune dysfunction in MCS. Whether avoidance of exposures or different metabolic pathways in cases explain the observed lower VOC levels or the higher chloroform levels should be investigated.</text>
      <sentence>
        <offset>0</offset>
        <text>Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins and serum volatile organic compound measures.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamins</infon>
          <location offset="90" length="8"/>
          <text>vitamins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>145</offset>
        <text>BACKGROUND: Multiple chemical sensitivity (MCS), although poorly understood, is associated with considerable morbidity.</text>
      </sentence>
      <sentence>
        <offset>265</offset>
        <text>AIM: To investigate potential biological mechanisms underlying MCS in a case-control study.</text>
      </sentence>
      <sentence>
        <offset>357</offset>
        <text>METHODS: Two hundred and twenty-three MCS cases and 194 controls (urban females, aged 30-64 years) fulfilled reproducible eligibility criteria with discriminant validity.</text>
      </sentence>
      <sentence>
        <offset>528</offset>
        <text>Routine laboratory results and serum levels of volatile organic compounds (VOCs) were compared.</text>
      </sentence>
      <sentence>
        <offset>624</offset>
        <text>Dose-response relationships, a criterion for causality, were examined linking exposures to likelihood of case status.</text>
      </sentence>
      <sentence>
        <offset>742</offset>
        <text>RESULTS: Routine laboratory investigations revealed clinically unimportant case-control differences in means.</text>
      </sentence>
      <sentence>
        <offset>852</offset>
        <text>Confounder-adjusted odds ratios (OR) showed MCS was negatively associated with lymphocyte count and total plasma homocysteine, positively associated with mean cell haemoglobin concentration, alanine aminotransferase and serum vitamin B6, and not associated with thyroid stimulating hormone, folate or serum vitamin B12.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin b12</infon>
          <location offset="1159" length="11"/>
          <text>vitamin B12</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">homocysteine</infon>
          <location offset="965" length="12"/>
          <text>homocysteine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alanine</infon>
          <location offset="1043" length="7"/>
          <text>alanine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin b6</infon>
          <location offset="1078" length="10"/>
          <text>vitamin B6</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">folate</infon>
          <location offset="1143" length="6"/>
          <text>folate</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">haemoglobin</infon>
          <location offset="1016" length="11"/>
          <text>haemoglobin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alanine aminotransferase</infon>
          <location offset="1043" length="24"/>
          <text>alanine aminotransferase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">thyroid stimulating hormone</infon>
          <location offset="1114" length="27"/>
          <text>thyroid stimulating hormone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1172</offset>
        <text>More cases than controls had detectable serum chloroform (P = 0.001) with the OR for detectability 2.78 (95% confidence interval = 1.73-4.48, P &lt; 0.001).</text>
      </sentence>
      <sentence>
        <offset>1326</offset>
        <text>Chloroform levels were higher in cases.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloroform</infon>
          <location offset="1326" length="10"/>
          <text>Chloroform</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1366</offset>
        <text>However, cases had significantly lower means of detectable serum levels of ethylbenzene, m&amp;p-xylene, 3-methylpentane and hexane, and means of all serum levels of 1,3,5- and 1,2,3-trimethylbenzene, 2- and 3-methylpentane, and m&amp;p-xylene.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethylbenzene</infon>
          <location offset="1441" length="12"/>
          <text>ethylbenzene</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">m&amp;p-xylene</infon>
          <location offset="1455" length="10"/>
          <text>m&amp;p-xylene</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-methylpentane</infon>
          <location offset="1467" length="15"/>
          <text>3-methylpentane</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hexane</infon>
          <location offset="1487" length="6"/>
          <text>hexane</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,3,5- and 1,2,3-trimethylbenzene</infon>
          <location offset="1528" length="33"/>
          <text>1,3,5- and 1,2,3-trimethylbenzene</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2- and 3-methylpentane</infon>
          <location offset="1563" length="22"/>
          <text>2- and 3-methylpentane</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">m&amp;p-xylene</infon>
          <location offset="1591" length="10"/>
          <text>m&amp;p-xylene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1603</offset>
        <text>CONCLUSIONS: Our findings are inconsistent with proposals that MCS is associated with vitamin deficiency or thyroid dysfunction, but the association of lower lymphocyte counts with an increased likelihood of MCS is consistent with theories of immune dysfunction in MCS.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin</infon>
          <location offset="1689" length="7"/>
          <text>vitamin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1873</offset>
        <text>Whether avoidance of exposures or different metabolic pathways in cases explain the observed lower VOC levels or the higher chloroform levels should be investigated.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloroform</infon>
          <location offset="1997" length="10"/>
          <text>chloroform</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23590413</id>
    <passage>
      <offset>0</offset>
      <text>Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.	INTRODUCTION: Canagliflozin is an orally administered sodium glucose cotransporter 2 inhibitor proposed for the treatment of type 2 diabetes. Canagliflozin improves glycemic control in an insulin-independent fashion through inhibition of glucose reuptake in the kidney. AREAS COVERED: This article reviews the available data on the pharmacodynamics, the pharmacokinetics and metabolism, and the efficacy and safety of canagliflozin. Relevant articles were identified via PubMed using the search term canagliflozin with no date restriction. The authors also discuss the abstracts from canagliflozin studies presented at large diabetes conferences. EXPERT OPINION: Canagliflozin offers a relatively modest reduction in HbA1c, FPG, and PPG. It has a low incidence of hypoglycemia and a reduction in body weight. Dose adjustment may be recommended in the elderly, those on loop diuretics, and those with an estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73 m(2) if there are concerns or symptoms of volume-related side effects. Issues remain with observed increases in low-density lipoprotein cholesterol (LDL-C) and the odds of heart attack and stroke. Canagliflozin offers a novel mechanism of action, a modest glycemic control, and a favorable side-effect profile. It was approved by the US Food and Drug Administration in April 2013 and is undergoing evaluation by the European Medicines Agency.</text>
      <sentence>
        <offset>0</offset>
        <text>Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">canagliflozin</infon>
          <location offset="0" length="13"/>
          <text>Canagliflozin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium-glucose</infon>
          <location offset="32" length="14"/>
          <text>sodium-glucose</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sodium-glucose cotransporter 2</infon>
          <location offset="32" length="30"/>
          <text>sodium-glucose cotransporter 2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>111</offset>
        <text>INTRODUCTION: Canagliflozin is an orally administered sodium glucose cotransporter 2 inhibitor proposed for the treatment of type 2 diabetes.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">canagliflozin</infon>
          <location offset="125" length="13"/>
          <text>Canagliflozin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium glucose</infon>
          <location offset="165" length="14"/>
          <text>sodium glucose</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sodium glucose cotransporter 2</infon>
          <location offset="165" length="30"/>
          <text>sodium glucose cotransporter 2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>253</offset>
        <text>Canagliflozin improves glycemic control in an insulin-independent fashion through inhibition of glucose reuptake in the kidney.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">canagliflozin</infon>
          <location offset="253" length="13"/>
          <text>Canagliflozin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="349" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="299" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>381</offset>
        <text>AREAS COVERED: This article reviews the available data on the pharmacodynamics, the pharmacokinetics and metabolism, and the efficacy and safety of canagliflozin.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">canagliflozin</infon>
          <location offset="529" length="13"/>
          <text>canagliflozin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>544</offset>
        <text>Relevant articles were identified via PubMed using the search term canagliflozin with no date restriction.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">canagliflozin</infon>
          <location offset="611" length="13"/>
          <text>canagliflozin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>651</offset>
        <text>The authors also discuss the abstracts from canagliflozin studies presented at large diabetes conferences.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">canagliflozin</infon>
          <location offset="695" length="13"/>
          <text>canagliflozin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>758</offset>
        <text>EXPERT OPINION: Canagliflozin offers a relatively modest reduction in HbA1c, FPG, and PPG.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">canagliflozin</infon>
          <location offset="774" length="13"/>
          <text>Canagliflozin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hba1c</infon>
          <location offset="828" length="5"/>
          <text>HbA1c</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>849</offset>
        <text>It has a low incidence of hypoglycemia and a reduction in body weight.</text>
      </sentence>
      <sentence>
        <offset>920</offset>
        <text>Dose adjustment may be recommended in the elderly, those on loop diuretics, and those with an estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73 m(2) if there are concerns or symptoms of volume-related side effects.</text>
      </sentence>
      <sentence>
        <offset>1146</offset>
        <text>Issues remain with observed increases in low-density lipoprotein cholesterol (LDL-C) and the odds of heart attack and stroke.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1211" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">low-density lipoprotein</infon>
          <location offset="1187" length="23"/>
          <text>low-density lipoprotein</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl</infon>
          <location offset="1224" length="3"/>
          <text>LDL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1272</offset>
        <text>Canagliflozin offers a novel mechanism of action, a modest glycemic control, and a favorable side-effect profile.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">canagliflozin</infon>
          <location offset="1272" length="13"/>
          <text>Canagliflozin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1386</offset>
        <text>It was approved by the US Food and Drug Administration in April 2013 and is undergoing evaluation by the European Medicines Agency.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23537747</id>
    <passage>
      <offset>0</offset>
      <text>Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.	Hepatocyte growth factor (HGF), and its receptor, c-Met activation has recently been shown to play important roles in cancer invasion and metastasis in a wide variety of tumor cells. We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis. Among them, nobiletin markedly inhibited HGF-induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations. Data also showed nobiletin inhibited HGF-induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia. Furthermore, nobiletin could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38. Next, nobiletin significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration. In conclusion, nobiletin attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.</text>
      <sentence>
        <offset>0</offset>
        <text>Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nobiletin</infon>
          <location offset="0" length="9"/>
          <text>Nobiletin</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="41" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="49" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="54" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgf</infon>
          <location offset="70" length="3"/>
          <text>HGF</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>108</offset>
        <text>Hepatocyte growth factor (HGF), and its receptor, c-Met activation has recently been shown to play important roles in cancer invasion and metastasis in a wide variety of tumor cells.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hepatocyte growth factor</infon>
          <location offset="108" length="24"/>
          <text>Hepatocyte growth factor</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgf</infon>
          <location offset="134" length="3"/>
          <text>HGF</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-met</infon>
          <location offset="158" length="5"/>
          <text>c-Met</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>291</offset>
        <text>We use HGF as an invasive inducer of human HepG2 cells to investigate the effect of four flavones including apigenin, tricetin, tangeretin, and nobiletin on HGF/c-Met-mediated tumor invasion and metastasis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">apigenin</infon>
          <location offset="399" length="8"/>
          <text>apigenin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tricetin</infon>
          <location offset="409" length="8"/>
          <text>tricetin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tangeretin</infon>
          <location offset="419" length="10"/>
          <text>tangeretin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nobiletin</infon>
          <location offset="435" length="9"/>
          <text>nobiletin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgf</infon>
          <location offset="298" length="3"/>
          <text>HGF</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgf</infon>
          <location offset="448" length="3"/>
          <text>HGF</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-met</infon>
          <location offset="452" length="5"/>
          <text>c-Met</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>498</offset>
        <text>Among them, nobiletin markedly inhibited HGF-induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion/migration assay under non-cytotoxic concentrations.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nobiletin</infon>
          <location offset="510" length="9"/>
          <text>nobiletin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgf</infon>
          <location offset="539" length="3"/>
          <text>HGF</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>719</offset>
        <text>Data also showed nobiletin inhibited HGF-induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nobiletin</infon>
          <location offset="736" length="9"/>
          <text>nobiletin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgf</infon>
          <location offset="756" length="3"/>
          <text>HGF</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>845</offset>
        <text>Furthermore, nobiletin could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1/2 and p38.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nobiletin</infon>
          <location offset="858" length="9"/>
          <text>nobiletin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgf</infon>
          <location offset="882" length="3"/>
          <text>HGF</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-met</infon>
          <location offset="938" length="5"/>
          <text>c-Met</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk2</infon>
          <location offset="945" length="4"/>
          <text>ERK2</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="955" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphorylated jnk1/2</infon>
          <location offset="968" length="21"/>
          <text>phosphorylated JNK1/2</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p38</infon>
          <location offset="994" length="3"/>
          <text>p38</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>999</offset>
        <text>Next, nobiletin significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nobiletin</infon>
          <location offset="1005" length="9"/>
          <text>nobiletin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phospho</infon>
          <location offset="1053" length="7"/>
          <text>phospho</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phospho</infon>
          <location offset="1070" length="7"/>
          <text>phospho</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phospho-erk2</infon>
          <location offset="1053" length="12"/>
          <text>phospho-ERK2</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phospho-akt</infon>
          <location offset="1070" length="11"/>
          <text>phospho-Akt</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erk2</infon>
          <location offset="1085" length="4"/>
          <text>ERK2</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1093" length="3"/>
          <text>Akt</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1191</offset>
        <text>In conclusion, nobiletin attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nobiletin</infon>
          <location offset="1206" length="9"/>
          <text>nobiletin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hgf</infon>
          <location offset="1227" length="3"/>
          <text>HGF</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="1277" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi3k</infon>
          <location offset="1285" length="4"/>
          <text>PI3K</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1290" length="3"/>
          <text>Akt</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23614400</id>
    <passage>
      <offset>0</offset>
      <text>Topological Dangling Bonds with Large Spin Splitting and Enhanced Spin Polarization on the Surfaces of Bi2Se3.	We investigate the topological surface state properties at various surface cleaves in the topological insulator Bi2Se3, via first principles calculations and scanning tunneling microscopy/spectroscopy (STM/STS). While the typical surface termination occurs between two quintuple layers, we report the existence of a surface termination within a single quintuple layer where dangling bonds form with giant spin splitting owing to strong spin-orbit coupling. Unlike Rashba split states in a 2D electron gas, these states are constrained by the band topology of the host insulator with topological properties similar to the typical topological surface state, and thereby offer an alternative candidate for spintronics usage. We name these new states "topological dangling-bond states". The degree of the spin polarization of these states is greatly enhanced. Since dangling bonds are more chemically reactive, the observed topological dangling-bond states provide a new avenue for manipulating band dispersions and spin-textures by adsorbed atoms or molecules.</text>
      <sentence>
        <offset>0</offset>
        <text>Topological Dangling Bonds with Large Spin Splitting and Enhanced Spin Polarization on the Surfaces of Bi2Se3.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bi2se3</infon>
          <location offset="103" length="6"/>
          <text>Bi2Se3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>111</offset>
        <text>We investigate the topological surface state properties at various surface cleaves in the topological insulator Bi2Se3, via first principles calculations and scanning tunneling microscopy/spectroscopy (STM/STS).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bi2se3</infon>
          <location offset="223" length="6"/>
          <text>Bi2Se3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>323</offset>
        <text>While the typical surface termination occurs between two quintuple layers, we report the existence of a surface termination within a single quintuple layer where dangling bonds form with giant spin splitting owing to strong spin-orbit coupling.</text>
      </sentence>
      <sentence>
        <offset>568</offset>
        <text>Unlike Rashba split states in a 2D electron gas, these states are constrained by the band topology of the host insulator with topological properties similar to the typical topological surface state, and thereby offer an alternative candidate for spintronics usage.</text>
      </sentence>
      <sentence>
        <offset>833</offset>
        <text>We name these new states "topological dangling-bond states".</text>
      </sentence>
      <sentence>
        <offset>894</offset>
        <text>The degree of the spin polarization of these states is greatly enhanced.</text>
      </sentence>
      <sentence>
        <offset>967</offset>
        <text>Since dangling bonds are more chemically reactive, the observed topological dangling-bond states provide a new avenue for manipulating band dispersions and spin-textures by adsorbed atoms or molecules.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>2879901</id>
    <passage>
      <offset>0</offset>
      <text>Receptor-mediated pharmacodynamics of prednisolone in the rat.	A pharmacokinetic/pharmacodynamic model describing receptor-mediated effects of prednisolone is presented. The basis of the model is the generally accepted mechanism of action of steroid hormones in which corticosteroids bind to cytosolic receptors forming steroid-receptor complexes, which are activated and translocated into the nucleus. There the complexes associate with specific DNA sequences and modulate the rate of transcription of DNA into specific RNAs that code for the synthesis of proteins that elicit biological responses. Prednisolone, 5 or 50 mg/kg, was administered intravenously to adrenalectomized rats. Total plasma, free plasma, CBG-free plasma, and liver prednisolone concentrations were measured simultaneously with free hepatic cytosolic glucocorticoid receptor concentrations and tyrosine aminotransferase (TAT) activity of the liver as a function of time. The association/dissociation kinetics of prednisolone binding to the glucocorticoid receptor were measured separately in vitro at 37 degrees C. Total plasma, free plasma, and CBG-free plasma prednisolone concentrations could be used equally well in the model to account for the time course of receptor concentrations and TAT activity. However, use of liver steroid concentrations resulted in an overestimation of receptor depletion. Steroid concentrations in plasma increased 20 to 30-fold with a tenfold increase in dose, but receptor occupancy and TAT activity over time increased about threefold. While prednisolone pharmacokinetics were dose-dependent, parameters describing receptor kinetics and TAT activity were constant at each prednisolone dose. The major determinants of receptor-mediated glucocorticoid activity are confirmed to be the availability of the receptor, drug-receptor dissociation rate, and corticosteroid persistence in the biophase.</text>
      <sentence>
        <offset>0</offset>
        <text>Receptor-mediated pharmacodynamics of prednisolone in the rat.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="38" length="12"/>
          <text>prednisolone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>63</offset>
        <text>A pharmacokinetic/pharmacodynamic model describing receptor-mediated effects of prednisolone is presented.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="143" length="12"/>
          <text>prednisolone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>170</offset>
        <text>The basis of the model is the generally accepted mechanism of action of steroid hormones in which corticosteroids bind to cytosolic receptors forming steroid-receptor complexes, which are activated and translocated into the nucleus.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid hormones</infon>
          <location offset="242" length="16"/>
          <text>steroid hormones</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosteroids</infon>
          <location offset="268" length="15"/>
          <text>corticosteroids</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="320" length="7"/>
          <text>steroid</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytosolic receptors</infon>
          <location offset="292" length="19"/>
          <text>cytosolic receptors</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">steroid-receptor</infon>
          <location offset="320" length="16"/>
          <text>steroid-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>403</offset>
        <text>There the complexes associate with specific DNA sequences and modulate the rate of transcription of DNA into specific RNAs that code for the synthesis of proteins that elicit biological responses.</text>
      </sentence>
      <sentence>
        <offset>600</offset>
        <text>Prednisolone, 5 or 50 mg/kg, was administered intravenously to adrenalectomized rats.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="600" length="12"/>
          <text>Prednisolone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>686</offset>
        <text>Total plasma, free plasma, CBG-free plasma, and liver prednisolone concentrations were measured simultaneously with free hepatic cytosolic glucocorticoid receptor concentrations and tyrosine aminotransferase (TAT) activity of the liver as a function of time.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="740" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="868" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="825" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tyrosine aminotransferase</infon>
          <location offset="868" length="25"/>
          <text>tyrosine aminotransferase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tat</infon>
          <location offset="895" length="3"/>
          <text>TAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>945</offset>
        <text>The association/dissociation kinetics of prednisolone binding to the glucocorticoid receptor were measured separately in vitro at 37 degrees C.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="986" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="1014" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1089</offset>
        <text>Total plasma, free plasma, and CBG-free plasma prednisolone concentrations could be used equally well in the model to account for the time course of receptor concentrations and TAT activity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="1136" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tat</infon>
          <location offset="1266" length="3"/>
          <text>TAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1280</offset>
        <text>However, use of liver steroid concentrations resulted in an overestimation of receptor depletion.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="1302" length="7"/>
          <text>steroid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1378</offset>
        <text>Steroid concentrations in plasma increased 20 to 30-fold with a tenfold increase in dose, but receptor occupancy and TAT activity over time increased about threefold.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="1378" length="7"/>
          <text>Steroid</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tat</infon>
          <location offset="1495" length="3"/>
          <text>TAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1545</offset>
        <text>While prednisolone pharmacokinetics were dose-dependent, parameters describing receptor kinetics and TAT activity were constant at each prednisolone dose.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="1551" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="1681" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tat</infon>
          <location offset="1646" length="3"/>
          <text>TAT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1700</offset>
        <text>The major determinants of receptor-mediated glucocorticoid activity are confirmed to be the availability of the receptor, drug-receptor dissociation rate, and corticosteroid persistence in the biophase.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosteroid</infon>
          <location offset="1859" length="14"/>
          <text>corticosteroid</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23524160</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1.	A series of 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives was synthesized and their biological activity was evaluated. The chemical structures of the newly prepared compounds were confirmed by (1)H NMR, (13)C NMR and ESI-HRMS spectra data. All tested compounds proved to be potent 5-HT1A receptor and serotonin transporter protein (SERT) ligands. Among them, compounds 15, 18, 19 and 30 showed significant affinity for 5-HT1A and SERT. Computer docking simulations carried out for compounds 15, 31 and 32 to models of 5-HT1A receptor and SERT confirm the results of biological tests. Due to high affinity for the 5-HT1A receptor and moderate affinity for SERT, compounds 31, 32, 35, and 37 were evaluated for their affinity for D2L, 5-HT6, 5-HT7 and 5-HT2A receptors. In vivo tests, in turn, resulted in determining the functional activity of compounds 15, 18, 19 and 30 to the 5-HT1A receptor. The results of these tests indicate that all of the ligands possess properties characteristic of 5-HT1A receptor agonists.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrrolidine-2,5-dione</infon>
          <location offset="45" length="21"/>
          <text>pyrrolidine-2,5-dione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>115</offset>
        <text>Part 1.</text>
      </sentence>
      <sentence>
        <offset>123</offset>
        <text>A series of 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives was synthesized and their biological activity was evaluated.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-(1h-indol-3-yl)pyrrolidine-2,5-dione</infon>
          <location offset="135" length="38"/>
          <text>3-(1H-indol-3-yl)pyrrolidine-2,5-dione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>247</offset>
        <text>The chemical structures of the newly prepared compounds were confirmed by (1)H NMR, (13)C NMR and ESI-HRMS spectra data.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(1)h</infon>
          <location offset="321" length="4"/>
          <text>(1)H</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(13)c</infon>
          <location offset="331" length="5"/>
          <text>(13)C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>368</offset>
        <text>All tested compounds proved to be potent 5-HT1A receptor and serotonin transporter protein (SERT) ligands.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="429" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="409" length="6"/>
          <text>5-HT1A</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serotonin transporter protein</infon>
          <location offset="429" length="29"/>
          <text>serotonin transporter protein</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="460" length="4"/>
          <text>SERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>475</offset>
        <text>Among them, compounds 15, 18, 19 and 30 showed significant affinity for 5-HT1A and SERT.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="547" length="6"/>
          <text>5-HT1A</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="558" length="4"/>
          <text>SERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>564</offset>
        <text>Computer docking simulations carried out for compounds 15, 31 and 32 to models of 5-HT1A receptor and SERT confirm the results of biological tests.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="646" length="6"/>
          <text>5-HT1A</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="666" length="4"/>
          <text>SERT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>712</offset>
        <text>Due to high affinity for the 5-HT1A receptor and moderate affinity for SERT, compounds 31, 32, 35, and 37 were evaluated for their affinity for D2L, 5-HT6, 5-HT7 and 5-HT2A receptors.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="741" length="6"/>
          <text>5-HT1A</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sert</infon>
          <location offset="783" length="4"/>
          <text>SERT</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">d2l</infon>
          <location offset="856" length="3"/>
          <text>D2L</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht6</infon>
          <location offset="861" length="5"/>
          <text>5-HT6</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht7</infon>
          <location offset="868" length="5"/>
          <text>5-HT7</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2a</infon>
          <location offset="878" length="6"/>
          <text>5-HT2A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>896</offset>
        <text>In vivo tests, in turn, resulted in determining the functional activity of compounds 15, 18, 19 and 30 to the 5-HT1A receptor.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="1006" length="6"/>
          <text>5-HT1A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1023</offset>
        <text>The results of these tests indicate that all of the ligands possess properties characteristic of 5-HT1A receptor agonists.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="1120" length="6"/>
          <text>5-HT1A</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23311288</id>
    <passage>
      <offset>0</offset>
      <text>Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanine.	O(6)-Alkylguanine-DNA alkyltransferase (AGT) is a DNA repair protein which removes alkyl groups from the O-6 position of guanine, thereby providing strong resistance to anticancer agents which alkylate this position. The clinical usefulness of these anticancer agents would be substantially augmented if AGT could be selectively inhibited in tumor tissue, without a corresponding depletion in normal tissue. We report the synthesis of a new AGT inhibitor (5c) which selectively depletes AGT in hypoxic tumor cells.</text>
      <sentence>
        <offset>0</offset>
        <text>Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanine.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-(benzyloxy)-2-(aryldiazenyl)-9h-purines</infon>
          <location offset="104" length="41"/>
          <text>6-(benzyloxy)-2-(aryldiazenyl)-9H-purines</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o6-benzylguanine</infon>
          <location offset="161" length="16"/>
          <text>O6-benzylguanine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o6-alkylguanine</infon>
          <location offset="18" length="15"/>
          <text>O6-alkylguanine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">o6-alkylguanine-dna alkyltransferase</infon>
          <location offset="18" length="36"/>
          <text>O6-alkylguanine-DNA alkyltransferase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>179</offset>
        <text>O(6)-Alkylguanine-DNA alkyltransferase (AGT) is a DNA repair protein which removes alkyl groups from the O-6 position of guanine, thereby providing strong resistance to anticancer agents which alkylate this position.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o(6)-alkylguanine</infon>
          <location offset="179" length="17"/>
          <text>O(6)-Alkylguanine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">guanine</infon>
          <location offset="300" length="7"/>
          <text>guanine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">o(6)-alkylguanine-dna alkyltransferase</infon>
          <location offset="179" length="38"/>
          <text>O(6)-Alkylguanine-DNA alkyltransferase</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">agt</infon>
          <location offset="219" length="3"/>
          <text>AGT</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T6" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>396</offset>
        <text>The clinical usefulness of these anticancer agents would be substantially augmented if AGT could be selectively inhibited in tumor tissue, without a corresponding depletion in normal tissue.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">agt</infon>
          <location offset="483" length="3"/>
          <text>AGT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>587</offset>
        <text>We report the synthesis of a new AGT inhibitor (5c) which selectively depletes AGT in hypoxic tumor cells.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">agt</infon>
          <location offset="620" length="3"/>
          <text>AGT</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">agt</infon>
          <location offset="666" length="3"/>
          <text>AGT</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23282999</id>
    <passage>
      <offset>0</offset>
      <text>Zinc sulphate and vitamin E alleviate reproductive toxicity caused by aluminium sulphate in male albino rats.	This study was designed to investigate the reproductive toxicity of aluminium sulphate and the therapeutic effects of administration of zinc sulphate and vitamin E individually or in combination against the toxic effect caused by aluminium (Al) in male albino rats. The animals were divided into five groups: group 1 received distilled water and served as control; group 2 received only aluminium sulphate (50 mg/kg body weight (b.w.)); group 3 received aluminium sulphate (50 mg/kg b.w.) plus zinc sulphate (50 mg/kg b.w.); group 4 received aluminium sulphate (50 mg/kg b.w.) and vitamin E (15 mg/kg b.w.); group 5 received aluminium sulphate plus a combination of zinc sulphate and vitamin E in similar doses as above. Doses were administered orally once daily for 45 consecutive days. The results revealed that aluminium sulphate induced significant decrease in body weight gain and testis weight and significant increase in Al level in both serum and testes of male rats. Biochemical analysis showed significant decrease in serum total protein and phospholipids levels, while serum total lipid was significantly elevated post Al treatment. In addition, significant decrease in total protein, phospholipids and cholesterol levels in the testes of Al-treated rats was recorded. The data also showed significant decrease in the levels of serum testosterone, leutinizing hormone and follicle stimulating hormone and significant increase in the level of serum prolactin in Al-intoxicated rats. Moreover, histological examination showed that aluminium sulphate caused apparent alterations in the testicular structure of the treated animals. Treatment with zinc sulphate and vitamin E individually or in combination ameliorated the harmful effects of Al, which was proved histopathologically by the noticeable improvement in the testicular tissues. We can conclude that the tested dose of aluminium sulphate induced toxic effect on the reproductive system of male albino rats and the treatment with zinc sulphate and/or vitamin E alleviated these toxic effects. In some cases, vitamin E exerted a more potent effect, while in other cases, the more potent effect is related to zinc sulphate and the combination of both at most of the recorded data.</text>
      <sentence>
        <offset>0</offset>
        <text>Zinc sulphate and vitamin E alleviate reproductive toxicity caused by aluminium sulphate in male albino rats.</text>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc sulphate</infon>
          <location offset="0" length="13"/>
          <text>Zinc sulphate</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin e</infon>
          <location offset="18" length="9"/>
          <text>vitamin E</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium sulphate</infon>
          <location offset="70" length="18"/>
          <text>aluminium sulphate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>110</offset>
        <text>This study was designed to investigate the reproductive toxicity of aluminium sulphate and the therapeutic effects of administration of zinc sulphate and vitamin E individually or in combination against the toxic effect caused by aluminium (Al) in male albino rats.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc sulphate</infon>
          <location offset="246" length="13"/>
          <text>zinc sulphate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin e</infon>
          <location offset="264" length="9"/>
          <text>vitamin E</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium</infon>
          <location offset="340" length="9"/>
          <text>aluminium</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al</infon>
          <location offset="351" length="2"/>
          <text>Al</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium sulphate</infon>
          <location offset="178" length="18"/>
          <text>aluminium sulphate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>376</offset>
        <text>The animals were divided into five groups: group 1 received distilled water and served as control; group 2 received only aluminium sulphate (50 mg/kg body weight (b.w.)); group 3 received aluminium sulphate (50 mg/kg b.w.) plus zinc sulphate (50 mg/kg b.w.); group 4 received aluminium sulphate (50 mg/kg b.w.) and vitamin E (15 mg/kg b.w.); group 5 received aluminium sulphate plus a combination of zinc sulphate and vitamin E in similar doses as above.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium sulphate</infon>
          <location offset="497" length="18"/>
          <text>aluminium sulphate</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium sulphate</infon>
          <location offset="564" length="18"/>
          <text>aluminium sulphate</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc sulphate</infon>
          <location offset="604" length="13"/>
          <text>zinc sulphate</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium sulphate</infon>
          <location offset="652" length="18"/>
          <text>aluminium sulphate</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin e</infon>
          <location offset="691" length="9"/>
          <text>vitamin E</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium sulphate</infon>
          <location offset="735" length="18"/>
          <text>aluminium sulphate</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc sulphate</infon>
          <location offset="776" length="13"/>
          <text>zinc sulphate</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin e</infon>
          <location offset="794" length="9"/>
          <text>vitamin E</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>831</offset>
        <text>Doses were administered orally once daily for 45 consecutive days.</text>
      </sentence>
      <sentence>
        <offset>898</offset>
        <text>The results revealed that aluminium sulphate induced significant decrease in body weight gain and testis weight and significant increase in Al level in both serum and testes of male rats.</text>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium sulphate</infon>
          <location offset="924" length="18"/>
          <text>aluminium sulphate</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al</infon>
          <location offset="1038" length="2"/>
          <text>Al</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1086</offset>
        <text>Biochemical analysis showed significant decrease in serum total protein and phospholipids levels, while serum total lipid was significantly elevated post Al treatment.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al</infon>
          <location offset="1240" length="2"/>
          <text>Al</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1254</offset>
        <text>In addition, significant decrease in total protein, phospholipids and cholesterol levels in the testes of Al-treated rats was recorded.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1324" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al</infon>
          <location offset="1360" length="2"/>
          <text>Al</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1390</offset>
        <text>The data also showed significant decrease in the levels of serum testosterone, leutinizing hormone and follicle stimulating hormone and significant increase in the level of serum prolactin in Al-intoxicated rats.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">testosterone</infon>
          <location offset="1455" length="12"/>
          <text>testosterone</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al</infon>
          <location offset="1582" length="2"/>
          <text>Al</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">leutinizing hormone</infon>
          <location offset="1469" length="19"/>
          <text>leutinizing hormone</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">follicle stimulating hormone</infon>
          <location offset="1493" length="28"/>
          <text>follicle stimulating hormone</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">prolactin</infon>
          <location offset="1569" length="9"/>
          <text>prolactin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1603</offset>
        <text>Moreover, histological examination showed that aluminium sulphate caused apparent alterations in the testicular structure of the treated animals.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium sulphate</infon>
          <location offset="1650" length="18"/>
          <text>aluminium sulphate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1749</offset>
        <text>Treatment with zinc sulphate and vitamin E individually or in combination ameliorated the harmful effects of Al, which was proved histopathologically by the noticeable improvement in the testicular tissues.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc sulphate</infon>
          <location offset="1764" length="13"/>
          <text>zinc sulphate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin e</infon>
          <location offset="1782" length="9"/>
          <text>vitamin E</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al</infon>
          <location offset="1858" length="2"/>
          <text>Al</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1956</offset>
        <text>We can conclude that the tested dose of aluminium sulphate induced toxic effect on the reproductive system of male albino rats and the treatment with zinc sulphate and/or vitamin E alleviated these toxic effects.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aluminium sulphate</infon>
          <location offset="1996" length="18"/>
          <text>aluminium sulphate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc sulphate</infon>
          <location offset="2106" length="13"/>
          <text>zinc sulphate</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin e</infon>
          <location offset="2127" length="9"/>
          <text>vitamin E</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2169</offset>
        <text>In some cases, vitamin E exerted a more potent effect, while in other cases, the more potent effect is related to zinc sulphate and the combination of both at most of the recorded data.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin e</infon>
          <location offset="2184" length="9"/>
          <text>vitamin E</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc sulphate</infon>
          <location offset="2283" length="13"/>
          <text>zinc sulphate</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23603058</id>
    <passage>
      <offset>0</offset>
      <text>The Fusarium toxin deoxynivalenol (DON) modulates the LPS induced acute phase reaction in pigs.	The systemic effects of the Fusarium toxin deoxynivalenol (DON) and of bacterial lipopolysaccharides (LPS) were studied in male castrated pigs (40.4±3.7kg) infused intravenously with either DON or LPS alone (100μgDON/kg/h, 7.5μg/LPS/kg/h), or together (100μgDON plus 7.5μg/LPS/kg/h). The Control group received a saline infusion (n=6/treatment, 24h observation period). An additional DON infusion did not exacerbate the clinical signs observed in LPS-infused pigs. For example, rectal temperature climaxed after 4h (40.4±0.2°C) and 5h (40.1±0.3°C), in the LPS and LPS+DON groups, respectively. Saline and DON alone did not induce an acute phase reaction as indicated by unaltered plasma levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) while LPS caused a significant rise of both cytokines. TNF-alpha plasma peak concentrations were significantly higher in the LPS compared to the DON+LPS group (94.3±17.2ng/mL vs. 79.2±15.7ng/mL) while IL-6 climaxed earlier in the latter group (3h p.i. vs. 2h p.i.). From the tested clinical-chemical plasma characteristics the total bilirubin concentration and the ASAT activity were strongly elevated by the LPS infusion and additionally increased and decreased by DON, respectively. In conclusion, the LPS-induced effects were only marginally modified by DON.</text>
      <sentence>
        <offset>0</offset>
        <text>The Fusarium toxin deoxynivalenol (DON) modulates the LPS induced acute phase reaction in pigs.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deoxynivalenol</infon>
          <location offset="19" length="14"/>
          <text>deoxynivalenol</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="35" length="3"/>
          <text>DON</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>96</offset>
        <text>The systemic effects of the Fusarium toxin deoxynivalenol (DON) and of bacterial lipopolysaccharides (LPS) were studied in male castrated pigs (40.4±3.7kg) infused intravenously with either DON or LPS alone (100μgDON/kg/h, 7.5μg/LPS/kg/h), or together (100μgDON plus 7.5μg/LPS/kg/h).</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="286" length="3"/>
          <text>DON</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="309" length="3"/>
          <text>DON</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="354" length="3"/>
          <text>DON</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deoxynivalenol</infon>
          <location offset="139" length="14"/>
          <text>deoxynivalenol</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="155" length="3"/>
          <text>DON</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>380</offset>
        <text>The Control group received a saline infusion (n=6/treatment, 24h observation period).</text>
      </sentence>
      <sentence>
        <offset>466</offset>
        <text>An additional DON infusion did not exacerbate the clinical signs observed in LPS-infused pigs.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="480" length="3"/>
          <text>DON</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>561</offset>
        <text>For example, rectal temperature climaxed after 4h (40.4±0.2°C) and 5h (40.1±0.3°C), in the LPS and LPS+DON groups, respectively.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="664" length="3"/>
          <text>DON</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>690</offset>
        <text>Saline and DON alone did not induce an acute phase reaction as indicated by unaltered plasma levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) while LPS caused a significant rise of both cytokines.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="701" length="3"/>
          <text>DON</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor-alpha</infon>
          <location offset="793" length="27"/>
          <text>tumor necrosis factor-alpha</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="822" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin-6</infon>
          <location offset="837" length="13"/>
          <text>interleukin-6</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-6</infon>
          <location offset="852" length="4"/>
          <text>IL-6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>913</offset>
        <text>TNF-alpha plasma peak concentrations were significantly higher in the LPS compared to the DON+LPS group (94.3±17.2ng/mL vs. 79.2±15.7ng/mL) while IL-6 climaxed earlier in the latter group (3h p.i. vs. 2h p.i.).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="1003" length="3"/>
          <text>DON</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="913" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-6</infon>
          <location offset="1059" length="4"/>
          <text>IL-6</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1124</offset>
        <text>From the tested clinical-chemical plasma characteristics the total bilirubin concentration and the ASAT activity were strongly elevated by the LPS infusion and additionally increased and decreased by DON, respectively.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bilirubin</infon>
          <location offset="1191" length="9"/>
          <text>bilirubin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="1324" length="3"/>
          <text>DON</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">asat</infon>
          <location offset="1223" length="4"/>
          <text>ASAT</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1343</offset>
        <text>In conclusion, the LPS-induced effects were only marginally modified by DON.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">don</infon>
          <location offset="1415" length="3"/>
          <text>DON</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>7476290</id>
    <passage>
      <offset>0</offset>
      <text>Erythrocyte insulin and insulin-like growth factor-I receptor tyrosine kinase activity in hypertension in pregnancy.	We have shown that preeclampsia is associated with insulin resistance. In the present study, we examined young normal, preeclamptic (PE), and gestational hypertensive (GH) nulliparous African-American women at term to investigate cellular determinants of this resistance and insulin and insulin-like growth factor-I (IGF-I) binding to partially purified erythrocyte receptors and receptor tyrosine kinase activity (TKA). Blood pressure was significantly elevated in PE and GH subjects as compared with controls. Insulin binding was similar in number and affinity in the three groups (femtomoles per microgram). IGF-I binding was increased in PE subjects as compared with either normals or GH subjects (0.2 +/- 0.02, 0.15 +/- 0.01, and 0.14 +/- 0.02 fmol/microgram protein). Insulin receptor TKA was increased in PE subjects as compared with normals when assessed either per microgram protein or per femtomole insulin binding (P &lt; .01). In contrast, IGF-I-potentiated TKA was elevated in PE subjects only when assessed per microgram protein (P &lt; .03). Thus, the increased number of IGF-I receptors in erythrocytes of PE subjects yields a net increase in receptor tyrosine kinase. Also, there is an augmentation of insulin receptor TKA in PE subjects. Together, these two alterations may be a compensatory mechanism for the insulin resistance associated with hypertensive diseases of pregnancy.</text>
      <sentence>
        <offset>0</offset>
        <text>Erythrocyte insulin and insulin-like growth factor-I receptor tyrosine kinase activity in hypertension in pregnancy.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="62" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="12" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin-like growth factor-i receptor</infon>
          <location offset="24" length="37"/>
          <text>insulin-like growth factor-I receptor</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tyrosine kinase</infon>
          <location offset="62" length="15"/>
          <text>tyrosine kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>117</offset>
        <text>We have shown that preeclampsia is associated with insulin resistance.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="168" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>188</offset>
        <text>In the present study, we examined young normal, preeclamptic (PE), and gestational hypertensive (GH) nulliparous African-American women at term to investigate cellular determinants of this resistance and insulin and insulin-like growth factor-I (IGF-I) binding to partially purified erythrocyte receptors and receptor tyrosine kinase activity (TKA).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="506" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="392" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin-like growth factor-i</infon>
          <location offset="404" length="28"/>
          <text>insulin-like growth factor-I</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-i</infon>
          <location offset="434" length="5"/>
          <text>IGF-I</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">receptor tyrosine kinase</infon>
          <location offset="497" length="24"/>
          <text>receptor tyrosine kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>538</offset>
        <text>Blood pressure was significantly elevated in PE and GH subjects as compared with controls.</text>
      </sentence>
      <sentence>
        <offset>629</offset>
        <text>Insulin binding was similar in number and affinity in the three groups (femtomoles per microgram).</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="629" length="7"/>
          <text>Insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>728</offset>
        <text>IGF-I binding was increased in PE subjects as compared with either normals or GH subjects (0.2 +/- 0.02, 0.15 +/- 0.01, and 0.14 +/- 0.02 fmol/microgram protein).</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-i</infon>
          <location offset="728" length="5"/>
          <text>IGF-I</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>891</offset>
        <text>Insulin receptor TKA was increased in PE subjects as compared with normals when assessed either per microgram protein or per femtomole insulin binding (P &lt; .01).</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin receptor</infon>
          <location offset="891" length="16"/>
          <text>Insulin receptor</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1026" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1053</offset>
        <text>In contrast, IGF-I-potentiated TKA was elevated in PE subjects only when assessed per microgram protein (P &lt; .03).</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-i</infon>
          <location offset="1066" length="5"/>
          <text>IGF-I</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1168</offset>
        <text>Thus, the increased number of IGF-I receptors in erythrocytes of PE subjects yields a net increase in receptor tyrosine kinase.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="1279" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf-i receptors</infon>
          <location offset="1198" length="15"/>
          <text>IGF-I receptors</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">receptor tyrosine kinase</infon>
          <location offset="1270" length="24"/>
          <text>receptor tyrosine kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1296</offset>
        <text>Also, there is an augmentation of insulin receptor TKA in PE subjects.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin receptor</infon>
          <location offset="1330" length="16"/>
          <text>insulin receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1367</offset>
        <text>Together, these two alterations may be a compensatory mechanism for the insulin resistance associated with hypertensive diseases of pregnancy.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1439" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23583258</id>
    <passage>
      <offset>0</offset>
      <text>Phenolic compounds present in Sardinian wine extracts protect against the production of inflammatory cytokines induced by oxysterols in CaCo-2 human enterocyte-like cells.	Cholesterol auto-oxidation products, namely oxysterols, are widely present in cholesterol-rich foods. They are thought to potentially interfere with homeostasis of the human digestive tract, playing a role in intestinal mucosal damage. This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high cholesterol diet. This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive oxygen species through the colonic NADPH-oxidase NOX1 activation. Induction of NOX1 was markedly while not fully inhibited by CaCo-2 cell pre-incubation with phenolic extracts obtained from well-selected wines from typical grape varieties grown in Sardinia. Oxysterol-dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids. Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols. It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary oxysterols are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production. Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related NOX1 induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.</text>
      <sentence>
        <offset>0</offset>
        <text>Phenolic compounds present in Sardinian wine extracts protect against the production of inflammatory cytokines induced by oxysterols in CaCo-2 human enterocyte-like cells.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenolic</infon>
          <location offset="0" length="8"/>
          <text>Phenolic</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterols</infon>
          <location offset="122" length="10"/>
          <text>oxysterols</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>172</offset>
        <text>Cholesterol auto-oxidation products, namely oxysterols, are widely present in cholesterol-rich foods.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="172" length="11"/>
          <text>Cholesterol</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterols</infon>
          <location offset="216" length="10"/>
          <text>oxysterols</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="250" length="11"/>
          <text>cholesterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>274</offset>
        <text>They are thought to potentially interfere with homeostasis of the human digestive tract, playing a role in intestinal mucosal damage.</text>
      </sentence>
      <sentence>
        <offset>408</offset>
        <text>This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high cholesterol diet.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterols</infon>
          <location offset="580" length="10"/>
          <text>oxysterols</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="616" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">interleukins</infon>
          <location offset="528" length="12"/>
          <text>interleukins</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-6</infon>
          <location offset="542" length="4"/>
          <text>IL-6</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-8</infon>
          <location offset="551" length="4"/>
          <text>IL-8</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>634</offset>
        <text>This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive oxygen species through the colonic NADPH-oxidase NOX1 activation.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="790" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadph</infon>
          <location offset="825" length="5"/>
          <text>NADPH</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nadph-oxidase</infon>
          <location offset="825" length="13"/>
          <text>NADPH-oxidase</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox1</infon>
          <location offset="839" length="4"/>
          <text>NOX1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>856</offset>
        <text>Induction of NOX1 was markedly while not fully inhibited by CaCo-2 cell pre-incubation with phenolic extracts obtained from well-selected wines from typical grape varieties grown in Sardinia.</text>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox1</infon>
          <location offset="869" length="4"/>
          <text>NOX1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1048</offset>
        <text>Oxysterol-dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenolic acids</infon>
          <location offset="1233" length="14"/>
          <text>phenolic acids</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoids</infon>
          <location offset="1252" length="10"/>
          <text>flavonoids</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterol</infon>
          <location offset="1048" length="9"/>
          <text>Oxysterol</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox1</infon>
          <location offset="1068" length="4"/>
          <text>NOX1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">interleukin</infon>
          <location offset="1096" length="11"/>
          <text>interleukin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1264</offset>
        <text>Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterols</infon>
          <location offset="1468" length="10"/>
          <text>oxysterols</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox1</infon>
          <location offset="1383" length="4"/>
          <text>NOX1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">interleukin</infon>
          <location offset="1427" length="11"/>
          <text>interleukin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1480</offset>
        <text>It is thus likely that the effects of Sardinian wine extracts against intestinal inflammation induced by dietary oxysterols are mainly due to their high phenolic content: low doses of phenolics would be responsible only for direct scavenging oxysterol-dependent ROS production.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterols</infon>
          <location offset="1593" length="10"/>
          <text>oxysterols</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenolics</infon>
          <location offset="1664" length="9"/>
          <text>phenolics</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterol</infon>
          <location offset="1722" length="9"/>
          <text>oxysterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1758</offset>
        <text>Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related NOX1 induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenolic</infon>
          <location offset="1801" length="8"/>
          <text>phenolic</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterol</infon>
          <location offset="1896" length="9"/>
          <text>oxysterol</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxysterols</infon>
          <location offset="2019" length="10"/>
          <text>oxysterols</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nox1</infon>
          <location offset="1914" length="4"/>
          <text>NOX1</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23163726</id>
    <passage>
      <offset>0</offset>
      <text>The structure and properties of septin 3: a possible missing link in septin filament formation.	The human genome codes for 13 members of a family of filament-forming GTP-binding proteins known as septins. These have been divided into four different subgroups on the basis of sequence similarity. The differences between the subgroups are believed to control their correct assembly into heterofilaments which have specific roles in membrane remodelling events. Many different combinations of the 13 proteins are theoretically possible and it is therefore important to understand the structural basis of specific filament assembly. However, three-dimensional structures are currently available for only three of the four subgroups. In the present study we describe the crystal structure of a construct of human SEPT3 which belongs to the outstanding subgroup. This construct (SEPT3-GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis. In the crystal structure, SEPT3-GC forms foreshortened filaments which employ the same NC and G interfaces observed in the heterotrimeric complex of human septins 2, 6 and 7, reinforcing the notion of 'promiscuous' interactions described previously. In the present study we describe these two interfaces and relate the structure to its tendency to form monomers and its efficiency in the hydrolysis of GTP. The relevance of these results is emphasized by the fact that septins from the SEPT3 subgroup may be important determinants of polymerization by occupying the terminal position in octameric units which themselves form the building blocks of at least some heterofilaments.</text>
      <sentence>
        <offset>0</offset>
        <text>The structure and properties of septin 3: a possible missing link in septin filament formation.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">septin 3</infon>
          <location offset="32" length="8"/>
          <text>septin 3</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">septin</infon>
          <location offset="69" length="6"/>
          <text>septin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>96</offset>
        <text>The human genome codes for 13 members of a family of filament-forming GTP-binding proteins known as septins.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gtp</infon>
          <location offset="166" length="3"/>
          <text>GTP</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">septins</infon>
          <location offset="196" length="7"/>
          <text>septins</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gtp-binding proteins</infon>
          <location offset="166" length="20"/>
          <text>GTP-binding proteins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>205</offset>
        <text>These have been divided into four different subgroups on the basis of sequence similarity.</text>
      </sentence>
      <sentence>
        <offset>296</offset>
        <text>The differences between the subgroups are believed to control their correct assembly into heterofilaments which have specific roles in membrane remodelling events.</text>
      </sentence>
      <sentence>
        <offset>460</offset>
        <text>Many different combinations of the 13 proteins are theoretically possible and it is therefore important to understand the structural basis of specific filament assembly.</text>
      </sentence>
      <sentence>
        <offset>630</offset>
        <text>However, three-dimensional structures are currently available for only three of the four subgroups.</text>
      </sentence>
      <sentence>
        <offset>730</offset>
        <text>In the present study we describe the crystal structure of a construct of human SEPT3 which belongs to the outstanding subgroup.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human sept3</infon>
          <location offset="803" length="11"/>
          <text>human SEPT3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>858</offset>
        <text>This construct (SEPT3-GC), which includes the GTP-binding and C-terminal domains, purifies as a nucleotide-free monomer, allowing for its characterization in terms of GTP-binding and hydrolysis.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gtp</infon>
          <location offset="904" length="3"/>
          <text>GTP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c</infon>
          <location offset="920" length="1"/>
          <text>C</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotide</infon>
          <location offset="954" length="10"/>
          <text>nucleotide</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gtp</infon>
          <location offset="1025" length="3"/>
          <text>GTP</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sept3</infon>
          <location offset="874" length="5"/>
          <text>SEPT3</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gtp-binding and c-terminal domains</infon>
          <location offset="904" length="34"/>
          <text>GTP-binding and C-terminal domains</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1053</offset>
        <text>In the crystal structure, SEPT3-GC forms foreshortened filaments which employ the same NC and G interfaces observed in the heterotrimeric complex of human septins 2, 6 and 7, reinforcing the notion of 'promiscuous' interactions described previously.</text>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human septins 2, 6 and 7</infon>
          <location offset="1202" length="24"/>
          <text>human septins 2, 6 and 7</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sept3</infon>
          <location offset="1079" length="5"/>
          <text>SEPT3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1303</offset>
        <text>In the present study we describe these two interfaces and relate the structure to its tendency to form monomers and its efficiency in the hydrolysis of GTP.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gtp</infon>
          <location offset="1455" length="3"/>
          <text>GTP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1460</offset>
        <text>The relevance of these results is emphasized by the fact that septins from the SEPT3 subgroup may be important determinants of polymerization by occupying the terminal position in octameric units which themselves form the building blocks of at least some heterofilaments.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sept3</infon>
          <location offset="1539" length="5"/>
          <text>SEPT3</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23589499</id>
    <passage>
      <offset>0</offset>
      <text>MAO Inhibitory Activity of 2-Arylbenzofurans versus 3-Arylcoumarins: Synthesis, in vitro Study, and Docking Calculations.	Monoamine oxidase (MAO) is an important drug target for the treatment of neurological disorders. Several 3-arylcoumarin derivatives were previously described as interesting selective MAO-B inhibitors. Preserving the trans-stilbene structure, a series of 2-arylbenzofuran and corresponding 3-arylcoumarin derivatives were synthesized and evaluated as inhibitors of both MAO isoforms, MAO-A and MAO-B. In general, both types of derivatives were found to be selective MAO-B inhibitors, with IC50 values in the nano- to micromolar range. 5-Nitro-2-(4-methoxyphenyl)benzofuran (8) is the most active compound of the benzofuran series, presenting MAO-B selectivity and reversible inhibition (IC50 =140 nM). 3-(4'-Methoxyphenyl)-6-nitrocoumarin (15), with the same substitution pattern as that of compound 8, was found to be the most active MAO-B inhibitor of the coumarin series (IC50 =3 nM). However, 3-phenylcoumarin 14 showed activity in the same range (IC50 =6 nM), is reversible, and also severalfold more selective than compound 15. Docking experiments for the most active compounds into the MAO-B and MAO-A binding pockets highlighted different interactions between the derivative classes (2-arylbenzofurans and 3-arylcoumarins), and provided new information about the enzyme-inhibitor interaction and the potential therapeutic application of these scaffolds.</text>
      <sentence>
        <offset>0</offset>
        <text>MAO Inhibitory Activity of 2-Arylbenzofurans versus 3-Arylcoumarins: Synthesis, in vitro Study, and Docking Calculations.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-arylbenzofurans</infon>
          <location offset="27" length="17"/>
          <text>2-Arylbenzofurans</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-arylcoumarins</infon>
          <location offset="52" length="15"/>
          <text>3-Arylcoumarins</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mao</infon>
          <location offset="0" length="3"/>
          <text>MAO</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>122</offset>
        <text>Monoamine oxidase (MAO) is an important drug target for the treatment of neurological disorders.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="122" length="9"/>
          <text>Monoamine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">monoamine oxidase</infon>
          <location offset="122" length="17"/>
          <text>Monoamine oxidase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mao</infon>
          <location offset="141" length="3"/>
          <text>MAO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>219</offset>
        <text>Several 3-arylcoumarin derivatives were previously described as interesting selective MAO-B inhibitors.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-arylcoumarin</infon>
          <location offset="227" length="14"/>
          <text>3-arylcoumarin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="305" length="5"/>
          <text>MAO-B</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>323</offset>
        <text>Preserving the trans-stilbene structure, a series of 2-arylbenzofuran and corresponding 3-arylcoumarin derivatives were synthesized and evaluated as inhibitors of both MAO isoforms, MAO-A and MAO-B.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trans-stilbene</infon>
          <location offset="338" length="14"/>
          <text>trans-stilbene</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-arylbenzofuran</infon>
          <location offset="376" length="16"/>
          <text>2-arylbenzofuran</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-arylcoumarin</infon>
          <location offset="411" length="14"/>
          <text>3-arylcoumarin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mao</infon>
          <location offset="491" length="3"/>
          <text>MAO</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-a</infon>
          <location offset="505" length="5"/>
          <text>MAO-A</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="515" length="5"/>
          <text>MAO-B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>522</offset>
        <text>In general, both types of derivatives were found to be selective MAO-B inhibitors, with IC50 values in the nano- to micromolar range.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="587" length="5"/>
          <text>MAO-B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>656</offset>
        <text>5-Nitro-2-(4-methoxyphenyl)benzofuran (8) is the most active compound of the benzofuran series, presenting MAO-B selectivity and reversible inhibition (IC50 =140 nM).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-nitro-2-(4-methoxyphenyl)benzofuran</infon>
          <location offset="656" length="37"/>
          <text>5-Nitro-2-(4-methoxyphenyl)benzofuran</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzofuran</infon>
          <location offset="733" length="10"/>
          <text>benzofuran</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="763" length="5"/>
          <text>MAO-B</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>823</offset>
        <text>3-(4'-Methoxyphenyl)-6-nitrocoumarin (15), with the same substitution pattern as that of compound 8, was found to be the most active MAO-B inhibitor of the coumarin series (IC50 =3 nM).</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-(4'-methoxyphenyl)-6-nitrocoumarin</infon>
          <location offset="823" length="36"/>
          <text>3-(4'-Methoxyphenyl)-6-nitrocoumarin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coumarin</infon>
          <location offset="979" length="8"/>
          <text>coumarin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="956" length="5"/>
          <text>MAO-B</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1009</offset>
        <text>However, 3-phenylcoumarin 14 showed activity in the same range (IC50 =6 nM), is reversible, and also severalfold more selective than compound 15.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-phenylcoumarin</infon>
          <location offset="1018" length="16"/>
          <text>3-phenylcoumarin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1155</offset>
        <text>Docking experiments for the most active compounds into the MAO-B and MAO-A binding pockets highlighted different interactions between the derivative classes (2-arylbenzofurans and 3-arylcoumarins), and provided new information about the enzyme-inhibitor interaction and the potential therapeutic application of these scaffolds.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-arylbenzofurans</infon>
          <location offset="1313" length="17"/>
          <text>2-arylbenzofurans</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-arylcoumarins</infon>
          <location offset="1335" length="15"/>
          <text>3-arylcoumarins</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="1214" length="5"/>
          <text>MAO-B</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-a</infon>
          <location offset="1224" length="5"/>
          <text>MAO-A</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11430635</id>
    <passage>
      <offset>0</offset>
      <text>Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.	OBJECTIVES: In this paper we investigated the effect of indomethacin, acetazolamide and their combination in vitro and in vivo on carbonic anhydrase (CA) isozymes. METHOD: In vitro experiments followed the effect of the two substances at concentrations between 10(-8)-10(-4) M on purified human red cell CA I and II as well as on human gastric mucosa CA IV using dose-response relationships. Kinetic studies were also performed. The effects of single and combined administration of indomethacin and acetazolamide on red cell CA and on gastric acid secretion were studied in vivo. RESULTS: Indomethacin, in vitro and in vivo. induces an increase in erythorcyte CA I and CA II activity. Acetazolamide, a specific inhibitor of CA, reduces the activity of CA I and CA II from red cells. Indomethacin completely antagonizes CA activity, i.e. abolishes the inhibitory effect of acetazolamide on CA. In humans, an increase or decrease in erythrocyte CA II activity is correlated with an increase or decrease in gastric acid secretion. CONCLUSIONS: Our results show that indomethacin, a known cyclooxygenase (COX) inhibitor, is also an activator of CA. Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme. In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, CA activation induced by indomethacin might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.</text>
      <sentence>
        <offset>0</offset>
        <text>Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="0" length="12"/>
          <text>Indomethacin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetazolamide</infon>
          <location offset="114" length="13"/>
          <text>acetazolamide</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonic</infon>
          <location offset="23" length="8"/>
          <text>carbonic</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonic</infon>
          <location offset="85" length="8"/>
          <text>carbonic</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">carbonic anhydrase</infon>
          <location offset="23" length="18"/>
          <text>carbonic anhydrase</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">carbonic anhydrase</infon>
          <location offset="85" length="18"/>
          <text>carbonic anhydrase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>162</offset>
        <text>OBJECTIVES: In this paper we investigated the effect of indomethacin, acetazolamide and their combination in vitro and in vivo on carbonic anhydrase (CA) isozymes.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbonic</infon>
          <location offset="292" length="8"/>
          <text>carbonic</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="218" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetazolamide</infon>
          <location offset="232" length="13"/>
          <text>acetazolamide</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">carbonic anhydrase</infon>
          <location offset="292" length="18"/>
          <text>carbonic anhydrase</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ca</infon>
          <location offset="312" length="2"/>
          <text>CA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>326</offset>
        <text>METHOD: In vitro experiments followed the effect of the two substances at concentrations between 10(-8)-10(-4) M on purified human red cell CA I and II as well as on human gastric mucosa CA IV using dose-response relationships.</text>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human red cell ca i and ii</infon>
          <location offset="451" length="26"/>
          <text>human red cell CA I and II</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human gastric mucosa ca iv</infon>
          <location offset="492" length="26"/>
          <text>human gastric mucosa CA IV</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>554</offset>
        <text>Kinetic studies were also performed.</text>
      </sentence>
      <sentence>
        <offset>591</offset>
        <text>The effects of single and combined administration of indomethacin and acetazolamide on red cell CA and on gastric acid secretion were studied in vivo.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="644" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetazolamide</infon>
          <location offset="661" length="13"/>
          <text>acetazolamide</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ca</infon>
          <location offset="687" length="2"/>
          <text>CA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>742</offset>
        <text>RESULTS: Indomethacin, in vitro and in vivo.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="751" length="12"/>
          <text>Indomethacin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>787</offset>
        <text>induces an increase in erythorcyte CA I and CA II activity.</text>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ca i</infon>
          <location offset="822" length="4"/>
          <text>CA I</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ca ii</infon>
          <location offset="831" length="5"/>
          <text>CA II</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>847</offset>
        <text>Acetazolamide, a specific inhibitor of CA, reduces the activity of CA I and CA II from red cells.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetazolamide</infon>
          <location offset="847" length="13"/>
          <text>Acetazolamide</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ca</infon>
          <location offset="886" length="2"/>
          <text>CA</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ca i</infon>
          <location offset="914" length="4"/>
          <text>CA I</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ca ii</infon>
          <location offset="923" length="5"/>
          <text>CA II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>945</offset>
        <text>Indomethacin completely antagonizes CA activity, i.e. abolishes the inhibitory effect of acetazolamide on CA.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="945" length="12"/>
          <text>Indomethacin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetazolamide</infon>
          <location offset="1034" length="13"/>
          <text>acetazolamide</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ca</infon>
          <location offset="981" length="2"/>
          <text>CA</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ca</infon>
          <location offset="1051" length="2"/>
          <text>CA</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1055</offset>
        <text>In humans, an increase or decrease in erythrocyte CA II activity is correlated with an increase or decrease in gastric acid secretion.</text>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ca ii</infon>
          <location offset="1105" length="5"/>
          <text>CA II</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1190</offset>
        <text>CONCLUSIONS: Our results show that indomethacin, a known cyclooxygenase (COX) inhibitor, is also an activator of CA.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="1225" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyclooxygenase</infon>
          <location offset="1247" length="14"/>
          <text>cyclooxygenase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1263" length="3"/>
          <text>COX</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ca</infon>
          <location offset="1303" length="2"/>
          <text>CA</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1307</offset>
        <text>Our data also prove that indomethacin is not only an activator of CA but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="1332" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetazolamide</infon>
          <location offset="1411" length="13"/>
          <text>acetazolamide</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ca</infon>
          <location offset="1373" length="2"/>
          <text>CA</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1463</offset>
        <text>In view of the role of CA in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly, CA activation induced by indomethacin might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indomethacin</infon>
          <location offset="1709" length="12"/>
          <text>indomethacin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ca</infon>
          <location offset="1486" length="2"/>
          <text>CA</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ca</infon>
          <location offset="1684" length="2"/>
          <text>CA</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1745" length="3"/>
          <text>COX</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cox</infon>
          <location offset="1824" length="3"/>
          <text>COX</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>6687626</id>
    <passage>
      <offset>0</offset>
      <text>Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor cDNA.	The nonapeptide hormone oxytocin-like arginine-vasopressin (AVP) is synthesized as part of a larger precursor polypeptide. The precursor also includes the neurophysin molecule with which the hormone is associated in the neurosecretory granules of the hypothalamo-pituitary tract. A protein of molecular weight (Mr) approximately 20,000 has been isolated from supraoptic nuclei of rat hypothalami which, after tryptic cleavage, released a neurophysin-like molecule of Mr approximately 10,000 and an oligopeptide related to oxytocin. This result was complemented by in vitro translation of bovine hypothalamic mRNA. Among the primary translation products a single polypeptide of Mr approximately 16,500 was shown to contain antigenic determinants recognized by specific antisera against bovine neurophysin I and oxytocin. Here we report the amino acid sequence of the bovine oxytocin-neurophysin I (OT-NpI) precursor which was derived from sequence analysis of the cloned cDNA. As is the case for the bovine arginine-vasopressin-neurophysin II (AVP-NpII) precursor, the signal sequence of the OT-NpI precursor is immediately followed by the nonapeptide hormone which is connected to neurophysin I by a Gly-Lys-Arg sequence. A striking feature of the nucleic acid sequence is the 197-nucleotide long perfect homology with the AVP-NpII precursor mRNA sequence encoding the conserved middle part of neurophysins I and II.</text>
      <sentence>
        <offset>0</offset>
        <text>Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor cDNA.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="44" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="8" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bovine oxytocin-neurophysin i precursor</infon>
          <location offset="37" length="39"/>
          <text>bovine oxytocin-neurophysin I precursor</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>83</offset>
        <text>The nonapeptide hormone oxytocin-like arginine-vasopressin (AVP) is synthesized as part of a larger precursor polypeptide.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="107" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arginine</infon>
          <location offset="121" length="8"/>
          <text>arginine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vasopressin</infon>
          <location offset="130" length="11"/>
          <text>vasopressin</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avp</infon>
          <location offset="143" length="3"/>
          <text>AVP</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="107" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">arginine-vasopressin</infon>
          <location offset="121" length="20"/>
          <text>arginine-vasopressin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">avp</infon>
          <location offset="143" length="3"/>
          <text>AVP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>206</offset>
        <text>The precursor also includes the neurophysin molecule with which the hormone is associated in the neurosecretory granules of the hypothalamo-pituitary tract.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">neurophysin</infon>
          <location offset="238" length="11"/>
          <text>neurophysin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>363</offset>
        <text>A protein of molecular weight (Mr) approximately 20,000 has been isolated from supraoptic nuclei of rat hypothalami which, after tryptic cleavage, released a neurophysin-like molecule of Mr approximately 10,000 and an oligopeptide related to oxytocin.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="605" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">neurophysin</infon>
          <location offset="521" length="11"/>
          <text>neurophysin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="605" length="8"/>
          <text>oxytocin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>615</offset>
        <text>This result was complemented by in vitro translation of bovine hypothalamic mRNA.</text>
      </sentence>
      <sentence>
        <offset>697</offset>
        <text>Among the primary translation products a single polypeptide of Mr approximately 16,500 was shown to contain antigenic determinants recognized by specific antisera against bovine neurophysin I and oxytocin.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="893" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bovine neurophysin i</infon>
          <location offset="868" length="20"/>
          <text>bovine neurophysin I</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="893" length="8"/>
          <text>oxytocin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>903</offset>
        <text>Here we report the amino acid sequence of the bovine oxytocin-neurophysin I (OT-NpI) precursor which was derived from sequence analysis of the cloned cDNA.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="922" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxytocin</infon>
          <location offset="956" length="8"/>
          <text>oxytocin</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bovine oxytocin-neurophysin i (ot-npi) precursor</infon>
          <location offset="949" length="48"/>
          <text>bovine oxytocin-neurophysin I (OT-NpI) precursor</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T12" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1059</offset>
        <text>As is the case for the bovine arginine-vasopressin-neurophysin II (AVP-NpII) precursor, the signal sequence of the OT-NpI precursor is immediately followed by the nonapeptide hormone which is connected to neurophysin I by a Gly-Lys-Arg sequence.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arginine</infon>
          <location offset="1089" length="8"/>
          <text>arginine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vasopressin</infon>
          <location offset="1098" length="11"/>
          <text>vasopressin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avp</infon>
          <location offset="1126" length="3"/>
          <text>AVP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gly-lys-arg</infon>
          <location offset="1283" length="11"/>
          <text>Gly-Lys-Arg</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">avp-npii</infon>
          <location offset="1126" length="8"/>
          <text>AVP-NpII</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ot-npi</infon>
          <location offset="1174" length="6"/>
          <text>OT-NpI</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neurophysin i</infon>
          <location offset="1264" length="13"/>
          <text>neurophysin I</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gly-lys-arg</infon>
          <location offset="1283" length="11"/>
          <text>Gly-Lys-Arg</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bovine arginine-vasopressin-neurophysin ii (avp-npii) precursor</infon>
          <location offset="1082" length="63"/>
          <text>bovine arginine-vasopressin-neurophysin II (AVP-NpII) precursor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1305</offset>
        <text>A striking feature of the nucleic acid sequence is the 197-nucleotide long perfect homology with the AVP-NpII precursor mRNA sequence encoding the conserved middle part of neurophysins I and II.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">avp</infon>
          <location offset="1406" length="3"/>
          <text>AVP</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">avp-npii precursor</infon>
          <location offset="1406" length="18"/>
          <text>AVP-NpII precursor</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">neurophysins i and ii</infon>
          <location offset="1477" length="21"/>
          <text>neurophysins I and II</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23327533</id>
    <passage>
      <offset>0</offset>
      <text>Species-dependent metabolism of a novel selective α7 neuronal acetylcholine receptor agonist ABT-107.	Abstract 1. Metabolism of ABT-107 was investigated in in vitro hepatic systems, in rat and monkey receiving [(14)C]ABT-107, and in vivo plasma in rat, dog, monkey and human. 2. In in vitro hepatic systems, ABT-107 was primarily cleared via oxidative metabolism, and proceeded via two parallel pathways. Pathway 1, ABT-107 was oxidized at the nitrogen of quinuclidine moiety to form M1. Pathway 2, oxidation occurred at indole-containing moiety to form M2. Metabolism via N-oxidation was predominant in dog and rat, while in monkey and human, metabolism proceeded primarily via oxidation of indole-containing moiety. 3. ABT-107 was extensively metabolized in vivo in rat and monkey. M1 was primarily found in rat urine and bile; whereas, M2 was the major metabolite in monkey urine and feces. M1 was the predominant circulating metabolite in dog and rat. M2 was the primary circulating metabolite in monkey and human. 4. Enzymatic studies suggested M1 formation was primarily mediated by renal FMO1. CYP3A4, 1A2, 2J2 and 2D6 were primary enzymes catalyzing M2 formation. 5. Biotransformation of ABT-107 in human and monkey is markedly different from that in dog and rat, suggesting that monkey is an appropriate model for predicting human biotransformation and toxicology of ABT-107.</text>
      <sentence>
        <offset>0</offset>
        <text>Species-dependent metabolism of a novel selective α7 neuronal acetylcholine receptor agonist ABT-107.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="62" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">α7 neuronal acetylcholine receptor</infon>
          <location offset="50" length="34"/>
          <text>α7 neuronal acetylcholine receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>102</offset>
        <text>Abstract 1.</text>
      </sentence>
      <sentence>
        <offset>114</offset>
        <text>Metabolism of ABT-107 was investigated in in vitro hepatic systems, in rat and monkey receiving [(14)C]ABT-107, and in vivo plasma in rat, dog, monkey and human.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(14)c]abt-107</infon>
          <location offset="210" length="14"/>
          <text>[(14)C]ABT-107</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abt-107</infon>
          <location offset="128" length="7"/>
          <text>ABT-107</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>276</offset>
        <text>2. In in vitro hepatic systems, ABT-107 was primarily cleared via oxidative metabolism, and proceeded via two parallel pathways.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abt-107</infon>
          <location offset="308" length="7"/>
          <text>ABT-107</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>405</offset>
        <text>Pathway 1, ABT-107 was oxidized at the nitrogen of quinuclidine moiety to form M1.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abt-107</infon>
          <location offset="416" length="7"/>
          <text>ABT-107</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitrogen</infon>
          <location offset="444" length="8"/>
          <text>nitrogen</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quinuclidine</infon>
          <location offset="456" length="12"/>
          <text>quinuclidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>488</offset>
        <text>Pathway 2, oxidation occurred at indole-containing moiety to form M2.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indole</infon>
          <location offset="521" length="6"/>
          <text>indole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>558</offset>
        <text>Metabolism via N-oxidation was predominant in dog and rat, while in monkey and human, metabolism proceeded primarily via oxidation of indole-containing moiety.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="573" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indole</infon>
          <location offset="692" length="6"/>
          <text>indole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>718</offset>
        <text>3. ABT-107 was extensively metabolized in vivo in rat and monkey.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abt-107</infon>
          <location offset="721" length="7"/>
          <text>ABT-107</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>784</offset>
        <text>M1 was primarily found in rat urine and bile; whereas, M2 was the major metabolite in monkey urine and feces.</text>
      </sentence>
      <sentence>
        <offset>894</offset>
        <text>M1 was the predominant circulating metabolite in dog and rat.</text>
      </sentence>
      <sentence>
        <offset>956</offset>
        <text>M2 was the primary circulating metabolite in monkey and human.</text>
      </sentence>
      <sentence>
        <offset>1019</offset>
        <text>4. Enzymatic studies suggested M1 formation was primarily mediated by renal FMO1.</text>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fmo1</infon>
          <location offset="1095" length="4"/>
          <text>FMO1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1101</offset>
        <text>CYP3A4, 1A2, 2J2 and 2D6 were primary enzymes catalyzing M2 formation.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cyp3a4, 1a2, 2j2 and 2d6</infon>
          <location offset="1101" length="24"/>
          <text>CYP3A4, 1A2, 2J2 and 2D6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1172</offset>
        <text>5. Biotransformation of ABT-107 in human and monkey is markedly different from that in dog and rat, suggesting that monkey is an appropriate model for predicting human biotransformation and toxicology of ABT-107.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abt-107</infon>
          <location offset="1196" length="7"/>
          <text>ABT-107</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abt-107</infon>
          <location offset="1376" length="7"/>
          <text>ABT-107</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17427197</id>
    <passage>
      <offset>0</offset>
      <text>D-glucose stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium.	Elevated extracellular D-glucose increases transforming growth factor beta1 (TGF-beta1) release from human umbilical vein endothelium (HUVEC). TGF-beta1, via TGF-beta receptors I (TbetaRI) and TbetaRII, activates Smad2 and mitogen-activated protein kinases p44 and p42 (p42/44(mapk)). We studied whether D-glucose-stimulation of L-arginine transport and nitric oxide synthesis involves TGF-beta1 in primary cultures of HUVEC. TGF-beta1 release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) D-glucose. TGF-beta1 increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport. TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation. TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor). However, TGF-beta1 and high D-glucose were ineffective in cells expressing a truncated, negative dominant TbetaRII. High D-glucose increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC. Thus, TGF-beta1 could play a crucial role under conditions of hyperglycemia, such as gestational diabetes mellitus, which is associated with fetal endothelial dysfunction.</text>
      <sentence>
        <offset>0</offset>
        <text>D-glucose stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="0" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-arginine</infon>
          <location offset="25" length="10"/>
          <text>L-arginine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="50" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mitogen-activated protein kinases p42/44</infon>
          <location offset="100" length="40"/>
          <text>mitogen-activated protein kinases p42/44</text>
        </annotation>
        <annotation id="T58">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smad2</infon>
          <location offset="145" length="5"/>
          <text>Smad2</text>
        </annotation>
        <annotation id="T59">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">type ii tgf-beta receptors</infon>
          <location offset="172" length="26"/>
          <text>type II TGF-beta receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T58" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>236</offset>
        <text>Elevated extracellular D-glucose increases transforming growth factor beta1 (TGF-beta1) release from human umbilical vein endothelium (HUVEC).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="259" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">transforming growth factor beta1</infon>
          <location offset="279" length="32"/>
          <text>transforming growth factor beta1</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="313" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T53" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>379</offset>
        <text>TGF-beta1, via TGF-beta receptors I (TbetaRI) and TbetaRII, activates Smad2 and mitogen-activated protein kinases p44 and p42 (p42/44(mapk)).</text>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="379" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta receptors i</infon>
          <location offset="394" length="20"/>
          <text>TGF-beta receptors I</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tbetari</infon>
          <location offset="416" length="7"/>
          <text>TbetaRI</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tbetarii</infon>
          <location offset="429" length="8"/>
          <text>TbetaRII</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smad2</infon>
          <location offset="449" length="5"/>
          <text>Smad2</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mitogen-activated protein kinases</infon>
          <location offset="459" length="33"/>
          <text>mitogen-activated protein kinases</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p44</infon>
          <location offset="493" length="3"/>
          <text>p44</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p42</infon>
          <location offset="501" length="3"/>
          <text>p42</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p42/44</infon>
          <location offset="506" length="6"/>
          <text>p42/44</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="513" length="4"/>
          <text>mapk</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>521</offset>
        <text>We studied whether D-glucose-stimulation of L-arginine transport and nitric oxide synthesis involves TGF-beta1 in primary cultures of HUVEC.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="540" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-arginine</infon>
          <location offset="565" length="10"/>
          <text>L-arginine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nitric oxide</infon>
          <location offset="590" length="12"/>
          <text>nitric oxide</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="622" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>662</offset>
        <text>TGF-beta1 release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) D-glucose.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="761" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="662" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>772</offset>
        <text>TGF-beta1 increases L-arginine transport (half maximal effect approximately 1.6 ng/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-arginine</infon>
          <location offset="792" length="10"/>
          <text>L-arginine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="869" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="903" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-arginine</infon>
          <location offset="923" length="10"/>
          <text>L-arginine</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="772" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>945</offset>
        <text>TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="964" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-[(3)h]citrulline</infon>
          <location offset="1072" length="18"/>
          <text>L-[(3)H]citrulline</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-[(3)h]arginine</infon>
          <location offset="1106" length="16"/>
          <text>L-[(3)H]arginine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="1133" length="2"/>
          <text>NO</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">no</infon>
          <location offset="1163" length="2"/>
          <text>NO</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="945" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hcat-1</infon>
          <location offset="984" length="6"/>
          <text>hCAT-1</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">endothelial no synthase</infon>
          <location offset="1151" length="23"/>
          <text>endothelial NO synthase</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">enos</infon>
          <location offset="1176" length="4"/>
          <text>eNOS</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">enos</infon>
          <location offset="1219" length="4"/>
          <text>eNOS</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T52" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T18" role="head"/>
          <node refid="T55" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T18" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1241</offset>
        <text>TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="1260" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pd-98059</infon>
          <location offset="1341" length="8"/>
          <text>PD-98059</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="1241" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p42/44</infon>
          <location offset="1280" length="6"/>
          <text>p42/44</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1287" length="4"/>
          <text>mapk</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smad2</infon>
          <location offset="1297" length="5"/>
          <text>Smad2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mek1/2</infon>
          <location offset="1351" length="6"/>
          <text>MEK1/2</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1370</offset>
        <text>However, TGF-beta1 and high D-glucose were ineffective in cells expressing a truncated, negative dominant TbetaRII.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="1398" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="1379" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tbetarii</infon>
          <location offset="1476" length="8"/>
          <text>TbetaRII</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1486</offset>
        <text>High D-glucose increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-glucose</infon>
          <location offset="1491" length="9"/>
          <text>D-glucose</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-arginine</infon>
          <location offset="1511" length="10"/>
          <text>L-arginine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">enos</infon>
          <location offset="1536" length="4"/>
          <text>eNOS</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tbetarii</infon>
          <location offset="1562" length="8"/>
          <text>TbetaRII</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="1585" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p42/44</infon>
          <location offset="1605" length="6"/>
          <text>p42/44</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mapk</infon>
          <location offset="1612" length="4"/>
          <text>mapk</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smad2</infon>
          <location offset="1622" length="5"/>
          <text>Smad2</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1638</offset>
        <text>Thus, TGF-beta1 could play a crucial role under conditions of hyperglycemia, such as gestational diabetes mellitus, which is associated with fetal endothelial dysfunction.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tgf-beta1</infon>
          <location offset="1644" length="9"/>
          <text>TGF-beta1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23050902</id>
    <passage>
      <offset>0</offset>
      <text>Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression.	Coagulation FVII (Factor VII) is a vitamin K-dependent glycoprotein synthesized in hepatocytes. It was reported previously that FVII gene (F7) expression was up-regulated by ribavirin treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown. In the present study, we investigated the molecular mechanism of ribavirin-induced up-regulation of F7 expression in HepG2 (human hepatoma cell line). We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression. FVII mRNA transcription was mainly enhanced by accelerated transcription elongation, which was mediated by the P-TEFb (positive-transcription elongation factor b) complex, rather than by promoter activation. Ribavirin unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation. We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation. Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to F7. These data suggest that ribavirin-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation. Collectively, we have elucidated a basal mechanism for ribavirin-induced FVII mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in vivo.</text>
      <sentence>
        <offset>0</offset>
        <text>Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="0" length="9"/>
          <text>Ribavirin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gtp</infon>
          <location offset="32" length="3"/>
          <text>GTP</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">coagulation factor vii</infon>
          <location offset="84" length="22"/>
          <text>coagulation factor VII</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>124</offset>
        <text>Coagulation FVII (Factor VII) is a vitamin K-dependent glycoprotein synthesized in hepatocytes.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin k</infon>
          <location offset="159" length="9"/>
          <text>vitamin K</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">coagulation fvii</infon>
          <location offset="124" length="16"/>
          <text>Coagulation FVII</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor vii</infon>
          <location offset="142" length="10"/>
          <text>Factor VII</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>220</offset>
        <text>It was reported previously that FVII gene (F7) expression was up-regulated by ribavirin treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="298" length="9"/>
          <text>ribavirin</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fvii</infon>
          <location offset="252" length="4"/>
          <text>FVII</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">f7</infon>
          <location offset="263" length="2"/>
          <text>F7</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>419</offset>
        <text>In the present study, we investigated the molecular mechanism of ribavirin-induced up-regulation of F7 expression in HepG2 (human hepatoma cell line).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="484" length="9"/>
          <text>ribavirin</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">f7</infon>
          <location offset="519" length="2"/>
          <text>F7</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>570</offset>
        <text>We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gtp</infon>
          <location offset="598" length="3"/>
          <text>GTP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="615" length="9"/>
          <text>ribavirin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">inosine-5'-monophosphate</infon>
          <location offset="649" length="24"/>
          <text>inosine-5'-monophosphate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mycophenolic acid</infon>
          <location offset="709" length="17"/>
          <text>mycophenolic acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-mercaptopurine</infon>
          <location offset="731" length="16"/>
          <text>6-mercaptopurine</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">impdh</infon>
          <location offset="642" length="5"/>
          <text>IMPDH</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">inosine-5'-monophosphate dehydrogenase</infon>
          <location offset="649" length="38"/>
          <text>inosine-5'-monophosphate dehydrogenase</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">f7</infon>
          <location offset="762" length="2"/>
          <text>F7</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>777</offset>
        <text>FVII mRNA transcription was mainly enhanced by accelerated transcription elongation, which was mediated by the P-TEFb (positive-transcription elongation factor b) complex, rather than by promoter activation.</text>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fvii</infon>
          <location offset="777" length="4"/>
          <text>FVII</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-tefb</infon>
          <location offset="888" length="6"/>
          <text>P-TEFb</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">positive-transcription elongation factor b</infon>
          <location offset="896" length="42"/>
          <text>positive-transcription elongation factor b</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>985</offset>
        <text>Ribavirin unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="985" length="9"/>
          <text>Ribavirin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lysine</infon>
          <location offset="1028" length="6"/>
          <text>lysine</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ell</infon>
          <location offset="1007" length="3"/>
          <text>ELL</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">eleven-nineteen lysine-rich leukaemia) 3</infon>
          <location offset="1012" length="40"/>
          <text>eleven-nineteen lysine-rich leukaemia) 3</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">f7</infon>
          <location offset="1076" length="2"/>
          <text>F7</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T45" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1094</offset>
        <text>We observed that ribavirin enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished ribavirin-induced FVII mRNA up-regulation.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="1191" length="9"/>
          <text>ribavirin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="1111" length="9"/>
          <text>ribavirin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ell3</infon>
          <location offset="1130" length="4"/>
          <text>ELL3</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">f7</infon>
          <location offset="1150" length="2"/>
          <text>F7</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ell3</infon>
          <location offset="1175" length="4"/>
          <text>ELL3</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fvii</infon>
          <location offset="1209" length="4"/>
          <text>FVII</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1234</offset>
        <text>Ribavirin also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to F7.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="1234" length="9"/>
          <text>Ribavirin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cdk9</infon>
          <location offset="1273" length="4"/>
          <text>CDK9</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin-dependent kinase 9</infon>
          <location offset="1279" length="25"/>
          <text>cyclin-dependent kinase 9</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aff4</infon>
          <location offset="1310" length="4"/>
          <text>AFF4</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">f7</infon>
          <location offset="1318" length="2"/>
          <text>F7</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1322</offset>
        <text>These data suggest that ribavirin-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="1346" length="9"/>
          <text>ribavirin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gtp</infon>
          <location offset="1378" length="3"/>
          <text>GTP</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-tefb</infon>
          <location offset="1439" length="6"/>
          <text>P-TEFb</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aff4</infon>
          <location offset="1447" length="4"/>
          <text>AFF4</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ell3</infon>
          <location offset="1456" length="4"/>
          <text>ELL3</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">f7</infon>
          <location offset="1465" length="2"/>
          <text>F7</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fvii</infon>
          <location offset="1483" length="4"/>
          <text>FVII</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1519</offset>
        <text>Collectively, we have elucidated a basal mechanism for ribavirin-induced FVII mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in vivo.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ribavirin</infon>
          <location offset="1574" length="9"/>
          <text>ribavirin</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fvii</infon>
          <location offset="1592" length="4"/>
          <text>FVII</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15325927</id>
    <passage>
      <offset>0</offset>
      <text>Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.	Although the benefits of carvedilol in patients with heart failure and depressed ejection fraction (EF) have been elucidated, those in patients with preserved EF are not understood. We enrolled 40 patients with mild or moderate heart failure and EF &gt;/=45%. They were randomly assigned to carvedilol (n = 19) or conventional therapy (n = 21). After 12 months of treatment, carvedilol significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p &lt;0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p &lt;0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p &lt;0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs). Univariate regression analyses showed that only the use of carvedilol was correlated with the decrease in plasma BNP concentration (p &lt;0.03). Multivariate analyses demonstrated that an ischemic cause of heart failure (p &lt;0.02), high plasma concentration of BNP (p &lt;0.02), left ventricular dilation (p &lt;0.03), and use of carvedilol (p &lt;0.04) at baseline were predictive of a decrease in plasma concentration of BNP. In conclusion, carvedilol potentially decreased neurohumoral activation, decreased symptoms, and increased exercise capacity in patients with heart failure and preserved EF.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="11" length="10"/>
          <text>carvedilol</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasma b-type natriuretic peptide</infon>
          <location offset="25" length="33"/>
          <text>plasma B-type natriuretic peptide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>150</offset>
        <text>Although the benefits of carvedilol in patients with heart failure and depressed ejection fraction (EF) have been elucidated, those in patients with preserved EF are not understood.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="175" length="10"/>
          <text>carvedilol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>332</offset>
        <text>We enrolled 40 patients with mild or moderate heart failure and EF &gt;/=45%.</text>
      </sentence>
      <sentence>
        <offset>407</offset>
        <text>They were randomly assigned to carvedilol (n = 19) or conventional therapy (n = 21).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="438" length="10"/>
          <text>carvedilol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>492</offset>
        <text>After 12 months of treatment, carvedilol significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p &lt;0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p &lt;0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p &lt;0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="522" length="10"/>
          <text>carvedilol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">b-type natriuretic peptide</infon>
          <location offset="596" length="26"/>
          <text>B-type natriuretic peptide</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bnp</infon>
          <location offset="624" length="3"/>
          <text>BNP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasma bnp</infon>
          <location offset="981" length="10"/>
          <text>plasma BNP</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1221</offset>
        <text>Univariate regression analyses showed that only the use of carvedilol was correlated with the decrease in plasma BNP concentration (p &lt;0.03).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="1280" length="10"/>
          <text>carvedilol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasma bnp</infon>
          <location offset="1327" length="10"/>
          <text>plasma BNP</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1363</offset>
        <text>Multivariate analyses demonstrated that an ischemic cause of heart failure (p &lt;0.02), high plasma concentration of BNP (p &lt;0.02), left ventricular dilation (p &lt;0.03), and use of carvedilol (p &lt;0.04) at baseline were predictive of a decrease in plasma concentration of BNP.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="1541" length="10"/>
          <text>carvedilol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bnp</infon>
          <location offset="1478" length="3"/>
          <text>BNP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bnp</infon>
          <location offset="1631" length="3"/>
          <text>BNP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1636</offset>
        <text>In conclusion, carvedilol potentially decreased neurohumoral activation, decreased symptoms, and increased exercise capacity in patients with heart failure and preserved EF.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="1651" length="10"/>
          <text>carvedilol</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23403537</id>
    <passage>
      <offset>0</offset>
      <text>Accurate quantum chemical energies for tetrapeptide conformations: why MP2 data with an insufficient basis set should be handled with caution.	High-level quantum chemical calculations have been carried out for biologically-relevant conformers of tetrapeptides. Our results indicate potential problems if the widely-applied MP2 approach is used in such situations with basis sets of insufficient size. Efficient alternatives are discussed.</text>
      <sentence>
        <offset>0</offset>
        <text>Accurate quantum chemical energies for tetrapeptide conformations: why MP2 data with an insufficient basis set should be handled with caution.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetrapeptide</infon>
          <location offset="39" length="12"/>
          <text>tetrapeptide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>143</offset>
        <text>High-level quantum chemical calculations have been carried out for biologically-relevant conformers of tetrapeptides.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetrapeptides</infon>
          <location offset="246" length="13"/>
          <text>tetrapeptides</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>261</offset>
        <text>Our results indicate potential problems if the widely-applied MP2 approach is used in such situations with basis sets of insufficient size.</text>
      </sentence>
      <sentence>
        <offset>401</offset>
        <text>Efficient alternatives are discussed.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>9673855</id>
    <passage>
      <offset>0</offset>
      <text>Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.	Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's disease. As the first MAO-B inhibitor approved for the treatment of Parkinson's disease, concerns were raised about the safety of the drug based on the adverse effect profiles of older, nonselective MAO inhibitors. Unlike the nonselective MAO inhibitors, selegiline does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease. Selegiline has been well tolerated when given alone. The most frequent adverse events seen during monotherapy have been insomnia, nausea, benign cardiac arrhythmias, dizziness and headache. When combined with levodopa, selegiline can potentiate the typical adverse effects of levodopa, if the dose of levodopa is not reduced sufficiently. Thus, the most common adverse effects associated with this combination are nausea, dizziness, fatigue, constipation and insomnia. At the later stages of Parkinson's disease when fluctuations in disability occur, peak dose dyskinesias, psychiatric complications like hallucinations and insomnia, and orthostatic hypotension are further potentiated by selegiline. Mortality was recently reported to be increased when selegiline and levodopa were given together in comparison with treatment with levodopa alone, but a large meta-analysis of 5 long term studies and 4 separate studies did not support this conclusion. Selegiline seems to be generally well tolerated in combination with other drugs. However, when pethidine (meperidine) has been given to patients who are receiving selegiline therapy, severe adverse effects have been reported. Thus, the concomitant use of these drugs is not recommended. A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible MAO-A inhibitor, moclobemide. Several adverse effects have been reported when fluoxetine and selegiline have been used together. A recent survey revealed that the incidence of a true serotonin syndrome is, however, very low with this combination. Concomitant use of selegiline and other selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) like citalopram, which have generally less interactions than fluoxetine, seems to be well tolerated. Nevertheless, caution is advised when combining a SSRI or a tricyclic antidepressant and selegiline.</text>
      <sentence>
        <offset>0</offset>
        <text>Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.</text>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="10" length="10"/>
          <text>selegiline</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deprenyl</infon>
          <location offset="22" length="8"/>
          <text>deprenyl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>73</offset>
        <text>Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's disease.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="73" length="10"/>
          <text>Selegiline</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deprenyl</infon>
          <location offset="85" length="8"/>
          <text>deprenyl</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoamine</infon>
          <location offset="135" length="9"/>
          <text>monoamine</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monoamine oxidase type b</infon>
          <location offset="135" length="24"/>
          <text>monoamine oxidase type B</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="161" length="5"/>
          <text>MAO-B</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T41" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>224</offset>
        <text>As the first MAO-B inhibitor approved for the treatment of Parkinson's disease, concerns were raised about the safety of the drug based on the adverse effect profiles of older, nonselective MAO inhibitors.</text>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-b</infon>
          <location offset="237" length="5"/>
          <text>MAO-B</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mao</infon>
          <location offset="414" length="3"/>
          <text>MAO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>430</offset>
        <text>Unlike the nonselective MAO inhibitors, selegiline does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="470" length="10"/>
          <text>selegiline</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyramine</infon>
          <location offset="515" length="8"/>
          <text>tyramine</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mao</infon>
          <location offset="454" length="3"/>
          <text>MAO</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T25" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>648</offset>
        <text>Selegiline has been well tolerated when given alone.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="648" length="10"/>
          <text>Selegiline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>701</offset>
        <text>The most frequent adverse events seen during monotherapy have been insomnia, nausea, benign cardiac arrhythmias, dizziness and headache.</text>
      </sentence>
      <sentence>
        <offset>838</offset>
        <text>When combined with levodopa, selegiline can potentiate the typical adverse effects of levodopa, if the dose of levodopa is not reduced sufficiently.</text>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="857" length="8"/>
          <text>levodopa</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="867" length="10"/>
          <text>selegiline</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="924" length="8"/>
          <text>levodopa</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="949" length="8"/>
          <text>levodopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>987</offset>
        <text>Thus, the most common adverse effects associated with this combination are nausea, dizziness, fatigue, constipation and insomnia.</text>
      </sentence>
      <sentence>
        <offset>1117</offset>
        <text>At the later stages of Parkinson's disease when fluctuations in disability occur, peak dose dyskinesias, psychiatric complications like hallucinations and insomnia, and orthostatic hypotension are further potentiated by selegiline.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="1337" length="10"/>
          <text>selegiline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1349</offset>
        <text>Mortality was recently reported to be increased when selegiline and levodopa were given together in comparison with treatment with levodopa alone, but a large meta-analysis of 5 long term studies and 4 separate studies did not support this conclusion.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="1402" length="10"/>
          <text>selegiline</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="1417" length="8"/>
          <text>levodopa</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">levodopa</infon>
          <location offset="1480" length="8"/>
          <text>levodopa</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1601</offset>
        <text>Selegiline seems to be generally well tolerated in combination with other drugs.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="1601" length="10"/>
          <text>Selegiline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1682</offset>
        <text>However, when pethidine (meperidine) has been given to patients who are receiving selegiline therapy, severe adverse effects have been reported.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pethidine</infon>
          <location offset="1696" length="9"/>
          <text>pethidine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">meperidine</infon>
          <location offset="1707" length="10"/>
          <text>meperidine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="1764" length="10"/>
          <text>selegiline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1827</offset>
        <text>Thus, the concomitant use of these drugs is not recommended.</text>
      </sentence>
      <sentence>
        <offset>1888</offset>
        <text>A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyramine</infon>
          <location offset="1894" length="8"/>
          <text>tyramine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="1926" length="10"/>
          <text>selegiline</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">moclobemide</infon>
          <location offset="2033" length="11"/>
          <text>moclobemide</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mao</infon>
          <location offset="1972" length="3"/>
          <text>MAO</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mao-a</infon>
          <location offset="2016" length="5"/>
          <text>MAO-A</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2046</offset>
        <text>Several adverse effects have been reported when fluoxetine and selegiline have been used together.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="2094" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="2109" length="10"/>
          <text>selegiline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2145</offset>
        <text>A recent survey revealed that the incidence of a true serotonin syndrome is, however, very low with this combination.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="2199" length="9"/>
          <text>serotonin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2263</offset>
        <text>Concomitant use of selegiline and other selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) like citalopram, which have generally less interactions than fluoxetine, seems to be well tolerated.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="2282" length="10"/>
          <text>selegiline</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="2313" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-hydroxytryptamine</infon>
          <location offset="2324" length="19"/>
          <text>5-hydroxytryptamine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="2345" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">citalopram</infon>
          <location offset="2384" length="10"/>
          <text>citalopram</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="2440" length="10"/>
          <text>fluoxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2480</offset>
        <text>Nevertheless, caution is advised when combining a SSRI or a tricyclic antidepressant and selegiline.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tricyclic</infon>
          <location offset="2540" length="9"/>
          <text>tricyclic</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">selegiline</infon>
          <location offset="2569" length="10"/>
          <text>selegiline</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23607964</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis and antiprogestational properties of novel 17-fluorinated steroids.	Progesterone receptor (PR) plays a key role in reproductive functions, and compounds that inhibit progesterone action (antiprogestins) have potential use in the treatment of estrogen- and progesterone-dependent diseases, including uterine leiomyomas and breast cancer. In the present study, we chemically synthesized novel 17-fluorinated steroids and evaluated the cytotoxicity profiles of these compounds in T47D breast cancer cells compared to the activity of known antiprogestins, including ZK230 211, RU-486, CDB2914, CDB4124 and ORG33628. We analyzed in vitro receptor-binding assays and PR-transactivation assays to establish the antiprogestational activity of these molecules. The representative antiprogestin EC304 was found to inhibit in vitro tumorigenicity in a dose-dependent fashion in T47D cells by a colony formation assay at 1 and 10nM concentrations. The potent in vivo antiprogestational activity of EC304 was also demonstrated in an antinidation assay for the interruption of early pregnancy in rats. The strong antiprogestational activity and absence of antiglucocorticoid activity in EC compounds may demonstrate their utility in the treatment of leiomyoma, endometriosis and breast cancer.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis and antiprogestational properties of novel 17-fluorinated steroids.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">17-fluorinated steroids</infon>
          <location offset="53" length="23"/>
          <text>17-fluorinated steroids</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>78</offset>
        <text>Progesterone receptor (PR) plays a key role in reproductive functions, and compounds that inhibit progesterone action (antiprogestins) have potential use in the treatment of estrogen- and progesterone-dependent diseases, including uterine leiomyomas and breast cancer.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="78" length="12"/>
          <text>Progesterone</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">antiprogestins</infon>
          <location offset="197" length="14"/>
          <text>antiprogestins</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="252" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="266" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="176" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptor</infon>
          <location offset="78" length="21"/>
          <text>Progesterone receptor</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="101" length="2"/>
          <text>PR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>347</offset>
        <text>In the present study, we chemically synthesized novel 17-fluorinated steroids and evaluated the cytotoxicity profiles of these compounds in T47D breast cancer cells compared to the activity of known antiprogestins, including ZK230 211, RU-486, CDB2914, CDB4124 and ORG33628.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">17-fluorinated steroids</infon>
          <location offset="401" length="23"/>
          <text>17-fluorinated steroids</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">antiprogestins</infon>
          <location offset="546" length="14"/>
          <text>antiprogestins</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zk230 211</infon>
          <location offset="572" length="9"/>
          <text>ZK230 211</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ru-486</infon>
          <location offset="583" length="6"/>
          <text>RU-486</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb2914</infon>
          <location offset="591" length="7"/>
          <text>CDB2914</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cdb4124</infon>
          <location offset="600" length="7"/>
          <text>CDB4124</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">org33628</infon>
          <location offset="612" length="8"/>
          <text>ORG33628</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>622</offset>
        <text>We analyzed in vitro receptor-binding assays and PR-transactivation assays to establish the antiprogestational activity of these molecules.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="671" length="2"/>
          <text>PR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>762</offset>
        <text>The representative antiprogestin EC304 was found to inhibit in vitro tumorigenicity in a dose-dependent fashion in T47D cells by a colony formation assay at 1 and 10nM concentrations.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ec304</infon>
          <location offset="795" length="5"/>
          <text>EC304</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>946</offset>
        <text>The potent in vivo antiprogestational activity of EC304 was also demonstrated in an antinidation assay for the interruption of early pregnancy in rats.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ec304</infon>
          <location offset="996" length="5"/>
          <text>EC304</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1098</offset>
        <text>The strong antiprogestational activity and absence of antiglucocorticoid activity in EC compounds may demonstrate their utility in the treatment of leiomyoma, endometriosis and breast cancer.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10430100</id>
    <passage>
      <offset>0</offset>
      <text>Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.	We studied the antitumor activity and toxicity of ZD1694 (tomudex), a specific inhibitor of thymidylate synthase (TS), in nude mice bearing human head and neck squamous cell carcinoma A253 and FaDu xenografts. Mice were treated by single i.v. push (i.v. x 1), i.v. push once a week for 3 weeks (weekly x 3), and i.v. push once a day for 5 days (daily x 5), and the maximum tolerated doses (MTDs) of ZD1694 were 300 mg/kg, 60 mg/kg/week, and 30 mg/kg/day, respectively. ZD1694 was moderately active against both A253 and FaDu xenografts. Antitumor activity was schedule-dependent in both tumors: weekly x 3 &gt; or = i.v. x 1 &gt;&gt; daily x 5. In contrast, the rank order of toxicity was daily x 5 &gt;&gt; weekly x 3 &gt; or = i.v. x 1. ZD1694 at the MTD produced 20% complete tumor regression and 20% partial tumor regression (PR) with i.v. x 1 and weekly x 3 schedules and 12-day tumor growth delay with daily x 5 schedule against FaDu xenografts. No complete tumor regression was achieved with ZD1694 with any schedule against A253; a 20% PR, 40% PR, and 10-day tumor growth delay were observed with i.v. x 1, weekly x 3, and daily x 5 schedules, respectively. The data indicate that ZD1694 was slightly more effective against FaDu than against A253. Of interest and potential clinical importance was the observation that ZD1694 was still active at doses lower than the MTD (&gt; or =1/3 MTD), which showed a high therapeutic index and wide safety margin. Study of ZD1694 compared with 5-fluorouracil and 5-fluoro-2'-deoxyuridine at the MTD revealed that the antitumor activity of ZD1694 was comparable with or superior to 5-fluorouracil and 5-fluoro-2'-deoxyuridine against both A253 and FaDu xenografts, with less toxicity. High plasma thymidine in mouse relative to human (approximately 1.3 microM and &lt;0.1 microM, respectively) may complicate the study of antitumor activity and toxicity of TS inhibitors with human tumor xenografts grown in the mouse. To test this hypothesis, we preadministered methoxypolyethyleneglycol-conjugated thymidine phosphorylase (MPEG-TPase; 2500 units/kg/dose) to reduce mouse plasma thymidine, then treated with various doses of ZD1694 using the daily x 5 or i.v. x 1 schedules in the A253 tumor model. MPEG-TPase significantly increased the toxicity of ZD1694; the MTD of ZD1694 plus MPEG-TPase was reduced 3- and 10-fold compared with ZD1694 alone for i.v x 1 and daily x 5 schedules, respectively. However, preadministration of MPEG-TPase did not potentiate the antitumor activity of ZD1694 with either schedule. The data indicate that the study of TS inhibitors in rodent models may not be suitable for predicting a safe dose for clinical study. However, rodent models, particularly human tumor xenografts, are still useful models for evaluation of antitumor activity and schedule selection for TS inhibitors.</text>
      <sentence>
        <offset>0</offset>
        <text>Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidine</infon>
          <location offset="131" length="9"/>
          <text>thymidine</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="22" length="6"/>
          <text>ZD1694</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tomudex</infon>
          <location offset="30" length="7"/>
          <text>tomudex</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>142</offset>
        <text>We studied the antitumor activity and toxicity of ZD1694 (tomudex), a specific inhibitor of thymidylate synthase (TS), in nude mice bearing human head and neck squamous cell carcinoma A253 and FaDu xenografts.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="192" length="6"/>
          <text>ZD1694</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tomudex</infon>
          <location offset="200" length="7"/>
          <text>tomudex</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidylate</infon>
          <location offset="234" length="11"/>
          <text>thymidylate</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ts</infon>
          <location offset="256" length="2"/>
          <text>TS</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thymidylate synthase</infon>
          <location offset="234" length="20"/>
          <text>thymidylate synthase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T23" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>352</offset>
        <text>Mice were treated by single i.v. push (i.v. x 1), i.v. push once a week for 3 weeks (weekly x 3), and i.v. push once a day for 5 days (daily x 5), and the maximum tolerated doses (MTDs) of ZD1694 were 300 mg/kg, 60 mg/kg/week, and 30 mg/kg/day, respectively.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="541" length="6"/>
          <text>ZD1694</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>611</offset>
        <text>ZD1694 was moderately active against both A253 and FaDu xenografts.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="611" length="6"/>
          <text>ZD1694</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>679</offset>
        <text>Antitumor activity was schedule-dependent in both tumors: weekly x 3 &gt; or = i.v. x 1 &gt;&gt; daily x 5.</text>
      </sentence>
      <sentence>
        <offset>778</offset>
        <text>In contrast, the rank order of toxicity was daily x 5 &gt;&gt; weekly x 3 &gt; or = i.v. x 1.</text>
      </sentence>
      <sentence>
        <offset>863</offset>
        <text>ZD1694 at the MTD produced 20% complete tumor regression and 20% partial tumor regression (PR) with i.v. x 1 and weekly x 3 schedules and 12-day tumor growth delay with daily x 5 schedule against FaDu xenografts.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="863" length="6"/>
          <text>ZD1694</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1076</offset>
        <text>No complete tumor regression was achieved with ZD1694 with any schedule against A253; a 20% PR, 40% PR, and 10-day tumor growth delay were observed with i.v. x 1, weekly x 3, and daily x 5 schedules, respectively.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="1123" length="6"/>
          <text>ZD1694</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1290</offset>
        <text>The data indicate that ZD1694 was slightly more effective against FaDu than against A253.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="1313" length="6"/>
          <text>ZD1694</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1380</offset>
        <text>Of interest and potential clinical importance was the observation that ZD1694 was still active at doses lower than the MTD (&gt; or =1/3 MTD), which showed a high therapeutic index and wide safety margin.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="1451" length="6"/>
          <text>ZD1694</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1582</offset>
        <text>Study of ZD1694 compared with 5-fluorouracil and 5-fluoro-2'-deoxyuridine at the MTD revealed that the antitumor activity of ZD1694 was comparable with or superior to 5-fluorouracil and 5-fluoro-2'-deoxyuridine against both A253 and FaDu xenografts, with less toxicity.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="1591" length="6"/>
          <text>ZD1694</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluorouracil</infon>
          <location offset="1612" length="14"/>
          <text>5-fluorouracil</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluoro-2'-deoxyuridine</infon>
          <location offset="1631" length="24"/>
          <text>5-fluoro-2'-deoxyuridine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="1707" length="6"/>
          <text>ZD1694</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluorouracil</infon>
          <location offset="1749" length="14"/>
          <text>5-fluorouracil</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-fluoro-2'-deoxyuridine</infon>
          <location offset="1768" length="24"/>
          <text>5-fluoro-2'-deoxyuridine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1852</offset>
        <text>High plasma thymidine in mouse relative to human (approximately 1.3 microM and &lt;0.1 microM, respectively) may complicate the study of antitumor activity and toxicity of TS inhibitors with human tumor xenografts grown in the mouse.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidine</infon>
          <location offset="1864" length="9"/>
          <text>thymidine</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ts</infon>
          <location offset="2021" length="2"/>
          <text>TS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2083</offset>
        <text>To test this hypothesis, we preadministered methoxypolyethyleneglycol-conjugated thymidine phosphorylase (MPEG-TPase; 2500 units/kg/dose) to reduce mouse plasma thymidine, then treated with various doses of ZD1694 using the daily x 5 or i.v. x 1 schedules in the A253 tumor model.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methoxypolyethyleneglycol</infon>
          <location offset="2127" length="25"/>
          <text>methoxypolyethyleneglycol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidine</infon>
          <location offset="2164" length="9"/>
          <text>thymidine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mpeg</infon>
          <location offset="2189" length="4"/>
          <text>MPEG</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidine</infon>
          <location offset="2244" length="9"/>
          <text>thymidine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="2290" length="6"/>
          <text>ZD1694</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">methoxypolyethyleneglycol-conjugated thymidine phosphorylase</infon>
          <location offset="2127" length="60"/>
          <text>methoxypolyethyleneglycol-conjugated thymidine phosphorylase</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mpeg-tpase</infon>
          <location offset="2189" length="10"/>
          <text>MPEG-TPase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2364</offset>
        <text>MPEG-TPase significantly increased the toxicity of ZD1694; the MTD of ZD1694 plus MPEG-TPase was reduced 3- and 10-fold compared with ZD1694 alone for i.v x 1 and daily x 5 schedules, respectively.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="2415" length="6"/>
          <text>ZD1694</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="2434" length="6"/>
          <text>ZD1694</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mpeg</infon>
          <location offset="2446" length="4"/>
          <text>MPEG</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="2498" length="6"/>
          <text>ZD1694</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mpeg-tpase</infon>
          <location offset="2364" length="10"/>
          <text>MPEG-TPase</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mpeg-tpase</infon>
          <location offset="2446" length="10"/>
          <text>MPEG-TPase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2562</offset>
        <text>However, preadministration of MPEG-TPase did not potentiate the antitumor activity of ZD1694 with either schedule.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd1694</infon>
          <location offset="2648" length="6"/>
          <text>ZD1694</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mpeg-tpase</infon>
          <location offset="2592" length="10"/>
          <text>MPEG-TPase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2677</offset>
        <text>The data indicate that the study of TS inhibitors in rodent models may not be suitable for predicting a safe dose for clinical study.</text>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ts</infon>
          <location offset="2713" length="2"/>
          <text>TS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2811</offset>
        <text>However, rodent models, particularly human tumor xenografts, are still useful models for evaluation of antitumor activity and schedule selection for TS inhibitors.</text>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ts</infon>
          <location offset="2960" length="2"/>
          <text>TS</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23578952</id>
    <passage>
      <offset>0</offset>
      <text>Monoacylglycerol lipase inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice.	The hypothalamus-pituitary-adrenal-axis is strongly controlled by the endocannabinoid system. The specific impact of enhanced 2-arachidonoylglycerol signaling on corticosterone plasma levels, however, was not investigated so far. Here we studied the effects of the recently developed monoacylglycerol lipase inhibitor JZL184 on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses. Since acute changes in corticosterone levels can affect behavior, JZL184 was administered concurrently with the corticosterone synthesis inhibitor metyrapone, to investigate whether the previously shown behavioral effects of JZL184 are dependent on corticosterone. We found that in the elevated plus-maze, the effects of JZL184 on "classical" anxiety-related measures were abolished by corticosterone synthesis blockade. By contrast, effects on the "ethological" measures of anxiety (i.e. risk assessment) were not affected by metyrapone. In the open-field, the locomotion-enhancing effects of the compound were not changed either. These findings show that monoacylglycerol lipase inhibition dramatically increases basal levels of corticosterone. This endocrine effect partly affects the anxiolytic, but not the locomotion-enhancing effects of monoacylglycerol lipase blockade.</text>
      <sentence>
        <offset>0</offset>
        <text>Monoacylglycerol lipase inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoacylglycerol</infon>
          <location offset="0" length="16"/>
          <text>Monoacylglycerol</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="61" length="14"/>
          <text>corticosterone</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monoacylglycerol lipase</infon>
          <location offset="0" length="23"/>
          <text>Monoacylglycerol lipase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>133</offset>
        <text>The hypothalamus-pituitary-adrenal-axis is strongly controlled by the endocannabinoid system.</text>
      </sentence>
      <sentence>
        <offset>227</offset>
        <text>The specific impact of enhanced 2-arachidonoylglycerol signaling on corticosterone plasma levels, however, was not investigated so far.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-arachidonoylglycerol</infon>
          <location offset="259" length="22"/>
          <text>2-arachidonoylglycerol</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="295" length="14"/>
          <text>corticosterone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>363</offset>
        <text>Here we studied the effects of the recently developed monoacylglycerol lipase inhibitor JZL184 on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoacylglycerol</infon>
          <location offset="417" length="16"/>
          <text>monoacylglycerol</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">jzl184</infon>
          <location offset="451" length="6"/>
          <text>JZL184</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="486" length="14"/>
          <text>corticosterone</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monoacylglycerol lipase</infon>
          <location offset="417" length="23"/>
          <text>monoacylglycerol lipase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>627</offset>
        <text>Since acute changes in corticosterone levels can affect behavior, JZL184 was administered concurrently with the corticosterone synthesis inhibitor metyrapone, to investigate whether the previously shown behavioral effects of JZL184 are dependent on corticosterone.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="650" length="14"/>
          <text>corticosterone</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">jzl184</infon>
          <location offset="693" length="6"/>
          <text>JZL184</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="739" length="14"/>
          <text>corticosterone</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metyrapone</infon>
          <location offset="774" length="10"/>
          <text>metyrapone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">jzl184</infon>
          <location offset="852" length="6"/>
          <text>JZL184</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="876" length="14"/>
          <text>corticosterone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>892</offset>
        <text>We found that in the elevated plus-maze, the effects of JZL184 on "classical" anxiety-related measures were abolished by corticosterone synthesis blockade.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">jzl184</infon>
          <location offset="948" length="6"/>
          <text>JZL184</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="1013" length="14"/>
          <text>corticosterone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1048</offset>
        <text>By contrast, effects on the "ethological" measures of anxiety (i.e. risk assessment) were not affected by metyrapone.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metyrapone</infon>
          <location offset="1154" length="10"/>
          <text>metyrapone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1166</offset>
        <text>In the open-field, the locomotion-enhancing effects of the compound were not changed either.</text>
      </sentence>
      <sentence>
        <offset>1259</offset>
        <text>These findings show that monoacylglycerol lipase inhibition dramatically increases basal levels of corticosterone.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoacylglycerol</infon>
          <location offset="1284" length="16"/>
          <text>monoacylglycerol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">corticosterone</infon>
          <location offset="1358" length="14"/>
          <text>corticosterone</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monoacylglycerol lipase</infon>
          <location offset="1284" length="23"/>
          <text>monoacylglycerol lipase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1374</offset>
        <text>This endocrine effect partly affects the anxiolytic, but not the locomotion-enhancing effects of monoacylglycerol lipase blockade.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monoacylglycerol</infon>
          <location offset="1471" length="16"/>
          <text>monoacylglycerol</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monoacylglycerol lipase</infon>
          <location offset="1471" length="23"/>
          <text>monoacylglycerol lipase</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23639586</id>
    <passage>
      <offset>0</offset>
      <text>Gene expression profiling and pathway analysis of hepatotoxicity induced by triptolide in Wistar rats.	Triptolide (TP), a major component of TWHF, is widely used to treat rheumatoid arthritis, systemic lupus erythematosus, nephritis and leprosy. However, its clinical use is limited by hepatotoxicity. To further elucidate the underlying mechanism of its hepatotoxic effects, hepatic gene expression profiles were analyzed. TP (1000 and 300μg/kg) was orally administered to Wistar rats for 14days. Current study indicated that female rats were more sensitive to TP-induced hepatotoxicity than males. Genome-wide microarray analyses identified 3329 differentially expressed genes in liver of female rats. Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen. In addition, it was observed for the first time that glucocorticoids and IGF1 might get involved in TP-induced hepatotoxicity. These data suggest that TP treatment could alter the hepatic redox status, reduce serum glucose and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in insulin signaling pathway, glucose metabolism pathway and cell stress pathway, all of which might contribute to the overall TP-induced hepatotoxicity.</text>
      <sentence>
        <offset>0</offset>
        <text>Gene expression profiling and pathway analysis of hepatotoxicity induced by triptolide in Wistar rats.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triptolide</infon>
          <location offset="76" length="10"/>
          <text>triptolide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>103</offset>
        <text>Triptolide (TP), a major component of TWHF, is widely used to treat rheumatoid arthritis, systemic lupus erythematosus, nephritis and leprosy.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triptolide</infon>
          <location offset="103" length="10"/>
          <text>Triptolide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>246</offset>
        <text>However, its clinical use is limited by hepatotoxicity.</text>
      </sentence>
      <sentence>
        <offset>302</offset>
        <text>To further elucidate the underlying mechanism of its hepatotoxic effects, hepatic gene expression profiles were analyzed.</text>
      </sentence>
      <sentence>
        <offset>424</offset>
        <text>TP (1000 and 300μg/kg) was orally administered to Wistar rats for 14days.</text>
      </sentence>
      <sentence>
        <offset>498</offset>
        <text>Current study indicated that female rats were more sensitive to TP-induced hepatotoxicity than males.</text>
      </sentence>
      <sentence>
        <offset>600</offset>
        <text>Genome-wide microarray analyses identified 3329 differentially expressed genes in liver of female rats.</text>
      </sentence>
      <sentence>
        <offset>704</offset>
        <text>Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="809" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="981" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="990" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gssg</infon>
          <location offset="994" length="4"/>
          <text>GSSG</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1006" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphoenolpyruvate</infon>
          <location offset="1032" length="19"/>
          <text>phosphoenolpyruvate</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="782" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="939" length="9"/>
          <text>Caspase-3</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucose-6-phosphatase</infon>
          <location offset="1006" length="21"/>
          <text>glucose-6-phosphatase</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">phosphoenolpyruvate carboxykinase</infon>
          <location offset="1032" length="33"/>
          <text>phosphoenolpyruvate carboxykinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1094</offset>
        <text>In addition, it was observed for the first time that glucocorticoids and IGF1 might get involved in TP-induced hepatotoxicity.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">igf1</infon>
          <location offset="1167" length="4"/>
          <text>IGF1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1221</offset>
        <text>These data suggest that TP treatment could alter the hepatic redox status, reduce serum glucose and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in insulin signaling pathway, glucose metabolism pathway and cell stress pathway, all of which might contribute to the overall TP-induced hepatotoxicity.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1309" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1442" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1415" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12142814</id>
    <passage>
      <offset>0</offset>
      <text>Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.	OBJECTIVES: Medical treatment of tyrosinemia I relies on the herbicide NTBC [Orfadin 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione], an inhibitor of plant and mammalian 2-oxoacid-utilizing dioxygenases with a collective catalytic cycle ('HAG' mechanism). We hypothesize that NTBC-treated tyrosinemia I is a human model for the pathogenic role of two major enzymes in this class, 4-hydroxyphenylpyruvate dioxygenase (4-HPPD; EC 1.13.11.27) and prolyl 4-hydroxylase (P4-H; E.C. 1.14.11.2), essential for tyrosine and collagen metabolism, respectively. METHODS: In a patient with established tyrosinemia I, we monitored the in vivo activities of 4-HPPD and P4-H via five biomarkers before and during NTBC medication. Hypothesis testing at the molecular level was performed by computational modeling of NTBC binding to the crystal structure-derived active site of 4-HPPD, and then relating these findings to our experimental results and to known P4-H data. RESULTS: NTBC rapidly normalized the biomarkers for 4-HPPD activity. However, those for P4-H activity remained uniformly elevated after one hundred days on NTBC, the PIIINP biomarker even increasing above its grossly abnormal, initial level. This selective enzyme inhibition despite a collective catalytic cycle is attributed to the conformation of NTBC, which only fits the active site of 4-HPPD, as confirmed by its crystal structure. CONCLUSIONS: Normalization of hepatic collagen formation, highly desirable in all fibrotic liver diseases, is not achieved by NTBC in tyrosinemia I. By establishing the molecular cause for this failure, our results also establish a rational approach to identify inhibitors that achieve that goal, either by joint 4-HPPD / P-4H inhibition, or by inhibition of only P-4H.</text>
      <sentence>
        <offset>0</offset>
        <text>Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosinemia i</infon>
          <location offset="0" length="13"/>
          <text>Tyrosinemia I</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-oxoacid</infon>
          <location offset="54" length="9"/>
          <text>2-oxoacid</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">collagen</infon>
          <location offset="147" length="8"/>
          <text>collagen</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dioxygenases</infon>
          <location offset="74" length="12"/>
          <text>dioxygenases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>168</offset>
        <text>OBJECTIVES: Medical treatment of tyrosinemia I relies on the herbicide NTBC [Orfadin 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione], an inhibitor of plant and mammalian 2-oxoacid-utilizing dioxygenases with a collective catalytic cycle ('HAG' mechanism).</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-oxoacid</infon>
          <location offset="350" length="9"/>
          <text>2-oxoacid</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosinemia i</infon>
          <location offset="201" length="13"/>
          <text>tyrosinemia I</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ntbc</infon>
          <location offset="239" length="4"/>
          <text>NTBC</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">orfadin</infon>
          <location offset="245" length="7"/>
          <text>Orfadin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione</infon>
          <location offset="253" length="58"/>
          <text>2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dioxygenases</infon>
          <location offset="370" length="12"/>
          <text>dioxygenases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>436</offset>
        <text>We hypothesize that NTBC-treated tyrosinemia I is a human model for the pathogenic role of two major enzymes in this class, 4-hydroxyphenylpyruvate dioxygenase (4-HPPD; EC 1.13.11.27) and prolyl 4-hydroxylase (P4-H; E.C.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ntbc</infon>
          <location offset="456" length="4"/>
          <text>NTBC</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-hydroxyphenylpyruvate</infon>
          <location offset="560" length="23"/>
          <text>4-hydroxyphenylpyruvate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prolyl</infon>
          <location offset="624" length="6"/>
          <text>prolyl</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">4-hydroxyphenylpyruvate dioxygenase</infon>
          <location offset="560" length="35"/>
          <text>4-hydroxyphenylpyruvate dioxygenase</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">4-hppd</infon>
          <location offset="597" length="6"/>
          <text>4-HPPD</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ec 1.13.11.27</infon>
          <location offset="605" length="13"/>
          <text>EC 1.13.11.27</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">prolyl 4-hydroxylase</infon>
          <location offset="624" length="20"/>
          <text>prolyl 4-hydroxylase</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p4-h</infon>
          <location offset="646" length="4"/>
          <text>P4-H</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">e.c. 1.14.11.2</infon>
          <location offset="652" length="14"/>
          <text>E.C. 1.14.11.2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>657</offset>
        <text>1.14.11.2), essential for tyrosine and collagen metabolism, respectively.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="683" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">collagen</infon>
          <location offset="696" length="8"/>
          <text>collagen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>731</offset>
        <text>METHODS: In a patient with established tyrosinemia I, we monitored the in vivo activities of 4-HPPD and P4-H via five biomarkers before and during NTBC medication.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ntbc</infon>
          <location offset="878" length="4"/>
          <text>NTBC</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">4-hppd</infon>
          <location offset="824" length="6"/>
          <text>4-HPPD</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p4-h</infon>
          <location offset="835" length="4"/>
          <text>P4-H</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>895</offset>
        <text>Hypothesis testing at the molecular level was performed by computational modeling of NTBC binding to the crystal structure-derived active site of 4-HPPD, and then relating these findings to our experimental results and to known P4-H data.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ntbc</infon>
          <location offset="980" length="4"/>
          <text>NTBC</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p4-h</infon>
          <location offset="1123" length="4"/>
          <text>P4-H</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1134</offset>
        <text>RESULTS: NTBC rapidly normalized the biomarkers for 4-HPPD activity.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">4-hppd</infon>
          <location offset="1186" length="6"/>
          <text>4-HPPD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1203</offset>
        <text>However, those for P4-H activity remained uniformly elevated after one hundred days on NTBC, the PIIINP biomarker even increasing above its grossly abnormal, initial level.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ntbc</infon>
          <location offset="1290" length="4"/>
          <text>NTBC</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p4-h</infon>
          <location offset="1222" length="4"/>
          <text>P4-H</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">piiinp</infon>
          <location offset="1300" length="6"/>
          <text>PIIINP</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1376</offset>
        <text>This selective enzyme inhibition despite a collective catalytic cycle is attributed to the conformation of NTBC, which only fits the active site of 4-HPPD, as confirmed by its crystal structure.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ntbc</infon>
          <location offset="1483" length="4"/>
          <text>NTBC</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">4-hppd</infon>
          <location offset="1524" length="6"/>
          <text>4-HPPD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1571</offset>
        <text>CONCLUSIONS: Normalization of hepatic collagen formation, highly desirable in all fibrotic liver diseases, is not achieved by NTBC in tyrosinemia I.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ntbc</infon>
          <location offset="1697" length="4"/>
          <text>NTBC</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">collagen</infon>
          <location offset="1609" length="8"/>
          <text>collagen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1720</offset>
        <text>By establishing the molecular cause for this failure, our results also establish a rational approach to identify inhibitors that achieve that goal, either by joint 4-HPPD / P-4H inhibition, or by inhibition of only P-4H.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">4-hppd</infon>
          <location offset="1884" length="6"/>
          <text>4-HPPD</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-4h</infon>
          <location offset="1893" length="4"/>
          <text>P-4H</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-4h</infon>
          <location offset="1935" length="4"/>
          <text>P-4H</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23416007</id>
    <passage>
      <offset>0</offset>
      <text>A multivalent peptide as an activator of hypoxia inducible factor-1α.	Hypoxia inducible factor-1α (HIF-1α) is a transcription factor found in mammalian cells under hypoxia. While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its proline hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex. Previously, peptide inhibitors against this interaction between hydroxylated HIF-1α and VBC have been developed to stabilize the transcriptional activity of HIF-1α by preventing the degradation of the protein even under normoxia. Despite the specific inhibition by these peptides, their poor inhibition potency needs to be improved for further clinical application. In this work, we have designed and prepared a streptavidin-based multivalent peptide inhibitor against the HIF-1α-VBC complexation. We have evaluated the potency of the multivalent peptide in terms of stabilization of HIF-1α and the downstream effect. As the result, we have found that the inhibitor showed about 13-fold lowered IC50 value compared with that of the corresponding monovalent peptide, thereby activating HIF-1α and leading to up-regulation of VEGF protein at the cellular level.</text>
      <sentence>
        <offset>0</offset>
        <text>A multivalent peptide as an activator of hypoxia inducible factor-1α.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hypoxia inducible factor-1α</infon>
          <location offset="41" length="27"/>
          <text>hypoxia inducible factor-1α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>70</offset>
        <text>Hypoxia inducible factor-1α (HIF-1α) is a transcription factor found in mammalian cells under hypoxia.</text>
        <annotation id="T2">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hypoxia inducible factor-1α</infon>
          <location offset="70" length="27"/>
          <text>Hypoxia inducible factor-1α</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hif-1α</infon>
          <location offset="99" length="6"/>
          <text>HIF-1α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>173</offset>
        <text>While HIF-1α in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1α is degraded under normoxia, which involves its proline hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">proline</infon>
          <location offset="375" length="7"/>
          <text>proline</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1α</infon>
          <location offset="179" length="6"/>
          <text>HIF-1α</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="273" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="309" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1α</infon>
          <location offset="321" length="6"/>
          <text>HIF-1α</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">von hippel-lindau protein</infon>
          <location offset="427" length="25"/>
          <text>von Hippel-Lindau protein</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">elongin b</infon>
          <location offset="453" length="9"/>
          <text>Elongin B</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">elogin c</infon>
          <location offset="463" length="8"/>
          <text>Elogin C</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vbc</infon>
          <location offset="473" length="3"/>
          <text>VBC</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>487</offset>
        <text>Previously, peptide inhibitors against this interaction between hydroxylated HIF-1α and VBC have been developed to stabilize the transcriptional activity of HIF-1α by preventing the degradation of the protein even under normoxia.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1α</infon>
          <location offset="564" length="6"/>
          <text>HIF-1α</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vbc</infon>
          <location offset="575" length="3"/>
          <text>VBC</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1α</infon>
          <location offset="644" length="6"/>
          <text>HIF-1α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>717</offset>
        <text>Despite the specific inhibition by these peptides, their poor inhibition potency needs to be improved for further clinical application.</text>
      </sentence>
      <sentence>
        <offset>853</offset>
        <text>In this work, we have designed and prepared a streptavidin-based multivalent peptide inhibitor against the HIF-1α-VBC complexation.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1α</infon>
          <location offset="960" length="6"/>
          <text>HIF-1α</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">vbc</infon>
          <location offset="967" length="3"/>
          <text>VBC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>985</offset>
        <text>We have evaluated the potency of the multivalent peptide in terms of stabilization of HIF-1α and the downstream effect.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1α</infon>
          <location offset="1071" length="6"/>
          <text>HIF-1α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1105</offset>
        <text>As the result, we have found that the inhibitor showed about 13-fold lowered IC50 value compared with that of the corresponding monovalent peptide, thereby activating HIF-1α and leading to up-regulation of VEGF protein at the cellular level.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif-1α</infon>
          <location offset="1272" length="6"/>
          <text>HIF-1α</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="1311" length="4"/>
          <text>VEGF</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1908244</id>
    <passage>
      <offset>0</offset>
      <text>The effect of estramustine derivatives on microtubule assembly in vitro depends on the charge of the substituent.	Estramustine, and derivatives of estramustine with a charged substituent at position 17 on the estrogen moiety, have been investigated for their effects on bovine brain microtubules in vitro. The negatively charged estramustine phosphate has been found previously to be a microtubule-associated protein (MAP)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985]. In the present study the binding of estramustine phosphate to MAP2 and tau was investigated. Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains. The Kd for the binding of estramustine phosphate to MAP2 was estimated to be 20 microM at 4 degrees, and for the binding of tau, 200 microM. The rate of dissociation was very low (T1/2 greater than 2 hr), which indicates that the binding of estramustine phosphate may stabilize the protein-drug complex by changing the protein conformation. Two new negatively charged estramustine derivatives, estramustine sulphate and estramustine glucuronide, were found to be similar MAP-dependent microtubule inhibitors. The concentration for 50% inhibition of assembly was 100 microM for the sulphate derivative, the same as found previously for estramustine phosphate, and 250 microM for the more bulky estramustine glucuronide. A positively charged derivative, estramustine sarcosinate, did not inhibit microtubule assembly or alter the composition of the coassembled MAPs. The morphology of the microtubules was, however, affected. The uncharged estramustine bound to both tubulin and MAPs, but no effects were seen on microtubule assembly, the composition of coassembled MAPs or the microtubule morphology. Our results suggest that only negatively charged estramustine derivatives have a MAP-dependent microtubule inhibitory effect. The two new negatively charged derivatives could therefore be valuable tools in the study of tubulin-MAP interactions. The results also confirm that these interactions between tubulin and MAPs are mainly electrostatic.</text>
      <sentence>
        <offset>0</offset>
        <text>The effect of estramustine derivatives on microtubule assembly in vitro depends on the charge of the substituent.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="14" length="12"/>
          <text>estramustine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>114</offset>
        <text>Estramustine, and derivatives of estramustine with a charged substituent at position 17 on the estrogen moiety, have been investigated for their effects on bovine brain microtubules in vitro.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="114" length="12"/>
          <text>Estramustine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="147" length="12"/>
          <text>estramustine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="209" length="8"/>
          <text>estrogen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>306</offset>
        <text>The negatively charged estramustine phosphate has been found previously to be a microtubule-associated protein (MAP)-dependent microtubule inhibitor [Wallin M, Deinum J and Friden B, FEBS Lett 179: 289-293, 1985].</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine phosphate</infon>
          <location offset="329" length="22"/>
          <text>estramustine phosphate</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">microtubule-associated protein</infon>
          <location offset="386" length="30"/>
          <text>microtubule-associated protein</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">map</infon>
          <location offset="418" length="3"/>
          <text>MAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>520</offset>
        <text>In the present study the binding of estramustine phosphate to MAP2 and tau was investigated.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine phosphate</infon>
          <location offset="556" length="22"/>
          <text>estramustine phosphate</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">map2</infon>
          <location offset="582" length="4"/>
          <text>MAP2</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tau</infon>
          <location offset="591" length="3"/>
          <text>tau</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>613</offset>
        <text>Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine phosphate</infon>
          <location offset="679" length="22"/>
          <text>estramustine phosphate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino acid</infon>
          <location offset="756" length="10"/>
          <text>amino acid</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">maps</infon>
          <location offset="624" length="4"/>
          <text>MAPs</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">maps</infon>
          <location offset="784" length="4"/>
          <text>MAPs</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tubulin</infon>
          <location offset="820" length="7"/>
          <text>tubulin</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>845</offset>
        <text>The Kd for the binding of estramustine phosphate to MAP2 was estimated to be 20 microM at 4 degrees, and for the binding of tau, 200 microM.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine phosphate</infon>
          <location offset="871" length="22"/>
          <text>estramustine phosphate</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">map2</infon>
          <location offset="897" length="4"/>
          <text>MAP2</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>986</offset>
        <text>The rate of dissociation was very low (T1/2 greater than 2 hr), which indicates that the binding of estramustine phosphate may stabilize the protein-drug complex by changing the protein conformation.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine phosphate</infon>
          <location offset="1086" length="22"/>
          <text>estramustine phosphate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1186</offset>
        <text>Two new negatively charged estramustine derivatives, estramustine sulphate and estramustine glucuronide, were found to be similar MAP-dependent microtubule inhibitors.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="1213" length="12"/>
          <text>estramustine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine sulphate</infon>
          <location offset="1239" length="21"/>
          <text>estramustine sulphate</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine glucuronide</infon>
          <location offset="1265" length="24"/>
          <text>estramustine glucuronide</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">map</infon>
          <location offset="1316" length="3"/>
          <text>MAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1354</offset>
        <text>The concentration for 50% inhibition of assembly was 100 microM for the sulphate derivative, the same as found previously for estramustine phosphate, and 250 microM for the more bulky estramustine glucuronide.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulphate</infon>
          <location offset="1426" length="8"/>
          <text>sulphate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine phosphate</infon>
          <location offset="1480" length="22"/>
          <text>estramustine phosphate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine glucuronide</infon>
          <location offset="1538" length="24"/>
          <text>estramustine glucuronide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1564</offset>
        <text>A positively charged derivative, estramustine sarcosinate, did not inhibit microtubule assembly or alter the composition of the coassembled MAPs.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine sarcosinate</infon>
          <location offset="1597" length="24"/>
          <text>estramustine sarcosinate</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">maps</infon>
          <location offset="1704" length="4"/>
          <text>MAPs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1710</offset>
        <text>The morphology of the microtubules was, however, affected.</text>
      </sentence>
      <sentence>
        <offset>1769</offset>
        <text>The uncharged estramustine bound to both tubulin and MAPs, but no effects were seen on microtubule assembly, the composition of coassembled MAPs or the microtubule morphology.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="1783" length="12"/>
          <text>estramustine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tubulin</infon>
          <location offset="1810" length="7"/>
          <text>tubulin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">maps</infon>
          <location offset="1822" length="4"/>
          <text>MAPs</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">maps</infon>
          <location offset="1909" length="4"/>
          <text>MAPs</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1945</offset>
        <text>Our results suggest that only negatively charged estramustine derivatives have a MAP-dependent microtubule inhibitory effect.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="1994" length="12"/>
          <text>estramustine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">map</infon>
          <location offset="2026" length="3"/>
          <text>MAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2071</offset>
        <text>The two new negatively charged derivatives could therefore be valuable tools in the study of tubulin-MAP interactions.</text>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tubulin</infon>
          <location offset="2164" length="7"/>
          <text>tubulin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">map</infon>
          <location offset="2172" length="3"/>
          <text>MAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2190</offset>
        <text>The results also confirm that these interactions between tubulin and MAPs are mainly electrostatic.</text>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tubulin</infon>
          <location offset="2247" length="7"/>
          <text>tubulin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">maps</infon>
          <location offset="2259" length="4"/>
          <text>MAPs</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>24261583</id>
    <passage>
      <offset>0</offset>
      <text>Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.	INTRODUCTION: Macitentan is a novel dual endothelin receptor antagonist (ERA) showing sustained receptor occupancy. In vitro and in vivo animal studies have demonstrated its potency in antagonizing endothelin-induced disorders. A large morbidity/mortality study in patients with pulmonary arterial hypertension (PAH) taking macitentan has been completed recently. AREAS COVERED: This drug evaluation reviews the efficacy, safety and clinical pharmacology of macitentan in the treatment of PAH. EXPERT OPINION: The large Phase III study (SERAPHIN) tested macitentan in more than 700 PAH patients and has provided unique long-term outcome data for this ERA, not available for other members of this class. The effect on a composite clinically relevant morbidity/mortality end point was highly significant at a 10 mg/day dose. The safety profile of macitentan appears to be superior with respect to hepatic safety and edema/fluid retention than bosentan and ambrisentan, respectively, and is similar when considering decrease in hemoglobin concentration. The drug has a low propensity for drug-drug interactions and has one circulating pharmacologically active metabolite. The pharmacokinetics of macitentan in patients with renal or hepatic impairment does not require dose adjustments. Based on its characteristics, macitentan is an important addition to the therapeutic armamentarium in the long-term treatment of PAH. Its potential use in other disorders is under investigation.</text>
      <sentence>
        <offset>0</offset>
        <text>Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">macitentan</infon>
          <location offset="46" length="10"/>
          <text>macitentan</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">endothelin receptor</infon>
          <location offset="80" length="19"/>
          <text>endothelin receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>165</offset>
        <text>INTRODUCTION: Macitentan is a novel dual endothelin receptor antagonist (ERA) showing sustained receptor occupancy.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">macitentan</infon>
          <location offset="179" length="10"/>
          <text>Macitentan</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">endothelin receptor</infon>
          <location offset="206" length="19"/>
          <text>endothelin receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>281</offset>
        <text>In vitro and in vivo animal studies have demonstrated its potency in antagonizing endothelin-induced disorders.</text>
      </sentence>
      <sentence>
        <offset>393</offset>
        <text>A large morbidity/mortality study in patients with pulmonary arterial hypertension (PAH) taking macitentan has been completed recently.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">macitentan</infon>
          <location offset="489" length="10"/>
          <text>macitentan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>529</offset>
        <text>AREAS COVERED: This drug evaluation reviews the efficacy, safety and clinical pharmacology of macitentan in the treatment of PAH.</text>
      </sentence>
      <sentence>
        <offset>659</offset>
        <text>EXPERT OPINION: The large Phase III study (SERAPHIN) tested macitentan in more than 700 PAH patients and has provided unique long-term outcome data for this ERA, not available for other members of this class.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">macitentan</infon>
          <location offset="719" length="10"/>
          <text>macitentan</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>868</offset>
        <text>The effect on a composite clinically relevant morbidity/mortality end point was highly significant at a 10 mg/day dose.</text>
      </sentence>
      <sentence>
        <offset>988</offset>
        <text>The safety profile of macitentan appears to be superior with respect to hepatic safety and edema/fluid retention than bosentan and ambrisentan, respectively, and is similar when considering decrease in hemoglobin concentration.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">macitentan</infon>
          <location offset="1010" length="10"/>
          <text>macitentan</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="1106" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ambrisentan</infon>
          <location offset="1119" length="11"/>
          <text>ambrisentan</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hemoglobin</infon>
          <location offset="1190" length="10"/>
          <text>hemoglobin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1216</offset>
        <text>The drug has a low propensity for drug-drug interactions and has one circulating pharmacologically active metabolite.</text>
      </sentence>
      <sentence>
        <offset>1334</offset>
        <text>The pharmacokinetics of macitentan in patients with renal or hepatic impairment does not require dose adjustments.</text>
      </sentence>
      <sentence>
        <offset>1449</offset>
        <text>Based on its characteristics, macitentan is an important addition to the therapeutic armamentarium in the long-term treatment of PAH.</text>
      </sentence>
      <sentence>
        <offset>1583</offset>
        <text>Its potential use in other disorders is under investigation.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23494481</id>
    <passage>
      <offset>0</offset>
      <text>Neuroprotection against neuroblastoma cell death induced by depletion of mitochondrial glutathione.	Mitochondrial glutathione pool is vital in protecting cells against oxidative stress as the majority of the cellular reactive oxygen species are generated in mitochondria. Oxidative stress is implicated as a causative factor in neuronal death in neurodegenerative disorders. We hypothesized that depletion of mitochondrial glutathione leads to mitochondrial dysfunction and apoptotic death of SK-N-SH (human neuroblastoma) cells and investigated the neuroprotective strategies against GSH depletion. SK-N-SH cells were treated with two distinct inhibitors of glutathione metabolism: L-buthionine-(S, R)-sulfoximine (BSO) and ethacrynic acid (EA). EA treatment caused depletion of both the total and mitochondrial glutathione (while BSO had no effect on mitochondrial glutathione), enhanced rotenone-induced ROS production, and reduced the viability of SK-N-SH cells. Glutathione depletion by BSO or EA demonstrated positive features of mitochondria-mediated apoptosis in neuroblastoma cell death. Prevention of apoptosis by Bcl2 overexpression or use of antioxidant ebselen did not confer neuroprotection. Co-culture with U-87 (human glioblastoma) cells protected SK-N-SH cells from the cell death. Our data suggest that depletion of mitochondrial glutathione leads to mitochondrial dysfunction and apoptosis. The study indicates that preventing mitochondrial glutathione depletion could become a novel strategy for the development of neuroprotective therapeutics in neurodegenerative disorders.</text>
      <sentence>
        <offset>0</offset>
        <text>Neuroprotection against neuroblastoma cell death induced by depletion of mitochondrial glutathione.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="87" length="11"/>
          <text>glutathione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>100</offset>
        <text>Mitochondrial glutathione pool is vital in protecting cells against oxidative stress as the majority of the cellular reactive oxygen species are generated in mitochondria.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="226" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="114" length="11"/>
          <text>glutathione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>272</offset>
        <text>Oxidative stress is implicated as a causative factor in neuronal death in neurodegenerative disorders.</text>
      </sentence>
      <sentence>
        <offset>375</offset>
        <text>We hypothesized that depletion of mitochondrial glutathione leads to mitochondrial dysfunction and apoptotic death of SK-N-SH (human neuroblastoma) cells and investigated the neuroprotective strategies against GSH depletion.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="423" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="585" length="3"/>
          <text>GSH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>600</offset>
        <text>SK-N-SH cells were treated with two distinct inhibitors of glutathione metabolism: L-buthionine-(S, R)-sulfoximine (BSO) and ethacrynic acid (EA).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="659" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-buthionine-(s, r)-sulfoximine</infon>
          <location offset="683" length="31"/>
          <text>L-buthionine-(S, R)-sulfoximine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bso</infon>
          <location offset="716" length="3"/>
          <text>BSO</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethacrynic acid</infon>
          <location offset="725" length="15"/>
          <text>ethacrynic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>747</offset>
        <text>EA treatment caused depletion of both the total and mitochondrial glutathione (while BSO had no effect on mitochondrial glutathione), enhanced rotenone-induced ROS production, and reduced the viability of SK-N-SH cells.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="813" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bso</infon>
          <location offset="832" length="3"/>
          <text>BSO</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="867" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rotenone</infon>
          <location offset="890" length="8"/>
          <text>rotenone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>967</offset>
        <text>Glutathione depletion by BSO or EA demonstrated positive features of mitochondria-mediated apoptosis in neuroblastoma cell death.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="967" length="11"/>
          <text>Glutathione</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bso</infon>
          <location offset="992" length="3"/>
          <text>BSO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1097</offset>
        <text>Prevention of apoptosis by Bcl2 overexpression or use of antioxidant ebselen did not confer neuroprotection.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ebselen</infon>
          <location offset="1166" length="7"/>
          <text>ebselen</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2</infon>
          <location offset="1124" length="4"/>
          <text>Bcl2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1206</offset>
        <text>Co-culture with U-87 (human glioblastoma) cells protected SK-N-SH cells from the cell death.</text>
      </sentence>
      <sentence>
        <offset>1299</offset>
        <text>Our data suggest that depletion of mitochondrial glutathione leads to mitochondrial dysfunction and apoptosis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1348" length="11"/>
          <text>glutathione</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1410</offset>
        <text>The study indicates that preventing mitochondrial glutathione depletion could become a novel strategy for the development of neuroprotective therapeutics in neurodegenerative disorders.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1460" length="11"/>
          <text>glutathione</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23409842</id>
    <passage>
      <offset>0</offset>
      <text>Mechanistic insights into water-protein interactions of filamentous bacteriophage.	Water plays a major structural and functional role around proteins. In an attempt to explore this mechanistic structural aspect of proteins, we present site-specific interaction of hydration water with the major coat protein subunit of filamentous virus Pf1 by magic angle spinning (MAS) solid-state NMR. The interaction of surrounding water with 36 MDa Pf1 virion is investigated in uniformly (13)C, (15)N isotopically labeled; polyethylene glycol precipitated fully hydrated samples by solid-state nuclear magnetic resonance spectroscopy. Dipolar edited two-dimensional (2D) (1)H-(15)N heteronuclear correlation (HETCOR) experiments lead to unambiguous assignments of cross-peaks originating exclusively from (1)H resonances of water molecules correlating to the protein amide nitrogen. An enhanced resolved (1)H chemical shift dimension in these experiments also precludes the need of perdeuteration. We report seven residues spanning the 40-residue continuous α-helical conformation assembly of Pf1 interacting with surrounding water. It shows a highly hydrated inner core inside this viral filamentous assembly. The results obtained also suggest the first evidence of a water-mediated interface cluster formed at the site of Arg44 with the single-stranded DNA genome of the filamentous phage supramolecular assembly.</text>
      <sentence>
        <offset>0</offset>
        <text>Mechanistic insights into water-protein interactions of filamentous bacteriophage.</text>
      </sentence>
      <sentence>
        <offset>83</offset>
        <text>Water plays a major structural and functional role around proteins.</text>
      </sentence>
      <sentence>
        <offset>151</offset>
        <text>In an attempt to explore this mechanistic structural aspect of proteins, we present site-specific interaction of hydration water with the major coat protein subunit of filamentous virus Pf1 by magic angle spinning (MAS) solid-state NMR.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">major coat protein</infon>
          <location offset="289" length="18"/>
          <text>major coat protein</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>388</offset>
        <text>The interaction of surrounding water with 36 MDa Pf1 virion is investigated in uniformly (13)C, (15)N isotopically labeled; polyethylene glycol precipitated fully hydrated samples by solid-state nuclear magnetic resonance spectroscopy.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(13)c</infon>
          <location offset="477" length="5"/>
          <text>(13)C</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(15)n</infon>
          <location offset="484" length="5"/>
          <text>(15)N</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyethylene glycol</infon>
          <location offset="512" length="19"/>
          <text>polyethylene glycol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>624</offset>
        <text>Dipolar edited two-dimensional (2D) (1)H-(15)N heteronuclear correlation (HETCOR) experiments lead to unambiguous assignments of cross-peaks originating exclusively from (1)H resonances of water molecules correlating to the protein amide nitrogen.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(1)h</infon>
          <location offset="660" length="4"/>
          <text>(1)H</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(15)n</infon>
          <location offset="665" length="5"/>
          <text>(15)N</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(1)h</infon>
          <location offset="794" length="4"/>
          <text>(1)H</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amide nitrogen</infon>
          <location offset="856" length="14"/>
          <text>amide nitrogen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>872</offset>
        <text>An enhanced resolved (1)H chemical shift dimension in these experiments also precludes the need of perdeuteration.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(1)h</infon>
          <location offset="893" length="4"/>
          <text>(1)H</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>987</offset>
        <text>We report seven residues spanning the 40-residue continuous α-helical conformation assembly of Pf1 interacting with surrounding water.</text>
      </sentence>
      <sentence>
        <offset>1122</offset>
        <text>It shows a highly hydrated inner core inside this viral filamentous assembly.</text>
      </sentence>
      <sentence>
        <offset>1200</offset>
        <text>The results obtained also suggest the first evidence of a water-mediated interface cluster formed at the site of Arg44 with the single-stranded DNA genome of the filamentous phage supramolecular assembly.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arg</infon>
          <location offset="1313" length="3"/>
          <text>Arg</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1438284</id>
    <passage>
      <offset>0</offset>
      <text>Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis.	Torpedo acetylcholinesterase (AcChoEase, EC 3.1.1.7) and human butyrylcholinesterase (BtChoEase, EC 3.1.1.8), while clearly differing in substrate specificity and sensitivity to inhibitors, possess 53% sequence homology; this permitted modeling human BtChoEase on the basis of the three-dimensional structure of Torpedo AcChoEase. The modeled BtChoEase structure closely resembled that of AcChoEase in overall features. However, six conserved aromatic residues that line the active-site gorge, which is a prominent feature of the AcChoEase structure, are absent in BtChoEase. Modeling showed that two such residues, Phe-288 and Phe-290, replaced by leucine and valine, respectively, in BtChoEase, may prevent entrance of butyrylcholine into the acyl-binding pocket. Their mutation to leucine and valine in AcChoEase, by site-directed mutagenesis, produced a double mutant that hydrolyzed butyrylthiocholine almost as well as acetylthiocholine. The mutated enzyme was also inhibited well by the bulky, BtChoEase-selective organophosphate inhibitor (tetraisopropylpyrophosphoramide, iso-OMPA). Trp-279, at the entrance of the active-site gorge in AcChoEase, is absent in BtChoEase. Modeling designated it as part of the "peripheral" anionic site, which is lacking in BtChoEase. The mutant W279A displayed strongly reduced inhibition by the peripheral site-specific ligand propidium relative to wild-type Torpedo AcChoEase, whereas inhibition by the catalytic-site inhibitor edrophonium was unaffected.</text>
      <sentence>
        <offset>0</offset>
        <text>Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis.</text>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="14" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">butyrylcholinesterase</infon>
          <location offset="38" length="21"/>
          <text>butyrylcholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>87</offset>
        <text>Torpedo acetylcholinesterase (AcChoEase, EC 3.1.1.7) and human butyrylcholinesterase (BtChoEase, EC 3.1.1.8), while clearly differing in substrate specificity and sensitivity to inhibitors, possess 53% sequence homology; this permitted modeling human BtChoEase on the basis of the three-dimensional structure of Torpedo AcChoEase.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">torpedo acetylcholinesterase</infon>
          <location offset="87" length="28"/>
          <text>Torpedo acetylcholinesterase</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human btchoease</infon>
          <location offset="332" length="15"/>
          <text>human BtChoEase</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acchoease</infon>
          <location offset="117" length="9"/>
          <text>AcChoEase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">torpedo acchoease</infon>
          <location offset="399" length="17"/>
          <text>Torpedo AcChoEase</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ec 3.1.1.7</infon>
          <location offset="128" length="10"/>
          <text>EC 3.1.1.7</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human butyrylcholinesterase</infon>
          <location offset="144" length="27"/>
          <text>human butyrylcholinesterase</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">btchoease</infon>
          <location offset="173" length="9"/>
          <text>BtChoEase</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ec 3.1.1.8</infon>
          <location offset="184" length="10"/>
          <text>EC 3.1.1.8</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>418</offset>
        <text>The modeled BtChoEase structure closely resembled that of AcChoEase in overall features.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">btchoease</infon>
          <location offset="430" length="9"/>
          <text>BtChoEase</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acchoease</infon>
          <location offset="476" length="9"/>
          <text>AcChoEase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>507</offset>
        <text>However, six conserved aromatic residues that line the active-site gorge, which is a prominent feature of the AcChoEase structure, are absent in BtChoEase.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acchoease</infon>
          <location offset="617" length="9"/>
          <text>AcChoEase</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">btchoease</infon>
          <location offset="652" length="9"/>
          <text>BtChoEase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>663</offset>
        <text>Modeling showed that two such residues, Phe-288 and Phe-290, replaced by leucine and valine, respectively, in BtChoEase, may prevent entrance of butyrylcholine into the acyl-binding pocket.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phe</infon>
          <location offset="703" length="3"/>
          <text>Phe</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phe</infon>
          <location offset="715" length="3"/>
          <text>Phe</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leucine</infon>
          <location offset="736" length="7"/>
          <text>leucine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">valine</infon>
          <location offset="748" length="6"/>
          <text>valine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">butyrylcholine</infon>
          <location offset="808" length="14"/>
          <text>butyrylcholine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acyl</infon>
          <location offset="832" length="4"/>
          <text>acyl</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">btchoease</infon>
          <location offset="773" length="9"/>
          <text>BtChoEase</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">acyl-binding pocket</infon>
          <location offset="832" length="19"/>
          <text>acyl-binding pocket</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T9" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T9" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>853</offset>
        <text>Their mutation to leucine and valine in AcChoEase, by site-directed mutagenesis, produced a double mutant that hydrolyzed butyrylthiocholine almost as well as acetylthiocholine.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">leucine</infon>
          <location offset="871" length="7"/>
          <text>leucine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">valine</infon>
          <location offset="883" length="6"/>
          <text>valine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">butyrylthiocholine</infon>
          <location offset="975" length="18"/>
          <text>butyrylthiocholine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylthiocholine</infon>
          <location offset="1012" length="17"/>
          <text>acetylthiocholine</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acchoease</infon>
          <location offset="893" length="9"/>
          <text>AcChoEase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T15" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T13" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T14" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T16" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1031</offset>
        <text>The mutated enzyme was also inhibited well by the bulky, BtChoEase-selective organophosphate inhibitor (tetraisopropylpyrophosphoramide, iso-OMPA).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">organophosphate</infon>
          <location offset="1108" length="15"/>
          <text>organophosphate</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tetraisopropylpyrophosphoramide</infon>
          <location offset="1135" length="31"/>
          <text>tetraisopropylpyrophosphoramide</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iso-ompa</infon>
          <location offset="1168" length="8"/>
          <text>iso-OMPA</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">btchoease</infon>
          <location offset="1088" length="9"/>
          <text>BtChoEase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1179</offset>
        <text>Trp-279, at the entrance of the active-site gorge in AcChoEase, is absent in BtChoEase.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trp</infon>
          <location offset="1179" length="3"/>
          <text>Trp</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acchoease</infon>
          <location offset="1232" length="9"/>
          <text>AcChoEase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">btchoease</infon>
          <location offset="1256" length="9"/>
          <text>BtChoEase</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T4" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1267</offset>
        <text>Modeling designated it as part of the "peripheral" anionic site, which is lacking in BtChoEase.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">btchoease</infon>
          <location offset="1352" length="9"/>
          <text>BtChoEase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1363</offset>
        <text>The mutant W279A displayed strongly reduced inhibition by the peripheral site-specific ligand propidium relative to wild-type Torpedo AcChoEase, whereas inhibition by the catalytic-site inhibitor edrophonium was unaffected.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">propidium</infon>
          <location offset="1457" length="9"/>
          <text>propidium</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">edrophonium</infon>
          <location offset="1559" length="11"/>
          <text>edrophonium</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">w279a</infon>
          <location offset="1374" length="5"/>
          <text>W279A</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">torpedo acchoease</infon>
          <location offset="1489" length="17"/>
          <text>Torpedo AcChoEase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23561166</id>
    <passage>
      <offset>0</offset>
      <text>Effects of fisetin supplementation on hepatic lipogenesis and glucose metabolism in Sprague-Dawley rats fed on a high fat diet.	The modulatory effects of daily fisetin supplementation for 8weeks on genes involved in hepatic lipogenesis and gluconeogenesis and hyperglycemia in rats fed a high fat (HF) diet were evaluated. Elevated levels of triglyceride (TG), along with hepatic TG content and glucose concentrations in a high fat diet group were found to be reduced by fisetin supplementation. The high fat diet significantly increased hepatic mRNA expressions of PPARγ, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with fisetin. In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group. Finally, epididymal mRNA abundance of GLUT4 was significantly increased by fisetin supplementation, compared to levels in the control and HF groups. Enhancement of GLUT4 expression by fisetin was further confirmed in differentiated 3T3-L1 adipocytes. Fisetin supplementation decreases cardiovascular risks by ameliorating hepatic steatosis and lowering circulating glucose concentrations.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of fisetin supplementation on hepatic lipogenesis and glucose metabolism in Sprague-Dawley rats fed on a high fat diet.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="11" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="62" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>128</offset>
        <text>The modulatory effects of daily fisetin supplementation for 8weeks on genes involved in hepatic lipogenesis and gluconeogenesis and hyperglycemia in rats fed a high fat (HF) diet were evaluated.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="160" length="7"/>
          <text>fisetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>323</offset>
        <text>Elevated levels of triglyceride (TG), along with hepatic TG content and glucose concentrations in a high fat diet group were found to be reduced by fisetin supplementation.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triglyceride</infon>
          <location offset="342" length="12"/>
          <text>triglyceride</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="395" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="471" length="7"/>
          <text>fisetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>496</offset>
        <text>The high fat diet significantly increased hepatic mRNA expressions of PPARγ, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with fisetin.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="688" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="566" length="5"/>
          <text>PPARγ</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">srebp1c</infon>
          <location offset="573" length="7"/>
          <text>SREBP1C</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">scd-1</infon>
          <location offset="585" length="5"/>
          <text>SCD-1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>697</offset>
        <text>In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="710" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fas</infon>
          <location offset="782" length="3"/>
          <text>FAS</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">atpcl</infon>
          <location offset="787" length="5"/>
          <text>ATPCL</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g6pase</infon>
          <location offset="797" length="6"/>
          <text>G6Pase</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>835</offset>
        <text>Finally, epididymal mRNA abundance of GLUT4 was significantly increased by fisetin supplementation, compared to levels in the control and HF groups.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="910" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glut4</infon>
          <location offset="873" length="5"/>
          <text>GLUT4</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>984</offset>
        <text>Enhancement of GLUT4 expression by fisetin was further confirmed in differentiated 3T3-L1 adipocytes.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="1019" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glut4</infon>
          <location offset="999" length="5"/>
          <text>GLUT4</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1086</offset>
        <text>Fisetin supplementation decreases cardiovascular risks by ameliorating hepatic steatosis and lowering circulating glucose concentrations.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="1200" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="1086" length="7"/>
          <text>Fisetin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23151612</id>
    <passage>
      <offset>0</offset>
      <text>A review of anti-inflammatory agents for symptoms of schizophrenia.	Schizophrenia is a chronic debilitating mental disorder that affects about 1% of the US population. The pathophysiology and etiology remain unknown, thus new treatment targets have been challenging and few novel treatments with new mechanisms of action have come to market in the past few decades. Increasing attention has been paid to the role of inflammation in schizophrenia and new data suggests that decreasing inflammation and inflammatory biomarkers may play some role in schizophrenia treatment. This review summarizes the clinical trial literature regarding medications that possess anti-inflammatory properties that have been tested for schizophrenia symptoms and covers such medications as non-steroidal anti-inflammatory agents, such as the cyclo-oxygenase-2 (COX-2) inhibitors and aspirin, omega-3 fatty acids, neurosteroids and minocycline. Overall, there is accumulating evidence, albeit mostly adjunctive treatments, that agents working on inflammatory pathways have some benefits in people with schizophrenia. In the next few years the field will begin to see data on many treatments with anti-inflammatory properties that are currently under study. Hopefully advancements in understanding inflammation and effective treatments having anti-inflammatory properties may help revolutionize our understanding and provide new targets for prevention and treatment in schizophrenia.</text>
      <sentence>
        <offset>0</offset>
        <text>A review of anti-inflammatory agents for symptoms of schizophrenia.</text>
      </sentence>
      <sentence>
        <offset>68</offset>
        <text>Schizophrenia is a chronic debilitating mental disorder that affects about 1% of the US population.</text>
      </sentence>
      <sentence>
        <offset>168</offset>
        <text>The pathophysiology and etiology remain unknown, thus new treatment targets have been challenging and few novel treatments with new mechanisms of action have come to market in the past few decades.</text>
      </sentence>
      <sentence>
        <offset>366</offset>
        <text>Increasing attention has been paid to the role of inflammation in schizophrenia and new data suggests that decreasing inflammation and inflammatory biomarkers may play some role in schizophrenia treatment.</text>
      </sentence>
      <sentence>
        <offset>572</offset>
        <text>This review summarizes the clinical trial literature regarding medications that possess anti-inflammatory properties that have been tested for schizophrenia symptoms and covers such medications as non-steroidal anti-inflammatory agents, such as the cyclo-oxygenase-2 (COX-2) inhibitors and aspirin, omega-3 fatty acids, neurosteroids and minocycline.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroidal</infon>
          <location offset="773" length="9"/>
          <text>steroidal</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspirin</infon>
          <location offset="862" length="7"/>
          <text>aspirin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">omega-3 fatty acids</infon>
          <location offset="871" length="19"/>
          <text>omega-3 fatty acids</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">neurosteroids</infon>
          <location offset="892" length="13"/>
          <text>neurosteroids</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">minocycline</infon>
          <location offset="910" length="11"/>
          <text>minocycline</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclo-oxygenase-2</infon>
          <location offset="821" length="17"/>
          <text>cyclo-oxygenase-2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="840" length="5"/>
          <text>COX-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>923</offset>
        <text>Overall, there is accumulating evidence, albeit mostly adjunctive treatments, that agents working on inflammatory pathways have some benefits in people with schizophrenia.</text>
      </sentence>
      <sentence>
        <offset>1095</offset>
        <text>In the next few years the field will begin to see data on many treatments with anti-inflammatory properties that are currently under study.</text>
      </sentence>
      <sentence>
        <offset>1235</offset>
        <text>Hopefully advancements in understanding inflammation and effective treatments having anti-inflammatory properties may help revolutionize our understanding and provide new targets for prevention and treatment in schizophrenia.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10831596</id>
    <passage>
      <offset>0</offset>
      <text>Severe impairment of salivation in Na+/K+/2Cl- cotransporter (NKCC1)-deficient mice.	The salivary fluid secretory mechanism is thought to require Na(+)/K(+)/2Cl(-) cotransporter-mediated Cl(-) uptake. To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter. In wild-type mice NKCC1 was localized to the basolateral membranes of parotid acinar cells, whereas expression was not detected in duct cells. The lack of functional NKCC1 resulted in a dramatic reduction (&gt;60%) in the volume of saliva secreted in response to a muscarinic agonist, the primary in situ salivation signal. Consistent with defective Cl(-) uptake, a loss of bumetanide-sensitive Cl(-) influx was observed in parotid acinar cells from mice lacking NKCC1. Cl(-)/ HCO(3)(-) exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl(-) uptake. Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter. Furthermore, the ability of the parotid gland to conserve NaCl was abolished in NKCC1-deficient mice. This deficit was not associated with changes in the morphology of the ducts, but transcript levels for the alpha-, beta-, and gamma-subunits of the epithelial Na(+) channel were reduced. These data directly demonstrate that NKCC1 is the major Cl(-) uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.</text>
      <sentence>
        <offset>0</offset>
        <text>Severe impairment of salivation in Na+/K+/2Cl- cotransporter (NKCC1)-deficient mice.</text>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na+</infon>
          <location offset="35" length="3"/>
          <text>Na+</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k+</infon>
          <location offset="39" length="2"/>
          <text>K+</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2cl-</infon>
          <location offset="42" length="4"/>
          <text>2Cl-</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na+/k+/2cl- cotransporter</infon>
          <location offset="35" length="25"/>
          <text>Na+/K+/2Cl- cotransporter</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nkcc1</infon>
          <location offset="62" length="5"/>
          <text>NKCC1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>85</offset>
        <text>The salivary fluid secretory mechanism is thought to require Na(+)/K(+)/2Cl(-) cotransporter-mediated Cl(-) uptake.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cl(-)</infon>
          <location offset="187" length="5"/>
          <text>Cl(-)</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="146" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k(+)</infon>
          <location offset="152" length="4"/>
          <text>K(+)</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2cl(-)</infon>
          <location offset="157" length="6"/>
          <text>2Cl(-)</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na(+)/k(+)/2cl(-) cotransporter</infon>
          <location offset="146" length="31"/>
          <text>Na(+)/K(+)/2Cl(-) cotransporter</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>201</offset>
        <text>To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na(+)/K(+)/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na(+)/K(+)/2Cl(-) cotransporter.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="359" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k(+)</infon>
          <location offset="365" length="4"/>
          <text>K(+)</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2cl(-)</infon>
          <location offset="370" length="6"/>
          <text>2Cl(-)</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="441" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k(+)</infon>
          <location offset="447" length="4"/>
          <text>K(+)</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2cl(-)</infon>
          <location offset="452" length="6"/>
          <text>2Cl(-)</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">na(+)/k(+)/2cl(-) cotransporter isoform 1</infon>
          <location offset="359" length="41"/>
          <text>Na(+)/K(+)/2Cl(-) cotransporter isoform 1</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nkcc1</infon>
          <location offset="402" length="5"/>
          <text>Nkcc1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na(+)/k(+)/2cl(-) cotransporter</infon>
          <location offset="441" length="31"/>
          <text>Na(+)/K(+)/2Cl(-) cotransporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>474</offset>
        <text>In wild-type mice NKCC1 was localized to the basolateral membranes of parotid acinar cells, whereas expression was not detected in duct cells.</text>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nkcc1</infon>
          <location offset="492" length="5"/>
          <text>NKCC1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>617</offset>
        <text>The lack of functional NKCC1 resulted in a dramatic reduction (&gt;60%) in the volume of saliva secreted in response to a muscarinic agonist, the primary in situ salivation signal.</text>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nkcc1</infon>
          <location offset="640" length="5"/>
          <text>NKCC1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>795</offset>
        <text>Consistent with defective Cl(-) uptake, a loss of bumetanide-sensitive Cl(-) influx was observed in parotid acinar cells from mice lacking NKCC1.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cl(-)</infon>
          <location offset="821" length="5"/>
          <text>Cl(-)</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bumetanide</infon>
          <location offset="845" length="10"/>
          <text>bumetanide</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cl(-)</infon>
          <location offset="866" length="5"/>
          <text>Cl(-)</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nkcc1</infon>
          <location offset="934" length="5"/>
          <text>NKCC1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>941</offset>
        <text>Cl(-)/ HCO(3)(-) exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl(-) uptake.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cl(-)</infon>
          <location offset="1155" length="5"/>
          <text>Cl(-)</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cl(-)</infon>
          <location offset="941" length="5"/>
          <text>Cl(-)</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hco(3)(-)</infon>
          <location offset="948" length="9"/>
          <text>HCO(3)(-)</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nkcc1</infon>
          <location offset="1104" length="5"/>
          <text>NKCC1</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cl(-)/ hco(3)(-) exchanger</infon>
          <location offset="941" length="26"/>
          <text>Cl(-)/ HCO(3)(-) exchanger</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1169</offset>
        <text>Indeed, expression of the Cl(-)/ HCO(3)(-) exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na(+)/K(+)/2Cl(-) cotransporter.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cl(-)</infon>
          <location offset="1195" length="5"/>
          <text>Cl(-)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hco(3)(-)</infon>
          <location offset="1202" length="9"/>
          <text>HCO(3)(-)</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1311" length="5"/>
          <text>Na(+)</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">k(+)</infon>
          <location offset="1317" length="4"/>
          <text>K(+)</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2cl(-)</infon>
          <location offset="1322" length="6"/>
          <text>2Cl(-)</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cl(-)/ hco(3)(-) exchanger</infon>
          <location offset="1195" length="26"/>
          <text>Cl(-)/ HCO(3)(-) exchanger</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ae2</infon>
          <location offset="1222" length="3"/>
          <text>AE2</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">na(+)/k(+)/2cl(-) cotransporter</infon>
          <location offset="1311" length="31"/>
          <text>Na(+)/K(+)/2Cl(-) cotransporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1344</offset>
        <text>Furthermore, the ability of the parotid gland to conserve NaCl was abolished in NKCC1-deficient mice.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nacl</infon>
          <location offset="1402" length="4"/>
          <text>NaCl</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nkcc1</infon>
          <location offset="1424" length="5"/>
          <text>NKCC1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1446</offset>
        <text>This deficit was not associated with changes in the morphology of the ducts, but transcript levels for the alpha-, beta-, and gamma-subunits of the epithelial Na(+) channel were reduced.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">na(+)</infon>
          <location offset="1605" length="5"/>
          <text>Na(+)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1633</offset>
        <text>These data directly demonstrate that NKCC1 is the major Cl(-) uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cl(-)</infon>
          <location offset="1689" length="5"/>
          <text>Cl(-)</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nkcc1</infon>
          <location offset="1670" length="5"/>
          <text>NKCC1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T10" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23524313</id>
    <passage>
      <offset>0</offset>
      <text>Hypocholesterolemic effect of daily fisetin supplementation in high fat fed Sprague-Dawley rats.	We aimed to test whether fisetin could modulate cholesterol homeostasis in rats with diet-induced hypercholesterolemia, and further investigated the underlying mechanisms by which fisetin exerts its cholesterol lowering effect. Blood lipid profile, hepatic cholesterol content, as well as gene expressions in cholesterol metabolism were examined. Elevated levels of total cholesterol and LDL-cholesterol, along with hepatic cholesterol content in a high fat group were found to be significantly reduced by fisetin. The high fat diet significantly decreased hepatic mRNA levels of LDLR, SREBP2, HMGCR and PCSK9 in comparison to the control diet, however, fisetin did not further elicit any changes in mRNA levels of the same genes. The high fat diet dramatically increased the transcript levels of CYP7A1, which was subsequently reversed by the fisetin. In HepG2 cells, fisetin was found to increase the levels of a nuclear form of SREBP2 and LDLR. In conclusion, fisetin supplementation displayed hypocholesterolemic effects by modulating the expression of genes associated with cholesterol and bile acid metabolism.</text>
      <sentence>
        <offset>0</offset>
        <text>Hypocholesterolemic effect of daily fisetin supplementation in high fat fed Sprague-Dawley rats.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="36" length="7"/>
          <text>fisetin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>97</offset>
        <text>We aimed to test whether fisetin could modulate cholesterol homeostasis in rats with diet-induced hypercholesterolemia, and further investigated the underlying mechanisms by which fisetin exerts its cholesterol lowering effect.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="277" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="296" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="122" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="145" length="11"/>
          <text>cholesterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>325</offset>
        <text>Blood lipid profile, hepatic cholesterol content, as well as gene expressions in cholesterol metabolism were examined.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="354" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="406" length="11"/>
          <text>cholesterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>444</offset>
        <text>Elevated levels of total cholesterol and LDL-cholesterol, along with hepatic cholesterol content in a high fat group were found to be significantly reduced by fisetin.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="469" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="489" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="521" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="603" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldl</infon>
          <location offset="485" length="3"/>
          <text>LDL</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>612</offset>
        <text>The high fat diet significantly decreased hepatic mRNA levels of LDLR, SREBP2, HMGCR and PCSK9 in comparison to the control diet, however, fisetin did not further elicit any changes in mRNA levels of the same genes.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="751" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldlr</infon>
          <location offset="677" length="4"/>
          <text>LDLR</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">srebp2</infon>
          <location offset="683" length="6"/>
          <text>SREBP2</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hmgcr</infon>
          <location offset="691" length="5"/>
          <text>HMGCR</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pcsk9</infon>
          <location offset="701" length="5"/>
          <text>PCSK9</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>828</offset>
        <text>The high fat diet dramatically increased the transcript levels of CYP7A1, which was subsequently reversed by the fisetin.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="941" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp7a1</infon>
          <location offset="894" length="6"/>
          <text>CYP7A1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>950</offset>
        <text>In HepG2 cells, fisetin was found to increase the levels of a nuclear form of SREBP2 and LDLR.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="966" length="7"/>
          <text>fisetin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">srebp2</infon>
          <location offset="1028" length="6"/>
          <text>SREBP2</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ldlr</infon>
          <location offset="1039" length="4"/>
          <text>LDLR</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1045</offset>
        <text>In conclusion, fisetin supplementation displayed hypocholesterolemic effects by modulating the expression of genes associated with cholesterol and bile acid metabolism.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1176" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bile acid</infon>
          <location offset="1192" length="9"/>
          <text>bile acid</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fisetin</infon>
          <location offset="1060" length="7"/>
          <text>fisetin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>1403790</id>
    <passage>
      <offset>0</offset>
      <text>The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.	Pigeons were trained to discriminate i.m. injections of the atypical antipsychotic clozapine (1.0 mg/kg) from saline in a two-key operant procedure. In substitution tests, compounds that shared antagonistic action at 5-hydroxytryptamine (5-HT)1C and 5-HT2 receptors produced discriminative stimulus effects similar to clozapine: cyproheptadine, metergoline, mianserin, pizotifen and fluperlapine. 5-HT antagonists selective for 5-HT2 vs. 5-HT1C receptors (e.g., ketanserin, pirenperone, risperidone and methiothepin) failed to produce substantial clozapine-appropriate responding. Other serotonergic compounds failed to produce substantial clozapine-appropriate responding: the 5-HT3 antagonist, ondansetron; the 5-HT1A agonists, (+-)-8-hydroxy-2-(di-n-propylamino)tetralin and BMY 14802; the 5-HT1A/1B agonist, RU24969; the 5-HT1A partial agonist, NAN190; the 5-HT1C/2 antagonist, mesulergine; the 5-HT1 agonist, I-5-hydroxytryptophane; and the 5-HT1C/2 agonist, quipazine. Other reference compounds such as the typical antipsychotics, chlorpromazine and thioridazine; the selective dopamine D-2 antagonists, droperidol and sulpiride; the dopamine D-1 antagonist, SCH 23390; the antimuscarinics, atropine and scopolamine; the antihistamines, pyrilamine and diphenhydramine; the alpha-1 antagonist, prazosin; and the antidepressants, imipramine and chloromipramine also failed to produce clozapine-appropriate responding. Promethazine, cinanserin and amitriptyline produced only partial generalization to the clozapine cue. The results suggest that blockade of both 5-HT2 and/or 5-HT1C receptors is important in the pharmacological mediation of the discriminative stimulus effects of clozapine. Blockade of 5-HT2 receptors appears not to be sufficient to produce clozapine-like discriminative stimulus effects. The precise role of 5-HT1C receptors in the clozapine discriminative stimulus is unclear due to the lack of compounds selective for this receptor.(ABSTRACT TRUNCATED AT 250 WORDS)</text>
      <sentence>
        <offset>0</offset>
        <text>The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.</text>
        <annotation id="T47">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="39" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T65">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-hydroxytryptamine2</infon>
          <location offset="102" length="20"/>
          <text>5-hydroxytryptamine2</text>
        </annotation>
        <annotation id="T66">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-hydroxytryptamine1c</infon>
          <location offset="76" length="21"/>
          <text>5-hydroxytryptamine1C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>134</offset>
        <text>Pigeons were trained to discriminate i.m. injections of the atypical antipsychotic clozapine (1.0 mg/kg) from saline in a two-key operant procedure.</text>
        <annotation id="T42">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="217" length="9"/>
          <text>clozapine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>283</offset>
        <text>In substitution tests, compounds that shared antagonistic action at 5-hydroxytryptamine (5-HT)1C and 5-HT2 receptors produced discriminative stimulus effects similar to clozapine: cyproheptadine, metergoline, mianserin, pizotifen and fluperlapine.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-hydroxytryptamine</infon>
          <location offset="351" length="19"/>
          <text>5-hydroxytryptamine</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="372" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="452" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyproheptadine</infon>
          <location offset="463" length="14"/>
          <text>cyproheptadine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metergoline</infon>
          <location offset="479" length="11"/>
          <text>metergoline</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mianserin</infon>
          <location offset="492" length="9"/>
          <text>mianserin</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pizotifen</infon>
          <location offset="503" length="9"/>
          <text>pizotifen</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluperlapine</infon>
          <location offset="517" length="12"/>
          <text>fluperlapine</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-hydroxytryptamine (5-ht)1c</infon>
          <location offset="351" length="28"/>
          <text>5-hydroxytryptamine (5-HT)1C</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2</infon>
          <location offset="384" length="5"/>
          <text>5-HT2</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T25" role="head"/>
          <node refid="T55" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T28" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T29" role="head"/>
          <node refid="T55" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T30" role="head"/>
          <node refid="T55" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T28" role="head"/>
          <node refid="T55" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T27" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T26" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T27" role="head"/>
          <node refid="T55" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T25" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T26" role="head"/>
          <node refid="T55" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T29" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T30" role="head"/>
          <node refid="T54" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>531</offset>
        <text>5-HT antagonists selective for 5-HT2 vs. 5-HT1C receptors (e.g., ketanserin, pirenperone, risperidone and methiothepin) failed to produce substantial clozapine-appropriate responding.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="531" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketanserin</infon>
          <location offset="596" length="10"/>
          <text>ketanserin</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pirenperone</infon>
          <location offset="608" length="11"/>
          <text>pirenperone</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">risperidone</infon>
          <location offset="621" length="11"/>
          <text>risperidone</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methiothepin</infon>
          <location offset="637" length="12"/>
          <text>methiothepin</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="681" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2</infon>
          <location offset="562" length="5"/>
          <text>5-HT2</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1c</infon>
          <location offset="572" length="6"/>
          <text>5-HT1C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>715</offset>
        <text>Other serotonergic compounds failed to produce substantial clozapine-appropriate responding: the 5-HT3 antagonist, ondansetron; the 5-HT1A agonists, (+-)-8-hydroxy-2-(di-n-propylamino)tetralin and BMY 14802; the 5-HT1A/1B agonist, RU24969; the 5-HT1A partial agonist, NAN190; the 5-HT1C/2 antagonist, mesulergine; the 5-HT1 agonist, I-5-hydroxytryptophane; and the 5-HT1C/2 agonist, quipazine.</text>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="774" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ondansetron</infon>
          <location offset="830" length="11"/>
          <text>ondansetron</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(+-)-8-hydroxy-2-(di-n-propylamino)tetralin</infon>
          <location offset="864" length="43"/>
          <text>(+-)-8-hydroxy-2-(di-n-propylamino)tetralin</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bmy 14802</infon>
          <location offset="912" length="9"/>
          <text>BMY 14802</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ru24969</infon>
          <location offset="946" length="7"/>
          <text>RU24969</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nan190</infon>
          <location offset="983" length="6"/>
          <text>NAN190</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mesulergine</infon>
          <location offset="1016" length="11"/>
          <text>mesulergine</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">i-5-hydroxytryptophane</infon>
          <location offset="1048" length="22"/>
          <text>I-5-hydroxytryptophane</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quipazine</infon>
          <location offset="1098" length="9"/>
          <text>quipazine</text>
        </annotation>
        <annotation id="T58">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht3</infon>
          <location offset="812" length="5"/>
          <text>5-HT3</text>
        </annotation>
        <annotation id="T59">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="847" length="6"/>
          <text>5-HT1A</text>
        </annotation>
        <annotation id="T60">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1a/1b</infon>
          <location offset="927" length="9"/>
          <text>5-HT1A/1B</text>
        </annotation>
        <annotation id="T61">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="959" length="6"/>
          <text>5-HT1A</text>
        </annotation>
        <annotation id="T62">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1c/2</infon>
          <location offset="995" length="8"/>
          <text>5-HT1C/2</text>
        </annotation>
        <annotation id="T63">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1</infon>
          <location offset="1033" length="5"/>
          <text>5-HT1</text>
        </annotation>
        <annotation id="T64">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1c/2</infon>
          <location offset="1080" length="8"/>
          <text>5-HT1C/2</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T45" role="head"/>
          <node refid="T63" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T43" role="head"/>
          <node refid="T61" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T40" role="head"/>
          <node refid="T59" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T38" role="head"/>
          <node refid="T58" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T39" role="head"/>
          <node refid="T59" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1109</offset>
        <text>Other reference compounds such as the typical antipsychotics, chlorpromazine and thioridazine; the selective dopamine D-2 antagonists, droperidol and sulpiride; the dopamine D-1 antagonist, SCH 23390; the antimuscarinics, atropine and scopolamine; the antihistamines, pyrilamine and diphenhydramine; the alpha-1 antagonist, prazosin; and the antidepressants, imipramine and chloromipramine also failed to produce clozapine-appropriate responding.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorpromazine</infon>
          <location offset="1171" length="14"/>
          <text>chlorpromazine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thioridazine</infon>
          <location offset="1190" length="12"/>
          <text>thioridazine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1218" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">droperidol</infon>
          <location offset="1244" length="10"/>
          <text>droperidol</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulpiride</infon>
          <location offset="1259" length="9"/>
          <text>sulpiride</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1274" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sch 23390</infon>
          <location offset="1299" length="9"/>
          <text>SCH 23390</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atropine</infon>
          <location offset="1331" length="8"/>
          <text>atropine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">scopolamine</infon>
          <location offset="1344" length="11"/>
          <text>scopolamine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrilamine</infon>
          <location offset="1377" length="10"/>
          <text>pyrilamine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diphenhydramine</infon>
          <location offset="1392" length="15"/>
          <text>diphenhydramine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prazosin</infon>
          <location offset="1433" length="8"/>
          <text>prazosin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imipramine</infon>
          <location offset="1468" length="10"/>
          <text>imipramine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chloromipramine</infon>
          <location offset="1483" length="15"/>
          <text>chloromipramine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="1522" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine d-2</infon>
          <location offset="1218" length="12"/>
          <text>dopamine D-2</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine d-1</infon>
          <location offset="1274" length="12"/>
          <text>dopamine D-1</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T49" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1556</offset>
        <text>Promethazine, cinanserin and amitriptyline produced only partial generalization to the clozapine cue.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">promethazine</infon>
          <location offset="1556" length="12"/>
          <text>Promethazine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cinanserin</infon>
          <location offset="1570" length="10"/>
          <text>cinanserin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amitriptyline</infon>
          <location offset="1585" length="13"/>
          <text>amitriptyline</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="1643" length="9"/>
          <text>clozapine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1658</offset>
        <text>The results suggest that blockade of both 5-HT2 and/or 5-HT1C receptors is important in the pharmacological mediation of the discriminative stimulus effects of clozapine.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="1818" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2</infon>
          <location offset="1700" length="5"/>
          <text>5-HT2</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1c</infon>
          <location offset="1713" length="6"/>
          <text>5-HT1C</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1829</offset>
        <text>Blockade of 5-HT2 receptors appears not to be sufficient to produce clozapine-like discriminative stimulus effects.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="1897" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht2</infon>
          <location offset="1841" length="5"/>
          <text>5-HT2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1945</offset>
        <text>The precise role of 5-HT1C receptors in the clozapine discriminative stimulus is unclear due to the lack of compounds selective for this receptor.(ABSTRACT TRUNCATED AT 250 WORDS)</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clozapine</infon>
          <location offset="1989" length="9"/>
          <text>clozapine</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">5-ht1c</infon>
          <location offset="1965" length="6"/>
          <text>5-HT1C</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23353748</id>
    <passage>
      <offset>0</offset>
      <text>Design, synthesis and biological evaluation of novel hybrid compounds of imidazole scaffold-based 2-benzylbenzofuran as potent anticancer agents.	A series of novel hybrid compounds between 2-benzylbenzofuran and imidazole has been prepared and evaluated in vitro against a panel of human tumor cell lines. The results suggest that the existence of benzimidazole ring and substitution of the imidazolyl-3-position with a naphthylacyl or 4-methoxyphenacyl group were vital for modulating cytotoxic activity. In particular, hybrid compounds 46 and 47 were found to be the most potent derivatives against 5 strains human tumor cell lines and more active than cisplatin (DDP), and exhibited cytotoxic activities selectively against breast carcinoma (MCF-7) and myeloid liver carcinoma (SMMC-7721), respectively.</text>
      <sentence>
        <offset>0</offset>
        <text>Design, synthesis and biological evaluation of novel hybrid compounds of imidazole scaffold-based 2-benzylbenzofuran as potent anticancer agents.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imidazole</infon>
          <location offset="73" length="9"/>
          <text>imidazole</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-benzylbenzofuran</infon>
          <location offset="98" length="18"/>
          <text>2-benzylbenzofuran</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>146</offset>
        <text>A series of novel hybrid compounds between 2-benzylbenzofuran and imidazole has been prepared and evaluated in vitro against a panel of human tumor cell lines.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-benzylbenzofuran</infon>
          <location offset="189" length="18"/>
          <text>2-benzylbenzofuran</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imidazole</infon>
          <location offset="212" length="9"/>
          <text>imidazole</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>306</offset>
        <text>The results suggest that the existence of benzimidazole ring and substitution of the imidazolyl-3-position with a naphthylacyl or 4-methoxyphenacyl group were vital for modulating cytotoxic activity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzimidazole</infon>
          <location offset="348" length="13"/>
          <text>benzimidazole</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imidazolyl</infon>
          <location offset="391" length="10"/>
          <text>imidazolyl</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">naphthylacyl</infon>
          <location offset="420" length="12"/>
          <text>naphthylacyl</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-methoxyphenacyl</infon>
          <location offset="436" length="17"/>
          <text>4-methoxyphenacyl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>506</offset>
        <text>In particular, hybrid compounds 46 and 47 were found to be the most potent derivatives against 5 strains human tumor cell lines and more active than cisplatin (DDP), and exhibited cytotoxic activities selectively against breast carcinoma (MCF-7) and myeloid liver carcinoma (SMMC-7721), respectively.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cisplatin</infon>
          <location offset="655" length="9"/>
          <text>cisplatin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ddp</infon>
          <location offset="666" length="3"/>
          <text>DDP</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12065695</id>
    <passage>
      <offset>0</offset>
      <text>Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells.	Nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to induce apoptosis in a variety of cell lines. In this study, we examined the effect of NSAIDs on the growth and apoptosis of synovial cells from patients with rheumatoid arthritis and analyzed the activation of peroxisome proliferator-activated receptor gamma (PPARgamma) as a possible mechanism of action of NSAIDs. Cell proliferation and viability were assessed from 5-bromo-2'-deoxyuridine incorporation and by 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) assay, respectively. The apoptosis of synovial cells was identified by DNA fragmentation assay and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. Indometacin, diclofenac, oxaprozin, and zaltoprofen reduced cell proliferation and induced apoptotic cell death in synovial cells, whereas ketoprofen and acetaminophen did not. N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis. Rheumatoid synovial cells expressed PPARgamma mRNA, and the PPARgamma ligands 15-deoxy-Delta(12,14)-prostaglandin J(2) and troglitazone reduced the proliferation and induced apoptosis in synovial cells. Luciferase reporter assay demonstrated that not only PPARgamma ligands but also NSAIDs, which could induce apoptosis, increased the activation of PPARgamma in synovial cells. Furthermore, the ability of NSAIDs and PPARgamma ligands to stimulate the activation of PPARgamma correlated with their ability to decrease cell viability(r = 0.92, p &lt; 0.01) and ability to induce DNA fragmentation (r = 0.97, p &lt; 0.001) in synovial cells. These results suggest that PPARgamma is an attractive target for induction of apoptosis in rheumatoid synovial cells and that the activation of the PPARgamma pathway is associated with the apoptotic action of NSAIDs.</text>
      <sentence>
        <offset>0</offset>
        <text>Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor gamma</infon>
          <location offset="88" length="48"/>
          <text>peroxisome proliferator-activated receptor gamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>167</offset>
        <text>Nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to induce apoptosis in a variety of cell lines.</text>
      </sentence>
      <sentence>
        <offset>280</offset>
        <text>In this study, we examined the effect of NSAIDs on the growth and apoptosis of synovial cells from patients with rheumatoid arthritis and analyzed the activation of peroxisome proliferator-activated receptor gamma (PPARgamma) as a possible mechanism of action of NSAIDs.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor gamma</infon>
          <location offset="445" length="48"/>
          <text>peroxisome proliferator-activated receptor gamma</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="495" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>551</offset>
        <text>Cell proliferation and viability were assessed from 5-bromo-2'-deoxyuridine incorporation and by 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) assay, respectively.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-bromo-2'-deoxyuridine</infon>
          <location offset="603" length="23"/>
          <text>5-bromo-2'-deoxyuridine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2h-5-tetrazolio]-1,3-benzene disulfonate</infon>
          <location offset="648" length="78"/>
          <text>4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">wst-1</infon>
          <location offset="728" length="5"/>
          <text>WST-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>756</offset>
        <text>The apoptosis of synovial cells was identified by DNA fragmentation assay and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay.</text>
      </sentence>
      <sentence>
        <offset>911</offset>
        <text>Indometacin, diclofenac, oxaprozin, and zaltoprofen reduced cell proliferation and induced apoptotic cell death in synovial cells, whereas ketoprofen and acetaminophen did not.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">indometacin</infon>
          <location offset="911" length="11"/>
          <text>Indometacin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">diclofenac</infon>
          <location offset="924" length="10"/>
          <text>diclofenac</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxaprozin</infon>
          <location offset="936" length="9"/>
          <text>oxaprozin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zaltoprofen</infon>
          <location offset="951" length="11"/>
          <text>zaltoprofen</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketoprofen</infon>
          <location offset="1050" length="10"/>
          <text>ketoprofen</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetaminophen</infon>
          <location offset="1065" length="13"/>
          <text>acetaminophen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1088</offset>
        <text>N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide</infon>
          <location offset="1088" length="55"/>
          <text>N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ns-398</infon>
          <location offset="1145" length="6"/>
          <text>NS-398</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclooxygenase-2</infon>
          <location offset="1166" length="16"/>
          <text>cyclooxygenase-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1265</offset>
        <text>Rheumatoid synovial cells expressed PPARgamma mRNA, and the PPARgamma ligands 15-deoxy-Delta(12,14)-prostaglandin J(2) and troglitazone reduced the proliferation and induced apoptosis in synovial cells.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">15-deoxy-delta(12,14)-prostaglandin j(2)</infon>
          <location offset="1343" length="40"/>
          <text>15-deoxy-Delta(12,14)-prostaglandin J(2)</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="1388" length="12"/>
          <text>troglitazone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1301" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1325" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1468</offset>
        <text>Luciferase reporter assay demonstrated that not only PPARgamma ligands but also NSAIDs, which could induce apoptosis, increased the activation of PPARgamma in synovial cells.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1521" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1614" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1643</offset>
        <text>Furthermore, the ability of NSAIDs and PPARgamma ligands to stimulate the activation of PPARgamma correlated with their ability to decrease cell viability(r = 0.92, p &lt; 0.01) and ability to induce DNA fragmentation (r = 0.97, p &lt; 0.001) in synovial cells.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1682" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1731" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1899</offset>
        <text>These results suggest that PPARgamma is an attractive target for induction of apoptosis in rheumatoid synovial cells and that the activation of the PPARgamma pathway is associated with the apoptotic action of NSAIDs.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1926" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="2047" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23402744</id>
    <passage>
      <offset>0</offset>
      <text>Sexually dimorphic behavior after developmental exposure to characterize endocrine-mediated effects of different non-dioxin-like PCBs in rats.	Many chemicals are known to exhibit endocrine activity and affect reproductive functions in vertebrates and invertebrates. Endocrine effects include influences on sexual differentiation of the brain during development and reproductive and non-reproductive behavior in adult offspring. We previously demonstrated that developmental exposure to a mixture of polychlorinated biphenyls (PCBs) which was reconstituted according to the congener pattern found in human breast milk caused feminization of sweet preference as a sexually dimorphic behavior in adult male rats, following decreases in aromatase activity in the brain of newborn male pups. This result may be due to dioxin-like or non-dioxin-like (NDL) PCBs and their respective effects on steroid hormones. The aim of the present experiments was to determine if exposure to highly purified NDL-PCBs (to remove Ah receptor active contaminants) also results in alteration of sweet preference. Pregnant rats were orally exposed to PCB52 (6 dose groups, total dose of 0-3000mg/kg body weight) or PCB180 (6 dose groups, total dose of 0-1000mg/kg body weight). In a further experiment rat dams were treated with equimolar doses of PCB74 or PCB95 (total dose, 760μmol/kg body weight, corresponding to 229mg/kg or 248mg/kg body weight of PCB74 and PCB95, respectively). Adult male and female offspring were given a choice between a bottle of saccharin solution (0.25%) and a bottle of tap water on five consecutive days. Control females consumed approximately twice as much sweetened solution compared with control males, thus, demonstrating sexual dimorphism of this behavior. Only non-significant reduction of sweet preference was found at the top dose level in female offspring after exposure to PCB52. Female offspring exposed to PCB180 exhibited signs of supernormal behavior as illustrated by increased saccharin consumption at intermediate dose levels. Decreased sweet preference was observed in females after developmental PCB74, whereas males were unaffected. Only PCB95 increased saccharin consumption in exposed males, leading to decreased sexual dimorphism of this behavior and behavioral feminization. The results demonstrate that different NDL-PCBs exhibit differential effects on sexually dimorphic behavior and that feminization occurs after removal of Ah receptor active contaminants. Comparison with data from the literature reveals little evidence for a relation to anti-androgenic activity of the studied NDL-PCBs.</text>
      <sentence>
        <offset>0</offset>
        <text>Sexually dimorphic behavior after developmental exposure to characterize endocrine-mediated effects of different non-dioxin-like PCBs in rats.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dioxin</infon>
          <location offset="117" length="6"/>
          <text>dioxin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcbs</infon>
          <location offset="129" length="4"/>
          <text>PCBs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>143</offset>
        <text>Many chemicals are known to exhibit endocrine activity and affect reproductive functions in vertebrates and invertebrates.</text>
      </sentence>
      <sentence>
        <offset>266</offset>
        <text>Endocrine effects include influences on sexual differentiation of the brain during development and reproductive and non-reproductive behavior in adult offspring.</text>
      </sentence>
      <sentence>
        <offset>428</offset>
        <text>We previously demonstrated that developmental exposure to a mixture of polychlorinated biphenyls (PCBs) which was reconstituted according to the congener pattern found in human breast milk caused feminization of sweet preference as a sexually dimorphic behavior in adult male rats, following decreases in aromatase activity in the brain of newborn male pups.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polychlorinated biphenyls</infon>
          <location offset="499" length="25"/>
          <text>polychlorinated biphenyls</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcbs</infon>
          <location offset="526" length="4"/>
          <text>PCBs</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">aromatase</infon>
          <location offset="733" length="9"/>
          <text>aromatase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>787</offset>
        <text>This result may be due to dioxin-like or non-dioxin-like (NDL) PCBs and their respective effects on steroid hormones.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dioxin</infon>
          <location offset="813" length="6"/>
          <text>dioxin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dioxin</infon>
          <location offset="832" length="6"/>
          <text>dioxin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcbs</infon>
          <location offset="850" length="4"/>
          <text>PCBs</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">steroid</infon>
          <location offset="887" length="7"/>
          <text>steroid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>905</offset>
        <text>The aim of the present experiments was to determine if exposure to highly purified NDL-PCBs (to remove Ah receptor active contaminants) also results in alteration of sweet preference.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcbs</infon>
          <location offset="992" length="4"/>
          <text>PCBs</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ah receptor</infon>
          <location offset="1008" length="11"/>
          <text>Ah receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1089</offset>
        <text>Pregnant rats were orally exposed to PCB52 (6 dose groups, total dose of 0-3000mg/kg body weight) or PCB180 (6 dose groups, total dose of 0-1000mg/kg body weight).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb180</infon>
          <location offset="1190" length="6"/>
          <text>PCB180</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb52</infon>
          <location offset="1126" length="5"/>
          <text>PCB52</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1253</offset>
        <text>In a further experiment rat dams were treated with equimolar doses of PCB74 or PCB95 (total dose, 760μmol/kg body weight, corresponding to 229mg/kg or 248mg/kg body weight of PCB74 and PCB95, respectively).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb74</infon>
          <location offset="1323" length="5"/>
          <text>PCB74</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb95</infon>
          <location offset="1332" length="5"/>
          <text>PCB95</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb74</infon>
          <location offset="1428" length="5"/>
          <text>PCB74</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb95</infon>
          <location offset="1438" length="5"/>
          <text>PCB95</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1460</offset>
        <text>Adult male and female offspring were given a choice between a bottle of saccharin solution (0.25%) and a bottle of tap water on five consecutive days.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">saccharin</infon>
          <location offset="1532" length="9"/>
          <text>saccharin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1611</offset>
        <text>Control females consumed approximately twice as much sweetened solution compared with control males, thus, demonstrating sexual dimorphism of this behavior.</text>
      </sentence>
      <sentence>
        <offset>1768</offset>
        <text>Only non-significant reduction of sweet preference was found at the top dose level in female offspring after exposure to PCB52.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb52</infon>
          <location offset="1889" length="5"/>
          <text>PCB52</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1896</offset>
        <text>Female offspring exposed to PCB180 exhibited signs of supernormal behavior as illustrated by increased saccharin consumption at intermediate dose levels.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb180</infon>
          <location offset="1924" length="6"/>
          <text>PCB180</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">saccharin</infon>
          <location offset="1999" length="9"/>
          <text>saccharin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2050</offset>
        <text>Decreased sweet preference was observed in females after developmental PCB74, whereas males were unaffected.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb74</infon>
          <location offset="2121" length="5"/>
          <text>PCB74</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2159</offset>
        <text>Only PCB95 increased saccharin consumption in exposed males, leading to decreased sexual dimorphism of this behavior and behavioral feminization.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcb95</infon>
          <location offset="2164" length="5"/>
          <text>PCB95</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">saccharin</infon>
          <location offset="2180" length="9"/>
          <text>saccharin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2305</offset>
        <text>The results demonstrate that different NDL-PCBs exhibit differential effects on sexually dimorphic behavior and that feminization occurs after removal of Ah receptor active contaminants.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcbs</infon>
          <location offset="2348" length="4"/>
          <text>PCBs</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ah receptor</infon>
          <location offset="2459" length="11"/>
          <text>Ah receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2492</offset>
        <text>Comparison with data from the literature reveals little evidence for a relation to anti-androgenic activity of the studied NDL-PCBs.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pcbs</infon>
          <location offset="2619" length="4"/>
          <text>PCBs</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10666203</id>
    <passage>
      <offset>0</offset>
      <text>Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1.	Streptokinase activates platelets, limiting its effectiveness as a thrombolytic agent. The role of antistreptokinase antibodies and proteases in streptokinase-induced platelet activation was investigated. Streptokinase induced localization of human IgG to the platelet surface, platelet aggregation, and thromboxane A(2) production. These effects were inhibited by a monoclonal antibody to the platelet Fc receptor, IV.3. The platelet response to streptokinase was also blocked by an antibody directed against the cleavage site of the platelet thrombin receptor, protease-activated receptor-1 (PAR-1), but not by hirudin or an active site thrombin inhibitor, Ro46-6240. In plasma depleted of plasminogen, exogenous wild-type plasminogen, but not an inactive mutant protein, S(741)A plasminogen, supported platelet aggregation, suggesting that the protease cleaving PAR-1 was streptokinase-plasminogen. Streptokinase-plasminogen cleaved a synthetic peptide corresponding to PAR-1, resulting in generation of PAR-1 tethered ligand sequence and selectively reduced binding of a cleavage-sensitive PAR-1 antibody in intact cells. A combination of streptokinase, plasminogen, and antistreptokinase antibodies activated human erythroleukemic cells and was inhibited by pretreatment with IV.3 or pretreating the cells with the PAR-1 agonist SFLLRN, suggesting Fc receptor and PAR-1 interactions are necessary for cell activation in this system also. Streptokinase-induced platelet activation is dependent on both antistreptokinase-Fc receptor interactions and cleavage of PAR-1. (Blood. 2000;95:1301-1308)</text>
      <sentence>
        <offset>0</offset>
        <text>Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1.</text>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">streptokinase</infon>
          <location offset="0" length="13"/>
          <text>Streptokinase</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">protease-activated receptor-1</infon>
          <location offset="96" length="29"/>
          <text>protease-activated receptor-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>127</offset>
        <text>Streptokinase activates platelets, limiting its effectiveness as a thrombolytic agent.</text>
        <annotation id="T2">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">streptokinase</infon>
          <location offset="127" length="13"/>
          <text>Streptokinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>214</offset>
        <text>The role of antistreptokinase antibodies and proteases in streptokinase-induced platelet activation was investigated.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteases</infon>
          <location offset="259" length="9"/>
          <text>proteases</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">streptokinase</infon>
          <location offset="272" length="13"/>
          <text>streptokinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>332</offset>
        <text>Streptokinase induced localization of human IgG to the platelet surface, platelet aggregation, and thromboxane A(2) production.</text>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">streptokinase</infon>
          <location offset="332" length="13"/>
          <text>Streptokinase</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human igg</infon>
          <location offset="370" length="9"/>
          <text>human IgG</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>460</offset>
        <text>These effects were inhibited by a monoclonal antibody to the platelet Fc receptor, IV.3.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fc receptor, iv.3</infon>
          <location offset="530" length="17"/>
          <text>Fc receptor, IV.3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>549</offset>
        <text>The platelet response to streptokinase was also blocked by an antibody directed against the cleavage site of the platelet thrombin receptor, protease-activated receptor-1 (PAR-1), but not by hirudin or an active site thrombin inhibitor, Ro46-6240.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ro46-6240</infon>
          <location offset="786" length="9"/>
          <text>Ro46-6240</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">streptokinase</infon>
          <location offset="574" length="13"/>
          <text>streptokinase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">platelet thrombin receptor</infon>
          <location offset="662" length="26"/>
          <text>platelet thrombin receptor</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">protease-activated receptor-1</infon>
          <location offset="690" length="29"/>
          <text>protease-activated receptor-1</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">par-1</infon>
          <location offset="721" length="5"/>
          <text>PAR-1</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thrombin</infon>
          <location offset="766" length="8"/>
          <text>thrombin</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>797</offset>
        <text>In plasma depleted of plasminogen, exogenous wild-type plasminogen, but not an inactive mutant protein, S(741)A plasminogen, supported platelet aggregation, suggesting that the protease cleaving PAR-1 was streptokinase-plasminogen.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen</infon>
          <location offset="819" length="11"/>
          <text>plasminogen</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen</infon>
          <location offset="852" length="11"/>
          <text>plasminogen</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">s(741)a</infon>
          <location offset="901" length="7"/>
          <text>S(741)A</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen</infon>
          <location offset="909" length="11"/>
          <text>plasminogen</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protease</infon>
          <location offset="974" length="8"/>
          <text>protease</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">par-1</infon>
          <location offset="992" length="5"/>
          <text>PAR-1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">streptokinase</infon>
          <location offset="1002" length="13"/>
          <text>streptokinase</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen</infon>
          <location offset="1016" length="11"/>
          <text>plasminogen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1029</offset>
        <text>Streptokinase-plasminogen cleaved a synthetic peptide corresponding to PAR-1, resulting in generation of PAR-1 tethered ligand sequence and selectively reduced binding of a cleavage-sensitive PAR-1 antibody in intact cells.</text>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">par-1</infon>
          <location offset="1134" length="5"/>
          <text>PAR-1</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">par-1</infon>
          <location offset="1221" length="5"/>
          <text>PAR-1</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">streptokinase</infon>
          <location offset="1029" length="13"/>
          <text>Streptokinase</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen</infon>
          <location offset="1043" length="11"/>
          <text>plasminogen</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">par-1</infon>
          <location offset="1100" length="5"/>
          <text>PAR-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1253</offset>
        <text>A combination of streptokinase, plasminogen, and antistreptokinase antibodies activated human erythroleukemic cells and was inhibited by pretreatment with IV.3 or pretreating the cells with the PAR-1 agonist SFLLRN, suggesting Fc receptor and PAR-1 interactions are necessary for cell activation in this system also.</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">streptokinase</infon>
          <location offset="1270" length="13"/>
          <text>streptokinase</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">plasminogen</infon>
          <location offset="1285" length="11"/>
          <text>plasminogen</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">iv.3</infon>
          <location offset="1408" length="4"/>
          <text>IV.3</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">par-1</infon>
          <location offset="1447" length="5"/>
          <text>PAR-1</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fc receptor</infon>
          <location offset="1480" length="11"/>
          <text>Fc receptor</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">par-1</infon>
          <location offset="1496" length="5"/>
          <text>PAR-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1570</offset>
        <text>Streptokinase-induced platelet activation is dependent on both antistreptokinase-Fc receptor interactions and cleavage of PAR-1.</text>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">streptokinase</infon>
          <location offset="1570" length="13"/>
          <text>Streptokinase</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fc receptor</infon>
          <location offset="1651" length="11"/>
          <text>Fc receptor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">par-1</infon>
          <location offset="1692" length="5"/>
          <text>PAR-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1699</offset>
        <text>(Blood. 2000;95:1301-1308)</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23474386</id>
    <passage>
      <offset>0</offset>
      <text>Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.	A series of novel 5-(benzyloxy)pyridin-2(1H)-ones were designed, synthesized and biologically evaluated for c-Met inhibition. Various amides and benzoimidazoles at C-3 position were investigated. A potent compound 12b with a c-Met IC50 of 12nM was identified. This compound exhibited potent inhibition of EBC-1 cell associated with c-Met constitutive activation and showed high selectivity for c-Met than other tested 11 kinases. The binding model 12b with c-Met was disclosed by docking analysis.</text>
      <sentence>
        <offset>0</offset>
        <text>Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-(benzyloxy)pyridin-2(1h)-one</infon>
          <location offset="6" length="30"/>
          <text>5-(benzyloxy)pyridin-2(1H)-one</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-met</infon>
          <location offset="59" length="5"/>
          <text>c-Met</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>77</offset>
        <text>A series of novel 5-(benzyloxy)pyridin-2(1H)-ones were designed, synthesized and biologically evaluated for c-Met inhibition.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-(benzyloxy)pyridin-2(1h)-ones</infon>
          <location offset="95" length="31"/>
          <text>5-(benzyloxy)pyridin-2(1H)-ones</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-met</infon>
          <location offset="185" length="5"/>
          <text>c-Met</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>203</offset>
        <text>Various amides and benzoimidazoles at C-3 position were investigated.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amides</infon>
          <location offset="211" length="6"/>
          <text>amides</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzoimidazoles</infon>
          <location offset="222" length="15"/>
          <text>benzoimidazoles</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>273</offset>
        <text>A potent compound 12b with a c-Met IC50 of 12nM was identified.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-met</infon>
          <location offset="302" length="5"/>
          <text>c-Met</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>337</offset>
        <text>This compound exhibited potent inhibition of EBC-1 cell associated with c-Met constitutive activation and showed high selectivity for c-Met than other tested 11 kinases.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-met</infon>
          <location offset="409" length="5"/>
          <text>c-Met</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-met</infon>
          <location offset="471" length="5"/>
          <text>c-Met</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinases</infon>
          <location offset="498" length="7"/>
          <text>kinases</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>507</offset>
        <text>The binding model 12b with c-Met was disclosed by docking analysis.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">c-met</infon>
          <location offset="534" length="5"/>
          <text>c-Met</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15106733</id>
    <passage>
      <offset>0</offset>
      <text>Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts.	The expression of cyclooxygenase-2 (COX-2) is a characteristic response to inflammation and can be inhibited with sodium salicylate. TNF-alpha plus IFN-gamma can induce extracellular signal-regulated kinase (ERK), IKK, IkappaB degradation and NF-kappaB activation. The inhibition of the ERK pathway with selective inhibitor, PD098059, blocked cytokine-induced COX-2 expression and PGE2 release. Salicylate treatment inhibited COX-2 expression induced by TNF-alpha/IFN-gamma and regulated the activation of ERK, IKK and IkappaB degradation and subsequent NF-kappaB activation in MC3T3E1 osteoblasts. As well, antioxidant-catalase, N-acetyl-cysteine or reduced glutathione-attenuated COX-2 expression in combined cytokines-treated cells. These antioxidants also inhibited the activation of ERK, IKK and NF-kappaB in MC3T3E1 osteoblasts. In addition, TNF-alpha/IFN-gamma stimulated ROS release in the osteoblasts. However salicylate had no obvious effect on ROS release in DCFDA assay. The results showed that salicylate inhibited the activation of ERK and IKK, IkappaB degradation and NF-kappaB activation independent of ROS release and suggested that salicylate exerts its anti-inflammatory action in part through inhibition of the ERK, IKK, IkappaB, NF-kappaB and resultant COX-2 expression pathway.</text>
      <sentence>
        <offset>0</offset>
        <text>Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylate</infon>
          <location offset="0" length="10"/>
          <text>Salicylate</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="21" length="5"/>
          <text>COX-2</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="46" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="65" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>102</offset>
        <text>The expression of cyclooxygenase-2 (COX-2) is a characteristic response to inflammation and can be inhibited with sodium salicylate.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium salicylate</infon>
          <location offset="216" length="17"/>
          <text>sodium salicylate</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclooxygenase-2</infon>
          <location offset="120" length="16"/>
          <text>cyclooxygenase-2</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="138" length="5"/>
          <text>COX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>235</offset>
        <text>TNF-alpha plus IFN-gamma can induce extracellular signal-regulated kinase (ERK), IKK, IkappaB degradation and NF-kappaB activation.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="235" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ifn-gamma</infon>
          <location offset="250" length="9"/>
          <text>IFN-gamma</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">extracellular signal-regulated kinase</infon>
          <location offset="271" length="37"/>
          <text>extracellular signal-regulated kinase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="310" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikk</infon>
          <location offset="316" length="3"/>
          <text>IKK</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikappab</infon>
          <location offset="321" length="7"/>
          <text>IkappaB</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="345" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>367</offset>
        <text>The inhibition of the ERK pathway with selective inhibitor, PD098059, blocked cytokine-induced COX-2 expression and PGE2 release.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pd098059</infon>
          <location offset="427" length="8"/>
          <text>PD098059</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="389" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="445" length="8"/>
          <text>cytokine</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="462" length="5"/>
          <text>COX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T28" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>497</offset>
        <text>Salicylate treatment inhibited COX-2 expression induced by TNF-alpha/IFN-gamma and regulated the activation of ERK, IKK and IkappaB degradation and subsequent NF-kappaB activation in MC3T3E1 osteoblasts.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylate</infon>
          <location offset="497" length="10"/>
          <text>Salicylate</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="528" length="5"/>
          <text>COX-2</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="556" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ifn-gamma</infon>
          <location offset="566" length="9"/>
          <text>IFN-gamma</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="608" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikk</infon>
          <location offset="613" length="3"/>
          <text>IKK</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikappab</infon>
          <location offset="621" length="7"/>
          <text>IkappaB</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="656" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>701</offset>
        <text>As well, antioxidant-catalase, N-acetyl-cysteine or reduced glutathione-attenuated COX-2 expression in combined cytokines-treated cells.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-acetyl-cysteine</infon>
          <location offset="732" length="17"/>
          <text>N-acetyl-cysteine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="761" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="722" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="784" length="5"/>
          <text>COX-2</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="813" length="9"/>
          <text>cytokines</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>838</offset>
        <text>These antioxidants also inhibited the activation of ERK, IKK and NF-kappaB in MC3T3E1 osteoblasts.</text>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="890" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikk</infon>
          <location offset="895" length="3"/>
          <text>IKK</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="903" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>937</offset>
        <text>In addition, TNF-alpha/IFN-gamma stimulated ROS release in the osteoblasts.</text>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-alpha</infon>
          <location offset="950" length="9"/>
          <text>TNF-alpha</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ifn-gamma</infon>
          <location offset="960" length="9"/>
          <text>IFN-gamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1013</offset>
        <text>However salicylate had no obvious effect on ROS release in DCFDA assay.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylate</infon>
          <location offset="1021" length="10"/>
          <text>salicylate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1085</offset>
        <text>The results showed that salicylate inhibited the activation of ERK and IKK, IkappaB degradation and NF-kappaB activation independent of ROS release and suggested that salicylate exerts its anti-inflammatory action in part through inhibition of the ERK, IKK, IkappaB, NF-kappaB and resultant COX-2 expression pathway.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylate</infon>
          <location offset="1109" length="10"/>
          <text>salicylate</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylate</infon>
          <location offset="1252" length="10"/>
          <text>salicylate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="1148" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikk</infon>
          <location offset="1156" length="3"/>
          <text>IKK</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikappab</infon>
          <location offset="1161" length="7"/>
          <text>IkappaB</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1185" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">erk</infon>
          <location offset="1333" length="3"/>
          <text>ERK</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikk</infon>
          <location offset="1338" length="3"/>
          <text>IKK</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikappab</infon>
          <location offset="1343" length="7"/>
          <text>IkappaB</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1352" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="1376" length="5"/>
          <text>COX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22749926</id>
    <passage>
      <offset>0</offset>
      <text>Nicotine facilitates memory consolidation in perceptual learning.	Perceptual learning is a special type of non-declarative learning that involves experience-dependent plasticity in sensory cortices. The cholinergic system is known to modulate declarative learning. In particular, reduced levels or efficacy of the neurotransmitter acetylcholine were found to facilitate declarative memory consolidation. However, little is known about the role of the cholinergic system in memory consolidation of non-declarative learning. Here we compared two groups of non-smoking men who learned a visual texture discrimination task (TDT). One group received chewing tobacco containing nicotine for 1 h directly following the TDT training. The other group received a similar tasting control substance without nicotine. Electroencephalographic recordings during substance consumption showed reduced alpha activity and P300 latencies in the nicotine group compared to the control group. When re-tested on the TDT the following day, both groups responded more accurately and more rapidly than during training. These improvements were specific to the retinal location and orientation of the texture elements of the TDT suggesting that learning involved early visual cortex. A group comparison showed that learning effects were more pronounced in the nicotine group than in the control group. These findings suggest that oral consumption of nicotine enhances the efficacy of nicotinic acetylcholine receptors. Our findings further suggest that enhanced efficacy of the cholinergic system facilitates memory consolidation in perceptual learning (and possibly other types of non-declarative learning). In that regard acetylcholine seems to affect consolidation processes in perceptual learning in a different manner than in declarative learning. Alternatively, our findings might reflect dose-dependent cholinergic modulation of memory consolidation. This article is part of a Special Issue entitled 'Cognitive Enhancers'.</text>
      <sentence>
        <offset>0</offset>
        <text>Nicotine facilitates memory consolidation in perceptual learning.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotine</infon>
          <location offset="0" length="8"/>
          <text>Nicotine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>66</offset>
        <text>Perceptual learning is a special type of non-declarative learning that involves experience-dependent plasticity in sensory cortices.</text>
      </sentence>
      <sentence>
        <offset>199</offset>
        <text>The cholinergic system is known to modulate declarative learning.</text>
      </sentence>
      <sentence>
        <offset>265</offset>
        <text>In particular, reduced levels or efficacy of the neurotransmitter acetylcholine were found to facilitate declarative memory consolidation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="331" length="13"/>
          <text>acetylcholine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>404</offset>
        <text>However, little is known about the role of the cholinergic system in memory consolidation of non-declarative learning.</text>
      </sentence>
      <sentence>
        <offset>523</offset>
        <text>Here we compared two groups of non-smoking men who learned a visual texture discrimination task (TDT).</text>
      </sentence>
      <sentence>
        <offset>626</offset>
        <text>One group received chewing tobacco containing nicotine for 1 h directly following the TDT training.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotine</infon>
          <location offset="672" length="8"/>
          <text>nicotine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>726</offset>
        <text>The other group received a similar tasting control substance without nicotine.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotine</infon>
          <location offset="795" length="8"/>
          <text>nicotine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>805</offset>
        <text>Electroencephalographic recordings during substance consumption showed reduced alpha activity and P300 latencies in the nicotine group compared to the control group.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotine</infon>
          <location offset="925" length="8"/>
          <text>nicotine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p300</infon>
          <location offset="903" length="4"/>
          <text>P300</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>971</offset>
        <text>When re-tested on the TDT the following day, both groups responded more accurately and more rapidly than during training.</text>
      </sentence>
      <sentence>
        <offset>1093</offset>
        <text>These improvements were specific to the retinal location and orientation of the texture elements of the TDT suggesting that learning involved early visual cortex.</text>
      </sentence>
      <sentence>
        <offset>1256</offset>
        <text>A group comparison showed that learning effects were more pronounced in the nicotine group than in the control group.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotine</infon>
          <location offset="1332" length="8"/>
          <text>nicotine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1374</offset>
        <text>These findings suggest that oral consumption of nicotine enhances the efficacy of nicotinic acetylcholine receptors.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotine</infon>
          <location offset="1422" length="8"/>
          <text>nicotine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="1466" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nicotinic acetylcholine receptors</infon>
          <location offset="1456" length="33"/>
          <text>nicotinic acetylcholine receptors</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1491</offset>
        <text>Our findings further suggest that enhanced efficacy of the cholinergic system facilitates memory consolidation in perceptual learning (and possibly other types of non-declarative learning).</text>
      </sentence>
      <sentence>
        <offset>1681</offset>
        <text>In that regard acetylcholine seems to affect consolidation processes in perceptual learning in a different manner than in declarative learning.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="1696" length="13"/>
          <text>acetylcholine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1825</offset>
        <text>Alternatively, our findings might reflect dose-dependent cholinergic modulation of memory consolidation.</text>
      </sentence>
      <sentence>
        <offset>1930</offset>
        <text>This article is part of a Special Issue entitled 'Cognitive Enhancers'.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>14610216</id>
    <passage>
      <offset>0</offset>
      <text>Interactions of human organic anion transporters with diuretics.	The tubular secretion of diuretics in the proximal tubule has been shown to be critical for the action of drugs. To elucidate the molecular mechanisms for the tubular excretion of diuretics, we have elucidated the interactions of human organic anion transporters (hOATs) with diuretics using cells stably expressing hOATs. Diuretics tested were thiazides, including chlorothiazide, cyclothiazide, hydrochlorothiazide, and trichlormethiazide; loop diuretics, including bumetanide, ethacrynic acid, and furosemide; and carbonic anhydrase inhibitors, including acetazolamide and methazolamide. These diuretics inhibited organic anion uptake mediated by hOAT1, hOAT2, hOAT3, and hOAT4 in a competitive manner. hOAT1 exhibited the highest affinity interactions for thiazides, whereas hOAT3 did those for loop diuretics. hOAT1, hOAT3, and hOAT4 but not hOAT2, mediated the uptake of bumetanide. hOAT3 and hOAT4, but not hOAT1 mediated the efflux of bumetanide. hOAT1 and hOAT3, but not hOAT2 and hOAT4 mediated the uptake of furosemide. In conclusion, it was suggested that hOAT1 may play an important role in the basolateral uptake of thiazides, and hOAT3 in the uptake of loop diuretics. In addition, it was also suggested that bumetanide taken up by hOAT3 and/or hOAT1 is excreted into the urine by hOAT4.</text>
      <sentence>
        <offset>0</offset>
        <text>Interactions of human organic anion transporters with diuretics.</text>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human organic anion transporters</infon>
          <location offset="16" length="32"/>
          <text>human organic anion transporters</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>65</offset>
        <text>The tubular secretion of diuretics in the proximal tubule has been shown to be critical for the action of drugs.</text>
      </sentence>
      <sentence>
        <offset>178</offset>
        <text>To elucidate the molecular mechanisms for the tubular excretion of diuretics, we have elucidated the interactions of human organic anion transporters (hOATs) with diuretics using cells stably expressing hOATs.</text>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human organic anion transporters</infon>
          <location offset="295" length="32"/>
          <text>human organic anion transporters</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hoats</infon>
          <location offset="329" length="5"/>
          <text>hOATs</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hoats</infon>
          <location offset="381" length="5"/>
          <text>hOATs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>388</offset>
        <text>Diuretics tested were thiazides, including chlorothiazide, cyclothiazide, hydrochlorothiazide, and trichlormethiazide; loop diuretics, including bumetanide, ethacrynic acid, and furosemide; and carbonic anhydrase inhibitors, including acetazolamide and methazolamide.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiazides</infon>
          <location offset="410" length="9"/>
          <text>thiazides</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">chlorothiazide</infon>
          <location offset="431" length="14"/>
          <text>chlorothiazide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclothiazide</infon>
          <location offset="447" length="13"/>
          <text>cyclothiazide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrochlorothiazide</infon>
          <location offset="462" length="19"/>
          <text>hydrochlorothiazide</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trichlormethiazide</infon>
          <location offset="487" length="18"/>
          <text>trichlormethiazide</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bumetanide</infon>
          <location offset="533" length="10"/>
          <text>bumetanide</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethacrynic acid</infon>
          <location offset="545" length="15"/>
          <text>ethacrynic acid</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">furosemide</infon>
          <location offset="566" length="10"/>
          <text>furosemide</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetazolamide</infon>
          <location offset="623" length="13"/>
          <text>acetazolamide</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methazolamide</infon>
          <location offset="641" length="13"/>
          <text>methazolamide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>656</offset>
        <text>These diuretics inhibited organic anion uptake mediated by hOAT1, hOAT2, hOAT3, and hOAT4 in a competitive manner.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat1</infon>
          <location offset="715" length="5"/>
          <text>hOAT1</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat2</infon>
          <location offset="722" length="5"/>
          <text>hOAT2</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat3</infon>
          <location offset="729" length="5"/>
          <text>hOAT3</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat4</infon>
          <location offset="740" length="5"/>
          <text>hOAT4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>771</offset>
        <text>hOAT1 exhibited the highest affinity interactions for thiazides, whereas hOAT3 did those for loop diuretics.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiazides</infon>
          <location offset="825" length="9"/>
          <text>thiazides</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat1</infon>
          <location offset="771" length="5"/>
          <text>hOAT1</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat3</infon>
          <location offset="844" length="5"/>
          <text>hOAT3</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>880</offset>
        <text>hOAT1, hOAT3, and hOAT4 but not hOAT2, mediated the uptake of bumetanide.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bumetanide</infon>
          <location offset="942" length="10"/>
          <text>bumetanide</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat1</infon>
          <location offset="880" length="5"/>
          <text>hOAT1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat3</infon>
          <location offset="887" length="5"/>
          <text>hOAT3</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat4</infon>
          <location offset="898" length="5"/>
          <text>hOAT4</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat2</infon>
          <location offset="912" length="5"/>
          <text>hOAT2</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T13" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>954</offset>
        <text>hOAT3 and hOAT4, but not hOAT1 mediated the efflux of bumetanide.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bumetanide</infon>
          <location offset="1008" length="10"/>
          <text>bumetanide</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat3</infon>
          <location offset="954" length="5"/>
          <text>hOAT3</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat4</infon>
          <location offset="964" length="5"/>
          <text>hOAT4</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat1</infon>
          <location offset="979" length="5"/>
          <text>hOAT1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T14" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T14" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1020</offset>
        <text>hOAT1 and hOAT3, but not hOAT2 and hOAT4 mediated the uptake of furosemide.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">furosemide</infon>
          <location offset="1084" length="10"/>
          <text>furosemide</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat1</infon>
          <location offset="1020" length="5"/>
          <text>hOAT1</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat3</infon>
          <location offset="1030" length="5"/>
          <text>hOAT3</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat2</infon>
          <location offset="1045" length="5"/>
          <text>hOAT2</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat4</infon>
          <location offset="1055" length="5"/>
          <text>hOAT4</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T1" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1096</offset>
        <text>In conclusion, it was suggested that hOAT1 may play an important role in the basolateral uptake of thiazides, and hOAT3 in the uptake of loop diuretics.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat1</infon>
          <location offset="1133" length="5"/>
          <text>hOAT1</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat3</infon>
          <location offset="1210" length="5"/>
          <text>hOAT3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1249</offset>
        <text>In addition, it was also suggested that bumetanide taken up by hOAT3 and/or hOAT1 is excreted into the urine by hOAT4.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat3</infon>
          <location offset="1312" length="5"/>
          <text>hOAT3</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat1</infon>
          <location offset="1325" length="5"/>
          <text>hOAT1</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hoat4</infon>
          <location offset="1361" length="5"/>
          <text>hOAT4</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10475242</id>
    <passage>
      <offset>0</offset>
      <text>Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro.	Troglitazone and rosiglitazone (BRL49653), members of the thiazolidinedione (TZD) class of antidiabetic drugs, are peroxisome proliferator-activated receptor gamma (PPARgamma) ligands that induce adipocyte differentiation and increase the expression of PPARgamma protein. Here, we report the characterization of a PPARgamma specific monoclonal antibody (MAb), PgammaA53.25, and its use to monitor PPARgamma expression in the noncommitted pluripotent murine mesenchymal stem cell line, C3H10T1/2, treated with TZDs. MAb PgammaA53.25 was raised against a region in the N-terminal domain of human PPARgamma shared by splice variants PPARgamma1 and PPARgamma2. It recognizes immunizing antigen in enzyme-linked immunoadsorbent assay (ELISA), and does not cross-react with the N-terminal domains of PPARalpha or PPARdelta. In Western blotting, PgammaA53.25 reacts with the immunizing antigen as well as distinct protein bands corresponding to the molecular weight of full length PPARgamma from C3H10T1/2 cells and rat tissue lysates. In fluorescent microscopy, PgammaA53.25 immunostains nuclei of C3H10T1/2 cells treated with PPARgamma ligands. The fluorescence intensity of the treated cells is TZD dose-dependent, and correlates with lipid accumulation consistent with adipogenesis. Based on these results, we propose that MAb PgammaA53.25 will be a useful tool for elucidating the role of PPARgamma in fatty acid metabolism and adipocyte differentiation.</text>
      <sentence>
        <offset>0</offset>
        <text>Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiazolidinediones</infon>
          <location offset="64" length="18"/>
          <text>thiazolidinediones</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar gamma</infon>
          <location offset="90" length="10"/>
          <text>PPAR gamma</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppar gamma</infon>
          <location offset="9" length="10"/>
          <text>PPAR gamma</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>131</offset>
        <text>Troglitazone and rosiglitazone (BRL49653), members of the thiazolidinedione (TZD) class of antidiabetic drugs, are peroxisome proliferator-activated receptor gamma (PPARgamma) ligands that induce adipocyte differentiation and increase the expression of PPARgamma protein.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="131" length="12"/>
          <text>Troglitazone</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosiglitazone</infon>
          <location offset="148" length="13"/>
          <text>rosiglitazone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">brl49653</infon>
          <location offset="163" length="8"/>
          <text>BRL49653</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiazolidinedione</infon>
          <location offset="189" length="17"/>
          <text>thiazolidinedione</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tzd</infon>
          <location offset="208" length="3"/>
          <text>TZD</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor gamma</infon>
          <location offset="246" length="48"/>
          <text>peroxisome proliferator-activated receptor gamma</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="296" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="384" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>403</offset>
        <text>Here, we report the characterization of a PPARgamma specific monoclonal antibody (MAb), PgammaA53.25, and its use to monitor PPARgamma expression in the noncommitted pluripotent murine mesenchymal stem cell line, C3H10T1/2, treated with TZDs.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="445" length="9"/>
          <text>PPARgamma</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="528" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>646</offset>
        <text>MAb PgammaA53.25 was raised against a region in the N-terminal domain of human PPARgamma shared by splice variants PPARgamma1 and PPARgamma2.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="698" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human ppargamma</infon>
          <location offset="719" length="15"/>
          <text>human PPARgamma</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma1</infon>
          <location offset="761" length="10"/>
          <text>PPARgamma1</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma2</infon>
          <location offset="776" length="10"/>
          <text>PPARgamma2</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>788</offset>
        <text>It recognizes immunizing antigen in enzyme-linked immunoadsorbent assay (ELISA), and does not cross-react with the N-terminal domains of PPARalpha or PPARdelta.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="903" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="925" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppardelta</infon>
          <location offset="938" length="9"/>
          <text>PPARdelta</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>949</offset>
        <text>In Western blotting, PgammaA53.25 reacts with the immunizing antigen as well as distinct protein bands corresponding to the molecular weight of full length PPARgamma from C3H10T1/2 cells and rat tissue lysates.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1105" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1160</offset>
        <text>In fluorescent microscopy, PgammaA53.25 immunostains nuclei of C3H10T1/2 cells treated with PPARgamma ligands.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1252" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1271</offset>
        <text>The fluorescence intensity of the treated cells is TZD dose-dependent, and correlates with lipid accumulation consistent with adipogenesis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tzd</infon>
          <location offset="1322" length="3"/>
          <text>TZD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1411</offset>
        <text>Based on these results, we propose that MAb PgammaA53.25 will be a useful tool for elucidating the role of PPARgamma in fatty acid metabolism and adipocyte differentiation.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="1531" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ppargamma</infon>
          <location offset="1518" length="9"/>
          <text>PPARgamma</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15002740</id>
    <passage>
      <offset>0</offset>
      <text>The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.	The present study examined the potential membrane retention of desipramine (DMI) following exposures of 293-hNET cells to DMI, and its effect on [3H]NE uptake. Incubation of cells with 500 nM DMI for 1 h or 1 day persistently inhibited the uptake of [3H]NE up to 7 days, despite daily repeated washing of cells with drug-free medium. Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI. [3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET. A similar cellular retention was observed following incubation of cells with nisoxetine. The results demonstrate that DMI and nisoxetine are persistently retained in cell membranes, at least partly in association with the NET. The retention and slow diffusion of DMI and nisoxetine from membranes may contribute to their pharmacological and modulatory action on NET.</text>
      <sentence>
        <offset>0</offset>
        <text>The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desipramine</infon>
          <location offset="37" length="11"/>
          <text>desipramine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norepinephrine</infon>
          <location offset="78" length="14"/>
          <text>norepinephrine</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">norepinephrine transporter</infon>
          <location offset="78" length="26"/>
          <text>norepinephrine transporter</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>115</offset>
        <text>The present study examined the potential membrane retention of desipramine (DMI) following exposures of 293-hNET cells to DMI, and its effect on [3H]NE uptake.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dmi</infon>
          <location offset="237" length="3"/>
          <text>DMI</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]ne</infon>
          <location offset="260" length="6"/>
          <text>[3H]NE</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desipramine</infon>
          <location offset="178" length="11"/>
          <text>desipramine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dmi</infon>
          <location offset="191" length="3"/>
          <text>DMI</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hnet</infon>
          <location offset="223" length="4"/>
          <text>hNET</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>275</offset>
        <text>Incubation of cells with 500 nM DMI for 1 h or 1 day persistently inhibited the uptake of [3H]NE up to 7 days, despite daily repeated washing of cells with drug-free medium.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dmi</infon>
          <location offset="307" length="3"/>
          <text>DMI</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]ne</infon>
          <location offset="365" length="6"/>
          <text>[3H]NE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>449</offset>
        <text>Uptake inhibition was paralleled by persistent retention of DMI associated with cells, as determined by HPLC and by radiotracer experiments using [3H]DMI.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dmi</infon>
          <location offset="509" length="3"/>
          <text>DMI</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]dmi</infon>
          <location offset="595" length="7"/>
          <text>[3H]DMI</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>604</offset>
        <text>[3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine, in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]dmi</infon>
          <location offset="604" length="7"/>
          <text>[3H]DMI</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nisoxetine</infon>
          <location offset="695" length="10"/>
          <text>nisoxetine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[3h]dmi</infon>
          <location offset="777" length="7"/>
          <text>[3H]DMI</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">net</infon>
          <location offset="680" length="3"/>
          <text>NET</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">net</infon>
          <location offset="794" length="3"/>
          <text>NET</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>799</offset>
        <text>A similar cellular retention was observed following incubation of cells with nisoxetine.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nisoxetine</infon>
          <location offset="876" length="10"/>
          <text>nisoxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>888</offset>
        <text>The results demonstrate that DMI and nisoxetine are persistently retained in cell membranes, at least partly in association with the NET.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dmi</infon>
          <location offset="917" length="3"/>
          <text>DMI</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nisoxetine</infon>
          <location offset="925" length="10"/>
          <text>nisoxetine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">net</infon>
          <location offset="1021" length="3"/>
          <text>NET</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1026</offset>
        <text>The retention and slow diffusion of DMI and nisoxetine from membranes may contribute to their pharmacological and modulatory action on NET.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dmi</infon>
          <location offset="1062" length="3"/>
          <text>DMI</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nisoxetine</infon>
          <location offset="1070" length="10"/>
          <text>nisoxetine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">net</infon>
          <location offset="1161" length="3"/>
          <text>NET</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11607047</id>
    <passage>
      <offset>0</offset>
      <text>A review of the pharmacological and clinical profile of mirtazapine.	The novel antidepressant mirtazapine has a dual mode of action. It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic alpha2-autoreceptors and alpha2-heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors. It enhances, therefore, the release of norepinephrine and 5-HT1A-mediated serotonergic transmission. This dual mode of action may conceivably be responsible for mirtazapine's rapid onset of action. Mirtazapine is extensively metabolized in the liver. The cytochrome (CYP) P450 isoenzymes CYP1A2, CYP2D6, and CYP3A4 are mainly responsible for its metabolism. Using once daily dosing, steady-state concentrations are reached after 4 days in adults and 6 days in the elderly. In vitro studies suggest that mirtazapine is unlikely to cause clinically significant drug-drug interactions. Dry mouth, sedation, and increases in appetite and body weight are the most common adverse effects. In contrast to selective serotonin reuptake inhibitors (SSRIs), mirtazapine has no sexual side effects. The antidepressant efficacy of mirtazapine was established in several placebo-controlled trials. In major depression, its efficacy is comparable to that of amitriptyline, clomipramine, doxepin, fluoxetine, paroxetine, citalopram, or venlafaxine. Mirtazapine also appears to be useful in patients suffering from depression comorbid with anxiety symptoms and sleep disturbance. It seems to be safe and effective during long-term use.</text>
      <sentence>
        <offset>0</offset>
        <text>A review of the pharmacological and clinical profile of mirtazapine.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mirtazapine</infon>
          <location offset="56" length="11"/>
          <text>mirtazapine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>69</offset>
        <text>The novel antidepressant mirtazapine has a dual mode of action.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mirtazapine</infon>
          <location offset="94" length="11"/>
          <text>mirtazapine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>133</offset>
        <text>It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic alpha2-autoreceptors and alpha2-heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adrenergic alpha2-autoreceptors</infon>
          <location offset="234" length="31"/>
          <text>adrenergic alpha2-autoreceptors</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha2-heteroreceptors</infon>
          <location offset="270" length="22"/>
          <text>alpha2-heteroreceptors</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht2</infon>
          <location offset="316" length="5"/>
          <text>5-HT2</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht3</infon>
          <location offset="326" length="5"/>
          <text>5-HT3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>343</offset>
        <text>It enhances, therefore, the release of norepinephrine and 5-HT1A-mediated serotonergic transmission.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norepinephrine</infon>
          <location offset="382" length="14"/>
          <text>norepinephrine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht1a</infon>
          <location offset="401" length="6"/>
          <text>5-HT1A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>444</offset>
        <text>This dual mode of action may conceivably be responsible for mirtazapine's rapid onset of action.</text>
      </sentence>
      <sentence>
        <offset>541</offset>
        <text>Mirtazapine is extensively metabolized in the liver.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mirtazapine</infon>
          <location offset="541" length="11"/>
          <text>Mirtazapine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>594</offset>
        <text>The cytochrome (CYP) P450 isoenzymes CYP1A2, CYP2D6, and CYP3A4 are mainly responsible for its metabolism.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome (cyp) p450</infon>
          <location offset="598" length="21"/>
          <text>cytochrome (CYP) P450</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a2</infon>
          <location offset="631" length="6"/>
          <text>CYP1A2</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="639" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="651" length="6"/>
          <text>CYP3A4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>701</offset>
        <text>Using once daily dosing, steady-state concentrations are reached after 4 days in adults and 6 days in the elderly.</text>
      </sentence>
      <sentence>
        <offset>816</offset>
        <text>In vitro studies suggest that mirtazapine is unlikely to cause clinically significant drug-drug interactions.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mirtazapine</infon>
          <location offset="846" length="11"/>
          <text>mirtazapine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>926</offset>
        <text>Dry mouth, sedation, and increases in appetite and body weight are the most common adverse effects.</text>
      </sentence>
      <sentence>
        <offset>1026</offset>
        <text>In contrast to selective serotonin reuptake inhibitors (SSRIs), mirtazapine has no sexual side effects.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mirtazapine</infon>
          <location offset="1090" length="11"/>
          <text>mirtazapine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="1051" length="9"/>
          <text>serotonin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1130</offset>
        <text>The antidepressant efficacy of mirtazapine was established in several placebo-controlled trials.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mirtazapine</infon>
          <location offset="1161" length="11"/>
          <text>mirtazapine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1227</offset>
        <text>In major depression, its efficacy is comparable to that of amitriptyline, clomipramine, doxepin, fluoxetine, paroxetine, citalopram, or venlafaxine.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amitriptyline</infon>
          <location offset="1286" length="13"/>
          <text>amitriptyline</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clomipramine</infon>
          <location offset="1301" length="12"/>
          <text>clomipramine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxepin</infon>
          <location offset="1315" length="7"/>
          <text>doxepin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fluoxetine</infon>
          <location offset="1324" length="10"/>
          <text>fluoxetine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paroxetine</infon>
          <location offset="1336" length="10"/>
          <text>paroxetine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">citalopram</infon>
          <location offset="1348" length="10"/>
          <text>citalopram</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">venlafaxine</infon>
          <location offset="1363" length="11"/>
          <text>venlafaxine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1376</offset>
        <text>Mirtazapine also appears to be useful in patients suffering from depression comorbid with anxiety symptoms and sleep disturbance.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mirtazapine</infon>
          <location offset="1376" length="11"/>
          <text>Mirtazapine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1506</offset>
        <text>It seems to be safe and effective during long-term use.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23246798</id>
    <passage>
      <offset>0</offset>
      <text>Preparation of highly porous gastroretentive metformin tablets using a sublimation method.	The present investigation is aimed to formulate floating gastroretentive tablets containing metformin using a sublimation material. In this study, the release of the drug from a matrix tablet was highly dependent on the polymer concentrations. In all formulations, initial rapid drug release was observed, possibly due to the properties of the drug and polymer. The effect of the amount of PEO on swelling and eroding of the tablets was determined. The water-uptake and erosion behavior of the gastroretentive (GR) tablets were highly dependent on the amount of PEO. The water-uptake increased with increasing PEO concentration in the tablet matrix. The weight loss from tablets decreased with increasing amounts of PEO. Camphor was used as the sublimation material to prepare GR tablets that are low-density and easily floatable. Camphor was changed to pores in the tablet during the sublimation process. SEM revealed that the GR tablets have a highly porous morphology. Floating properties of tablets and tablet density were affected by the sublimation of camphor. Prepared floating gastroretentive tablets floated for over 24 h and had no floating lag time. However, as the amount of camphor in the tablet matrix increased, the crushing strength of the tablet decreased after sublimation. Release profiles of the drug from the GR tablets were not affected by tablet density or porosity. In pharmacokinetic studies, the mean plasma concentration of the GR tablets after oral administration was greater than the concentration of glucophase XR. Also, the mean AUC(0-∞) values for the GR tablets were significantly greater than the plasma concentrations of glucophase XR.</text>
      <sentence>
        <offset>0</offset>
        <text>Preparation of highly porous gastroretentive metformin tablets using a sublimation method.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="45" length="9"/>
          <text>metformin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>91</offset>
        <text>The present investigation is aimed to formulate floating gastroretentive tablets containing metformin using a sublimation material.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metformin</infon>
          <location offset="183" length="9"/>
          <text>metformin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>223</offset>
        <text>In this study, the release of the drug from a matrix tablet was highly dependent on the polymer concentrations.</text>
      </sentence>
      <sentence>
        <offset>335</offset>
        <text>In all formulations, initial rapid drug release was observed, possibly due to the properties of the drug and polymer.</text>
      </sentence>
      <sentence>
        <offset>453</offset>
        <text>The effect of the amount of PEO on swelling and eroding of the tablets was determined.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peo</infon>
          <location offset="481" length="3"/>
          <text>PEO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>540</offset>
        <text>The water-uptake and erosion behavior of the gastroretentive (GR) tablets were highly dependent on the amount of PEO.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peo</infon>
          <location offset="653" length="3"/>
          <text>PEO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>658</offset>
        <text>The water-uptake increased with increasing PEO concentration in the tablet matrix.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peo</infon>
          <location offset="701" length="3"/>
          <text>PEO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>741</offset>
        <text>The weight loss from tablets decreased with increasing amounts of PEO.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peo</infon>
          <location offset="807" length="3"/>
          <text>PEO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>812</offset>
        <text>Camphor was used as the sublimation material to prepare GR tablets that are low-density and easily floatable.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camphor</infon>
          <location offset="812" length="7"/>
          <text>Camphor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>922</offset>
        <text>Camphor was changed to pores in the tablet during the sublimation process.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camphor</infon>
          <location offset="922" length="7"/>
          <text>Camphor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>997</offset>
        <text>SEM revealed that the GR tablets have a highly porous morphology.</text>
      </sentence>
      <sentence>
        <offset>1063</offset>
        <text>Floating properties of tablets and tablet density were affected by the sublimation of camphor.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camphor</infon>
          <location offset="1149" length="7"/>
          <text>camphor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1158</offset>
        <text>Prepared floating gastroretentive tablets floated for over 24 h and had no floating lag time.</text>
      </sentence>
      <sentence>
        <offset>1252</offset>
        <text>However, as the amount of camphor in the tablet matrix increased, the crushing strength of the tablet decreased after sublimation.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camphor</infon>
          <location offset="1278" length="7"/>
          <text>camphor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1383</offset>
        <text>Release profiles of the drug from the GR tablets were not affected by tablet density or porosity.</text>
      </sentence>
      <sentence>
        <offset>1481</offset>
        <text>In pharmacokinetic studies, the mean plasma concentration of the GR tablets after oral administration was greater than the concentration of glucophase XR.</text>
      </sentence>
      <sentence>
        <offset>1636</offset>
        <text>Also, the mean AUC(0-∞) values for the GR tablets were significantly greater than the plasma concentrations of glucophase XR.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11985583</id>
    <passage>
      <offset>0</offset>
      <text>Purification and biochemical characterization of some of the properties of recombinant human kynureninase.	Recombinant human kynureninase (L-kynurenine hydrolase, EC 3.7.1.3) was purified to homogeneity (60-fold) from Spodoptera frugiperda (Sf9) cells infected with baculovirus containing the kynureninase gene. The purification protocol comprised ammonium sulfate precipitation and several chromatographic steps, including DEAE-Sepharose CL-6B, hydroxyapatite, strong anionic and cationic separations. The purity of the enzyme was determined by SDS/PAGE, and the molecular mass verified by MALDI-TOF MS. The monomeric molecular mass of 52.4 kDa determined was &gt; 99.99% of the predicted molecular mass. A UV absorption spectrum of the holoenzyme resulted in a peak at 432 nm. The optimum pH was 8.25 and the enzyme displayed a strong dependence on the ionic strength of the buffer for optimum activity. This cloned enzyme was highly specific for 3-hydroxykynurenine (Km = 3.0 microm +/- 0.10) and was inhibited by L-kynurenine (Ki = 20 microm), d-kynurenine (Ki = 12 microm) and a synthetic substrate analogue D,L-3,7-dihydroxydesaminokynurenine (Ki = 100 nm). The activity/concentration profile for kynureninase from this source was sigmoidal in all instances. There appeared to be partial inhibition by substrate, and excess pyridoxal 5'-phosphate was found to be inhibitory.</text>
      <sentence>
        <offset>0</offset>
        <text>Purification and biochemical characterization of some of the properties of recombinant human kynureninase.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human kynureninase</infon>
          <location offset="87" length="18"/>
          <text>human kynureninase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>107</offset>
        <text>Recombinant human kynureninase (L-kynurenine hydrolase, EC 3.7.1.3) was purified to homogeneity (60-fold) from Spodoptera frugiperda (Sf9) cells infected with baculovirus containing the kynureninase gene.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-kynurenine</infon>
          <location offset="139" length="12"/>
          <text>L-kynurenine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human kynureninase</infon>
          <location offset="119" length="18"/>
          <text>human kynureninase</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kynureninase</infon>
          <location offset="293" length="12"/>
          <text>kynureninase</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">l-kynurenine hydrolase</infon>
          <location offset="139" length="22"/>
          <text>L-kynurenine hydrolase</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ec 3.7.1.3</infon>
          <location offset="163" length="10"/>
          <text>EC 3.7.1.3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>312</offset>
        <text>The purification protocol comprised ammonium sulfate precipitation and several chromatographic steps, including DEAE-Sepharose CL-6B, hydroxyapatite, strong anionic and cationic separations.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ammonium sulfate</infon>
          <location offset="348" length="16"/>
          <text>ammonium sulfate</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxyapatite</infon>
          <location offset="446" length="14"/>
          <text>hydroxyapatite</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>503</offset>
        <text>The purity of the enzyme was determined by SDS/PAGE, and the molecular mass verified by MALDI-TOF MS.</text>
      </sentence>
      <sentence>
        <offset>605</offset>
        <text>The monomeric molecular mass of 52.4 kDa determined was &gt; 99.99% of the predicted molecular mass.</text>
      </sentence>
      <sentence>
        <offset>703</offset>
        <text>A UV absorption spectrum of the holoenzyme resulted in a peak at 432 nm.</text>
      </sentence>
      <sentence>
        <offset>776</offset>
        <text>The optimum pH was 8.25 and the enzyme displayed a strong dependence on the ionic strength of the buffer for optimum activity.</text>
      </sentence>
      <sentence>
        <offset>903</offset>
        <text>This cloned enzyme was highly specific for 3-hydroxykynurenine (Km = 3.0 microm +/- 0.10) and was inhibited by L-kynurenine (Ki = 20 microm), d-kynurenine (Ki = 12 microm) and a synthetic substrate analogue D,L-3,7-dihydroxydesaminokynurenine (Ki = 100 nm).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d,l-3,7-dihydroxydesaminokynurenine</infon>
          <location offset="1110" length="35"/>
          <text>D,L-3,7-dihydroxydesaminokynurenine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-hydroxykynurenine</infon>
          <location offset="946" length="19"/>
          <text>3-hydroxykynurenine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">l-kynurenine</infon>
          <location offset="1014" length="12"/>
          <text>L-kynurenine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-kynurenine</infon>
          <location offset="1045" length="12"/>
          <text>d-kynurenine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1161</offset>
        <text>The activity/concentration profile for kynureninase from this source was sigmoidal in all instances.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">kynureninase</infon>
          <location offset="1200" length="12"/>
          <text>kynureninase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1262</offset>
        <text>There appeared to be partial inhibition by substrate, and excess pyridoxal 5'-phosphate was found to be inhibitory.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyridoxal 5'-phosphate</infon>
          <location offset="1327" length="22"/>
          <text>pyridoxal 5'-phosphate</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23334403</id>
    <passage>
      <offset>0</offset>
      <text>Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.	PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual orexin receptor antagonist almorexant. METHODS: Pharmacokinetic interactions were investigated (n = 14 healthy male subjects in two treatment groups) between almorexant at steady-state when administered either concomitantly or 2 h after administration of single doses of simvastatin (40 mg) or atorvastatin (40 mg). RESULTS: Almorexant dose-dependently increased simvastatin exposure (AUC(0-∞)) when administered concomitantly [geometric mean ratios (90 % CI): 2.5 (2.1, 2.9) (100 mg), 3.9 (3.3, 4.6) (200 mg)], but not C(max) [3.7 (3.0, 4.5) for both doses]. Time-separated administration resulted in relevant reductions of the interaction [AUC(0-∞): 1.4 (1.2, 1.7) (100 mg), 1.7 (1.5, 2.0) (200 mg); C(max): 1.5 (1.3, 1.9) (100 mg), 1.9 (1.6, 2.4) (200 mg)]. Similar results were obtained for hydroxyacid simvastatin. Independent of almorexant dose and relative time of administration, AUC(0-∞) and C(max) of atorvastatin increased (ratios ranged from 1.1 to 1.5). AUC(0-∞) and C(max) of o-hydroxy atorvastatin decreased dose-independently [AUC(0-∞): 0.8 (0.8, 0.9) (100 mg), 0.6 (0.5, 0.6) (200 mg); C(max): 0.3 (0.3, 0.4) (100 mg), 0.2 (0.2, 0.3) (200 mg)] when atorvastatin was concomitantly administered. C(max) of o-hydroxy atorvastatin slightly decreased (0.8 for both doses) following time-separated administration; AUC(0-∞) was unchanged. CONCLUSIONS: Whereas almorexant increased simvastatin exposure dose- and relative time of administration-dependently, atorvastatin exposure increased to a smaller extent and irrespective of dose and time. This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with atorvastatin is more due to hepatic CYP3A4 inhibition.</text>
      <sentence>
        <offset>0</offset>
        <text>Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">almorexant</infon>
          <location offset="0" length="10"/>
          <text>Almorexant</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">simvastatin</infon>
          <location offset="105" length="11"/>
          <text>simvastatin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atorvastatin</infon>
          <location offset="121" length="12"/>
          <text>atorvastatin</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="22" length="6"/>
          <text>CYP3A4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>135</offset>
        <text>PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual orexin receptor antagonist almorexant.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">almorexant</infon>
          <location offset="272" length="10"/>
          <text>almorexant</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">orexin receptor</infon>
          <location offset="245" length="15"/>
          <text>orexin receptor</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome p450 3a4</infon>
          <location offset="192" length="19"/>
          <text>cytochrome P450 3A4</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="213" length="6"/>
          <text>CYP3A4</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>284</offset>
        <text>METHODS: Pharmacokinetic interactions were investigated (n = 14 healthy male subjects in two treatment groups) between almorexant at steady-state when administered either concomitantly or 2 h after administration of single doses of simvastatin (40 mg) or atorvastatin (40 mg).</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">almorexant</infon>
          <location offset="403" length="10"/>
          <text>almorexant</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">simvastatin</infon>
          <location offset="516" length="11"/>
          <text>simvastatin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atorvastatin</infon>
          <location offset="539" length="12"/>
          <text>atorvastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>561</offset>
        <text>RESULTS: Almorexant dose-dependently increased simvastatin exposure (AUC(0-∞)) when administered concomitantly [geometric mean ratios (90 % CI): 2.5 (2.1, 2.9) (100 mg), 3.9 (3.3, 4.6) (200 mg)], but not C(max) [3.7 (3.0, 4.5) for both doses].</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">almorexant</infon>
          <location offset="570" length="10"/>
          <text>Almorexant</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">simvastatin</infon>
          <location offset="608" length="11"/>
          <text>simvastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>805</offset>
        <text>Time-separated administration resulted in relevant reductions of the interaction [AUC(0-∞): 1.4 (1.2, 1.7) (100 mg), 1.7 (1.5, 2.0) (200 mg); C(max): 1.5 (1.3, 1.9) (100 mg), 1.9 (1.6, 2.4) (200 mg)].</text>
      </sentence>
      <sentence>
        <offset>1006</offset>
        <text>Similar results were obtained for hydroxyacid simvastatin.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxyacid simvastatin</infon>
          <location offset="1040" length="23"/>
          <text>hydroxyacid simvastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1065</offset>
        <text>Independent of almorexant dose and relative time of administration, AUC(0-∞) and C(max) of atorvastatin increased (ratios ranged from 1.1 to 1.5).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atorvastatin</infon>
          <location offset="1156" length="12"/>
          <text>atorvastatin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">almorexant</infon>
          <location offset="1080" length="10"/>
          <text>almorexant</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1212</offset>
        <text>AUC(0-∞) and C(max) of o-hydroxy atorvastatin decreased dose-independently [AUC(0-∞): 0.8 (0.8, 0.9) (100 mg), 0.6 (0.5, 0.6) (200 mg); C(max): 0.3 (0.3, 0.4) (100 mg), 0.2 (0.2, 0.3) (200 mg)] when atorvastatin was concomitantly administered.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o-hydroxy atorvastatin</infon>
          <location offset="1235" length="22"/>
          <text>o-hydroxy atorvastatin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atorvastatin</infon>
          <location offset="1411" length="12"/>
          <text>atorvastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1456</offset>
        <text>C(max) of o-hydroxy atorvastatin slightly decreased (0.8 for both doses) following time-separated administration; AUC(0-∞) was unchanged.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o-hydroxy atorvastatin</infon>
          <location offset="1466" length="22"/>
          <text>o-hydroxy atorvastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1594</offset>
        <text>CONCLUSIONS: Whereas almorexant increased simvastatin exposure dose- and relative time of administration-dependently, atorvastatin exposure increased to a smaller extent and irrespective of dose and time.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">almorexant</infon>
          <location offset="1615" length="10"/>
          <text>almorexant</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">simvastatin</infon>
          <location offset="1636" length="11"/>
          <text>simvastatin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atorvastatin</infon>
          <location offset="1712" length="12"/>
          <text>atorvastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1799</offset>
        <text>This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal CYP3A4 inhibition, whereas the interaction with atorvastatin is more due to hepatic CYP3A4 inhibition.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">almorexant</infon>
          <location offset="1846" length="10"/>
          <text>almorexant</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">simvastatin</infon>
          <location offset="1862" length="11"/>
          <text>simvastatin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atorvastatin</infon>
          <location offset="1953" length="12"/>
          <text>atorvastatin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="1905" length="6"/>
          <text>CYP3A4</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp3a4</infon>
          <location offset="1989" length="6"/>
          <text>CYP3A4</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23017392</id>
    <passage>
      <offset>0</offset>
      <text>Optimization of frozen sour cherries vacuum drying process.	The objective of this research was to optimize the vacuum-drying of frozen sour cherries in order to preserve health-beneficial phytochemicals, as well as textural characteristics. Investigated range of temperature was 46-74°C and, of pressure, 17-583mbar, in a new design of vacuum-dryer equipment. The total solids, a(w) value, total phenolics, vitamin C, antioxidant activity, anthocyanin content, total colour change and firmness were used as quality indicators of dried sour cherry. Within the experimental range of studied variables, the optimum conditions of 54.03°C and 148.16mbar were established for vacuum drying of sour cherry. Separate validation experiments were conducted, under optimum conditions, to verify predictions and adequacy of the second-order polynomial models. Under these optimal conditions, the predicted amount of total phenolics was 744mg CAE/100 dw, vitamin C 1.44mg/100g per dry weight (g dw), anthocyanin content 125mg/100g dw, IC(50) 3.23mg/ml, total solids 70.72%, a(w) value 0.646, total colour change 52.61 and firmness 3395.4g. The investigated parameters had a significant effect on the quality of the dried sour cherries.</text>
      <sentence>
        <offset>0</offset>
        <text>Optimization of frozen sour cherries vacuum drying process.</text>
      </sentence>
      <sentence>
        <offset>60</offset>
        <text>The objective of this research was to optimize the vacuum-drying of frozen sour cherries in order to preserve health-beneficial phytochemicals, as well as textural characteristics.</text>
      </sentence>
      <sentence>
        <offset>241</offset>
        <text>Investigated range of temperature was 46-74°C and, of pressure, 17-583mbar, in a new design of vacuum-dryer equipment.</text>
      </sentence>
      <sentence>
        <offset>360</offset>
        <text>The total solids, a(w) value, total phenolics, vitamin C, antioxidant activity, anthocyanin content, total colour change and firmness were used as quality indicators of dried sour cherry.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenolics</infon>
          <location offset="396" length="9"/>
          <text>phenolics</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin c</infon>
          <location offset="407" length="9"/>
          <text>vitamin C</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anthocyanin</infon>
          <location offset="440" length="11"/>
          <text>anthocyanin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>548</offset>
        <text>Within the experimental range of studied variables, the optimum conditions of 54.03°C and 148.16mbar were established for vacuum drying of sour cherry.</text>
      </sentence>
      <sentence>
        <offset>700</offset>
        <text>Separate validation experiments were conducted, under optimum conditions, to verify predictions and adequacy of the second-order polynomial models.</text>
      </sentence>
      <sentence>
        <offset>848</offset>
        <text>Under these optimal conditions, the predicted amount of total phenolics was 744mg CAE/100 dw, vitamin C 1.44mg/100g per dry weight (g dw), anthocyanin content 125mg/100g dw, IC(50) 3.23mg/ml, total solids 70.72%, a(w) value 0.646, total colour change 52.61 and firmness 3395.4g.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phenolics</infon>
          <location offset="910" length="9"/>
          <text>phenolics</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin c</infon>
          <location offset="942" length="9"/>
          <text>vitamin C</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">anthocyanin</infon>
          <location offset="987" length="11"/>
          <text>anthocyanin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1127</offset>
        <text>The investigated parameters had a significant effect on the quality of the dried sour cherries.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17168665</id>
    <passage>
      <offset>0</offset>
      <text>Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?	The expression and activity of Fatty Acid Synthase (FASN; the sole enzyme capable of the reductive de novo synthesis of long-chain fatty acids from acetyl-CoA, malonyl-CoA, and nicotinamide adenine dinucleotide phosphate -NADPH-) is extremely low in nearly all nonmalignant adult tissues, whereas it is significantly up-regulated or activated in many cancer types, thus creating the potential for a large therapeutic index. Since the pioneering observation that inhibition of FASN activity by the mycotoxin cerulenin preferentially kills cancer cells and retards the growth of tumors in xenografts models, numerous in vitro and in vivo studies have confirmed the potential of FASN as a target for antineoplastic intervention. Other FASN inhibitors such as the cerulenin derivative C75, the beta-lactone orlistat, the green tea polyphenol epigallocatechin-3-gallate (EGCG) and other naturally occurring flavonoids (i.e., luteolin, quercetin, and kaempferol), as well as the antibiotic triclosan, have been identified and have been shown to limit cancer cell growth by inducing apoptotic cell death. Though the exact mode of action of these FASN inhibitors is under discussion, it has been revealed that depletion of end-product fatty acids, toxic intracellular accumulation of supra-physiological concentrations of the FASN substrate malonyl-CoA and/or limited membrane synthesis and/or functioning by altered production of phospholipids partitioning into detergent-resistant membrane microdomains (lipid raft-aggregates), can explain, at least in part, the cytostatic, cytotoxic as well as the apoptotic effects occurring upon pharmacological inhibition of FASN activity in cancer cells. Moreover, several cancer-associated molecular features including nonfunctioning p53, overexpression of the Her-2/neu (erbB-2) oncogene, and hyperactivation of the PI-3'K down-stream effector protein kinase B (AKT), appear to determine an exacerbated sensitivity to FASN inhibition-induced cancer cell death. Although few of these inhibitors are expected to be "exclusively" selective for FASN, the potential of FASN as a target for antineoplastic intervention has eventually been confirmed by RNA interference (RNAi)-knockdown of FASN. Certainly, future studies should definitely elucidate the ultimate biochemical link between FASN inhibition and cancer cell death. Although the combination of FASN structural complexity and until recently the lack of X-ray crystallography data of mammalian FASN created a significant challenge in the exploitation of FASN as a valuable target for drug development, it is hoped that the improvement in the selectivity and potency of forthcoming novel FASN-targeted small molecule inhibitors by taking advantage, for instance, of the recent 4.5 A resolution X-ray crystallographic map of mammalian FASN, will direct the foundation of a new family of chemotherapeutic agents in cancer history.</text>
      <sentence>
        <offset>0</offset>
        <text>Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="30" length="10"/>
          <text>Fatty Acid</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="79" length="10"/>
          <text>fatty acid</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fatty acid synthase</infon>
          <location offset="30" length="19"/>
          <text>Fatty Acid Synthase</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="51" length="4"/>
          <text>FASN</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T21" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T21" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>138</offset>
        <text>The expression and activity of Fatty Acid Synthase (FASN; the sole enzyme capable of the reductive de novo synthesis of long-chain fatty acids from acetyl-CoA, malonyl-CoA, and nicotinamide adenine dinucleotide phosphate -NADPH-) is extremely low in nearly all nonmalignant adult tissues, whereas it is significantly up-regulated or activated in many cancer types, thus creating the potential for a large therapeutic index.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">long-chain fatty acids</infon>
          <location offset="258" length="22"/>
          <text>long-chain fatty acids</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetyl-coa</infon>
          <location offset="286" length="10"/>
          <text>acetyl-CoA</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malonyl-coa</infon>
          <location offset="298" length="11"/>
          <text>malonyl-CoA</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nicotinamide adenine dinucleotide phosphate</infon>
          <location offset="315" length="43"/>
          <text>nicotinamide adenine dinucleotide phosphate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadph</infon>
          <location offset="360" length="5"/>
          <text>NADPH</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="169" length="10"/>
          <text>Fatty Acid</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fatty acid synthase</infon>
          <location offset="169" length="19"/>
          <text>Fatty Acid Synthase</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="190" length="4"/>
          <text>FASN</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T5" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T1" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T6" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T4" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>562</offset>
        <text>Since the pioneering observation that inhibition of FASN activity by the mycotoxin cerulenin preferentially kills cancer cells and retards the growth of tumors in xenografts models, numerous in vitro and in vivo studies have confirmed the potential of FASN as a target for antineoplastic intervention.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cerulenin</infon>
          <location offset="645" length="9"/>
          <text>cerulenin</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="614" length="4"/>
          <text>FASN</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="814" length="4"/>
          <text>FASN</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>864</offset>
        <text>Other FASN inhibitors such as the cerulenin derivative C75, the beta-lactone orlistat, the green tea polyphenol epigallocatechin-3-gallate (EGCG) and other naturally occurring flavonoids (i.e., luteolin, quercetin, and kaempferol), as well as the antibiotic triclosan, have been identified and have been shown to limit cancer cell growth by inducing apoptotic cell death.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cerulenin</infon>
          <location offset="898" length="9"/>
          <text>cerulenin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">beta-lactone orlistat</infon>
          <location offset="928" length="21"/>
          <text>beta-lactone orlistat</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polyphenol</infon>
          <location offset="965" length="10"/>
          <text>polyphenol</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">epigallocatechin-3-gallate</infon>
          <location offset="976" length="26"/>
          <text>epigallocatechin-3-gallate</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">egcg</infon>
          <location offset="1004" length="4"/>
          <text>EGCG</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">flavonoids</infon>
          <location offset="1040" length="10"/>
          <text>flavonoids</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">luteolin</infon>
          <location offset="1058" length="8"/>
          <text>luteolin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">quercetin</infon>
          <location offset="1068" length="9"/>
          <text>quercetin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">kaempferol</infon>
          <location offset="1083" length="10"/>
          <text>kaempferol</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">triclosan</infon>
          <location offset="1122" length="9"/>
          <text>triclosan</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="870" length="4"/>
          <text>FASN</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1236</offset>
        <text>Though the exact mode of action of these FASN inhibitors is under discussion, it has been revealed that depletion of end-product fatty acids, toxic intracellular accumulation of supra-physiological concentrations of the FASN substrate malonyl-CoA and/or limited membrane synthesis and/or functioning by altered production of phospholipids partitioning into detergent-resistant membrane microdomains (lipid raft-aggregates), can explain, at least in part, the cytostatic, cytotoxic as well as the apoptotic effects occurring upon pharmacological inhibition of FASN activity in cancer cells.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acids</infon>
          <location offset="1365" length="11"/>
          <text>fatty acids</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malonyl-coa</infon>
          <location offset="1471" length="11"/>
          <text>malonyl-CoA</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="1277" length="4"/>
          <text>FASN</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="1456" length="4"/>
          <text>FASN</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="1795" length="4"/>
          <text>FASN</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1826</offset>
        <text>Moreover, several cancer-associated molecular features including nonfunctioning p53, overexpression of the Her-2/neu (erbB-2) oncogene, and hyperactivation of the PI-3'K down-stream effector protein kinase B (AKT), appear to determine an exacerbated sensitivity to FASN inhibition-induced cancer cell death.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="1906" length="3"/>
          <text>p53</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">her-2</infon>
          <location offset="1933" length="5"/>
          <text>Her-2</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">neu</infon>
          <location offset="1939" length="3"/>
          <text>neu</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">erbb-2</infon>
          <location offset="1944" length="6"/>
          <text>erbB-2</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pi-3'k</infon>
          <location offset="1989" length="6"/>
          <text>PI-3'K</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">protein kinase b</infon>
          <location offset="2017" length="16"/>
          <text>protein kinase B</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akt</infon>
          <location offset="2035" length="3"/>
          <text>AKT</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="2091" length="4"/>
          <text>FASN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2134</offset>
        <text>Although few of these inhibitors are expected to be "exclusively" selective for FASN, the potential of FASN as a target for antineoplastic intervention has eventually been confirmed by RNA interference (RNAi)-knockdown of FASN.</text>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="2214" length="4"/>
          <text>FASN</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="2237" length="4"/>
          <text>FASN</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="2356" length="4"/>
          <text>FASN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2362</offset>
        <text>Certainly, future studies should definitely elucidate the ultimate biochemical link between FASN inhibition and cancer cell death.</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="2454" length="4"/>
          <text>FASN</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2493</offset>
        <text>Although the combination of FASN structural complexity and until recently the lack of X-ray crystallography data of mammalian FASN created a significant challenge in the exploitation of FASN as a valuable target for drug development, it is hoped that the improvement in the selectivity and potency of forthcoming novel FASN-targeted small molecule inhibitors by taking advantage, for instance, of the recent 4.5 A resolution X-ray crystallographic map of mammalian FASN, will direct the foundation of a new family of chemotherapeutic agents in cancer history.</text>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="2521" length="4"/>
          <text>FASN</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mammalian fasn</infon>
          <location offset="2609" length="14"/>
          <text>mammalian FASN</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="2679" length="4"/>
          <text>FASN</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fasn</infon>
          <location offset="2812" length="4"/>
          <text>FASN</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mammalian fasn</infon>
          <location offset="2948" length="14"/>
          <text>mammalian FASN</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23410587</id>
    <passage>
      <offset>0</offset>
      <text>Benchmark dose for estimation of cadmium reference level for osteoporosis in a Chinese female population.	In this study, the reference level of cadmium in urine and blood related with bone damage was assessed using benchmark dose in a Chinese female population. Total of 338 women was recruited, and urine and blood samples were collected from each individual for determination of cadmium in urine (UCd) and blood (BCd). Bone mineral density was measured by dual energy X-ray absorptiometry. BMD and BMDL were calculated corresponding to additional risk of 5% and 10%. With benchmark response (BMR) of 5%/10%, the BMD of BCd, UCd related with osteoporosis was 1.88μg/L/3.23μg/L and 5.30μg/g crea/9.06μg/g crea, and the BMDL-05 was 1.39μg/L/2.38μg/L and 3.78μg/g crea/6.36μg/g crea; the BMD of BCd, UCd related with low bone mass was 0.95μg/L/3.12μg/L and 3.12μg/g crea/5.87μg/g crea, and the BMDL-05 was 0.72μg/L/1.35μg/L and 2.14μg/g crea/3.99μg/g crea. The BMD of UCd in people over 60years old was much lower than that of people less than 60years old. BMD value was related with ages and effects biomarkers. Our data showed that BMD of UCd associated with osteoporosis was lower than that previously estimated.</text>
      <sentence>
        <offset>0</offset>
        <text>Benchmark dose for estimation of cadmium reference level for osteoporosis in a Chinese female population.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="33" length="7"/>
          <text>cadmium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>106</offset>
        <text>In this study, the reference level of cadmium in urine and blood related with bone damage was assessed using benchmark dose in a Chinese female population.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="144" length="7"/>
          <text>cadmium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>262</offset>
        <text>Total of 338 women was recruited, and urine and blood samples were collected from each individual for determination of cadmium in urine (UCd) and blood (BCd).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cadmium</infon>
          <location offset="381" length="7"/>
          <text>cadmium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>421</offset>
        <text>Bone mineral density was measured by dual energy X-ray absorptiometry.</text>
      </sentence>
      <sentence>
        <offset>492</offset>
        <text>BMD and BMDL were calculated corresponding to additional risk of 5% and 10%.</text>
      </sentence>
      <sentence>
        <offset>569</offset>
        <text>With benchmark response (BMR) of 5%/10%, the BMD of BCd, UCd related with osteoporosis was 1.88μg/L/3.23μg/L and 5.30μg/g crea/9.06μg/g crea, and the BMDL-05 was 1.39μg/L/2.38μg/L and 3.78μg/g crea/6.36μg/g crea; the BMD of BCd, UCd related with low bone mass was 0.95μg/L/3.12μg/L and 3.12μg/g crea/5.87μg/g crea, and the BMDL-05 was 0.72μg/L/1.35μg/L and 2.14μg/g crea/3.99μg/g crea.</text>
      </sentence>
      <sentence>
        <offset>955</offset>
        <text>The BMD of UCd in people over 60years old was much lower than that of people less than 60years old.</text>
      </sentence>
      <sentence>
        <offset>1055</offset>
        <text>BMD value was related with ages and effects biomarkers.</text>
      </sentence>
      <sentence>
        <offset>1111</offset>
        <text>Our data showed that BMD of UCd associated with osteoporosis was lower than that previously estimated.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16289454</id>
    <passage>
      <offset>0</offset>
      <text>Effect of aminooxyacetic acid on extracellular level of D-serine in rat striatum: an in vivo microdialysis study.	To elucidate the effect of an inhibitor of pyridoxal phosphate-dependent enzymes, aminooxyacetic acid, on the activity of serine racemase in vivo, we have investigated the effect of aminooxyacetic acid on the extracellular concentration of D-serine in the rat striatum using an in vivo microdialysis technique. The intrastriatal perfusion of aminooxyacetic acid caused a significant decline in the extracellular concentration of D-serine. These data, together with the fact that serine racemase is a pyridoxal phosphate-dependent enzyme, suggest that the aminooxyacetic acid-induced reduction of the extracellular D-serine may be at least in part due to the drug's ability to inhibit serine racemase.</text>
      <sentence>
        <offset>0</offset>
        <text>Effect of aminooxyacetic acid on extracellular level of D-serine in rat striatum: an in vivo microdialysis study.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aminooxyacetic acid</infon>
          <location offset="10" length="19"/>
          <text>aminooxyacetic acid</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-serine</infon>
          <location offset="56" length="8"/>
          <text>D-serine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>114</offset>
        <text>To elucidate the effect of an inhibitor of pyridoxal phosphate-dependent enzymes, aminooxyacetic acid, on the activity of serine racemase in vivo, we have investigated the effect of aminooxyacetic acid on the extracellular concentration of D-serine in the rat striatum using an in vivo microdialysis technique.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="236" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aminooxyacetic acid</infon>
          <location offset="296" length="19"/>
          <text>aminooxyacetic acid</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-serine</infon>
          <location offset="354" length="8"/>
          <text>D-serine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyridoxal phosphate</infon>
          <location offset="157" length="19"/>
          <text>pyridoxal phosphate</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aminooxyacetic acid</infon>
          <location offset="196" length="19"/>
          <text>aminooxyacetic acid</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serine racemase</infon>
          <location offset="236" length="15"/>
          <text>serine racemase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>425</offset>
        <text>The intrastriatal perfusion of aminooxyacetic acid caused a significant decline in the extracellular concentration of D-serine.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aminooxyacetic acid</infon>
          <location offset="456" length="19"/>
          <text>aminooxyacetic acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-serine</infon>
          <location offset="543" length="8"/>
          <text>D-serine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>553</offset>
        <text>These data, together with the fact that serine racemase is a pyridoxal phosphate-dependent enzyme, suggest that the aminooxyacetic acid-induced reduction of the extracellular D-serine may be at least in part due to the drug's ability to inhibit serine racemase.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="593" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyridoxal phosphate</infon>
          <location offset="614" length="19"/>
          <text>pyridoxal phosphate</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aminooxyacetic acid</infon>
          <location offset="669" length="19"/>
          <text>aminooxyacetic acid</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">d-serine</infon>
          <location offset="728" length="8"/>
          <text>D-serine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serine</infon>
          <location offset="798" length="6"/>
          <text>serine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serine racemase</infon>
          <location offset="593" length="15"/>
          <text>serine racemase</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">serine racemase</infon>
          <location offset="798" length="15"/>
          <text>serine racemase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10485483</id>
    <passage>
      <offset>0</offset>
      <text>Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.	Cyclooxygenase (COX)-2 mRNA and protein expression were found to be frequently elevated in human pancreatic adenocarcinomas and cell lines derived from such tumors. Immunohistochemistry demonstrated cytoplasmic COX-2 expression in 14 of 21 (67%) pancreatic carcinomas. The level of COX-2 mRNA was found to be elevated in carcinomas, relative to histologically normal pancreas from a healthy individual, as assessed by reverse transcription-PCR. COX-2 protein expression was detected by the Western blot assay in three of five pancreatic carcinoma cell lines (BxPC-3, Capan-1, and MDAPanc-3), whereas COX-1 protein was detected in two of the five cell lines (BxPC-3 and Capan-1). Increased levels of COX-2 mRNA were found in four of five cell lines, and only in PANC-1 cells was the low level of transcript comparable to that in the normal pancreas. The level of COX-2 mRNA was positively correlated with the differentiation status of the tumor of origin for each cell line, COX-2 protein expression was up-regulated by epidermal growth factor when the cells were grown in absence of serum. Finally, two nonsteroidal anti-inflammatory drugs, sulindac sulfide and NS398, produced a dose-dependent inhibition of cell proliferation in all pancreatic cell lines tested. No correlation was found between the level of COX-2 or COX-1 expression and the extent of growth inhibition. Treatment of BxPC-3 cells with sulindac sulfide and NS398 resulted in an induction of COX-2 expression. Our findings indicate that COX-2 up-regulation is a frequent event in pancreatic cancers and suggest that nonsteroidal anti-inflammatory drugs may be useful in the chemoprevention and therapy of pancreatic carcinoma.</text>
      <sentence>
        <offset>0</offset>
        <text>Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclooxygenase-2</infon>
          <location offset="10" length="16"/>
          <text>cyclooxygenase-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>144</offset>
        <text>Cyclooxygenase (COX)-2 mRNA and protein expression were found to be frequently elevated in human pancreatic adenocarcinomas and cell lines derived from such tumors.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclooxygenase (cox)-2</infon>
          <location offset="144" length="22"/>
          <text>Cyclooxygenase (COX)-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>309</offset>
        <text>Immunohistochemistry demonstrated cytoplasmic COX-2 expression in 14 of 21 (67%) pancreatic carcinomas.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="355" length="5"/>
          <text>COX-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>413</offset>
        <text>The level of COX-2 mRNA was found to be elevated in carcinomas, relative to histologically normal pancreas from a healthy individual, as assessed by reverse transcription-PCR.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="426" length="5"/>
          <text>COX-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>589</offset>
        <text>COX-2 protein expression was detected by the Western blot assay in three of five pancreatic carcinoma cell lines (BxPC-3, Capan-1, and MDAPanc-3), whereas COX-1 protein was detected in two of the five cell lines (BxPC-3 and Capan-1).</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="589" length="5"/>
          <text>COX-2</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-1</infon>
          <location offset="744" length="5"/>
          <text>COX-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>823</offset>
        <text>Increased levels of COX-2 mRNA were found in four of five cell lines, and only in PANC-1 cells was the low level of transcript comparable to that in the normal pancreas.</text>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="843" length="5"/>
          <text>COX-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>993</offset>
        <text>The level of COX-2 mRNA was positively correlated with the differentiation status of the tumor of origin for each cell line, COX-2 protein expression was up-regulated by epidermal growth factor when the cells were grown in absence of serum.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor</infon>
          <location offset="1163" length="23"/>
          <text>epidermal growth factor</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="1006" length="5"/>
          <text>COX-2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="1118" length="5"/>
          <text>COX-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1234</offset>
        <text>Finally, two nonsteroidal anti-inflammatory drugs, sulindac sulfide and NS398, produced a dose-dependent inhibition of cell proliferation in all pancreatic cell lines tested.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulindac sulfide</infon>
          <location offset="1285" length="16"/>
          <text>sulindac sulfide</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ns398</infon>
          <location offset="1306" length="5"/>
          <text>NS398</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1409</offset>
        <text>No correlation was found between the level of COX-2 or COX-1 expression and the extent of growth inhibition.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="1455" length="5"/>
          <text>COX-2</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-1</infon>
          <location offset="1464" length="5"/>
          <text>COX-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1518</offset>
        <text>Treatment of BxPC-3 cells with sulindac sulfide and NS398 resulted in an induction of COX-2 expression.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sulindac sulfide</infon>
          <location offset="1549" length="16"/>
          <text>sulindac sulfide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ns398</infon>
          <location offset="1570" length="5"/>
          <text>NS398</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="1604" length="5"/>
          <text>COX-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1622</offset>
        <text>Our findings indicate that COX-2 up-regulation is a frequent event in pancreatic cancers and suggest that nonsteroidal anti-inflammatory drugs may be useful in the chemoprevention and therapy of pancreatic carcinoma.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cox-2</infon>
          <location offset="1649" length="5"/>
          <text>COX-2</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>21955206</id>
    <passage>
      <offset>0</offset>
      <text>Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.	BACKGROUND AND PURPOSE: Most patients with cancer die not because of the tumour in the primary site, but because it has spread to other sites. Common tumours, such as breast, multiple myeloma, and prostate tumours, frequently metastasize to the bone. To search for an inhibitor of cancer-induced bone loss, we investigated the effect of thiocolchicoside, a semi-synthetic colchicoside derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and tumour cells. EXPERIMENTAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well-established system for osteoclastogenesis, and evaluated the effect of thiocolchicoside on RANKL-induced NF-kappaB signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells. KEY RESULTS: Thiocolchicoside suppressed osteoclastogenesis induced by RANKL, and by breast cancer and multiple myeloma cells. Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB. Furthermore, an inhibitor of the IkappaBalpha kinase gamma or NF-kappaB essential modulator, the regulatory component of the IKK complex, demonstrated that the NF-kappaB signalling pathway is mandatory for osteoclastogenesis induced by RANKL. CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that thiocolchicoside significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the NF-kappaB signalling pathway. Thus, thiocolchicoside, a drug that has been used for almost half a century to treat muscle pain, may also be considered as a new treatment for bone loss.</text>
      <sentence>
        <offset>0</offset>
        <text>Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiocolchicoside</infon>
          <location offset="0" length="16"/>
          <text>Thiocolchicoside</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rankl</infon>
          <location offset="58" length="5"/>
          <text>RANKL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>153</offset>
        <text>BACKGROUND AND PURPOSE: Most patients with cancer die not because of the tumour in the primary site, but because it has spread to other sites.</text>
      </sentence>
      <sentence>
        <offset>296</offset>
        <text>Common tumours, such as breast, multiple myeloma, and prostate tumours, frequently metastasize to the bone.</text>
      </sentence>
      <sentence>
        <offset>404</offset>
        <text>To search for an inhibitor of cancer-induced bone loss, we investigated the effect of thiocolchicoside, a semi-synthetic colchicoside derived from the plant Gloriosa superba and clinically used as a muscle relaxant, on osteoclastogenesis induced by receptor activator of NF-kappaB ligand (RANKL) and tumour cells.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiocolchicoside</infon>
          <location offset="490" length="16"/>
          <text>thiocolchicoside</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">colchicoside</infon>
          <location offset="525" length="12"/>
          <text>colchicoside</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">receptor activator of nf-kappab ligand</infon>
          <location offset="653" length="38"/>
          <text>receptor activator of NF-kappaB ligand</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rankl</infon>
          <location offset="693" length="5"/>
          <text>RANKL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>718</offset>
        <text>EXPERIMENTAL APPROACH: We used RAW 264.7 (murine macrophage) cells, a well-established system for osteoclastogenesis, and evaluated the effect of thiocolchicoside on RANKL-induced NF-kappaB signalling and osteoclastogenesis as well as on osteoclastogenesis induced by tumour cells.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiocolchicoside</infon>
          <location offset="864" length="16"/>
          <text>thiocolchicoside</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rankl</infon>
          <location offset="884" length="5"/>
          <text>RANKL</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="898" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1000</offset>
        <text>KEY RESULTS: Thiocolchicoside suppressed osteoclastogenesis induced by RANKL, and by breast cancer and multiple myeloma cells.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiocolchicoside</infon>
          <location offset="1013" length="16"/>
          <text>Thiocolchicoside</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rankl</infon>
          <location offset="1071" length="5"/>
          <text>RANKL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1127</offset>
        <text>Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">colchicoside</infon>
          <location offset="1205" length="12"/>
          <text>colchicoside</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rankl</infon>
          <location offset="1228" length="5"/>
          <text>RANKL</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1242" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikappab kinase</infon>
          <location offset="1278" length="14"/>
          <text>IkappaB kinase</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikk</infon>
          <location offset="1294" length="3"/>
          <text>IKK</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nf-kappabalpha</infon>
          <location offset="1327" length="14"/>
          <text>NF-kappaBalpha</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikappabalpha</infon>
          <location offset="1343" length="12"/>
          <text>IkappaBalpha</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1406" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1145" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1417</offset>
        <text>Furthermore, an inhibitor of the IkappaBalpha kinase gamma or NF-kappaB essential modulator, the regulatory component of the IKK complex, demonstrated that the NF-kappaB signalling pathway is mandatory for osteoclastogenesis induced by RANKL.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ikappabalpha</infon>
          <location offset="1450" length="12"/>
          <text>IkappaBalpha</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">kinase</infon>
          <location offset="1463" length="6"/>
          <text>kinase</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1479" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ikk</infon>
          <location offset="1542" length="3"/>
          <text>IKK</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1577" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rankl</infon>
          <location offset="1653" length="5"/>
          <text>RANKL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1660</offset>
        <text>CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that thiocolchicoside significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the NF-kappaB signalling pathway.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiocolchicoside</infon>
          <location offset="1724" length="16"/>
          <text>thiocolchicoside</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rankl</infon>
          <location offset="1796" length="5"/>
          <text>RANKL</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-kappab</infon>
          <location offset="1827" length="9"/>
          <text>NF-kappaB</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1857</offset>
        <text>Thus, thiocolchicoside, a drug that has been used for almost half a century to treat muscle pain, may also be considered as a new treatment for bone loss.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thiocolchicoside</infon>
          <location offset="1863" length="16"/>
          <text>thiocolchicoside</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23292249</id>
    <passage>
      <offset>0</offset>
      <text>The physico-chemical "anatomy" of the tautomerization through the DPT of the biologically important pairs of hypoxanthine with DNA bases: QM and QTAIM perspectives.	The biologically important tautomerization of the Hyp·Cyt, Hyp*·Thy and Hyp·Hyp base pairs to the Hyp*·Cyt*, Hyp·Thy* and Hyp*·Hyp* base pairs, respectively, by the double proton transfer (DPT) was comprehensively studied in vacuo and in the continuum with a low dielectric constant (ε = 4) corresponding to hydrophobic interfaces of protein-nucleic acid interactions by combining theoretical investigations at the B3LYP/6-311++G(d,p) level of QM theory with QTAIM topological analysis. Based on the sweeps of the energetic, electron-topological, geometric and polar parameters, which describe the course of the tautomerization along the intrinsic reaction coordinate (IRC), it was proved that the tautomerization through the DPT is concerted and asynchronous process for the Hyp·Cyt and Hyp*·Thy base pairs, while concerted and synchronous for the Hyp·Hyp homodimer. The continuum with ε = 4 does not affect qualitatively the course of the tautomerization reaction for all studied complexes. The nine key points along the IRC of the Hyp·Cyt↔Hyp*·Cyt* and Hyp*·Thy↔Hyp·Thy* tautomerizations and the six key points of the Hyp·Hyp↔Hyp*·Hyp* tautomerization have been identified and fully characterized. These key points could be considered as electron-topological "fingerprints" of concerted asynchronous (for Hyp·Cyt and Hyp*·Thy) or synchronous (for Hyp·Hyp) tautomerization process via the DPT. It was found, that in the Hyp*·Cyt*, Hyp·Thy*, Hyp·Hyp and Hyp*·Hyp* base pairs all H-bonds are significantly cooperative and mutually reinforce each other, while the C2H…O2 H-bond in the Hyp·Cyt base pair and the O6H…O4 H-bond in the Hyp*·Thy base pair behave anti-cooperatively, i.e., they become weakened, while two others become strengthened.</text>
      <sentence>
        <offset>0</offset>
        <text>The physico-chemical "anatomy" of the tautomerization through the DPT of the biologically important pairs of hypoxanthine with DNA bases: QM and QTAIM perspectives.</text>
        <annotation id="T56">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hypoxanthine</infon>
          <location offset="109" length="12"/>
          <text>hypoxanthine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>165</offset>
        <text>The biologically important tautomerization of the Hyp·Cyt, Hyp*·Thy and Hyp·Hyp base pairs to the Hyp*·Cyt*, Hyp·Thy* and Hyp*·Hyp* base pairs, respectively, by the double proton transfer (DPT) was comprehensively studied in vacuo and in the continuum with a low dielectric constant (ε = 4) corresponding to hydrophobic interfaces of protein-nucleic acid interactions by combining theoretical investigations at the B3LYP/6-311++G(d,p) level of QM theory with QTAIM topological analysis.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyt</infon>
          <location offset="268" length="3"/>
          <text>Cyt</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="274" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thy</infon>
          <location offset="278" length="3"/>
          <text>Thy</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="287" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="292" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="215" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyt</infon>
          <location offset="219" length="3"/>
          <text>Cyt</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="224" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thy</infon>
          <location offset="229" length="3"/>
          <text>Thy</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="237" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="241" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="263" length="3"/>
          <text>Hyp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>652</offset>
        <text>Based on the sweeps of the energetic, electron-topological, geometric and polar parameters, which describe the course of the tautomerization along the intrinsic reaction coordinate (IRC), it was proved that the tautomerization through the DPT is concerted and asynchronous process for the Hyp·Cyt and Hyp*·Thy base pairs, while concerted and synchronous for the Hyp·Hyp homodimer.</text>
        <annotation id="T49">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="941" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyt</infon>
          <location offset="945" length="3"/>
          <text>Cyt</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="953" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thy</infon>
          <location offset="958" length="3"/>
          <text>Thy</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1014" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1018" length="3"/>
          <text>Hyp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1033</offset>
        <text>The continuum with ε = 4 does not affect qualitatively the course of the tautomerization reaction for all studied complexes.</text>
      </sentence>
      <sentence>
        <offset>1158</offset>
        <text>The nine key points along the IRC of the Hyp·Cyt↔Hyp*·Cyt* and Hyp*·Thy↔Hyp·Thy* tautomerizations and the six key points of the Hyp·Hyp↔Hyp*·Hyp* tautomerization have been identified and fully characterized.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1199" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyt</infon>
          <location offset="1203" length="3"/>
          <text>Cyt</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1207" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyt</infon>
          <location offset="1212" length="3"/>
          <text>Cyt</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1221" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thy</infon>
          <location offset="1226" length="3"/>
          <text>Thy</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1230" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thy</infon>
          <location offset="1234" length="3"/>
          <text>Thy</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1286" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1290" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1294" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1299" length="3"/>
          <text>Hyp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1366</offset>
        <text>These key points could be considered as electron-topological "fingerprints" of concerted asynchronous (for Hyp·Cyt and Hyp*·Thy) or synchronous (for Hyp·Hyp) tautomerization process via the DPT.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1473" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyt</infon>
          <location offset="1477" length="3"/>
          <text>Cyt</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1485" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thy</infon>
          <location offset="1490" length="3"/>
          <text>Thy</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1515" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1519" length="3"/>
          <text>Hyp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1561</offset>
        <text>It was found, that in the Hyp*·Cyt*, Hyp·Thy*, Hyp·Hyp and Hyp*·Hyp* base pairs all H-bonds are significantly cooperative and mutually reinforce each other, while the C2H…O2 H-bond in the Hyp·Cyt base pair and the O6H…O4 H-bond in the Hyp*·Thy base pair behave anti-cooperatively, i.e., they become weakened, while two others become strengthened.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1587" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyt</infon>
          <location offset="1592" length="3"/>
          <text>Cyt</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1598" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thy</infon>
          <location offset="1602" length="3"/>
          <text>Thy</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1608" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1612" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1620" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1625" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h</infon>
          <location offset="1645" length="1"/>
          <text>H</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">c2h</infon>
          <location offset="1728" length="3"/>
          <text>C2H</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o2 h</infon>
          <location offset="1732" length="4"/>
          <text>O2 H</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1749" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyt</infon>
          <location offset="1753" length="3"/>
          <text>Cyt</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o6</infon>
          <location offset="1775" length="2"/>
          <text>O6</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h</infon>
          <location offset="1777" length="1"/>
          <text>H</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o4</infon>
          <location offset="1779" length="2"/>
          <text>O4</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h</infon>
          <location offset="1782" length="1"/>
          <text>H</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hyp</infon>
          <location offset="1796" length="3"/>
          <text>Hyp</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thy</infon>
          <location offset="1801" length="3"/>
          <text>Thy</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15726024</id>
    <passage>
      <offset>0</offset>
      <text>Ziprasidone-induced galactorrhea: a case report.	OBJECTIVES: Second-generation antipsychotics presumably lack the typical side effects of conventional antipsychotics. METHODOLOGY: A 34 year old Caucasian woman with ICD-10 diagnosis of Recurrent depressive disorder with current moderate symptoms, and with a history of repeated self-injury was treated with lithium, clonazepam and ziprasidone. RESULTS: On the ninth day of ziprasidone administration, galactorrhea appeared. After 36 days of ziprasidone therapy, galactorrhea persisted. The prolactin plasma level was 28 ng/ml. Thyroid tests (TSH,T3,T4) and the lithium plasma level were within the normal range during ziprasidone treatment. Two weeks after the ziprasidone withdrawal, galactorrhea disappeared and the prolactin level decreased down to 18 ng/ml. CONCLUSION: Psychiatrists should be aware that even second-generation antipsychotics, including ziprasidone, have a propensity to cause side-effects associated with the dopamine D2 receptor blockade, such as galactorrhea.</text>
      <sentence>
        <offset>0</offset>
        <text>Ziprasidone-induced galactorrhea: a case report.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ziprasidone</infon>
          <location offset="0" length="11"/>
          <text>Ziprasidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>49</offset>
        <text>OBJECTIVES: Second-generation antipsychotics presumably lack the typical side effects of conventional antipsychotics.</text>
      </sentence>
      <sentence>
        <offset>167</offset>
        <text>METHODOLOGY: A 34 year old Caucasian woman with ICD-10 diagnosis of Recurrent depressive disorder with current moderate symptoms, and with a history of repeated self-injury was treated with lithium, clonazepam and ziprasidone.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lithium</infon>
          <location offset="357" length="7"/>
          <text>lithium</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clonazepam</infon>
          <location offset="366" length="10"/>
          <text>clonazepam</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ziprasidone</infon>
          <location offset="381" length="11"/>
          <text>ziprasidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>394</offset>
        <text>RESULTS: On the ninth day of ziprasidone administration, galactorrhea appeared.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ziprasidone</infon>
          <location offset="423" length="11"/>
          <text>ziprasidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>474</offset>
        <text>After 36 days of ziprasidone therapy, galactorrhea persisted.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ziprasidone</infon>
          <location offset="491" length="11"/>
          <text>ziprasidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>536</offset>
        <text>The prolactin plasma level was 28 ng/ml.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">prolactin</infon>
          <location offset="540" length="9"/>
          <text>prolactin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>577</offset>
        <text>Thyroid tests (TSH,T3,T4) and the lithium plasma level were within the normal range during ziprasidone treatment.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">t3</infon>
          <location offset="596" length="2"/>
          <text>T3</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">t4</infon>
          <location offset="599" length="2"/>
          <text>T4</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lithium</infon>
          <location offset="611" length="7"/>
          <text>lithium</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ziprasidone</infon>
          <location offset="668" length="11"/>
          <text>ziprasidone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>691</offset>
        <text>Two weeks after the ziprasidone withdrawal, galactorrhea disappeared and the prolactin level decreased down to 18 ng/ml.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ziprasidone</infon>
          <location offset="711" length="11"/>
          <text>ziprasidone</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">prolactin</infon>
          <location offset="768" length="9"/>
          <text>prolactin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>812</offset>
        <text>CONCLUSION: Psychiatrists should be aware that even second-generation antipsychotics, including ziprasidone, have a propensity to cause side-effects associated with the dopamine D2 receptor blockade, such as galactorrhea.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ziprasidone</infon>
          <location offset="908" length="11"/>
          <text>ziprasidone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="981" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d2 receptor</infon>
          <location offset="981" length="20"/>
          <text>dopamine D2 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23403085</id>
    <passage>
      <offset>0</offset>
      <text>Neuroprotective effects of mercaptoethylleonurine and mercaptoethylguanidine analogs on hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells.	A series of mercaptoethylleonurine and mercaptoethylguanidine derivatives were designed and synthesized. Their neuroprotective effects toward H2O2-induced apoptosis were investigated in human SH-SY5Y cells. The results from these studies identified several potent compounds, with compound 8k emerging as the most effective. Further investigation demonstrated that 8k reduced H2O2-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2. Moreover, the molecular mechanism underlying the observed neuroprotective effects of 8k was exerted via the Akt and JNK pathways. Compound 8k can be a lead compound for further discovery of neuroprotective medicine.</text>
      <sentence>
        <offset>0</offset>
        <text>Neuroprotective effects of mercaptoethylleonurine and mercaptoethylguanidine analogs on hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mercaptoethylleonurine</infon>
          <location offset="27" length="22"/>
          <text>mercaptoethylleonurine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mercaptoethylguanidine</infon>
          <location offset="54" length="22"/>
          <text>mercaptoethylguanidine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen peroxide</infon>
          <location offset="88" length="17"/>
          <text>hydrogen peroxide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>157</offset>
        <text>A series of mercaptoethylleonurine and mercaptoethylguanidine derivatives were designed and synthesized.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mercaptoethylleonurine</infon>
          <location offset="169" length="22"/>
          <text>mercaptoethylleonurine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mercaptoethylguanidine</infon>
          <location offset="196" length="22"/>
          <text>mercaptoethylguanidine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>262</offset>
        <text>Their neuroprotective effects toward H2O2-induced apoptosis were investigated in human SH-SY5Y cells.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="299" length="4"/>
          <text>H2O2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>364</offset>
        <text>The results from these studies identified several potent compounds, with compound 8k emerging as the most effective.</text>
      </sentence>
      <sentence>
        <offset>481</offset>
        <text>Further investigation demonstrated that 8k reduced H2O2-induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">h2o2</infon>
          <location offset="532" length="4"/>
          <text>H2O2</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">bax</infon>
          <location offset="615" length="3"/>
          <text>Bax</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="651" length="5"/>
          <text>Bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T9" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>658</offset>
        <text>Moreover, the molecular mechanism underlying the observed neuroprotective effects of 8k was exerted via the Akt and JNK pathways.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="766" length="3"/>
          <text>Akt</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">jnk</infon>
          <location offset="774" length="3"/>
          <text>JNK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>788</offset>
        <text>Compound 8k can be a lead compound for further discovery of neuroprotective medicine.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23305444</id>
    <passage>
      <offset>0</offset>
      <text>Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.	Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatase B (mPTPB) is a virulence factor secreted by the pathogen and mediates mycobacterial survival in macrophages by targeting host cell immune responses. Consequently, mPTPB represents an exciting new target to combat tuberculosis (TB) infection. We describe a medicinal chemistry oriented approach that transforms a benzofuran salicylic acid scaffold into a highly potent (IC(50) = 38 nM) and selective mPTPB inhibitor (&gt;50 fold against a large panel of PTPs). Importantly, the inhibitor is capable of reversing the altered host immune responses induced by the bacterial phosphatase and restoring the macrophage's full capacity to secrete IL-6 and undergo apoptosis in response to interferon-γ stimulation, validating the concept that chemical inhibition of mPTPB may be therapeutically useful for novel TB treatment. The study further demonstrates that bicyclic salicylic acid pharmacophores can be used to deliver PTP inhibitors with high potency, selectivity, and cellular efficacy.</text>
      <sentence>
        <offset>0</offset>
        <text>Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">6-hydroxy-benzofuran-5-carboxylic acid</infon>
          <location offset="102" length="38"/>
          <text>6-Hydroxy-benzofuran-5-carboxylic acid</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="70" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mycobacterium protein tyrosine phosphatase b</infon>
          <location offset="48" length="44"/>
          <text>mycobacterium protein tyrosine phosphatase B</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>151</offset>
        <text>Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatase B (mPTPB) is a virulence factor secreted by the pathogen and mediates mycobacterial survival in macrophages by targeting host cell immune responses.</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mycobacterium tuberculosis (mtb) protein tyrosine phosphatase b</infon>
          <location offset="151" length="63"/>
          <text>Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatase B</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mptpb</infon>
          <location offset="216" length="5"/>
          <text>mPTPB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>362</offset>
        <text>Consequently, mPTPB represents an exciting new target to combat tuberculosis (TB) infection.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mptpb</infon>
          <location offset="376" length="5"/>
          <text>mPTPB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>455</offset>
        <text>We describe a medicinal chemistry oriented approach that transforms a benzofuran salicylic acid scaffold into a highly potent (IC(50) = 38 nM) and selective mPTPB inhibitor (&gt;50 fold against a large panel of PTPs).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">benzofuran salicylic acid</infon>
          <location offset="525" length="25"/>
          <text>benzofuran salicylic acid</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mptpb</infon>
          <location offset="612" length="5"/>
          <text>mPTPB</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ptps</infon>
          <location offset="663" length="4"/>
          <text>PTPs</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T7" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T8" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>670</offset>
        <text>Importantly, the inhibitor is capable of reversing the altered host immune responses induced by the bacterial phosphatase and restoring the macrophage's full capacity to secrete IL-6 and undergo apoptosis in response to interferon-γ stimulation, validating the concept that chemical inhibition of mPTPB may be therapeutically useful for novel TB treatment.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">bacterial phosphatase</infon>
          <location offset="770" length="21"/>
          <text>bacterial phosphatase</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-6</infon>
          <location offset="848" length="4"/>
          <text>IL-6</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interferon-γ</infon>
          <location offset="890" length="12"/>
          <text>interferon-γ</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">mptpb</infon>
          <location offset="967" length="5"/>
          <text>mPTPB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1027</offset>
        <text>The study further demonstrates that bicyclic salicylic acid pharmacophores can be used to deliver PTP inhibitors with high potency, selectivity, and cellular efficacy.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">salicylic acid</infon>
          <location offset="1072" length="14"/>
          <text>salicylic acid</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ptp</infon>
          <location offset="1125" length="3"/>
          <text>PTP</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15465654</id>
    <passage>
      <offset>0</offset>
      <text>Viability assessment in sandwich-cultured rat hepatocytes after xenobiotic exposure.	Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile. Sandwich-cultured rat hepatocytes maintain functional sodium taurocholate co-transporting polypeptide and Bsep transport proteins, and may be useful to study inhibition of transport by xenobiotics at concentrations below the lowest observable adverse effect level (LOAEL). The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system. The neutral red assay was not amenable to use in this model due to crystal formation on the collagen. Troglitazone decreased viability in every assay examined, with a LOAEL approximately 100 microM. Bosentan also decreased viability as measured by the LDH, MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay. Glibenclamide did not decrease viability with any assay at the xenobiotic concentrations examined in this study. Based on the results of this study, the LDH or propidium iodide assays would be the methods of choice to assess viability in sandwich-cultured rat hepatocytes after xenobiotic exposure.</text>
      <sentence>
        <offset>0</offset>
        <text>Viability assessment in sandwich-cultured rat hepatocytes after xenobiotic exposure.</text>
      </sentence>
      <sentence>
        <offset>85</offset>
        <text>Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="85" length="12"/>
          <text>Troglitazone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="99" length="8"/>
          <text>bosentan</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glibenclamide</infon>
          <location offset="112" length="13"/>
          <text>glibenclamide</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">taurocholate</infon>
          <location offset="184" length="12"/>
          <text>taurocholate</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bile salt export pump</infon>
          <location offset="138" length="21"/>
          <text>bile salt export pump</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bsep</infon>
          <location offset="161" length="4"/>
          <text>Bsep</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T17" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T17" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>208</offset>
        <text>Sandwich-cultured rat hepatocytes maintain functional sodium taurocholate co-transporting polypeptide and Bsep transport proteins, and may be useful to study inhibition of transport by xenobiotics at concentrations below the lowest observable adverse effect level (LOAEL).</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium taurocholate</infon>
          <location offset="262" length="19"/>
          <text>sodium taurocholate</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sodium taurocholate co-transporting polypeptide</infon>
          <location offset="262" length="47"/>
          <text>sodium taurocholate co-transporting polypeptide</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bsep</infon>
          <location offset="314" length="4"/>
          <text>Bsep</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>481</offset>
        <text>The purpose of this study was to compare viability assessments determined with the neutral red, lactate dehydrogenase (LDH), alamar blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide assays in sandwich-cultured rat hepatocytes following exposure to xenobiotics known to inhibit Bsep, and to define the LOAEL for these xenobiotics in this system.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactate</infon>
          <location offset="577" length="7"/>
          <text>lactate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alamar blue</infon>
          <location offset="606" length="11"/>
          <text>alamar blue</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide</infon>
          <location offset="619" length="60"/>
          <text>3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="681" length="3"/>
          <text>MTT</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">propidium iodide</infon>
          <location offset="690" length="16"/>
          <text>propidium iodide</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">lactate dehydrogenase</infon>
          <location offset="577" length="21"/>
          <text>lactate dehydrogenase</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="600" length="3"/>
          <text>LDH</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bsep</infon>
          <location offset="802" length="4"/>
          <text>Bsep</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>870</offset>
        <text>The neutral red assay was not amenable to use in this model due to crystal formation on the collagen.</text>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">collagen</infon>
          <location offset="962" length="8"/>
          <text>collagen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>972</offset>
        <text>Troglitazone decreased viability in every assay examined, with a LOAEL approximately 100 microM.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">troglitazone</infon>
          <location offset="972" length="12"/>
          <text>Troglitazone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1069</offset>
        <text>Bosentan also decreased viability as measured by the LDH, MTT and propidium iodide assays, with a LOAEL approximately 200 microM; however, a significant decrease in viability was not observed with the alamar blue assay.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="1127" length="3"/>
          <text>MTT</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">propidium iodide</infon>
          <location offset="1135" length="16"/>
          <text>propidium iodide</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alamar blue</infon>
          <location offset="1270" length="11"/>
          <text>alamar blue</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bosentan</infon>
          <location offset="1069" length="8"/>
          <text>Bosentan</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="1122" length="3"/>
          <text>LDH</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1289</offset>
        <text>Glibenclamide did not decrease viability with any assay at the xenobiotic concentrations examined in this study.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glibenclamide</infon>
          <location offset="1289" length="13"/>
          <text>Glibenclamide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1402</offset>
        <text>Based on the results of this study, the LDH or propidium iodide assays would be the methods of choice to assess viability in sandwich-cultured rat hepatocytes after xenobiotic exposure.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">propidium iodide</infon>
          <location offset="1449" length="16"/>
          <text>propidium iodide</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ldh</infon>
          <location offset="1442" length="3"/>
          <text>LDH</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>14764656</id>
    <passage>
      <offset>0</offset>
      <text>Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats.	We performed a study in spontaneous hypertensive rats (SHR) to determine whether carvedilol, a nonselective beta-adrenoceptor antagonist, activates capsaicin-sensitive sensory neurons (CSSNs), thereby promoting the release of calcitonin gene-related peptide (CGRP), a neuropeptide with an important role in maintenance of cardiovascular homeostasis. Carvedilol given intravenously at a dose of 0.3 mg/kg transiently decreased the mean arterial blood pressure (MABP) and increased renal tissue blood flow with increases in CGRP levels in plasma and kidney. These effects induced by carvedilol were not seen in animals pretreated with capsazepine, an antagonist of capsaicin. Although 1.0 mg/kg cavedilol markedly decreased MABP, it neither increased renal tissue blood flow nor CGRP levels in plasma and kidney. Prazosin, a selective alpha(1)-adrenoceptor antagonist, and bisoprolol, a selective beta(1)-adrenoceptor antagonist, decreased MABP with capsazepine, showing no antagonistic action in either cases, and these agents increased neither renal tissue blood flow nor levels of CGRP in plasma and kidney. Both ICI 118,551 [(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-but anol], a selective beta(2)-adrenoceptor antagonist, at a dose of 0.25 mg/kg and capsaicin mimicked effects induced by 0.3 mg/kg carvedilol. Administration of 1.0 mg/kg ICI 118,551 produced effects similar to those induced by 1.0 mg/kg carvedilol. These observations strongly suggested that the low dose of carvedilol might activate CSSNs in SHR to increase the release of CGRP, thereby decreasing blood pressure with an increase in renal tissue blood flow. The effects induced by carvedilol seemed to be mediated by its beta(2)-adrenoceptor blockade activity.</text>
      <sentence>
        <offset>0</offset>
        <text>Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">capsaicin</infon>
          <location offset="14" length="9"/>
          <text>capsaicin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="53" length="10"/>
          <text>carvedilol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>128</offset>
        <text>We performed a study in spontaneous hypertensive rats (SHR) to determine whether carvedilol, a nonselective beta-adrenoceptor antagonist, activates capsaicin-sensitive sensory neurons (CSSNs), thereby promoting the release of calcitonin gene-related peptide (CGRP), a neuropeptide with an important role in maintenance of cardiovascular homeostasis.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">capsaicin</infon>
          <location offset="276" length="9"/>
          <text>capsaicin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="209" length="10"/>
          <text>carvedilol</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="236" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">calcitonin gene-related peptide</infon>
          <location offset="354" length="31"/>
          <text>calcitonin gene-related peptide</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cgrp</infon>
          <location offset="387" length="4"/>
          <text>CGRP</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T15" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>478</offset>
        <text>Carvedilol given intravenously at a dose of 0.3 mg/kg transiently decreased the mean arterial blood pressure (MABP) and increased renal tissue blood flow with increases in CGRP levels in plasma and kidney.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="478" length="10"/>
          <text>Carvedilol</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cgrp</infon>
          <location offset="650" length="4"/>
          <text>CGRP</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>684</offset>
        <text>These effects induced by carvedilol were not seen in animals pretreated with capsazepine, an antagonist of capsaicin.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="709" length="10"/>
          <text>carvedilol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">capsazepine</infon>
          <location offset="761" length="11"/>
          <text>capsazepine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">capsaicin</infon>
          <location offset="791" length="9"/>
          <text>capsaicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>802</offset>
        <text>Although 1.0 mg/kg cavedilol markedly decreased MABP, it neither increased renal tissue blood flow nor CGRP levels in plasma and kidney.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cavedilol</infon>
          <location offset="821" length="9"/>
          <text>cavedilol</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cgrp</infon>
          <location offset="905" length="4"/>
          <text>CGRP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>939</offset>
        <text>Prazosin, a selective alpha(1)-adrenoceptor antagonist, and bisoprolol, a selective beta(1)-adrenoceptor antagonist, decreased MABP with capsazepine, showing no antagonistic action in either cases, and these agents increased neither renal tissue blood flow nor levels of CGRP in plasma and kidney.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prazosin</infon>
          <location offset="939" length="8"/>
          <text>Prazosin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bisoprolol</infon>
          <location offset="999" length="10"/>
          <text>bisoprolol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">capsazepine</infon>
          <location offset="1076" length="11"/>
          <text>capsazepine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cgrp</infon>
          <location offset="1210" length="4"/>
          <text>CGRP</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)-adrenoceptor</infon>
          <location offset="961" length="21"/>
          <text>alpha(1)-adrenoceptor</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(1)-adrenoceptor</infon>
          <location offset="1023" length="20"/>
          <text>beta(1)-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T16" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1237</offset>
        <text>Both ICI 118,551 [(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-but anol], a selective beta(2)-adrenoceptor antagonist, at a dose of 0.25 mg/kg and capsaicin mimicked effects induced by 0.3 mg/kg carvedilol.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici 118,551</infon>
          <location offset="1242" length="11"/>
          <text>ICI 118,551</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(+/-)-1-[2,3-(dihydro-7-methyl-1h-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-but anol</infon>
          <location offset="1255" length="85"/>
          <text>(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-but anol</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">capsaicin</infon>
          <location offset="1416" length="9"/>
          <text>capsaicin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="1464" length="10"/>
          <text>carvedilol</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(2)-adrenoceptor</infon>
          <location offset="1355" length="20"/>
          <text>beta(2)-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T1" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1476</offset>
        <text>Administration of 1.0 mg/kg ICI 118,551 produced effects similar to those induced by 1.0 mg/kg carvedilol.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici 118,551</infon>
          <location offset="1504" length="11"/>
          <text>ICI 118,551</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="1571" length="10"/>
          <text>carvedilol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1583</offset>
        <text>These observations strongly suggested that the low dose of carvedilol might activate CSSNs in SHR to increase the release of CGRP, thereby decreasing blood pressure with an increase in renal tissue blood flow.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carvedilol</infon>
          <location offset="1642" length="10"/>
          <text>carvedilol</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cgrp</infon>
          <location offset="1708" length="4"/>
          <text>CGRP</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1793</offset>
        <text>The effects induced by carvedilol seemed to be mediated by its beta(2)-adrenoceptor blockade activity.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(2)-adrenoceptor</infon>
          <location offset="1856" length="20"/>
          <text>beta(2)-adrenoceptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16488503</id>
    <passage>
      <offset>0</offset>
      <text>Inhibition of gentamicin binding to rat renal brush-border membrane by megalin ligands and basic peptides.	Our previous studies showed that coadministration of cytochrome c and a 20-residue basic peptide, N-WASP181-200 (NISHTKEKKKGKAKKKRLTK, pI=10.87) inhibits renal accumulation of gentamicin. In this study, we examined effects of ligands of megalin, an endocytic receptor involved in renal uptake of gentamicin, and basic peptides including N-WASP180-200 and its mutant peptides on gentamicin binding to isolated rat renal brush-border membrane (BBM). Gentamicin binding to BBM was inhibited by megalin ligands, basic peptide fragments of cytochrome c, and N-WASP181-200 in a concentration-dependent manner. Klotz plot analysis showed that N-WASP181-200 inhibited the binding of gentamicin in a competitive manner. By substituting glycines for lysines in N-WASP181-200 at positions 9 and 15, the inhibitory effect on gentamicin binding to BBM was reduced, which may be related to a decrease in the alpha-helix content in the peptide. Gentamicin binding to BBM treated with trypsin, in which megalin completely disappeared, was significantly but not completely decreased compared with the native BBM. In addition, treatment of BBM with trypsin led to a decrease in the inhibitory effect of N-WASP181-200 on gentamicin binding. These observations support that megalin ligands and basic peptides including N-WASP181-200 decrease renal accumulation of gentamicin by inhibiting its binding to BBM of proximal tubule cells, partly interacting with megalin. In addition, the alpha-helix conformation may play an important role in the inhibitory effect of N-WASP181-200 on the binding of gentamicin to BBM.</text>
      <sentence>
        <offset>0</offset>
        <text>Inhibition of gentamicin binding to rat renal brush-border membrane by megalin ligands and basic peptides.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="14" length="10"/>
          <text>gentamicin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">megalin</infon>
          <location offset="71" length="7"/>
          <text>megalin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>107</offset>
        <text>Our previous studies showed that coadministration of cytochrome c and a 20-residue basic peptide, N-WASP181-200 (NISHTKEKKKGKAKKKRLTK, pI=10.87) inhibits renal accumulation of gentamicin.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="283" length="10"/>
          <text>gentamicin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nishtkekkkgkakkkrltk</infon>
          <location offset="220" length="20"/>
          <text>NISHTKEKKKGKAKKKRLTK</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="160" length="12"/>
          <text>cytochrome c</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>295</offset>
        <text>In this study, we examined effects of ligands of megalin, an endocytic receptor involved in renal uptake of gentamicin, and basic peptides including N-WASP180-200 and its mutant peptides on gentamicin binding to isolated rat renal brush-border membrane (BBM).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="403" length="10"/>
          <text>gentamicin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="485" length="10"/>
          <text>gentamicin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">megalin</infon>
          <location offset="344" length="7"/>
          <text>megalin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>555</offset>
        <text>Gentamicin binding to BBM was inhibited by megalin ligands, basic peptide fragments of cytochrome c, and N-WASP181-200 in a concentration-dependent manner.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="555" length="10"/>
          <text>Gentamicin</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">megalin</infon>
          <location offset="598" length="7"/>
          <text>megalin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="642" length="12"/>
          <text>cytochrome c</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>711</offset>
        <text>Klotz plot analysis showed that N-WASP181-200 inhibited the binding of gentamicin in a competitive manner.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="782" length="10"/>
          <text>gentamicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>818</offset>
        <text>By substituting glycines for lysines in N-WASP181-200 at positions 9 and 15, the inhibitory effect on gentamicin binding to BBM was reduced, which may be related to a decrease in the alpha-helix content in the peptide.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glycines</infon>
          <location offset="834" length="8"/>
          <text>glycines</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lysines</infon>
          <location offset="847" length="7"/>
          <text>lysines</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="920" length="10"/>
          <text>gentamicin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-helix</infon>
          <location offset="1001" length="11"/>
          <text>alpha-helix</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1037</offset>
        <text>Gentamicin binding to BBM treated with trypsin, in which megalin completely disappeared, was significantly but not completely decreased compared with the native BBM.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="1037" length="10"/>
          <text>Gentamicin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">trypsin</infon>
          <location offset="1076" length="7"/>
          <text>trypsin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">megalin</infon>
          <location offset="1094" length="7"/>
          <text>megalin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1203</offset>
        <text>In addition, treatment of BBM with trypsin led to a decrease in the inhibitory effect of N-WASP181-200 on gentamicin binding.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="1309" length="10"/>
          <text>gentamicin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">trypsin</infon>
          <location offset="1238" length="7"/>
          <text>trypsin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1329</offset>
        <text>These observations support that megalin ligands and basic peptides including N-WASP181-200 decrease renal accumulation of gentamicin by inhibiting its binding to BBM of proximal tubule cells, partly interacting with megalin.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="1451" length="10"/>
          <text>gentamicin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">megalin</infon>
          <location offset="1361" length="7"/>
          <text>megalin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">megalin</infon>
          <location offset="1545" length="7"/>
          <text>megalin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1554</offset>
        <text>In addition, the alpha-helix conformation may play an important role in the inhibitory effect of N-WASP181-200 on the binding of gentamicin to BBM.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gentamicin</infon>
          <location offset="1683" length="10"/>
          <text>gentamicin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha-helix</infon>
          <location offset="1571" length="11"/>
          <text>alpha-helix</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23477570</id>
    <passage>
      <offset>0</offset>
      <text>In situ forming reduction-sensitive degradable nanogels for facile loading and triggered intracellular release of proteins.	In situ forming reduction-sensitive degradable nanogels were designed and developed based on poly(ethylene glycol)-b-poly(2-(hydroxyethyl) methacrylate-co-acryloyl carbonate) (PEG-P(HEMA-co-AC)) block copolymers for efficient loading as well as triggered intracellular release of proteins. PEG-P(HEMA-co-AC) copolymers were prepared with controlled Mn of 9.1, 9.5, and 9.9 kg/mol and varying numbers of AC units per molecule of 7, 9 and 11, respectively (denoted as copolymer 1, 2, and 3) by reversible addition-fragmentation chain transfer copolymerization. These copolymers were freely soluble in phosphate buffer but formed disulfide-cross-linked nanogels with defined sizes ranging from 72.5 to 124.1 nm in the presence of cystamine via ring-opening reaction with cyclic carbonate groups. The sizes of nanogels decreased with increasing AC units as a result of increased cross-linking density. Dynamic light scattering studies showed that these nanogels though stable at physiological conditions were rapidly dissociated in response to 10 mM dithiothreitol (DTT). Interestingly, FITC-labeled cytochrome C (FITC-CC) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%). The in vitro release studies showed that release of FITC-CC was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM DTT with about 96.8% of FITC-CC released in 22 h from nanogel 1. In contrast, protein release from 1,4-butanediamine cross-linked nanogels (reduction-insensitive control) remained low under otherwise the same conditions. MTT assays showed that these nanogels were nontoxic to HeLa cells up to a tested concentration of 2 mg/mL. Confocal microscopy results showed that nanogel 1 delivered and released FITC-CC into the perinuclei region of HeLa cells following 8 h incubation. CC-loaded reductively degradable nanogels demonstrated apparently better apoptotic activity than free CC as well as reduction-insensitive controls. These in situ forming, surfactant and oil-free, and reduction-sensitive degradable nanogels are highly promising for targeted protein therapy.</text>
      <sentence>
        <offset>0</offset>
        <text>In situ forming reduction-sensitive degradable nanogels for facile loading and triggered intracellular release of proteins.</text>
      </sentence>
      <sentence>
        <offset>124</offset>
        <text>In situ forming reduction-sensitive degradable nanogels were designed and developed based on poly(ethylene glycol)-b-poly(2-(hydroxyethyl) methacrylate-co-acryloyl carbonate) (PEG-P(HEMA-co-AC)) block copolymers for efficient loading as well as triggered intracellular release of proteins.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg-p(hema-co-ac)</infon>
          <location offset="300" length="17"/>
          <text>PEG-P(HEMA-co-AC)</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly(ethylene glycol)-b-poly(2-(hydroxyethyl) methacrylate-co-acryloyl carbonate)</infon>
          <location offset="217" length="81"/>
          <text>poly(ethylene glycol)-b-poly(2-(hydroxyethyl) methacrylate-co-acryloyl carbonate)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>414</offset>
        <text>PEG-P(HEMA-co-AC) copolymers were prepared with controlled Mn of 9.1, 9.5, and 9.9 kg/mol and varying numbers of AC units per molecule of 7, 9 and 11, respectively (denoted as copolymer 1, 2, and 3) by reversible addition-fragmentation chain transfer copolymerization.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">peg-p(hema-co-ac)</infon>
          <location offset="414" length="17"/>
          <text>PEG-P(HEMA-co-AC)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>683</offset>
        <text>These copolymers were freely soluble in phosphate buffer but formed disulfide-cross-linked nanogels with defined sizes ranging from 72.5 to 124.1 nm in the presence of cystamine via ring-opening reaction with cyclic carbonate groups.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphate</infon>
          <location offset="723" length="9"/>
          <text>phosphate</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">disulfide</infon>
          <location offset="751" length="9"/>
          <text>disulfide</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cystamine</infon>
          <location offset="851" length="9"/>
          <text>cystamine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cyclic carbonate</infon>
          <location offset="892" length="16"/>
          <text>cyclic carbonate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>917</offset>
        <text>The sizes of nanogels decreased with increasing AC units as a result of increased cross-linking density.</text>
      </sentence>
      <sentence>
        <offset>1022</offset>
        <text>Dynamic light scattering studies showed that these nanogels though stable at physiological conditions were rapidly dissociated in response to 10 mM dithiothreitol (DTT).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dithiothreitol</infon>
          <location offset="1170" length="14"/>
          <text>dithiothreitol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dtt</infon>
          <location offset="1186" length="3"/>
          <text>DTT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1192</offset>
        <text>Interestingly, FITC-labeled cytochrome C (FITC-CC) could be readily loaded into nanogels with remarkable loading efficiencies (up to 98.2%) and loading contents (up to 48.2 wt.%).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fitc</infon>
          <location offset="1207" length="4"/>
          <text>FITC</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fitc</infon>
          <location offset="1234" length="4"/>
          <text>FITC</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome c</infon>
          <location offset="1220" length="12"/>
          <text>cytochrome C</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cc</infon>
          <location offset="1239" length="2"/>
          <text>CC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1372</offset>
        <text>The in vitro release studies showed that release of FITC-CC was minimal under physiological conditions but significantly enhanced under reductive conditions in the presence of 10 mM DTT with about 96.8% of FITC-CC released in 22 h from nanogel 1.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fitc</infon>
          <location offset="1424" length="4"/>
          <text>FITC</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dtt</infon>
          <location offset="1554" length="3"/>
          <text>DTT</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fitc</infon>
          <location offset="1578" length="4"/>
          <text>FITC</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cc</infon>
          <location offset="1429" length="2"/>
          <text>CC</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cc</infon>
          <location offset="1583" length="2"/>
          <text>CC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1619</offset>
        <text>In contrast, protein release from 1,4-butanediamine cross-linked nanogels (reduction-insensitive control) remained low under otherwise the same conditions.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,4-butanediamine</infon>
          <location offset="1653" length="17"/>
          <text>1,4-butanediamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1775</offset>
        <text>MTT assays showed that these nanogels were nontoxic to HeLa cells up to a tested concentration of 2 mg/mL.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="1775" length="3"/>
          <text>MTT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1882</offset>
        <text>Confocal microscopy results showed that nanogel 1 delivered and released FITC-CC into the perinuclei region of HeLa cells following 8 h incubation.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fitc</infon>
          <location offset="1955" length="4"/>
          <text>FITC</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cc</infon>
          <location offset="1960" length="2"/>
          <text>CC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2030</offset>
        <text>CC-loaded reductively degradable nanogels demonstrated apparently better apoptotic activity than free CC as well as reduction-insensitive controls.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cc</infon>
          <location offset="2030" length="2"/>
          <text>CC</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cc</infon>
          <location offset="2132" length="2"/>
          <text>CC</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2178</offset>
        <text>These in situ forming, surfactant and oil-free, and reduction-sensitive degradable nanogels are highly promising for targeted protein therapy.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17182172</id>
    <passage>
      <offset>0</offset>
      <text>The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438.	Long-term use of glucocorticoids (GC) can cause growth retardation in children due to their actions on growth plate chondrocytes. AL-438, a non-steroidal anti-inflammatory agent that acts through the glucocorticoid receptor (GR) retains full anti-inflammatory efficacy but has reduced negative effects on osteoblasts compared to those elicited by prednisolone (Pred) or dexamethasone (Dex). We have used the murine chondrogenic ATDC5 cell line to compare the effects of AL-438 with those of Dex and Pred on chondrocyte dynamics. Dex and Pred caused a reduction in cell proliferation and proteoglycan synthesis, whereas exposure to AL-438 had no effect. LPS-induced IL-6 production in ATDC5 cells was reduced by Dex or AL-438, showing that AL-438 has similar anti-inflammatory efficacy to Dex in these cells. Fetal mouse metatarsals grown in the presence of Dex were shorter than control bones whereas AL-438 treated metatarsals paralleled control bone growth. These results indicate that the adverse effects Dex or Pred have on chondrocyte proliferation and bone growth were attenuated following AL-438 exposure, suggesting that AL-438 has a reduced side effect profile on chondrocytes compared to other GCs. This could prove important in the search for new anti-inflammatory treatments for children.</text>
      <sentence>
        <offset>0</offset>
        <text>The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al-438</infon>
          <location offset="85" length="6"/>
          <text>AL-438</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="50" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>93</offset>
        <text>Long-term use of glucocorticoids (GC) can cause growth retardation in children due to their actions on growth plate chondrocytes.</text>
      </sentence>
      <sentence>
        <offset>223</offset>
        <text>AL-438, a non-steroidal anti-inflammatory agent that acts through the glucocorticoid receptor (GR) retains full anti-inflammatory efficacy but has reduced negative effects on osteoblasts compared to those elicited by prednisolone (Pred) or dexamethasone (Dex).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al-438</infon>
          <location offset="223" length="6"/>
          <text>AL-438</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="440" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pred</infon>
          <location offset="454" length="4"/>
          <text>Pred</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dexamethasone</infon>
          <location offset="463" length="13"/>
          <text>dexamethasone</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="478" length="3"/>
          <text>Dex</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucocorticoid receptor</infon>
          <location offset="293" length="23"/>
          <text>glucocorticoid receptor</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gr</infon>
          <location offset="318" length="2"/>
          <text>GR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>484</offset>
        <text>We have used the murine chondrogenic ATDC5 cell line to compare the effects of AL-438 with those of Dex and Pred on chondrocyte dynamics.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al-438</infon>
          <location offset="563" length="6"/>
          <text>AL-438</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="584" length="3"/>
          <text>Dex</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pred</infon>
          <location offset="592" length="4"/>
          <text>Pred</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>622</offset>
        <text>Dex and Pred caused a reduction in cell proliferation and proteoglycan synthesis, whereas exposure to AL-438 had no effect.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="622" length="3"/>
          <text>Dex</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pred</infon>
          <location offset="630" length="4"/>
          <text>Pred</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al-438</infon>
          <location offset="724" length="6"/>
          <text>AL-438</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">proteoglycan</infon>
          <location offset="680" length="12"/>
          <text>proteoglycan</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>746</offset>
        <text>LPS-induced IL-6 production in ATDC5 cells was reduced by Dex or AL-438, showing that AL-438 has similar anti-inflammatory efficacy to Dex in these cells.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="804" length="3"/>
          <text>Dex</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al-438</infon>
          <location offset="811" length="6"/>
          <text>AL-438</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al-438</infon>
          <location offset="832" length="6"/>
          <text>AL-438</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="881" length="3"/>
          <text>Dex</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">il-6</infon>
          <location offset="758" length="4"/>
          <text>IL-6</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>901</offset>
        <text>Fetal mouse metatarsals grown in the presence of Dex were shorter than control bones whereas AL-438 treated metatarsals paralleled control bone growth.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al-438</infon>
          <location offset="994" length="6"/>
          <text>AL-438</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1053</offset>
        <text>These results indicate that the adverse effects Dex or Pred have on chondrocyte proliferation and bone growth were attenuated following AL-438 exposure, suggesting that AL-438 has a reduced side effect profile on chondrocytes compared to other GCs.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dex</infon>
          <location offset="1101" length="3"/>
          <text>Dex</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pred</infon>
          <location offset="1108" length="4"/>
          <text>Pred</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al-438</infon>
          <location offset="1189" length="6"/>
          <text>AL-438</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">al-438</infon>
          <location offset="1222" length="6"/>
          <text>AL-438</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1302</offset>
        <text>This could prove important in the search for new anti-inflammatory treatments for children.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16719808</id>
    <passage>
      <offset>0</offset>
      <text>NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.	Glutamate receptors of the N-methyl-D-asparate (NMDA-) subtype are tetrameric allosteric and ligand-gated calcium channels. They are modulated by a variety of endogenous ligands and ions and play a pivotal role in memory-related signal transduction due to a voltage-dependent block by magnesium, which makes them Hebbian coincidence detectors. On the structural level NMDA receptors have an enormous flexibility due to seven genes (NR1, NR2A-D and NR3A-B), alternative splicing, RNA-editing and extensive posttranslational modifications, like phosphorylation and glycosylation. NMDA receptors are thought to be responsible for excitotoxicity and subsequent downstream events like neuroinflammation and apoptosis and thus have been implicated in many important human pathologies, ranging from amyotrophic lateral sclerosis, Alzheimer's and Parkinson' disease, depression, epilepsy, trauma and stroke to schizophrenia. This fundamental significance of NMDA receptor-related excitotoxicity is discussed in the context of the developing clinical success of Memantine, but moreover set into relation to various proteomic and genetic markers of said diseases. The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD). The flexibility and multitude of interaction partners and possibilities of these highly dynamic molecular systems are discussed in terms of drug development strategies, in particular comparing high affinity and sub-type specific ligands to currently successful or promising therapies.</text>
      <sentence>
        <offset>0</offset>
        <text>NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="0" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="118" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="189" length="9"/>
          <text>glutamate</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="52" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptors</infon>
          <location offset="0" length="14"/>
          <text>NMDA receptors</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">transient cholesterol-rich membrane domains</infon>
          <location offset="108" length="43"/>
          <text>transient cholesterol-rich membrane domains</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptor</infon>
          <location offset="52" length="13"/>
          <text>NMDA receptor</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">neuregulins</infon>
          <location offset="92" length="11"/>
          <text>neuregulins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>211</offset>
        <text>Glutamate receptors of the N-methyl-D-asparate (NMDA-) subtype are tetrameric allosteric and ligand-gated calcium channels.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutamate</infon>
          <location offset="211" length="9"/>
          <text>Glutamate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-methyl-d-asparate</infon>
          <location offset="238" length="19"/>
          <text>N-methyl-D-asparate</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="259" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutamate receptors</infon>
          <location offset="211" length="19"/>
          <text>Glutamate receptors</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ligand-gated calcium channels</infon>
          <location offset="304" length="29"/>
          <text>ligand-gated calcium channels</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>335</offset>
        <text>They are modulated by a variety of endogenous ligands and ions and play a pivotal role in memory-related signal transduction due to a voltage-dependent block by magnesium, which makes them Hebbian coincidence detectors.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">magnesium</infon>
          <location offset="496" length="9"/>
          <text>magnesium</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>555</offset>
        <text>On the structural level NMDA receptors have an enormous flexibility due to seven genes (NR1, NR2A-D and NR3A-B), alternative splicing, RNA-editing and extensive posttranslational modifications, like phosphorylation and glycosylation.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="579" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptors</infon>
          <location offset="579" length="14"/>
          <text>NMDA receptors</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">nr1</infon>
          <location offset="643" length="3"/>
          <text>NR1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nr2a-d</infon>
          <location offset="648" length="6"/>
          <text>NR2A-D</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nr3a-b</infon>
          <location offset="659" length="6"/>
          <text>NR3A-B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>789</offset>
        <text>NMDA receptors are thought to be responsible for excitotoxicity and subsequent downstream events like neuroinflammation and apoptosis and thus have been implicated in many important human pathologies, ranging from amyotrophic lateral sclerosis, Alzheimer's and Parkinson' disease, depression, epilepsy, trauma and stroke to schizophrenia.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="789" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptors</infon>
          <location offset="789" length="14"/>
          <text>NMDA receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1128</offset>
        <text>This fundamental significance of NMDA receptor-related excitotoxicity is discussed in the context of the developing clinical success of Memantine, but moreover set into relation to various proteomic and genetic markers of said diseases.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">memantine</infon>
          <location offset="1264" length="9"/>
          <text>Memantine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="1161" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptor</infon>
          <location offset="1161" length="13"/>
          <text>NMDA receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1365</offset>
        <text>The very complex localisational and functional regulation of NMDA receptors appears to be dependent on neuregulins and receptor tyrosine kinases in cholesterol-rich membrane domains (lipid rafts), calcium-related mitochondrial feedback-loops and subsynaptic structural elements like PSD-95 (post-synaptic density protein of 95 kD).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nmda</infon>
          <location offset="1426" length="4"/>
          <text>NMDA</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tyrosine</infon>
          <location offset="1493" length="8"/>
          <text>tyrosine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1513" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1562" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nmda receptors</infon>
          <location offset="1426" length="14"/>
          <text>NMDA receptors</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">neuregulins</infon>
          <location offset="1468" length="11"/>
          <text>neuregulins</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">receptor tyrosine kinases</infon>
          <location offset="1484" length="25"/>
          <text>receptor tyrosine kinases</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">psd-95</infon>
          <location offset="1648" length="6"/>
          <text>PSD-95</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">post-synaptic density protein of 95 kd</infon>
          <location offset="1656" length="38"/>
          <text>post-synaptic density protein of 95 kD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1697</offset>
        <text>The flexibility and multitude of interaction partners and possibilities of these highly dynamic molecular systems are discussed in terms of drug development strategies, in particular comparing high affinity and sub-type specific ligands to currently successful or promising therapies.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23394555</id>
    <passage>
      <offset>0</offset>
      <text>Thymidylate kinase: an old topic brings new perspectives.	Thymidylate kinase (TMPK) is a key enzyme for pyrimidine synthesis that catalyzes the phosphorylation of thymidine 5'-monophosphate (dTMP) in the presence of ATP and Mg(2+) to form thymidine 5'-diphosphate (dTDP), which is then converted to thymidine 5'-triphosphate (dTTP) by nucleoside-diphosphate kinase (NDK). TMPK has an important function in cell proliferation and its enzyme kinetics and related structures have been determined in various organisms. TMPK is well recognized as a potential drug target, with the most notable function being in the activation of anti-HIV nucleoside prodrugs. Recent studies have shown that TMPK is a validated target for antibiotic development against gram-positive bacterium of Staphylococcus aureus. In addition, inhibition of human TMPK increases the potential of anticancer agent doxorubicin toward colon cancer cells regardless of p53 status. Following the rapid expanding knowledge on TMPKs and the rising interests in TMPKs as a drug target, in this review we try to describe current research on TMPKs in various organisms of eukaryotes, prokaryotes and viruses and to provide information for designing new potential inhibitors against TMPKs.</text>
      <sentence>
        <offset>0</offset>
        <text>Thymidylate kinase: an old topic brings new perspectives.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidylate</infon>
          <location offset="0" length="11"/>
          <text>Thymidylate</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thymidylate kinase</infon>
          <location offset="0" length="18"/>
          <text>Thymidylate kinase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>58</offset>
        <text>Thymidylate kinase (TMPK) is a key enzyme for pyrimidine synthesis that catalyzes the phosphorylation of thymidine 5'-monophosphate (dTMP) in the presence of ATP and Mg(2+) to form thymidine 5'-diphosphate (dTDP), which is then converted to thymidine 5'-triphosphate (dTTP) by nucleoside-diphosphate kinase (NDK).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidylate</infon>
          <location offset="58" length="11"/>
          <text>Thymidylate</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidine 5'-monophosphate</infon>
          <location offset="163" length="26"/>
          <text>thymidine 5'-monophosphate</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dtmp</infon>
          <location offset="191" length="4"/>
          <text>dTMP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="216" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mg(2+)</infon>
          <location offset="224" length="6"/>
          <text>Mg(2+)</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidine 5'-diphosphate</infon>
          <location offset="239" length="24"/>
          <text>thymidine 5'-diphosphate</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dtdp</infon>
          <location offset="265" length="4"/>
          <text>dTDP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thymidine 5'-triphosphate</infon>
          <location offset="299" length="25"/>
          <text>thymidine 5'-triphosphate</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dttp</infon>
          <location offset="326" length="4"/>
          <text>dTTP</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleoside-diphosphate</infon>
          <location offset="335" length="22"/>
          <text>nucleoside-diphosphate</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrimidine</infon>
          <location offset="104" length="10"/>
          <text>pyrimidine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thymidylate kinase</infon>
          <location offset="58" length="18"/>
          <text>Thymidylate kinase</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tmpk</infon>
          <location offset="78" length="4"/>
          <text>TMPK</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T11" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T11" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>372</offset>
        <text>TMPK has an important function in cell proliferation and its enzyme kinetics and related structures have been determined in various organisms.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tmpk</infon>
          <location offset="372" length="4"/>
          <text>TMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>515</offset>
        <text>TMPK is well recognized as a potential drug target, with the most notable function being in the activation of anti-HIV nucleoside prodrugs.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleoside</infon>
          <location offset="634" length="10"/>
          <text>nucleoside</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tmpk</infon>
          <location offset="515" length="4"/>
          <text>TMPK</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>655</offset>
        <text>Recent studies have shown that TMPK is a validated target for antibiotic development against gram-positive bacterium of Staphylococcus aureus.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tmpk</infon>
          <location offset="686" length="4"/>
          <text>TMPK</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>798</offset>
        <text>In addition, inhibition of human TMPK increases the potential of anticancer agent doxorubicin toward colon cancer cells regardless of p53 status.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="880" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human tmpk</infon>
          <location offset="825" length="10"/>
          <text>human TMPK</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">p53</infon>
          <location offset="932" length="3"/>
          <text>p53</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>944</offset>
        <text>Following the rapid expanding knowledge on TMPKs and the rising interests in TMPKs as a drug target, in this review we try to describe current research on TMPKs in various organisms of eukaryotes, prokaryotes and viruses and to provide information for designing new potential inhibitors against TMPKs.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tmpks</infon>
          <location offset="1099" length="5"/>
          <text>TMPKs</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tmpks</infon>
          <location offset="1239" length="5"/>
          <text>TMPKs</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tmpks</infon>
          <location offset="987" length="5"/>
          <text>TMPKs</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tmpks</infon>
          <location offset="1021" length="5"/>
          <text>TMPKs</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22956632</id>
    <passage>
      <offset>0</offset>
      <text>Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology.	Inhibitor-of-apoptosis (IAP) proteins suppress apoptosis and are overexpressed in a variety of cancers. Small-molecule IAP antagonists are currently being tested in clinical trials as novel cancer therapeutics. GDC-0152 is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing IAPs. GDC-0152 induces NF-κB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-α) is the most important for single-agent tumor activity. TNF-α is a pleiotropic cytokine that drives a variety of cellular responses, comprising inflammation, proliferation, and cell survival or death depending on the cellular context. As malignant and normal cells produce TNF-α upon IAP antagonism, increased TNF-α could drive both efficacy and toxicity. The toxicity profile of GDC-0152 in dogs and rats was characterized after iv dose administration once every 2 weeks for four doses. Findings in both species consisted of a dose-related, acute, systemic inflammatory response, and hepatic injury. Laboratory findings included elevated plasma cytokines, an inflammatory leukogram, and increased liver transaminases with histopathological findings of inflammatory infiltrates and apoptosis/necrosis in multiple tissues; a toxicology profile consistent with TNF-α-mediated toxicity. Dogs exhibited more severe findings than rats, and humans did not exhibit these findings, at comparable exposures across species. Furthermore, elevations in blood neutrophil count, serum monocyte chemoattractant protein-1, and other markers of inflammation corresponded to GDC-0152 exposure and toxicity and thus may have utility as safety biomarkers.</text>
      <sentence>
        <offset>0</offset>
        <text>Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gdc-0152</infon>
          <location offset="50" length="8"/>
          <text>GDC-0152</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">iap</infon>
          <location offset="35" length="3"/>
          <text>IAP</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="72" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>92</offset>
        <text>Inhibitor-of-apoptosis (IAP) proteins suppress apoptosis and are overexpressed in a variety of cancers.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">inhibitor-of-apoptosis</infon>
          <location offset="92" length="22"/>
          <text>Inhibitor-of-apoptosis</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">iap</infon>
          <location offset="116" length="3"/>
          <text>IAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>196</offset>
        <text>Small-molecule IAP antagonists are currently being tested in clinical trials as novel cancer therapeutics.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">iap</infon>
          <location offset="211" length="3"/>
          <text>IAP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>303</offset>
        <text>GDC-0152 is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing IAPs.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gdc-0152</infon>
          <location offset="303" length="8"/>
          <text>GDC-0152</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">iaps</infon>
          <location offset="400" length="4"/>
          <text>IAPs</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>406</offset>
        <text>GDC-0152 induces NF-κB transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-α) is the most important for single-agent tumor activity.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gdc-0152</infon>
          <location offset="406" length="8"/>
          <text>GDC-0152</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nf-κb</infon>
          <location offset="423" length="5"/>
          <text>NF-κB</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">chemokines</infon>
          <location offset="487" length="10"/>
          <text>chemokines</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="502" length="9"/>
          <text>cytokines</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tumor necrosis factor alpha</infon>
          <location offset="522" length="27"/>
          <text>tumor necrosis factor alpha</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="551" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>613</offset>
        <text>TNF-α is a pleiotropic cytokine that drives a variety of cellular responses, comprising inflammation, proliferation, and cell survival or death depending on the cellular context.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="613" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokine</infon>
          <location offset="636" length="8"/>
          <text>cytokine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>792</offset>
        <text>As malignant and normal cells produce TNF-α upon IAP antagonism, increased TNF-α could drive both efficacy and toxicity.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="830" length="5"/>
          <text>TNF-α</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">iap</infon>
          <location offset="841" length="3"/>
          <text>IAP</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="867" length="5"/>
          <text>TNF-α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>913</offset>
        <text>The toxicity profile of GDC-0152 in dogs and rats was characterized after iv dose administration once every 2 weeks for four doses.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gdc-0152</infon>
          <location offset="937" length="8"/>
          <text>GDC-0152</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1045</offset>
        <text>Findings in both species consisted of a dose-related, acute, systemic inflammatory response, and hepatic injury.</text>
      </sentence>
      <sentence>
        <offset>1158</offset>
        <text>Laboratory findings included elevated plasma cytokines, an inflammatory leukogram, and increased liver transaminases with histopathological findings of inflammatory infiltrates and apoptosis/necrosis in multiple tissues; a toxicology profile consistent with TNF-α-mediated toxicity.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytokines</infon>
          <location offset="1203" length="9"/>
          <text>cytokines</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">liver transaminases</infon>
          <location offset="1255" length="19"/>
          <text>liver transaminases</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tnf-α</infon>
          <location offset="1416" length="5"/>
          <text>TNF-α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1441</offset>
        <text>Dogs exhibited more severe findings than rats, and humans did not exhibit these findings, at comparable exposures across species.</text>
      </sentence>
      <sentence>
        <offset>1571</offset>
        <text>Furthermore, elevations in blood neutrophil count, serum monocyte chemoattractant protein-1, and other markers of inflammation corresponded to GDC-0152 exposure and toxicity and thus may have utility as safety biomarkers.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gdc-0152</infon>
          <location offset="1714" length="8"/>
          <text>GDC-0152</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">monocyte chemoattractant protein-1</infon>
          <location offset="1628" length="34"/>
          <text>monocyte chemoattractant protein-1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23406497</id>
    <passage>
      <offset>0</offset>
      <text>Switchable Elastin-Like Polypeptides that Respond to Chemical Inducers of Dimerization.	Elastin-like polypeptides (ELPs) are protein polymers that reversibly phase separate in response to increased temperature, pressure, concentration, ionic strength, and molecular weight. If it were possible to engineer their phase separation to respond to specific molecular substrates, ELP fusion proteins might be engineered as biosensors, smart biomaterials, diagnostic imaging agents, and targeted therapies. What has been lacking is a strategy to design ELPs to respond to specific substrates. To address this deficiency, we report that ELP fusion proteins phase separate in response to chemical inducers of dimerization (CID). The rationale is that ELP phase separation depends on molecular weight, concentration, and local hydrophobicity; therefore, processes that affect these properties, including noncovalent dimerization, can be tuned to produce isothermal phase separation. To test this hypothesis, constructs were evaluated consisting of an immunophilin: human FK-506 binding protein 12 (FKBP) attached to an ELP. Under stoichiometric binding of a CID, the fusion protein homodimerizes and triggers phase separation. This dimerization is reversible upon saturation with excess CID or competitive binding of a small lipophilic macrolide to FKBP. By modulating the ELP molecular weight, phase separation was tuned for isothermal response to CID at physiological ionic strength and temperature (37 °C). To interpret the relationship between transition temperature and equilibrium binding constants, an empirical mathematical model was employed. To the best of our knowledge, this report is the first demonstration of reversible ELP switching in response to controlled dimerization. Due to its simplicity, this strategy may be useful to design ELP fusion proteins that respond to specific dimeric biological entities.</text>
      <sentence>
        <offset>0</offset>
        <text>Switchable Elastin-Like Polypeptides that Respond to Chemical Inducers of Dimerization.</text>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elastin-like polypeptides</infon>
          <location offset="11" length="25"/>
          <text>Elastin-Like Polypeptides</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>Elastin-like polypeptides (ELPs) are protein polymers that reversibly phase separate in response to increased temperature, pressure, concentration, ionic strength, and molecular weight.</text>
        <annotation id="T2">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elastin-like polypeptides</infon>
          <location offset="88" length="25"/>
          <text>Elastin-like polypeptides</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elps</infon>
          <location offset="115" length="4"/>
          <text>ELPs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>274</offset>
        <text>If it were possible to engineer their phase separation to respond to specific molecular substrates, ELP fusion proteins might be engineered as biosensors, smart biomaterials, diagnostic imaging agents, and targeted therapies.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elp</infon>
          <location offset="374" length="3"/>
          <text>ELP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>500</offset>
        <text>What has been lacking is a strategy to design ELPs to respond to specific substrates.</text>
        <annotation id="T10">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elps</infon>
          <location offset="546" length="4"/>
          <text>ELPs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>586</offset>
        <text>To address this deficiency, we report that ELP fusion proteins phase separate in response to chemical inducers of dimerization (CID).</text>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elp</infon>
          <location offset="629" length="3"/>
          <text>ELP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>720</offset>
        <text>The rationale is that ELP phase separation depends on molecular weight, concentration, and local hydrophobicity; therefore, processes that affect these properties, including noncovalent dimerization, can be tuned to produce isothermal phase separation.</text>
        <annotation id="T12">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elp</infon>
          <location offset="742" length="3"/>
          <text>ELP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>973</offset>
        <text>To test this hypothesis, constructs were evaluated consisting of an immunophilin: human FK-506 binding protein 12 (FKBP) attached to an ELP.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fk-506</infon>
          <location offset="1061" length="6"/>
          <text>FK-506</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fkbp</infon>
          <location offset="1088" length="4"/>
          <text>FKBP</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elp</infon>
          <location offset="1109" length="3"/>
          <text>ELP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">immunophilin</infon>
          <location offset="1041" length="12"/>
          <text>immunophilin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human fk-506 binding protein 12</infon>
          <location offset="1055" length="31"/>
          <text>human FK-506 binding protein 12</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1114</offset>
        <text>Under stoichiometric binding of a CID, the fusion protein homodimerizes and triggers phase separation.</text>
      </sentence>
      <sentence>
        <offset>1217</offset>
        <text>This dimerization is reversible upon saturation with excess CID or competitive binding of a small lipophilic macrolide to FKBP.</text>
      </sentence>
      <sentence>
        <offset>1345</offset>
        <text>By modulating the ELP molecular weight, phase separation was tuned for isothermal response to CID at physiological ionic strength and temperature (37 °C).</text>
        <annotation id="T5">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elp</infon>
          <location offset="1363" length="3"/>
          <text>ELP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1500</offset>
        <text>To interpret the relationship between transition temperature and equilibrium binding constants, an empirical mathematical model was employed.</text>
      </sentence>
      <sentence>
        <offset>1642</offset>
        <text>To the best of our knowledge, this report is the first demonstration of reversible ELP switching in response to controlled dimerization.</text>
        <annotation id="T6">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elp</infon>
          <location offset="1725" length="3"/>
          <text>ELP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1779</offset>
        <text>Due to its simplicity, this strategy may be useful to design ELP fusion proteins that respond to specific dimeric biological entities.</text>
        <annotation id="T7">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">elp</infon>
          <location offset="1840" length="3"/>
          <text>ELP</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23473805</id>
    <passage>
      <offset>0</offset>
      <text>Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition.	Multidrug resistance (MDR) is a major obstacle to effective cancer therapy. The membrane transporter MDR-1 (P-gp, ABCB1), a member of the ATP-binding cassette (ABC) transporter family, effluxes anti-cancer drugs from cancer cells. Increased activity of MDR-1 is known to be the main mechanism for multidrug resistance. MDR-1 is known to be localized in the cholesterol- and sphingolipid-enriched plasma membrane microdomains, known as lipid rafts. Disruption of lipid rafts by cholesterol depletion alters lipid raft functions, indicating that cholesterol is critical for raft function. Because ginsenosides are structurally similar to cholesterol, in this study, we investigated the effect of Rp1, a novel ginsenoside derivative, on drug resistance using drug-sensitive OVCAR-8 and drug-resistant NCI/ADR-RES and DXR cells. Rp1 treatment resulted in an accumulation of doxorubicin or rhodamine 123 by decreasing MDR-1 activity in doxorubicin-resistant cells. Rp1 synergistically induced cell death with actinomycin D in DXR cells. Rp1 appeared to redistribute lipid rafts and MDR-1 protein. Moreover, Rp1 reversed resistance to actinomycin D by decreasing MDR-1 protein levels and Src phosphorylation with modulation of lipid rafts. Addition of cholesterol attenuated Rp1-induced raft aggregation and MDR-1 redistribution. Rp1 and actinomycin D reduced Src activity, and overexpression of active Src decreased the synergistic effect of Rp1 with actinomycin D. Rp1-induced drug sensitization was also observed with several anti-cancer drugs, including doxorubicin. These data suggest that lipid raft-modulating agents can be used to inhibit MDR-1 activity and thus overcome drug resistance.</text>
      <sentence>
        <offset>0</offset>
        <text>Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="25" length="3"/>
          <text>Rp1</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="76" length="5"/>
          <text>MDR-1</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">src</infon>
          <location offset="86" length="3"/>
          <text>Src</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T27" role="head"/>
          <node refid="T43" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T27" role="head"/>
          <node refid="T44" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>102</offset>
        <text>Multidrug resistance (MDR) is a major obstacle to effective cancer therapy.</text>
      </sentence>
      <sentence>
        <offset>178</offset>
        <text>The membrane transporter MDR-1 (P-gp, ABCB1), a member of the ATP-binding cassette (ABC) transporter family, effluxes anti-cancer drugs from cancer cells.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="240" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="203" length="5"/>
          <text>MDR-1</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="210" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">abcb1</infon>
          <location offset="216" length="5"/>
          <text>ABCB1</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atp-binding cassette (abc) transporter family</infon>
          <location offset="240" length="45"/>
          <text>ATP-binding cassette (ABC) transporter family</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">membrane transporter</infon>
          <location offset="182" length="20"/>
          <text>membrane transporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>333</offset>
        <text>Increased activity of MDR-1 is known to be the main mechanism for multidrug resistance.</text>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="355" length="5"/>
          <text>MDR-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>421</offset>
        <text>MDR-1 is known to be localized in the cholesterol- and sphingolipid-enriched plasma membrane microdomains, known as lipid rafts.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="459" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sphingolipid</infon>
          <location offset="476" length="12"/>
          <text>sphingolipid</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="421" length="5"/>
          <text>MDR-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>550</offset>
        <text>Disruption of lipid rafts by cholesterol depletion alters lipid raft functions, indicating that cholesterol is critical for raft function.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="579" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="646" length="11"/>
          <text>cholesterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>689</offset>
        <text>Because ginsenosides are structurally similar to cholesterol, in this study, we investigated the effect of Rp1, a novel ginsenoside derivative, on drug resistance using drug-sensitive OVCAR-8 and drug-resistant NCI/ADR-RES and DXR cells.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ginsenosides</infon>
          <location offset="697" length="12"/>
          <text>ginsenosides</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="738" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="796" length="3"/>
          <text>Rp1</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ginsenoside</infon>
          <location offset="809" length="11"/>
          <text>ginsenoside</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>927</offset>
        <text>Rp1 treatment resulted in an accumulation of doxorubicin or rhodamine 123 by decreasing MDR-1 activity in doxorubicin-resistant cells.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="927" length="3"/>
          <text>Rp1</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="972" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rhodamine 123</infon>
          <location offset="987" length="13"/>
          <text>rhodamine 123</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1033" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="1015" length="5"/>
          <text>MDR-1</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T24" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T22" role="head"/>
          <node refid="T42" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1062</offset>
        <text>Rp1 synergistically induced cell death with actinomycin D in DXR cells.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">actinomycin d</infon>
          <location offset="1106" length="13"/>
          <text>actinomycin D</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="1062" length="3"/>
          <text>Rp1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1134</offset>
        <text>Rp1 appeared to redistribute lipid rafts and MDR-1 protein.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="1134" length="3"/>
          <text>Rp1</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="1179" length="5"/>
          <text>MDR-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1194</offset>
        <text>Moreover, Rp1 reversed resistance to actinomycin D by decreasing MDR-1 protein levels and Src phosphorylation with modulation of lipid rafts.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="1204" length="3"/>
          <text>Rp1</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">actinomycin d</infon>
          <location offset="1231" length="13"/>
          <text>actinomycin D</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="1259" length="5"/>
          <text>MDR-1</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">src</infon>
          <location offset="1284" length="3"/>
          <text>Src</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1336</offset>
        <text>Addition of cholesterol attenuated Rp1-induced raft aggregation and MDR-1 redistribution.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="1348" length="11"/>
          <text>cholesterol</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="1371" length="3"/>
          <text>Rp1</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="1404" length="5"/>
          <text>MDR-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1426</offset>
        <text>Rp1 and actinomycin D reduced Src activity, and overexpression of active Src decreased the synergistic effect of Rp1 with actinomycin D.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="1426" length="3"/>
          <text>Rp1</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">actinomycin d</infon>
          <location offset="1434" length="13"/>
          <text>actinomycin D</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="1539" length="3"/>
          <text>Rp1</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">actinomycin d</infon>
          <location offset="1548" length="13"/>
          <text>actinomycin D</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">src</infon>
          <location offset="1456" length="3"/>
          <text>Src</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">src</infon>
          <location offset="1499" length="3"/>
          <text>Src</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1563</offset>
        <text>Rp1-induced drug sensitization was also observed with several anti-cancer drugs, including doxorubicin.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp1</infon>
          <location offset="1563" length="3"/>
          <text>Rp1</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="1654" length="11"/>
          <text>doxorubicin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1667</offset>
        <text>These data suggest that lipid raft-modulating agents can be used to inhibit MDR-1 activity and thus overcome drug resistance.</text>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mdr-1</infon>
          <location offset="1743" length="5"/>
          <text>MDR-1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10381508</id>
    <passage>
      <offset>0</offset>
      <text>An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa.	Factor IXR94S is a naturally occurring hemophilia B defect, which results from an Arg 94 to Ser mutation in the second epidermal growth factor (EGF)-like module of factor IX. Recombinant factor IXR94S was activated by factor XIa/calcium with an approximately 50-fold reduced rate and by factor VIIa/tissue factor/phospholipid/calcium with an approximately 20-fold reduced rate compared with wild-type factor IX. The apparent molecular mass of the light chain of factor IXaR94S was approximately 6 kD higher than that of plasma or wild-type factor IX, which was not corrected by N-glycosidase F digestion. This result indicated the presence of additional O-linked carbohydrate in the mutant light chain, probably at new Ser 94. The initial rate of activation of factor X by factor IXaR94S in the presence of polylysine was 7% +/- 1% of the initial rate of activation of factor X by plasma factor IXa, and the kc/Km for activation of factor X by factor IXaR94S/factor VIIIa/phospholipid/calcium was 4% +/- 1% of the kc/Km for activation of factor X by plasma factor IXa/factor VIIIa/phospholipid/calcium. The reduced efficiency of activation of factor X by factor IXaR94S in the tenase enzyme complex was due to a 58-fold +/- 12-fold decrease in kcat with little effect on Km. In conclusion, the R94S mutation had introduced an O-linked carbohydrate, which markedly impaired both activation by factor XIa and turnover of factor X in the tenase enzyme complex.</text>
      <sentence>
        <offset>0</offset>
        <text>An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="101" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbohydrate</infon>
          <location offset="110" length="12"/>
          <text>carbohydrate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arg</infon>
          <location offset="3" length="3"/>
          <text>Arg</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="7" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor xia</infon>
          <location offset="158" length="10"/>
          <text>factor XIa</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor viia</infon>
          <location offset="173" length="11"/>
          <text>factor VIIa</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tissue factor</infon>
          <location offset="185" length="13"/>
          <text>Tissue factor</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="227" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epidermal growth factor-like module</infon>
          <location offset="38" length="35"/>
          <text>epidermal growth factor-like module</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="77" length="9"/>
          <text>factor IX</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T16" role="head"/>
          <node refid="T57" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T56" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T16" role="head"/>
          <node refid="T56" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>239</offset>
        <text>Factor IXR94S is a naturally occurring hemophilia B defect, which results from an Arg 94 to Ser mutation in the second epidermal growth factor (EGF)-like module of factor IX.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">arg</infon>
          <location offset="321" length="3"/>
          <text>Arg</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="331" length="3"/>
          <text>Ser</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="239" length="9"/>
          <text>Factor IX</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">epidermal growth factor (egf)-like module</infon>
          <location offset="358" length="41"/>
          <text>epidermal growth factor (EGF)-like module</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="403" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">arg 94 to ser</infon>
          <location offset="321" length="13"/>
          <text>Arg 94 to Ser</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">r94s</infon>
          <location offset="248" length="4"/>
          <text>R94S</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T11" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T11" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>414</offset>
        <text>Recombinant factor IXR94S was activated by factor XIa/calcium with an approximately 50-fold reduced rate and by factor VIIa/tissue factor/phospholipid/calcium with an approximately 20-fold reduced rate compared with wild-type factor IX.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="468" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="565" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="426" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">r94s</infon>
          <location offset="435" length="4"/>
          <text>R94S</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor xia</infon>
          <location offset="457" length="10"/>
          <text>factor XIa</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor viia</infon>
          <location offset="526" length="11"/>
          <text>factor VIIa</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tissue factor</infon>
          <location offset="538" length="13"/>
          <text>tissue factor</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="640" length="9"/>
          <text>factor IX</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>651</offset>
        <text>The apparent molecular mass of the light chain of factor IXaR94S was approximately 6 kD higher than that of plasma or wild-type factor IX, which was not corrected by N-glycosidase F digestion.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n</infon>
          <location offset="817" length="1"/>
          <text>N</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="701" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">r94s</infon>
          <location offset="711" length="4"/>
          <text>R94S</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ix</infon>
          <location offset="779" length="9"/>
          <text>factor IX</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">n-glycosidase f</infon>
          <location offset="817" length="15"/>
          <text>N-glycosidase F</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>844</offset>
        <text>This result indicated the presence of additional O-linked carbohydrate in the mutant light chain, probably at new Ser 94.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="893" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbohydrate</infon>
          <location offset="902" length="12"/>
          <text>carbohydrate</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ser</infon>
          <location offset="958" length="3"/>
          <text>Ser</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>966</offset>
        <text>The initial rate of activation of factor X by factor IXaR94S in the presence of polylysine was 7% +/- 1% of the initial rate of activation of factor X by plasma factor IXa, and the kc/Km for activation of factor X by factor IXaR94S/factor VIIIa/phospholipid/calcium was 4% +/- 1% of the kc/Km for activation of factor X by plasma factor IXa/factor VIIIa/phospholipid/calcium.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1333" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">calcium</infon>
          <location offset="1224" length="7"/>
          <text>calcium</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="1277" length="8"/>
          <text>factor X</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="1296" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor viiia</infon>
          <location offset="1307" length="12"/>
          <text>factor VIIIa</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="1000" length="8"/>
          <text>factor X</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="1012" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">r94s</infon>
          <location offset="1022" length="4"/>
          <text>R94S</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="1108" length="8"/>
          <text>factor X</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="1127" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="1171" length="8"/>
          <text>factor X</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="1183" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">r94s</infon>
          <location offset="1193" length="4"/>
          <text>R94S</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor viiia</infon>
          <location offset="1198" length="12"/>
          <text>factor VIIIa</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T48" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1342</offset>
        <text>The reduced efficiency of activation of factor X by factor IXaR94S in the tenase enzyme complex was due to a 58-fold +/- 12-fold decrease in kcat with little effect on Km.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="1382" length="8"/>
          <text>factor X</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor ixa</infon>
          <location offset="1394" length="10"/>
          <text>factor IXa</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">r94s</infon>
          <location offset="1404" length="4"/>
          <text>R94S</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tenase enzyme complex</infon>
          <location offset="1416" length="21"/>
          <text>tenase enzyme complex</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1514</offset>
        <text>In conclusion, the R94S mutation had introduced an O-linked carbohydrate, which markedly impaired both activation by factor XIa and turnover of factor X in the tenase enzyme complex.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o</infon>
          <location offset="1565" length="1"/>
          <text>O</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carbohydrate</infon>
          <location offset="1574" length="12"/>
          <text>carbohydrate</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">r94s</infon>
          <location offset="1533" length="4"/>
          <text>R94S</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor xia</infon>
          <location offset="1631" length="10"/>
          <text>factor XIa</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">factor x</infon>
          <location offset="1658" length="8"/>
          <text>factor X</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">tenase enzyme complex</infon>
          <location offset="1674" length="21"/>
          <text>tenase enzyme complex</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15714982</id>
    <passage>
      <offset>0</offset>
      <text>[Treatment of androgen-independent hormone refractory prostate cancer using docetaxel].	Although prostate cancer patients with metastatic lesion initially respond to androgen ablation therapy, almost patients develop to hormone-refractory states. The optimal treatment for men with hormone refractory prostate cancer (HRPC) has not been established. Docetaxel is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl-2 inactivation, which induce apoptosis. Docetaxel as single agent has significant anti-tumor effect in HRPC patients. Docetaxel combined with estramustine or other antimicrotubular agents have shown further significant cytotoxicity in HRPC patients. In the United States, Food and Drug Administration (FDA) approved docetaxel, injection in combination with prednisone for the treatment of patients with advanced metastatic prostate cancer in 2004.</text>
      <sentence>
        <offset>0</offset>
        <text>[Treatment of androgen-independent hormone refractory prostate cancer using docetaxel].</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="14" length="8"/>
          <text>androgen</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">docetaxel</infon>
          <location offset="76" length="9"/>
          <text>docetaxel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>Although prostate cancer patients with metastatic lesion initially respond to androgen ablation therapy, almost patients develop to hormone-refractory states.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">androgen</infon>
          <location offset="166" length="8"/>
          <text>androgen</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>247</offset>
        <text>The optimal treatment for men with hormone refractory prostate cancer (HRPC) has not been established.</text>
      </sentence>
      <sentence>
        <offset>350</offset>
        <text>Docetaxel is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl-2 inactivation, which induce apoptosis.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">docetaxel</infon>
          <location offset="350" length="9"/>
          <text>Docetaxel</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">taxane</infon>
          <location offset="379" length="6"/>
          <text>taxane</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="471" length="5"/>
          <text>bcl-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>515</offset>
        <text>Docetaxel as single agent has significant anti-tumor effect in HRPC patients.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">docetaxel</infon>
          <location offset="515" length="9"/>
          <text>Docetaxel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>593</offset>
        <text>Docetaxel combined with estramustine or other antimicrotubular agents have shown further significant cytotoxicity in HRPC patients.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">docetaxel</infon>
          <location offset="593" length="9"/>
          <text>Docetaxel</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estramustine</infon>
          <location offset="617" length="12"/>
          <text>estramustine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>725</offset>
        <text>In the United States, Food and Drug Administration (FDA) approved docetaxel, injection in combination with prednisone for the treatment of patients with advanced metastatic prostate cancer in 2004.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">docetaxel</infon>
          <location offset="791" length="9"/>
          <text>docetaxel</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisone</infon>
          <location offset="832" length="10"/>
          <text>prednisone</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>18079279</id>
    <passage>
      <offset>0</offset>
      <text>Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators.	Dehydroepiandrosterone (DHEA), a C19 human adrenal steroid, activates peroxisome proliferator-activated receptor alpha (PPARalpha) in vivo but does not ligand-activate PPARalpha in transient transfection experiments. We demonstrate that DHEA regulates PPARalpha action by altering both the levels and phosphorylation status of the receptor. Human hepatoma cells (HepG2) were transiently transfected with the expression plasmid encoding PPARalpha and a plasmid containing two copies of fatty acyl coenzyme oxidase (FACO) peroxisome-proliferator activated receptor responsive element consensus oligonucleotide in a luciferase reporter gene. Nafenopin treatment increased reporter gene activity in this system, whereas DHEA treatment did not. Okadaic acid significantly decreased nafenopin-induced reporter activity in a concentration-dependent manner. Okadaic acid treatment of primary rat hepatocytes decreased both DHEA- and nafenopin-induced FACO activity in primary rat hepatocytes. DHEA induced both PPARalpha mRNA and protein levels, as well as PP2A message in primary rat hepatocytes. Western blot analysis showed that the serines at positions 12 and 21 were rapidly dephosphorylated upon treatment with DHEA and nafenopin. Results using specific protein phosphatase inhibitors suggested that protein phosphatase 2A (PP2A) is responsible for DHEA action, and protein phosphatase 1 might be involved in nafenopin induction. Mutation of serines at position 6, 12, and 21 to an uncharged alanine residue significantly increased transcriptional activity, whereas mutation to negative charged aspartate residues (mimicking receptor phosphorylation) decreased transcriptional activity. DHEA action involves induction of PPARalpha mRNA and protein levels as well as increased PPARalpha transcriptional activity through decreasing receptor phosphorylation at serines in the AF1 region.</text>
      <sentence>
        <offset>0</offset>
        <text>Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dehydroepiandrosterone</infon>
          <location offset="120" length="22"/>
          <text>dehydroepiandrosterone</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">peroxisome proliferators</infon>
          <location offset="153" length="24"/>
          <text>peroxisome proliferators</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator activated receptor alpha</infon>
          <location offset="68" length="48"/>
          <text>peroxisome proliferator activated receptor alpha</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T38" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T21" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>179</offset>
        <text>Dehydroepiandrosterone (DHEA), a C19 human adrenal steroid, activates peroxisome proliferator-activated receptor alpha (PPARalpha) in vivo but does not ligand-activate PPARalpha in transient transfection experiments.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dehydroepiandrosterone</infon>
          <location offset="179" length="22"/>
          <text>Dehydroepiandrosterone</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhea</infon>
          <location offset="203" length="4"/>
          <text>DHEA</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="299" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="347" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor alpha</infon>
          <location offset="249" length="48"/>
          <text>peroxisome proliferator-activated receptor alpha</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T36" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>396</offset>
        <text>We demonstrate that DHEA regulates PPARalpha action by altering both the levels and phosphorylation status of the receptor.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhea</infon>
          <location offset="416" length="4"/>
          <text>DHEA</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="431" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T10" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>520</offset>
        <text>Human hepatoma cells (HepG2) were transiently transfected with the expression plasmid encoding PPARalpha and a plasmid containing two copies of fatty acyl coenzyme oxidase (FACO) peroxisome-proliferator activated receptor responsive element consensus oligonucleotide in a luciferase reporter gene.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acyl coenzyme</infon>
          <location offset="670" length="13"/>
          <text>acyl coenzyme</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="615" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fatty acyl coenzyme oxidase</infon>
          <location offset="664" length="27"/>
          <text>fatty acyl coenzyme oxidase</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">faco</infon>
          <location offset="693" length="4"/>
          <text>FACO</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">peroxisome-proliferator activated receptor responsive element</infon>
          <location offset="699" length="61"/>
          <text>peroxisome-proliferator activated receptor responsive element</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>818</offset>
        <text>Nafenopin treatment increased reporter gene activity in this system, whereas DHEA treatment did not.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nafenopin</infon>
          <location offset="818" length="9"/>
          <text>Nafenopin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhea</infon>
          <location offset="895" length="4"/>
          <text>DHEA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>919</offset>
        <text>Okadaic acid significantly decreased nafenopin-induced reporter activity in a concentration-dependent manner.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">okadaic acid</infon>
          <location offset="919" length="12"/>
          <text>Okadaic acid</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nafenopin</infon>
          <location offset="956" length="9"/>
          <text>nafenopin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1029</offset>
        <text>Okadaic acid treatment of primary rat hepatocytes decreased both DHEA- and nafenopin-induced FACO activity in primary rat hepatocytes.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">okadaic acid</infon>
          <location offset="1029" length="12"/>
          <text>Okadaic acid</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhea</infon>
          <location offset="1094" length="4"/>
          <text>DHEA</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nafenopin</infon>
          <location offset="1104" length="9"/>
          <text>nafenopin</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">faco</infon>
          <location offset="1122" length="4"/>
          <text>FACO</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T17" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1164</offset>
        <text>DHEA induced both PPARalpha mRNA and protein levels, as well as PP2A message in primary rat hepatocytes.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhea</infon>
          <location offset="1164" length="4"/>
          <text>DHEA</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="1182" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pp2a</infon>
          <location offset="1228" length="4"/>
          <text>PP2A</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1269</offset>
        <text>Western blot analysis showed that the serines at positions 12 and 21 were rapidly dephosphorylated upon treatment with DHEA and nafenopin.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhea</infon>
          <location offset="1388" length="4"/>
          <text>DHEA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1408</offset>
        <text>Results using specific protein phosphatase inhibitors suggested that protein phosphatase 2A (PP2A) is responsible for DHEA action, and protein phosphatase 1 might be involved in nafenopin induction.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhea</infon>
          <location offset="1526" length="4"/>
          <text>DHEA</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nafenopin</infon>
          <location offset="1586" length="9"/>
          <text>nafenopin</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein phosphatase</infon>
          <location offset="1431" length="19"/>
          <text>protein phosphatase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">protein phosphatase 2a</infon>
          <location offset="1477" length="22"/>
          <text>protein phosphatase 2A</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pp2a</infon>
          <location offset="1501" length="4"/>
          <text>PP2A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1607</offset>
        <text>Mutation of serines at position 6, 12, and 21 to an uncharged alanine residue significantly increased transcriptional activity, whereas mutation to negative charged aspartate residues (mimicking receptor phosphorylation) decreased transcriptional activity.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serines</infon>
          <location offset="1619" length="7"/>
          <text>serines</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alanine</infon>
          <location offset="1669" length="7"/>
          <text>alanine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aspartate</infon>
          <location offset="1772" length="9"/>
          <text>aspartate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1864</offset>
        <text>DHEA action involves induction of PPARalpha mRNA and protein levels as well as increased PPARalpha transcriptional activity through decreasing receptor phosphorylation at serines in the AF1 region.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dhea</infon>
          <location offset="1864" length="4"/>
          <text>DHEA</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serines</infon>
          <location offset="2035" length="7"/>
          <text>serines</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="1898" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparalpha</infon>
          <location offset="1953" length="9"/>
          <text>PPARalpha</text>
        </annotation>
        <relation id="">
          <infon key="type">PART-OF</infon>
          <node refid="T9" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23074173</id>
    <passage>
      <offset>0</offset>
      <text>The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.	Deferasirox is an orally effective iron (Fe) chelator currently used for the treatment of iron-overload disease and has been implemented as an alternative to the gold standard chelator, desferrioxamine (DFO). Earlier studies demonstrated that DFO exhibits anticancer activity due to its ability to deplete cancer cells of iron. In this investigation, we examined the in vitro and in vivo activity of deferasirox against cells from human solid tumors. To date, there have been no studies to investigate the effect of deferasirox on these types of tumors in vivo. Deferasirox demonstrated similar activity at inhibiting proliferation of DMS-53 lung carcinoma and SK-N-MC neuroepithelioma cell lines compared with DFO. Furthermore, deferasirox was generally similar or slightly more effective than DFO at mobilizing cellular (59)Fe and inhibiting iron uptake from human transferrin depending on the cell type. However, deferasirox potently inhibited DMS-53 xenograft growth in nude mice when given by oral gavage, with no marked alterations in normal tissue histology. To understand the antitumor activity of deferasirox, we investigated its effect on the expression of molecules that play key roles in metastasis, cell cycle control, and apoptosis. We demonstrated that deferasirox increased expression of the metastasis suppressor protein N-myc downstream-regulated gene 1 and upregulated the cyclin-dependent kinase inhibitor p21(CIP1/WAF1) while decreasing cyclin D1 levels. Moreover, this agent increased the expression of apoptosis markers, including cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase 1. Collectively, we demonstrate that deferasirox is an orally effective antitumor agent against solid tumors.</text>
      <sentence>
        <offset>0</offset>
        <text>The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deferasirox</infon>
          <location offset="19" length="11"/>
          <text>deferasirox</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="4" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>159</offset>
        <text>Deferasirox is an orally effective iron (Fe) chelator currently used for the treatment of iron-overload disease and has been implemented as an alternative to the gold standard chelator, desferrioxamine (DFO).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deferasirox</infon>
          <location offset="159" length="11"/>
          <text>Deferasirox</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desferrioxamine</infon>
          <location offset="345" length="15"/>
          <text>desferrioxamine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dfo</infon>
          <location offset="362" length="3"/>
          <text>DFO</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="194" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fe</infon>
          <location offset="200" length="2"/>
          <text>Fe</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="249" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>368</offset>
        <text>Earlier studies demonstrated that DFO exhibits anticancer activity due to its ability to deplete cancer cells of iron.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dfo</infon>
          <location offset="402" length="3"/>
          <text>DFO</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="481" length="4"/>
          <text>iron</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>487</offset>
        <text>In this investigation, we examined the in vitro and in vivo activity of deferasirox against cells from human solid tumors.</text>
      </sentence>
      <sentence>
        <offset>610</offset>
        <text>To date, there have been no studies to investigate the effect of deferasirox on these types of tumors in vivo.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deferasirox</infon>
          <location offset="675" length="11"/>
          <text>deferasirox</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>721</offset>
        <text>Deferasirox demonstrated similar activity at inhibiting proliferation of DMS-53 lung carcinoma and SK-N-MC neuroepithelioma cell lines compared with DFO.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deferasirox</infon>
          <location offset="721" length="11"/>
          <text>Deferasirox</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dfo</infon>
          <location offset="870" length="3"/>
          <text>DFO</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>875</offset>
        <text>Furthermore, deferasirox was generally similar or slightly more effective than DFO at mobilizing cellular (59)Fe and inhibiting iron uptake from human transferrin depending on the cell type.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deferasirox</infon>
          <location offset="888" length="11"/>
          <text>deferasirox</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dfo</infon>
          <location offset="954" length="3"/>
          <text>DFO</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(59)fe</infon>
          <location offset="981" length="6"/>
          <text>(59)Fe</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human transferrin</infon>
          <location offset="1020" length="17"/>
          <text>human transferrin</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T16" role="head"/>
          <node refid="T29" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1066</offset>
        <text>However, deferasirox potently inhibited DMS-53 xenograft growth in nude mice when given by oral gavage, with no marked alterations in normal tissue histology.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deferasirox</infon>
          <location offset="1075" length="11"/>
          <text>deferasirox</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1225</offset>
        <text>To understand the antitumor activity of deferasirox, we investigated its effect on the expression of molecules that play key roles in metastasis, cell cycle control, and apoptosis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deferasirox</infon>
          <location offset="1265" length="11"/>
          <text>deferasirox</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1406</offset>
        <text>We demonstrated that deferasirox increased expression of the metastasis suppressor protein N-myc downstream-regulated gene 1 and upregulated the cyclin-dependent kinase inhibitor p21(CIP1/WAF1) while decreasing cyclin D1 levels.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deferasirox</infon>
          <location offset="1427" length="11"/>
          <text>deferasirox</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">protein n-myc downstream-regulated gene 1</infon>
          <location offset="1489" length="41"/>
          <text>protein N-myc downstream-regulated gene 1</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin-dependent kinase inhibitor p21</infon>
          <location offset="1551" length="37"/>
          <text>cyclin-dependent kinase inhibitor p21</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cip1</infon>
          <location offset="1589" length="4"/>
          <text>CIP1</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">waf1</infon>
          <location offset="1594" length="4"/>
          <text>WAF1</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyclin d1</infon>
          <location offset="1617" length="9"/>
          <text>cyclin D1</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1635</offset>
        <text>Moreover, this agent increased the expression of apoptosis markers, including cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase 1.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">poly(adp-ribose)</infon>
          <location offset="1743" length="16"/>
          <text>poly(ADP-ribose)</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">caspase-3</infon>
          <location offset="1721" length="9"/>
          <text>caspase-3</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">poly(adp-ribose) polymerase 1</infon>
          <location offset="1743" length="29"/>
          <text>poly(ADP-ribose) polymerase 1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1774</offset>
        <text>Collectively, we demonstrate that deferasirox is an orally effective antitumor agent against solid tumors.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">deferasirox</infon>
          <location offset="1808" length="11"/>
          <text>deferasirox</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11504801</id>
    <passage>
      <offset>0</offset>
      <text>Alpha(1) and beta(2) adrenoreceptor agonists inhibit pentylenetetrazole-induced seizures in mice lacking norepinephrine.	It has been known for many years that norepinephrine (NE) is a potent endogenous anticonvulsant, yet there is confusion as to which receptor(s) mediate this effect. This is probably due to multiple factors, including the importance of distinct signaling pathways for different seizure paradigms, a lack of comprehensive pharmacological studies, and difficulty in interpreting existing pharmacological results due to the presence of endogenous NE. We sought to circumvent these problems by testing the anticonvulsant activity of selective agonists for most known adrenoreceptors (ARs) in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack endogenous NE. Dbh -/- mice are hypersensitive to pentylenetetrazole (PTZ)-induced seizures, demonstrating that endogenous NE inhibits PTZ-induced seizures in the wild type. Pretreatment of Dbh -/- mice with an alpha(1)AR or beta(2)AR, but not an alpha(2)AR or beta(1)AR agonist significantly protected against PTZ-induced seizures. In contrast, only the beta(2)AR agonist showed anticonvulsant activity in heterozygous controls. Furthermore, an alpha(1)AR antagonist exacerbated PTZ-induced seizures in control mice, whereas a beta(2)AR antagonist had no effect. We conclude that activation of the alpha(1)AR is primarily responsible for the anticonvulsant activity of endogenous NE in the murine PTZ model of epilepsy. Endogenous NE probably does not activate the beta(2)AR under these conditions, but exogenous activation of the beta(2)AR produces an anticonvulsant effect.</text>
      <sentence>
        <offset>0</offset>
        <text>Alpha(1) and beta(2) adrenoreceptor agonists inhibit pentylenetetrazole-induced seizures in mice lacking norepinephrine.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norepinephrine</infon>
          <location offset="105" length="14"/>
          <text>norepinephrine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pentylenetetrazole</infon>
          <location offset="53" length="18"/>
          <text>pentylenetetrazole</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1) and beta(2) adrenoreceptor</infon>
          <location offset="0" length="35"/>
          <text>Alpha(1) and beta(2) adrenoreceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>121</offset>
        <text>It has been known for many years that norepinephrine (NE) is a potent endogenous anticonvulsant, yet there is confusion as to which receptor(s) mediate this effect.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norepinephrine</infon>
          <location offset="159" length="14"/>
          <text>norepinephrine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ne</infon>
          <location offset="175" length="2"/>
          <text>NE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>286</offset>
        <text>This is probably due to multiple factors, including the importance of distinct signaling pathways for different seizure paradigms, a lack of comprehensive pharmacological studies, and difficulty in interpreting existing pharmacological results due to the presence of endogenous NE.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ne</infon>
          <location offset="564" length="2"/>
          <text>NE</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>568</offset>
        <text>We sought to circumvent these problems by testing the anticonvulsant activity of selective agonists for most known adrenoreceptors (ARs) in dopamine beta-hydroxylase knockout (Dbh -/-) mice that lack endogenous NE.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="708" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ne</infon>
          <location offset="779" length="2"/>
          <text>NE</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adrenoreceptors</infon>
          <location offset="683" length="15"/>
          <text>adrenoreceptors</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ars</infon>
          <location offset="700" length="3"/>
          <text>ARs</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine beta-hydroxylase</infon>
          <location offset="708" length="25"/>
          <text>dopamine beta-hydroxylase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dbh</infon>
          <location offset="744" length="3"/>
          <text>Dbh</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>783</offset>
        <text>Dbh -/- mice are hypersensitive to pentylenetetrazole (PTZ)-induced seizures, demonstrating that endogenous NE inhibits PTZ-induced seizures in the wild type.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pentylenetetrazole</infon>
          <location offset="818" length="18"/>
          <text>pentylenetetrazole</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ptz</infon>
          <location offset="838" length="3"/>
          <text>PTZ</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ne</infon>
          <location offset="891" length="2"/>
          <text>NE</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ptz</infon>
          <location offset="903" length="3"/>
          <text>PTZ</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dbh</infon>
          <location offset="783" length="3"/>
          <text>Dbh</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>942</offset>
        <text>Pretreatment of Dbh -/- mice with an alpha(1)AR or beta(2)AR, but not an alpha(2)AR or beta(1)AR agonist significantly protected against PTZ-induced seizures.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ptz</infon>
          <location offset="1079" length="3"/>
          <text>PTZ</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dbh</infon>
          <location offset="958" length="3"/>
          <text>Dbh</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)ar</infon>
          <location offset="979" length="10"/>
          <text>alpha(1)AR</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(2)ar</infon>
          <location offset="993" length="9"/>
          <text>beta(2)AR</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(2)ar</infon>
          <location offset="1015" length="10"/>
          <text>alpha(2)AR</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(1)ar</infon>
          <location offset="1029" length="9"/>
          <text>beta(1)AR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1101</offset>
        <text>In contrast, only the beta(2)AR agonist showed anticonvulsant activity in heterozygous controls.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(2)ar</infon>
          <location offset="1123" length="9"/>
          <text>beta(2)AR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1198</offset>
        <text>Furthermore, an alpha(1)AR antagonist exacerbated PTZ-induced seizures in control mice, whereas a beta(2)AR antagonist had no effect.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ptz</infon>
          <location offset="1248" length="3"/>
          <text>PTZ</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)ar</infon>
          <location offset="1214" length="10"/>
          <text>alpha(1)AR</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(2)ar</infon>
          <location offset="1296" length="9"/>
          <text>beta(2)AR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1332</offset>
        <text>We conclude that activation of the alpha(1)AR is primarily responsible for the anticonvulsant activity of endogenous NE in the murine PTZ model of epilepsy.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ne</infon>
          <location offset="1449" length="2"/>
          <text>NE</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ptz</infon>
          <location offset="1466" length="3"/>
          <text>PTZ</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)ar</infon>
          <location offset="1367" length="10"/>
          <text>alpha(1)AR</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1489</offset>
        <text>Endogenous NE probably does not activate the beta(2)AR under these conditions, but exogenous activation of the beta(2)AR produces an anticonvulsant effect.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ne</infon>
          <location offset="1500" length="2"/>
          <text>NE</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(2)ar</infon>
          <location offset="1534" length="9"/>
          <text>beta(2)AR</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta(2)ar</infon>
          <location offset="1600" length="9"/>
          <text>beta(2)AR</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23456363</id>
    <passage>
      <offset>0</offset>
      <text>Hypoxia-inducible factor and vascular endothelial growth factor are targets of dietary soy during acute stroke in female rats.	Dietary soy and soy isoflavones are neuroprotective in experimental cerebral ischemia. Because these isoflavones have estrogenic properties, we hypothesized that, like estrogens, they would inhibit acute vascular injury and the detrimental acute increase in hypoxia-induced vascular endothelial growth factor (VEGF) that leads to cerebral edema after stroke. Mature ovariectomized female Sprague Dawley rats were fed soy-free or soy-containing diets for 4 weeks followed by 90 minutes of transient middle cerebral artery occlusion. Similar to estrogens, dietary soy significantly reduced cerebral edema and vascular apoptosis 24 hours after stroke. Soy also inhibited the ischemia-induced increase in cortical VEGF and VEGF receptor (VEGFR)-2 protein expression observed 4 and 24 hours after stroke, although mRNA levels increased. The reduction in VEGF/VEGFR-2 was associated both with decreases in receptor phosphorylation and signaling to AKT and endothelial nitric oxide synthase. Furthermore degradation of the VEGFR-2 was increased with dietary soy. The primary ischemic stimulus for VEGF, hypoxia-inducible factor 1α (HIF1α), was similarly reduced by dietary soy 4 hours after transient middle cerebral artery occlusion in both the cortex and striatum. The inhibition of HIF1α activity was further confirmed by a significant decrease in the HIF1α-activated apoptotic mediator BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (Nip3-like protein X). These data suggest that soy isoflavones target events early in the ischemic cascade as part of their neuroprotective actions and counterbalance some of the detrimental effects of the endogenous response to cerebral injury.</text>
      <sentence>
        <offset>0</offset>
        <text>Hypoxia-inducible factor and vascular endothelial growth factor are targets of dietary soy during acute stroke in female rats.</text>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hypoxia-inducible factor</infon>
          <location offset="0" length="24"/>
          <text>Hypoxia-inducible factor</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="29" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>127</offset>
        <text>Dietary soy and soy isoflavones are neuroprotective in experimental cerebral ischemia.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoflavones</infon>
          <location offset="147" length="11"/>
          <text>isoflavones</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>214</offset>
        <text>Because these isoflavones have estrogenic properties, we hypothesized that, like estrogens, they would inhibit acute vascular injury and the detrimental acute increase in hypoxia-induced vascular endothelial growth factor (VEGF) that leads to cerebral edema after stroke.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoflavones</infon>
          <location offset="228" length="11"/>
          <text>isoflavones</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogens</infon>
          <location offset="295" length="9"/>
          <text>estrogens</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="401" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="437" length="4"/>
          <text>VEGF</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>486</offset>
        <text>Mature ovariectomized female Sprague Dawley rats were fed soy-free or soy-containing diets for 4 weeks followed by 90 minutes of transient middle cerebral artery occlusion.</text>
      </sentence>
      <sentence>
        <offset>659</offset>
        <text>Similar to estrogens, dietary soy significantly reduced cerebral edema and vascular apoptosis 24 hours after stroke.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogens</infon>
          <location offset="670" length="9"/>
          <text>estrogens</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>776</offset>
        <text>Soy also inhibited the ischemia-induced increase in cortical VEGF and VEGF receptor (VEGFR)-2 protein expression observed 4 and 24 hours after stroke, although mRNA levels increased.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="837" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf receptor (vegfr)-2</infon>
          <location offset="846" length="23"/>
          <text>VEGF receptor (VEGFR)-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>959</offset>
        <text>The reduction in VEGF/VEGFR-2 was associated both with decreases in receptor phosphorylation and signaling to AKT and endothelial nitric oxide synthase.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="976" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegfr-2</infon>
          <location offset="981" length="7"/>
          <text>VEGFR-2</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akt</infon>
          <location offset="1069" length="3"/>
          <text>AKT</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">endothelial nitric oxide synthase</infon>
          <location offset="1077" length="33"/>
          <text>endothelial nitric oxide synthase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1112</offset>
        <text>Furthermore degradation of the VEGFR-2 was increased with dietary soy.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegfr-2</infon>
          <location offset="1143" length="7"/>
          <text>VEGFR-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1183</offset>
        <text>The primary ischemic stimulus for VEGF, hypoxia-inducible factor 1α (HIF1α), was similarly reduced by dietary soy 4 hours after transient middle cerebral artery occlusion in both the cortex and striatum.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vegf</infon>
          <location offset="1217" length="4"/>
          <text>VEGF</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hypoxia-inducible factor 1α</infon>
          <location offset="1223" length="27"/>
          <text>hypoxia-inducible factor 1α</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif1α</infon>
          <location offset="1252" length="5"/>
          <text>HIF1α</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1387</offset>
        <text>The inhibition of HIF1α activity was further confirmed by a significant decrease in the HIF1α-activated apoptotic mediator BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (Nip3-like protein X).</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif1α</infon>
          <location offset="1405" length="5"/>
          <text>HIF1α</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hif1α</infon>
          <location offset="1475" length="5"/>
          <text>HIF1α</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl2/adenovirus e1b 19 kda protein-interacting protein 3</infon>
          <location offset="1510" length="56"/>
          <text>BCL2/adenovirus E1B 19 kDa protein-interacting protein 3</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nip3-like protein x</infon>
          <location offset="1568" length="19"/>
          <text>Nip3-like protein X</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1590</offset>
        <text>These data suggest that soy isoflavones target events early in the ischemic cascade as part of their neuroprotective actions and counterbalance some of the detrimental effects of the endogenous response to cerebral injury.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoflavones</infon>
          <location offset="1618" length="11"/>
          <text>isoflavones</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11060293</id>
    <passage>
      <offset>0</offset>
      <text>The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene.	The human aldo-keto reductase AKR1C1 (20alpha(3alpha)-hydroxysteroid dehydrogenase) is induced by electrophilic Michael acceptors and reactive oxygen species (ROS) via a presumptive antioxidant response element (Burczynski, M. E., Lin, H. K., and Penning, T. M. (1999) Cancer Res. 59, 607-614). Physiologically, AKR1C1 regulates progesterone action by converting the hormone into its inactive metabolite 20alpha-hydroxyprogesterone, and toxicologically this enzyme activates polycyclic aromatic hydrocarbon trans-dihydrodiols to redox-cycling o-quinones. However, the significance of its potent induction by Michael acceptors and oxidative stress is unknown. 4-Hydroxy-2-nonenal (HNE) and other alpha,beta-unsaturated aldehydes produced during lipid peroxidation were reduced by AKR1C1 with high catalytic efficiency. Kinetic studies revealed that AKR1C1 reduced HNE (K(m) = 34 microm, k(cat) = 8.8 min(-1)) with a k(cat)/K(m) similar to that for 20alpha-hydroxysteroids. Six other homogeneous recombinant AKRs were examined for their ability to reduce HNE. Of these, AKR1C1 possessed one of the highest specific activities and was the only isoform induced by oxidative stress and by agents that deplete glutathione (ethacrynic acid). Several hydroxysteroid dehydrogenases of the AKR1C subfamily catalyzed the reduction of HNE with higher activity than aldehyde reductase (AKR1A1). NMR spectroscopy identified the product of the NADPH-dependent reduction of HNE as 1,4-dihydroxy-2-nonene. The K(m) of recombinant AKR1C1 for nicotinamide cofactors (K(m) NADPH approximately 6 microm, K(m)(app) NADH &gt;6 mm) suggested that it is primed for reductive metabolism of HNE. Isoform-specific reverse transcription-polymerase chain reaction showed that exposure of HepG2 cells to HNE resulted in elevated levels of AKR1C1 mRNA. Thus, HNE induces its own metabolism via AKR1C1, and this enzyme may play a hitherto unrecognized role in a response mounted to counter oxidative stress. AKRs represent alternative GSH-independent/NADPH-dependent routes for the reductive elimination of HNE. Of these, AKR1C1 provides an inducible cytosolic barrier to HNE following ROS exposure.</text>
      <sentence>
        <offset>0</offset>
        <text>The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene.</text>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alpha,beta-unsaturated aldehyde</infon>
          <location offset="105" length="31"/>
          <text>alpha,beta-unsaturated aldehyde</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="13" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-hydroxy-2-nonenal</infon>
          <location offset="137" length="19"/>
          <text>4-hydroxy-2-nonenal</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,4-dihydroxy-2-nonene</infon>
          <location offset="160" length="22"/>
          <text>1,4-dihydroxy-2-nonene</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldo</infon>
          <location offset="66" length="4"/>
          <text>aldo</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">keto</infon>
          <location offset="71" length="4"/>
          <text>keto</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human aldo-keto reductase</infon>
          <location offset="60" length="25"/>
          <text>human aldo-keto reductase</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="86" length="6"/>
          <text>AKR1C1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>184</offset>
        <text>The human aldo-keto reductase AKR1C1 (20alpha(3alpha)-hydroxysteroid dehydrogenase) is induced by electrophilic Michael acceptors and reactive oxygen species (ROS) via a presumptive antioxidant response element (Burczynski, M. E., Lin, H. K., and Penning, T. M. (1999) Cancer Res. 59, 607-614).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldo</infon>
          <location offset="194" length="4"/>
          <text>aldo</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">oxygen</infon>
          <location offset="327" length="6"/>
          <text>oxygen</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">keto</infon>
          <location offset="199" length="4"/>
          <text>keto</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">20alpha(3alpha)-hydroxysteroid</infon>
          <location offset="222" length="30"/>
          <text>20alpha(3alpha)-hydroxysteroid</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="214" length="6"/>
          <text>AKR1C1</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">20alpha(3alpha)-hydroxysteroid dehydrogenase</infon>
          <location offset="222" length="44"/>
          <text>20alpha(3alpha)-hydroxysteroid dehydrogenase</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human aldo-keto reductase</infon>
          <location offset="188" length="25"/>
          <text>human aldo-keto reductase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>479</offset>
        <text>Physiologically, AKR1C1 regulates progesterone action by converting the hormone into its inactive metabolite 20alpha-hydroxyprogesterone, and toxicologically this enzyme activates polycyclic aromatic hydrocarbon trans-dihydrodiols to redox-cycling o-quinones.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="513" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">20alpha-hydroxyprogesterone</infon>
          <location offset="588" length="27"/>
          <text>20alpha-hydroxyprogesterone</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">polycyclic aromatic hydrocarbon</infon>
          <location offset="659" length="31"/>
          <text>polycyclic aromatic hydrocarbon</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">trans-dihydrodiols</infon>
          <location offset="691" length="18"/>
          <text>trans-dihydrodiols</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">o-quinones</infon>
          <location offset="727" length="10"/>
          <text>o-quinones</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="496" length="6"/>
          <text>AKR1C1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>739</offset>
        <text>However, the significance of its potent induction by Michael acceptors and oxidative stress is unknown.</text>
      </sentence>
      <sentence>
        <offset>843</offset>
        <text>4-Hydroxy-2-nonenal (HNE) and other alpha,beta-unsaturated aldehydes produced during lipid peroxidation were reduced by AKR1C1 with high catalytic efficiency.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-hydroxy-2-nonenal</infon>
          <location offset="843" length="19"/>
          <text>4-Hydroxy-2-nonenal</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="864" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">alpha,beta-unsaturated aldehydes</infon>
          <location offset="879" length="32"/>
          <text>alpha,beta-unsaturated aldehydes</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="963" length="6"/>
          <text>AKR1C1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1002</offset>
        <text>Kinetic studies revealed that AKR1C1 reduced HNE (K(m) = 34 microm, k(cat) = 8.8 min(-1)) with a k(cat)/K(m) similar to that for 20alpha-hydroxysteroids.</text>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="1047" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">20alpha-hydroxysteroids</infon>
          <location offset="1131" length="23"/>
          <text>20alpha-hydroxysteroids</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="1032" length="6"/>
          <text>AKR1C1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1156</offset>
        <text>Six other homogeneous recombinant AKRs were examined for their ability to reduce HNE.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="1237" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akrs</infon>
          <location offset="1190" length="4"/>
          <text>AKRs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1242</offset>
        <text>Of these, AKR1C1 possessed one of the highest specific activities and was the only isoform induced by oxidative stress and by agents that deplete glutathione (ethacrynic acid).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1388" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethacrynic acid</infon>
          <location offset="1401" length="15"/>
          <text>ethacrynic acid</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="1252" length="6"/>
          <text>AKR1C1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1419</offset>
        <text>Several hydroxysteroid dehydrogenases of the AKR1C subfamily catalyzed the reduction of HNE with higher activity than aldehyde reductase (AKR1A1).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxysteroid</infon>
          <location offset="1427" length="14"/>
          <text>hydroxysteroid</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="1507" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">aldehyde</infon>
          <location offset="1537" length="8"/>
          <text>aldehyde</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hydroxysteroid dehydrogenases</infon>
          <location offset="1427" length="29"/>
          <text>hydroxysteroid dehydrogenases</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c</infon>
          <location offset="1464" length="5"/>
          <text>AKR1C</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">aldehyde reductase</infon>
          <location offset="1537" length="18"/>
          <text>aldehyde reductase</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1a1</infon>
          <location offset="1557" length="6"/>
          <text>AKR1A1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1566</offset>
        <text>NMR spectroscopy identified the product of the NADPH-dependent reduction of HNE as 1,4-dihydroxy-2-nonene.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="1642" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">1,4-dihydroxy-2-nonene</infon>
          <location offset="1649" length="22"/>
          <text>1,4-dihydroxy-2-nonene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1673</offset>
        <text>The K(m) of recombinant AKR1C1 for nicotinamide cofactors (K(m) NADPH approximately 6 microm, K(m)(app) NADH &gt;6 mm) suggested that it is primed for reductive metabolism of HNE.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadph</infon>
          <location offset="1737" length="5"/>
          <text>NADPH</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadh</infon>
          <location offset="1777" length="4"/>
          <text>NADH</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="1845" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="1697" length="6"/>
          <text>AKR1C1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1850</offset>
        <text>Isoform-specific reverse transcription-polymerase chain reaction showed that exposure of HepG2 cells to HNE resulted in elevated levels of AKR1C1 mRNA.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="1954" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="1989" length="6"/>
          <text>AKR1C1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2002</offset>
        <text>Thus, HNE induces its own metabolism via AKR1C1, and this enzyme may play a hitherto unrecognized role in a response mounted to counter oxidative stress.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="2008" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="2043" length="6"/>
          <text>AKR1C1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2156</offset>
        <text>AKRs represent alternative GSH-independent/NADPH-dependent routes for the reductive elimination of HNE.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">gsh</infon>
          <location offset="2183" length="3"/>
          <text>GSH</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nadph</infon>
          <location offset="2199" length="5"/>
          <text>NADPH</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="2255" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">akrs</infon>
          <location offset="2156" length="4"/>
          <text>AKRs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2260</offset>
        <text>Of these, AKR1C1 provides an inducible cytosolic barrier to HNE following ROS exposure.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hne</infon>
          <location offset="2320" length="3"/>
          <text>HNE</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">akr1c1</infon>
          <location offset="2270" length="6"/>
          <text>AKR1C1</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11256847</id>
    <passage>
      <offset>0</offset>
      <text>Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.	Rosuvastatin (formerly ZD4522) is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) with distinct pharmacologic properties. Compared with most other statins, it is relatively hydrophilic, similar in this respect to pravastatin. Rosuvastatin has been shown to be a comparatively potent inhibitor of HMG-CoA reductase activity in a purified preparation of the catalytic domain of the human enzyme, as well as in rat and human hepatic microsomes. In rat hepatocytes, rosuvastatin was found to have significantly higher potency as an inhibitor of cholesterol synthesis than 5 other statins. Rosuvastatin was approximately 1,000-fold more potent in rat hepatocytes than in rat fibroblasts. Further studies in rat hepatocytes demonstrated that rosuvastatin is taken up into these cells by a high-affinity active uptake process. Rosuvastatin was also taken up selectively into the liver after intravenous administration in rats. Potent and prolonged HMG-CoA reductase inhibitory activity has been demonstrated after oral administration to rats and dogs. Pharmacokinetic studies in humans using oral doses of 5 to 80 mg showed that maximum plasma concentrations and areas under the concentration-time curve are approximately linear with dose. The terminal half-life is approximately 20 hours. Studies with human hepatic microsomes and human hepatocytes have suggested little or no metabolism via the cytochrome P-450 3A4 isoenzyme. On the basis of these observations, it is suggested that rosuvastatin has the potential to exert a profound effect on atherogenic lipoproteins.</text>
      <sentence>
        <offset>0</offset>
        <text>Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="41" length="12"/>
          <text>Rosuvastatin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-hydroxy-3-methylglutaryl coenzyme a</infon>
          <location offset="61" length="37"/>
          <text>3-hydroxy-3-methylglutaryl coenzyme A</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">3-hydroxy-3-methylglutaryl coenzyme a reductase</infon>
          <location offset="61" length="47"/>
          <text>3-hydroxy-3-methylglutaryl coenzyme A reductase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>120</offset>
        <text>Rosuvastatin (formerly ZD4522) is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) with distinct pharmacologic properties.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="120" length="12"/>
          <text>Rosuvastatin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zd4522</infon>
          <location offset="143" length="6"/>
          <text>ZD4522</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">3-hydroxy-3-methylglutaryl coenzyme a</infon>
          <location offset="160" length="37"/>
          <text>3-hydroxy-3-methylglutaryl coenzyme A</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hmg-coa</infon>
          <location offset="199" length="7"/>
          <text>HMG-CoA</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase</infon>
          <location offset="160" length="57"/>
          <text>3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>277</offset>
        <text>Compared with most other statins, it is relatively hydrophilic, similar in this respect to pravastatin.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pravastatin</infon>
          <location offset="368" length="11"/>
          <text>pravastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>381</offset>
        <text>Rosuvastatin has been shown to be a comparatively potent inhibitor of HMG-CoA reductase activity in a purified preparation of the catalytic domain of the human enzyme, as well as in rat and human hepatic microsomes.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="381" length="12"/>
          <text>Rosuvastatin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hmg-coa</infon>
          <location offset="451" length="7"/>
          <text>HMG-CoA</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hmg-coa reductase</infon>
          <location offset="451" length="17"/>
          <text>HMG-CoA reductase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>597</offset>
        <text>In rat hepatocytes, rosuvastatin was found to have significantly higher potency as an inhibitor of cholesterol synthesis than 5 other statins.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="617" length="12"/>
          <text>rosuvastatin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cholesterol</infon>
          <location offset="696" length="11"/>
          <text>cholesterol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>740</offset>
        <text>Rosuvastatin was approximately 1,000-fold more potent in rat hepatocytes than in rat fibroblasts.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="740" length="12"/>
          <text>Rosuvastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>838</offset>
        <text>Further studies in rat hepatocytes demonstrated that rosuvastatin is taken up into these cells by a high-affinity active uptake process.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="891" length="12"/>
          <text>rosuvastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>975</offset>
        <text>Rosuvastatin was also taken up selectively into the liver after intravenous administration in rats.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="975" length="12"/>
          <text>Rosuvastatin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1075</offset>
        <text>Potent and prolonged HMG-CoA reductase inhibitory activity has been demonstrated after oral administration to rats and dogs.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hmg-coa</infon>
          <location offset="1096" length="7"/>
          <text>HMG-CoA</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">hmg-coa</infon>
          <location offset="1096" length="7"/>
          <text>HMG-CoA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1200</offset>
        <text>Pharmacokinetic studies in humans using oral doses of 5 to 80 mg showed that maximum plasma concentrations and areas under the concentration-time curve are approximately linear with dose.</text>
      </sentence>
      <sentence>
        <offset>1388</offset>
        <text>The terminal half-life is approximately 20 hours.</text>
      </sentence>
      <sentence>
        <offset>1438</offset>
        <text>Studies with human hepatic microsomes and human hepatocytes have suggested little or no metabolism via the cytochrome P-450 3A4 isoenzyme.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cytochrome p-450 3a4</infon>
          <location offset="1545" length="20"/>
          <text>cytochrome P-450 3A4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1577</offset>
        <text>On the basis of these observations, it is suggested that rosuvastatin has the potential to exert a profound effect on atherogenic lipoproteins.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rosuvastatin</infon>
          <location offset="1634" length="12"/>
          <text>rosuvastatin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15995325</id>
    <passage>
      <offset>0</offset>
      <text>Modern diagnosis and treatment of primary eosinophilia.	The recent discovery of an eosinophilia-specific, imatinib-sensitive, karyotypically occult but fluorescence in situ hybridization-apparent molecular lesion in a subset of patients with blood eosinophilia has transformed the diagnostic as well as treatment approach to eosinophilic disorders. Primary (i.e. nonreactive) eosinophilia is considered either "clonal" or "idiopathic" based on the presence or absence, respectively, of either a molecular or bone marrow histological evidence for a myeloid neoplasm. Clonal eosinophilia might accompany a spectrum of clinicopathological entities, the minority of whom are molecularly characterized; Fip1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA(+)) systemic mastocytosis, platelet-derived growth factor receptor beta (PDGFRB)-rearranged atypical myeloproliferative disorder, chronic myeloid leukemia, and the 8p11 syndrome that is associated with fibroblast growth factor receptor 1 (FGFR1) rearrangement. Hypereosinophilic syndrome (HES) is a subcategory of idiopathic eosinophilia and is characterized by an absolute eosinophil count of &gt; or =1.5 x 10(9)/l for at least 6 months as well as eosinophil-mediated tissue damage. At present, a working diagnosis of primary eosinophilia mandates a bone marrow examination, karyotype analysis, and additional molecular studies in order to provide the patient with accurate prognostic information as well as select appropriate therapy. For example, the presence of either PDGFRA or PDGFRB mutations warrants the use of imatinib in clonal eosinophilia. In HES, prednisone, hydroxyurea, and interferon-alpha constitute first-line therapy, whereas imatinib, cladribine, and monoclonal antibodies to either interleukin-5 (mepolizumab) or CD52 (alemtuzumab) are considered investigational. Allogeneic transplantation offers a viable treatment option for drug-refractory cases.</text>
      <sentence>
        <offset>0</offset>
        <text>Modern diagnosis and treatment of primary eosinophilia.</text>
      </sentence>
      <sentence>
        <offset>56</offset>
        <text>The recent discovery of an eosinophilia-specific, imatinib-sensitive, karyotypically occult but fluorescence in situ hybridization-apparent molecular lesion in a subset of patients with blood eosinophilia has transformed the diagnostic as well as treatment approach to eosinophilic disorders.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="106" length="8"/>
          <text>imatinib</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>349</offset>
        <text>Primary (i.e. nonreactive) eosinophilia is considered either "clonal" or "idiopathic" based on the presence or absence, respectively, of either a molecular or bone marrow histological evidence for a myeloid neoplasm.</text>
      </sentence>
      <sentence>
        <offset>566</offset>
        <text>Clonal eosinophilia might accompany a spectrum of clinicopathological entities, the minority of whom are molecularly characterized; Fip1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA(+)) systemic mastocytosis, platelet-derived growth factor receptor beta (PDGFRB)-rearranged atypical myeloproliferative disorder, chronic myeloid leukemia, and the 8p11 syndrome that is associated with fibroblast growth factor receptor 1 (FGFR1) rearrangement.</text>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fip1-like-1</infon>
          <location offset="698" length="11"/>
          <text>Fip1-like-1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">platelet-derived growth factor receptor alpha</infon>
          <location offset="710" length="45"/>
          <text>platelet-derived growth factor receptor alpha</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fip1l1</infon>
          <location offset="757" length="6"/>
          <text>FIP1L1</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfra</infon>
          <location offset="764" length="6"/>
          <text>PDGFRA</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">platelet-derived growth factor receptor beta</infon>
          <location offset="798" length="44"/>
          <text>platelet-derived growth factor receptor beta</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfrb</infon>
          <location offset="844" length="6"/>
          <text>PDGFRB</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fibroblast growth factor receptor 1</infon>
          <location offset="973" length="35"/>
          <text>fibroblast growth factor receptor 1</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">fgfr1</infon>
          <location offset="1010" length="5"/>
          <text>FGFR1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1032</offset>
        <text>Hypereosinophilic syndrome (HES) is a subcategory of idiopathic eosinophilia and is characterized by an absolute eosinophil count of &gt; or =1.5 x 10(9)/l for at least 6 months as well as eosinophil-mediated tissue damage.</text>
      </sentence>
      <sentence>
        <offset>1253</offset>
        <text>At present, a working diagnosis of primary eosinophilia mandates a bone marrow examination, karyotype analysis, and additional molecular studies in order to provide the patient with accurate prognostic information as well as select appropriate therapy.</text>
      </sentence>
      <sentence>
        <offset>1506</offset>
        <text>For example, the presence of either PDGFRA or PDGFRB mutations warrants the use of imatinib in clonal eosinophilia.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1589" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfra</infon>
          <location offset="1542" length="6"/>
          <text>PDGFRA</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pdgfrb</infon>
          <location offset="1552" length="6"/>
          <text>PDGFRB</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1622</offset>
        <text>In HES, prednisone, hydroxyurea, and interferon-alpha constitute first-line therapy, whereas imatinib, cladribine, and monoclonal antibodies to either interleukin-5 (mepolizumab) or CD52 (alemtuzumab) are considered investigational.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisone</infon>
          <location offset="1630" length="10"/>
          <text>prednisone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydroxyurea</infon>
          <location offset="1642" length="11"/>
          <text>hydroxyurea</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">imatinib</infon>
          <location offset="1715" length="8"/>
          <text>imatinib</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cladribine</infon>
          <location offset="1725" length="10"/>
          <text>cladribine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">interferon-alpha</infon>
          <location offset="1659" length="16"/>
          <text>interferon-alpha</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">interleukin-5</infon>
          <location offset="1773" length="13"/>
          <text>interleukin-5</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1855</offset>
        <text>Allogeneic transplantation offers a viable treatment option for drug-refractory cases.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16495926</id>
    <passage>
      <offset>0</offset>
      <text>A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.	The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours. In the experimental lung metastasis xenograft models, treatment with bexarotene inhibited the development of the lung tumour nodule formation compared to control. In vivo angiogenesis assay utilising gelfoam sponges, bexarotene reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic fibroblast growth factor to various extent. To determine the basis of these observations, human breast and non-small-cell lung cancer cells were subjected to migration and invasion assays in the presence of bexarotene. Our data showed that bexarotene decrease migration and invasiveness of tumour cells in a dose-dependent manner. Furthermore, bexarotene inhibited angiogenesis by directly inhibiting human umbilical vein endothelial cell growth and indirectly inhibiting tumour cell-mediated migration of human umbilical vein endothelial cells through Matrigel matrix. Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases. The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma. Collectively, our results suggest a role of bexarotene in treatment of angiogenesis and metastasis in solid tumours.</text>
      <sentence>
        <offset>0</offset>
        <text>A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="12" length="8"/>
          <text>retinoid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="40" length="10"/>
          <text>bexarotene</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lgd1069</infon>
          <location offset="52" length="7"/>
          <text>LGD1069</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">targretin</infon>
          <location offset="61" length="9"/>
          <text>targretin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoid x receptor</infon>
          <location offset="12" length="19"/>
          <text>retinoid X receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T12" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T14" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T13" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>127</offset>
        <text>The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">retinoid</infon>
          <location offset="175" length="8"/>
          <text>retinoid</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="203" length="10"/>
          <text>bexarotene</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">retinoid x receptor</infon>
          <location offset="175" length="19"/>
          <text>retinoid X receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>263</offset>
        <text>In the experimental lung metastasis xenograft models, treatment with bexarotene inhibited the development of the lung tumour nodule formation compared to control.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="332" length="10"/>
          <text>bexarotene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>426</offset>
        <text>In vivo angiogenesis assay utilising gelfoam sponges, bexarotene reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic fibroblast growth factor to various extent.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="480" length="10"/>
          <text>bexarotene</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="534" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">epidermal growth factor</infon>
          <location offset="570" length="23"/>
          <text>epidermal growth factor</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">fibroblast growth factor</infon>
          <location offset="604" length="24"/>
          <text>fibroblast growth factor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>648</offset>
        <text>To determine the basis of these observations, human breast and non-small-cell lung cancer cells were subjected to migration and invasion assays in the presence of bexarotene.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="811" length="10"/>
          <text>bexarotene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>823</offset>
        <text>Our data showed that bexarotene decrease migration and invasiveness of tumour cells in a dose-dependent manner.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="844" length="10"/>
          <text>bexarotene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>935</offset>
        <text>Furthermore, bexarotene inhibited angiogenesis by directly inhibiting human umbilical vein endothelial cell growth and indirectly inhibiting tumour cell-mediated migration of human umbilical vein endothelial cells through Matrigel matrix.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="948" length="10"/>
          <text>bexarotene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1174</offset>
        <text>Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="1227" length="10"/>
          <text>bexarotene</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">matrix metalloproteinases</infon>
          <location offset="1288" length="25"/>
          <text>matrix metalloproteinases</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">matrix metalloproteinases</infon>
          <location offset="1352" length="25"/>
          <text>matrix metalloproteinases</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1379</offset>
        <text>The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="1394" length="10"/>
          <text>bexarotene</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">peroxisome proliferator-activated receptor gamma</infon>
          <location offset="1506" length="48"/>
          <text>peroxisome proliferator-activated receptor gamma</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1556</offset>
        <text>Collectively, our results suggest a role of bexarotene in treatment of angiogenesis and metastasis in solid tumours.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bexarotene</infon>
          <location offset="1600" length="10"/>
          <text>bexarotene</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23292797</id>
    <passage>
      <offset>0</offset>
      <text>Smoothened is a fully competent activator of the heterotrimeric G protein G(i).	Smoothened (Smo) is a 7-transmembrane protein essential to the activation of Gli transcription factors (Gli) by hedgehog morphogens. The structure of Smo implies interactions with heterotrimeric G proteins, but the degree to which G proteins participate in the actions of hedgehogs remains controversial. We posit that the G(i) family of G proteins provides to hedgehogs the ability to expand well beyond the bounds of Gli. In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor. We find that with use of [(35)S]guanosine 5'-(3-O-thio)triphosphate, first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity to activate G(i). This finding is true regardless of subtype of G(i) (e.g., G(i2), G(o), and G(z)) tested. We also find that Smo endogenous to HEK-293 cells, ostensibly through inhibition of adenylyl cyclase, decreases intracellular levels of cAMP. The results indicate that Smo is a receptor that can engage not only Gli but also other more immediate effectors.</text>
      <sentence>
        <offset>0</offset>
        <text>Smoothened is a fully competent activator of the heterotrimeric G protein G(i).</text>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smoothened</infon>
          <location offset="0" length="10"/>
          <text>Smoothened</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g protein</infon>
          <location offset="64" length="9"/>
          <text>G protein</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g(i)</infon>
          <location offset="74" length="4"/>
          <text>G(i)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>80</offset>
        <text>Smoothened (Smo) is a 7-transmembrane protein essential to the activation of Gli transcription factors (Gli) by hedgehog morphogens.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smoothened</infon>
          <location offset="80" length="10"/>
          <text>Smoothened</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli</infon>
          <location offset="184" length="3"/>
          <text>Gli</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smo</infon>
          <location offset="92" length="3"/>
          <text>Smo</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli</infon>
          <location offset="157" length="3"/>
          <text>Gli</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>213</offset>
        <text>The structure of Smo implies interactions with heterotrimeric G proteins, but the degree to which G proteins participate in the actions of hedgehogs remains controversial.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smo</infon>
          <location offset="230" length="3"/>
          <text>Smo</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g proteins</infon>
          <location offset="275" length="10"/>
          <text>G proteins</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g proteins</infon>
          <location offset="311" length="10"/>
          <text>G proteins</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>385</offset>
        <text>We posit that the G(i) family of G proteins provides to hedgehogs the ability to expand well beyond the bounds of Gli.</text>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g(i)</infon>
          <location offset="403" length="4"/>
          <text>G(i)</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g proteins</infon>
          <location offset="418" length="10"/>
          <text>G proteins</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli</infon>
          <location offset="499" length="3"/>
          <text>Gli</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>504</offset>
        <text>In this regard, we evaluate here the efficacy of Smo as it relates to the activation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessential G(i)-coupled receptor.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-hydroxytryptamine</infon>
          <location offset="624" length="19"/>
          <text>5-hydroxytryptamine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="649" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smo</infon>
          <location offset="553" length="3"/>
          <text>Smo</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g(i)</infon>
          <location offset="592" length="4"/>
          <text>G(i)</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smo</infon>
          <location offset="611" length="3"/>
          <text>Smo</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-hydroxytryptamine(1a)</infon>
          <location offset="624" length="23"/>
          <text>5-hydroxytryptamine(1A)</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht(1a)</infon>
          <location offset="649" length="8"/>
          <text>5-HT(1A)</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g(i)-coupled receptor</infon>
          <location offset="686" length="21"/>
          <text>G(i)-coupled receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>709</offset>
        <text>We find that with use of [(35)S]guanosine 5'-(3-O-thio)triphosphate, first, with forms of G(i) endogenous to human embryonic kidney (HEK)-293 cells made to express epitope-tagged receptors and, second, with individual forms of Gα(i) fused to the C terminus of each receptor, Smo is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity to activate G(i).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(35)s]guanosine 5'-(3-o-thio)triphosphate</infon>
          <location offset="734" length="42"/>
          <text>[(35)S]guanosine 5'-(3-O-thio)triphosphate</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">5-ht</infon>
          <location offset="1009" length="4"/>
          <text>5-HT</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g(i)</infon>
          <location offset="799" length="4"/>
          <text>G(i)</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gα(i)</infon>
          <location offset="936" length="5"/>
          <text>Gα(i)</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smo</infon>
          <location offset="984" length="3"/>
          <text>Smo</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5-ht(1a)</infon>
          <location offset="1009" length="8"/>
          <text>5-HT(1A)</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g(i)</infon>
          <location offset="1078" length="4"/>
          <text>G(i)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1084</offset>
        <text>This finding is true regardless of subtype of G(i) (e.g., G(i2), G(o), and G(z)) tested.</text>
        <annotation id="T9">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g(i)</infon>
          <location offset="1130" length="4"/>
          <text>G(i)</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g(i2)</infon>
          <location offset="1142" length="5"/>
          <text>G(i2)</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g(o)</infon>
          <location offset="1149" length="4"/>
          <text>G(o)</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">g(z)</infon>
          <location offset="1159" length="4"/>
          <text>G(z)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1173</offset>
        <text>We also find that Smo endogenous to HEK-293 cells, ostensibly through inhibition of adenylyl cyclase, decreases intracellular levels of cAMP.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenylyl</infon>
          <location offset="1257" length="8"/>
          <text>adenylyl</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">camp</infon>
          <location offset="1309" length="4"/>
          <text>cAMP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smo</infon>
          <location offset="1191" length="3"/>
          <text>Smo</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adenylyl cyclase</infon>
          <location offset="1257" length="16"/>
          <text>adenylyl cyclase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1315</offset>
        <text>The results indicate that Smo is a receptor that can engage not only Gli but also other more immediate effectors.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">smo</infon>
          <location offset="1341" length="3"/>
          <text>Smo</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gli</infon>
          <location offset="1384" length="3"/>
          <text>Gli</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23203941</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1.	Clearing the way: Glucagon-like peptide-1 (GLP-1) receptor agonists are proving a potent weapon in the treatment of type II diabetes. A new vitamin B(12)-GLP-1 conjugate is investigated and shown to have insulinotropic properties similar to the unmodified peptide. These results are critical to the exploitation of the vitamin B(12) oral uptake pathway for peptide delivery.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin-b(12)</infon>
          <location offset="52" length="13"/>
          <text>vitamin-B(12)</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon-like peptide-1</infon>
          <location offset="77" length="23"/>
          <text>glucagon-like peptide-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>102</offset>
        <text>Clearing the way: Glucagon-like peptide-1 (GLP-1) receptor agonists are proving a potent weapon in the treatment of type II diabetes.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon-like peptide-1</infon>
          <location offset="120" length="23"/>
          <text>Glucagon-like peptide-1</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glp-1</infon>
          <location offset="145" length="5"/>
          <text>GLP-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>236</offset>
        <text>A new vitamin B(12)-GLP-1 conjugate is investigated and shown to have insulinotropic properties similar to the unmodified peptide.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin b(12)</infon>
          <location offset="242" length="13"/>
          <text>vitamin B(12)</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glp-1</infon>
          <location offset="256" length="5"/>
          <text>GLP-1</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>367</offset>
        <text>These results are critical to the exploitation of the vitamin B(12) oral uptake pathway for peptide delivery.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">vitamin b(12)</infon>
          <location offset="421" length="13"/>
          <text>vitamin B(12)</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>10201371</id>
    <passage>
      <offset>0</offset>
      <text>Synthesis of thrombin-inhibiting heparin mimetics without side effects.	Unwanted side effects of pharmacologically active compounds can usually be eliminated by structural modifications. But the complex heterogeneous structure of the polysaccharide heparin has limited this approach to fragmentation, leading to slightly better-tolerated heparin preparations of low molecular mass. Despite this improvement, heparin-induced thrombocytopaenia (HIT), related to an interaction with platelet factor 4 (PF4) and, to a lesser extent, haemorrhages, remain significant side effects of heparinotherapy. Breakthroughs in oligosaccharide chemistry made possible the total synthesis of the pentasaccharide antithrombin-binding site of heparin. This pentasaccharide represents a new family of potential antithrombotic drugs, devoid of thrombin inhibitory properties, and free of undesired interactions with blood and vessel components. To obtain more potent and well-tolerated antithrombotic drugs, we wished to synthesize heparin mimetics able to inhibit thrombin, that is, longer oligosaccharides. Like thrombin inhibition, undesired interactions are directly correlated to the charge and the size of the molecules, so we had to design structures that were able to discriminate between thrombin and other proteins, particularly PF4. Here we describe the use of multistep converging synthesis to obtain sulphated oligosaccharides that meet these requirements.</text>
      <sentence>
        <offset>0</offset>
        <text>Synthesis of thrombin-inhibiting heparin mimetics without side effects.</text>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thrombin</infon>
          <location offset="13" length="8"/>
          <text>thrombin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>72</offset>
        <text>Unwanted side effects of pharmacologically active compounds can usually be eliminated by structural modifications.</text>
      </sentence>
      <sentence>
        <offset>187</offset>
        <text>But the complex heterogeneous structure of the polysaccharide heparin has limited this approach to fragmentation, leading to slightly better-tolerated heparin preparations of low molecular mass.</text>
      </sentence>
      <sentence>
        <offset>382</offset>
        <text>Despite this improvement, heparin-induced thrombocytopaenia (HIT), related to an interaction with platelet factor 4 (PF4) and, to a lesser extent, haemorrhages, remain significant side effects of heparinotherapy.</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">platelet factor 4</infon>
          <location offset="480" length="17"/>
          <text>platelet factor 4</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pf4</infon>
          <location offset="499" length="3"/>
          <text>PF4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>595</offset>
        <text>Breakthroughs in oligosaccharide chemistry made possible the total synthesis of the pentasaccharide antithrombin-binding site of heparin.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">antithrombin</infon>
          <location offset="695" length="12"/>
          <text>antithrombin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>733</offset>
        <text>This pentasaccharide represents a new family of potential antithrombotic drugs, devoid of thrombin inhibitory properties, and free of undesired interactions with blood and vessel components.</text>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thrombin</infon>
          <location offset="823" length="8"/>
          <text>thrombin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>924</offset>
        <text>To obtain more potent and well-tolerated antithrombotic drugs, we wished to synthesize heparin mimetics able to inhibit thrombin, that is, longer oligosaccharides.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thrombin</infon>
          <location offset="1044" length="8"/>
          <text>thrombin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1088</offset>
        <text>Like thrombin inhibition, undesired interactions are directly correlated to the charge and the size of the molecules, so we had to design structures that were able to discriminate between thrombin and other proteins, particularly PF4.</text>
        <annotation id="T1">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thrombin</infon>
          <location offset="1093" length="8"/>
          <text>thrombin</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">thrombin</infon>
          <location offset="1276" length="8"/>
          <text>thrombin</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pf4</infon>
          <location offset="1318" length="3"/>
          <text>PF4</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1323</offset>
        <text>Here we describe the use of multistep converging synthesis to obtain sulphated oligosaccharides that meet these requirements.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>11783365</id>
    <passage>
      <offset>0</offset>
      <text>[Effects of mifepristone on expression of estrogen receptor and progesterone receptor in cultured human eutopic and ectopic endometria].	OBJECTIVE: To investigate the effects of mifepristone on expression of estrogen receptor (ER) and progesterone receptor (PR) in cultured human eutopic and ectopic endometria. METHODS: Endometrial (n = 22) and endometriotic (n = 12) tissues, obtained from patients with endometriosis, were cultured with and without mifepristone (1 x 10(-6) mol/L, 1 x 10(-4) mol/L) for 7-10 days. The expressions of ER, PR were determined by semi-quantitative immunocytochemistry method. Thirteen normal endometrial samples served as controls. RESULTS: The expressions of ER and PR in normal and eutopic endometrial cells showed the same cyclic pattern. The only difference was the significantly higher PR glandular content in eutopic endometria of endometriosis patients, as compared with normal controls [histochemistry score (H-score) 2.77 +/- 0.32 Vs 2.20 +/- 0.26 P &lt; 0.05]. On the contrary, the ER, PR expressions in ectopic endometrial cells were significantly lower only during the proliferative phase (ER: gland 0.65-2.17 Vs 1.50-3.23, stroma 0.45-1.03 Vs 0.80-1.96; PR: gland 0.55-1.77 Vs 1.55-3.34, stroma 0.40-1.27 Vs 0.98-2.50; P &lt; 0.05-0.01); significantly higher only during the late secretory phase (ER: gland 3.27 +/- 0.31 Vs 0.28 +/- 0.11, stroma 1.87 +/- 0.31 Vs 0.26 +/- 0.15; PR: gland 3.33 +/- 0.23 Vs 0.36 +/- 0.23) as compared with those of eutopic endometria. 10(-6)-10(-4) mol/L of mifepristone significantly suppressed the expressions of ER, PR in both eutopic and ectopic endometrial cells of endometriosis patients (P &lt; 0.01) in a dose-dependent manner. CONCLUSIONS: Expression of ER, PR of endometriotic cells differed significantly from that of endometrial cells of patients with or without endometriosis. The down-regulatory effect on ER and PR may be one of the therapeutic mechanism of mifepristone on endometriosis.</text>
      <sentence>
        <offset>0</offset>
        <text>[Effects of mifepristone on expression of estrogen receptor and progesterone receptor in cultured human eutopic and ectopic endometria].</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="12" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="42" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="64" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor</infon>
          <location offset="42" length="17"/>
          <text>estrogen receptor</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptor</infon>
          <location offset="64" length="21"/>
          <text>progesterone receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>137</offset>
        <text>OBJECTIVE: To investigate the effects of mifepristone on expression of estrogen receptor (ER) and progesterone receptor (PR) in cultured human eutopic and ectopic endometria.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="178" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">estrogen</infon>
          <location offset="208" length="8"/>
          <text>estrogen</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">progesterone</infon>
          <location offset="235" length="12"/>
          <text>progesterone</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="258" length="2"/>
          <text>PR</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">estrogen receptor</infon>
          <location offset="208" length="17"/>
          <text>estrogen receptor</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="227" length="2"/>
          <text>ER</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">progesterone receptor</infon>
          <location offset="235" length="21"/>
          <text>progesterone receptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>312</offset>
        <text>METHODS: Endometrial (n = 22) and endometriotic (n = 12) tissues, obtained from patients with endometriosis, were cultured with and without mifepristone (1 x 10(-6) mol/L, 1 x 10(-4) mol/L) for 7-10 days.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="452" length="12"/>
          <text>mifepristone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>517</offset>
        <text>The expressions of ER, PR were determined by semi-quantitative immunocytochemistry method.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="536" length="2"/>
          <text>ER</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="540" length="2"/>
          <text>PR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>608</offset>
        <text>Thirteen normal endometrial samples served as controls.</text>
      </sentence>
      <sentence>
        <offset>664</offset>
        <text>RESULTS: The expressions of ER and PR in normal and eutopic endometrial cells showed the same cyclic pattern.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="692" length="2"/>
          <text>ER</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="699" length="2"/>
          <text>PR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>774</offset>
        <text>The only difference was the significantly higher PR glandular content in eutopic endometria of endometriosis patients, as compared with normal controls [histochemistry score (H-score) 2.77 +/- 0.32 Vs 2.20 +/- 0.26 P &lt; 0.05].</text>
      </sentence>
      <sentence>
        <offset>1000</offset>
        <text>On the contrary, the ER, PR expressions in ectopic endometrial cells were significantly lower only during the proliferative phase (ER: gland 0.65-2.17 Vs 1.50-3.23, stroma 0.45-1.03 Vs 0.80-1.96; PR: gland 0.55-1.77 Vs 1.55-3.34, stroma 0.40-1.27 Vs 0.98-2.50; P &lt; 0.05-0.01); significantly higher only during the late secretory phase (ER: gland 3.27 +/- 0.31 Vs 0.28 +/- 0.11, stroma 1.87 +/- 0.31 Vs 0.26 +/- 0.15; PR: gland 3.33 +/- 0.23 Vs 0.36 +/- 0.23) as compared with those of eutopic endometria.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="1196" length="2"/>
          <text>PR</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="1336" length="2"/>
          <text>ER</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="1417" length="2"/>
          <text>PR</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="1021" length="2"/>
          <text>ER</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="1025" length="2"/>
          <text>PR</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="1131" length="2"/>
          <text>ER</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1505</offset>
        <text>10(-6)-10(-4) mol/L of mifepristone significantly suppressed the expressions of ER, PR in both eutopic and ectopic endometrial cells of endometriosis patients (P &lt; 0.01) in a dose-dependent manner.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="1528" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="1585" length="2"/>
          <text>ER</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="1589" length="2"/>
          <text>PR</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INDIRECT-DOWNREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1703</offset>
        <text>CONCLUSIONS: Expression of ER, PR of endometriotic cells differed significantly from that of endometrial cells of patients with or without endometriosis.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="1730" length="2"/>
          <text>ER</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="1734" length="2"/>
          <text>PR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1857</offset>
        <text>The down-regulatory effect on ER and PR may be one of the therapeutic mechanism of mifepristone on endometriosis.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mifepristone</infon>
          <location offset="1940" length="12"/>
          <text>mifepristone</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">er</infon>
          <location offset="1887" length="2"/>
          <text>ER</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pr</infon>
          <location offset="1894" length="2"/>
          <text>PR</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23572405</id>
    <passage>
      <offset>0</offset>
      <text>Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism.	Due to stimulated overall metabolism, a state of nutritional inadequacy often ensues, during thyrotoxicosis. We aimed to investigate circulating levels of some major components of the system that regulates energy stores, glucose, and fat metabolism, during thyrotoxicosis compared to euthyroidism. Fasting serum ghrelin, leptin, adiponectin, insulin, glucagon, glucose, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). The same measurements were repeated an average 3 months later, when all patients achieved euthyroidism. Compared to euthyroidism, in thyrotoxicosis, patients had lower ghrelin and fat mass; had comparable insulin, HOMA-IR, glucagon, and leptin levels; higher levels of circulating adiponectin. Fasting serum glucose tended to be higher during thyrotoxicosis. The unique correlation of HOMA-IR was with the-glucagon to ghrelin ratio-(r = 0.801, p &lt; 0.001) in hyperthyrodism, and with glucagon itself in euthyroidism (r = -0.844, p &lt; 0.001). Circulating levels of ghrelin are decreased; leptin, insulin, glucagon are unchanged; adiponectin are increased during hyperthyroidism. The fasting HOMA-IR tends to be higher, despite the decreased adiposity in hyperthyroidism. The-glucagon to ghrelin ratio-strongly correlates with fasting HOMA-IR in hyperthyroidism.</text>
      <sentence>
        <offset>0</offset>
        <text>Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism.</text>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon</infon>
          <location offset="12" length="8"/>
          <text>glucagon</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ghrelin</infon>
          <location offset="24" length="7"/>
          <text>ghrelin</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="58" length="7"/>
          <text>insulin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>97</offset>
        <text>Due to stimulated overall metabolism, a state of nutritional inadequacy often ensues, during thyrotoxicosis.</text>
      </sentence>
      <sentence>
        <offset>206</offset>
        <text>We aimed to investigate circulating levels of some major components of the system that regulates energy stores, glucose, and fat metabolism, during thyrotoxicosis compared to euthyroidism.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="318" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>395</offset>
        <text>Fasting serum ghrelin, leptin, adiponectin, insulin, glucagon, glucose, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="458" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ghrelin</infon>
          <location offset="409" length="7"/>
          <text>ghrelin</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">leptin</infon>
          <location offset="418" length="6"/>
          <text>leptin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="426" length="11"/>
          <text>adiponectin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="439" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon</infon>
          <location offset="448" length="8"/>
          <text>glucagon</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>657</offset>
        <text>The same measurements were repeated an average 3 months later, when all patients achieved euthyroidism.</text>
      </sentence>
      <sentence>
        <offset>761</offset>
        <text>Compared to euthyroidism, in thyrotoxicosis, patients had lower ghrelin and fat mass; had comparable insulin, HOMA-IR, glucagon, and leptin levels; higher levels of circulating adiponectin.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ghrelin</infon>
          <location offset="825" length="7"/>
          <text>ghrelin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="862" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon</infon>
          <location offset="880" length="8"/>
          <text>glucagon</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">leptin</infon>
          <location offset="894" length="6"/>
          <text>leptin</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="938" length="11"/>
          <text>adiponectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>951</offset>
        <text>Fasting serum glucose tended to be higher during thyrotoxicosis.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="965" length="7"/>
          <text>glucose</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1016</offset>
        <text>The unique correlation of HOMA-IR was with the-glucagon to ghrelin ratio-(r = 0.801, p &lt; 0.001) in hyperthyrodism, and with glucagon itself in euthyroidism (r = -0.844, p &lt; 0.001).</text>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon</infon>
          <location offset="1140" length="8"/>
          <text>glucagon</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon</infon>
          <location offset="1063" length="8"/>
          <text>glucagon</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ghrelin</infon>
          <location offset="1075" length="7"/>
          <text>ghrelin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1197</offset>
        <text>Circulating levels of ghrelin are decreased; leptin, insulin, glucagon are unchanged; adiponectin are increased during hyperthyroidism.</text>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ghrelin</infon>
          <location offset="1219" length="7"/>
          <text>ghrelin</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">leptin</infon>
          <location offset="1242" length="6"/>
          <text>leptin</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="1250" length="7"/>
          <text>insulin</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon</infon>
          <location offset="1259" length="8"/>
          <text>glucagon</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adiponectin</infon>
          <location offset="1283" length="11"/>
          <text>adiponectin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1333</offset>
        <text>The fasting HOMA-IR tends to be higher, despite the decreased adiposity in hyperthyroidism.</text>
      </sentence>
      <sentence>
        <offset>1425</offset>
        <text>The-glucagon to ghrelin ratio-strongly correlates with fasting HOMA-IR in hyperthyroidism.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">glucagon</infon>
          <location offset="1429" length="8"/>
          <text>glucagon</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ghrelin</infon>
          <location offset="1441" length="7"/>
          <text>ghrelin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23348407</id>
    <passage>
      <offset>0</offset>
      <text>Dietary relevant mixtures of phytoestrogens inhibit adipocyte differentiation in vitro.	Phytoestrogens (PEs) are naturally occurring plant components, with the ability to induce biological responses in vertebrates by mimicking or modulating the action of endogenous hormones. Single isoflavones have been shown to affect adipocyte differentiation, but knowledge on the effect of dietary relevant mixtures of PEs, including for instance lignans, is lacking. In the current study dietary relevant mixtures of isoflavones and their metabolites, lignans and their metabolites, coumestrol, and a mixture containing all of them, were examined for effects on adipogenesis in 3T3-L1 adipocytes, as well as tested for their PPARγ activating abilities. The results showed that mixtures of isoflavonoid parent compounds and metabolites, respectively, a mixture of lignan metabolites, as well as coumestrol concentration-dependently inhibited adipocyte differentiation. Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of isoflavonoid metabolites were found to have PPARγ activating abilities. These results suggest that PEs can affect pathways known to play a role in obesity development, and indicate that the inhibitory effect on adipocyte differentiation does not appear to be strictly associated with PPARγ activation/inhibition. The current study support the hypothesis that compounds with endocrine activity can affect pathways playing a role in the development obesity and obesity related diseases.</text>
      <sentence>
        <offset>0</offset>
        <text>Dietary relevant mixtures of phytoestrogens inhibit adipocyte differentiation in vitro.</text>
      </sentence>
      <sentence>
        <offset>88</offset>
        <text>Phytoestrogens (PEs) are naturally occurring plant components, with the ability to induce biological responses in vertebrates by mimicking or modulating the action of endogenous hormones.</text>
      </sentence>
      <sentence>
        <offset>276</offset>
        <text>Single isoflavones have been shown to affect adipocyte differentiation, but knowledge on the effect of dietary relevant mixtures of PEs, including for instance lignans, is lacking.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoflavones</infon>
          <location offset="283" length="11"/>
          <text>isoflavones</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>457</offset>
        <text>In the current study dietary relevant mixtures of isoflavones and their metabolites, lignans and their metabolites, coumestrol, and a mixture containing all of them, were examined for effects on adipogenesis in 3T3-L1 adipocytes, as well as tested for their PPARγ activating abilities.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoflavones</infon>
          <location offset="507" length="11"/>
          <text>isoflavones</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lignans</infon>
          <location offset="542" length="7"/>
          <text>lignans</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coumestrol</infon>
          <location offset="573" length="10"/>
          <text>coumestrol</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="715" length="5"/>
          <text>PPARγ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>743</offset>
        <text>The results showed that mixtures of isoflavonoid parent compounds and metabolites, respectively, a mixture of lignan metabolites, as well as coumestrol concentration-dependently inhibited adipocyte differentiation.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoflavonoid</infon>
          <location offset="779" length="12"/>
          <text>isoflavonoid</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lignan</infon>
          <location offset="853" length="6"/>
          <text>lignan</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">coumestrol</infon>
          <location offset="884" length="10"/>
          <text>coumestrol</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>958</offset>
        <text>Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of isoflavonoid metabolites were found to have PPARγ activating abilities.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoflavonoid</infon>
          <location offset="984" length="12"/>
          <text>isoflavonoid</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isoflavonoid</infon>
          <location offset="1032" length="12"/>
          <text>isoflavonoid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="1076" length="5"/>
          <text>PPARγ</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1104</offset>
        <text>These results suggest that PEs can affect pathways known to play a role in obesity development, and indicate that the inhibitory effect on adipocyte differentiation does not appear to be strictly associated with PPARγ activation/inhibition.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">pparγ</infon>
          <location offset="1316" length="5"/>
          <text>PPARγ</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1345</offset>
        <text>The current study support the hypothesis that compounds with endocrine activity can affect pathways playing a role in the development obesity and obesity related diseases.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>22082827</id>
    <passage>
      <offset>0</offset>
      <text>Tissues distribution of heavy metals and erythrocytes antioxidant status in rats exposed to Nigerian bonny light crude oil.	The harmful effects of folkloric uses of Nigerian bonny light crude oil (BLCO) in ailments management may outweigh the expected beneficial effects. We investigated the levels of heavy metal concentrations in the tissues as well as the effect of BLCO on the antioxidant status of erythrocytes of rats after oral exposure to 0, 200 and 800 mg/kg BLCO for 7 days. Analysis of heavy metal concentrations in BLCO showed that Zn &gt; Fe &gt; Pb &gt; Cu &gt; Ni. The trend of accumulation of the metals in the tissues is blood-Fe &gt; Pb &gt;Zn whereas Cu and Ni levels were not affected; Liver-Ni &gt; Zn &gt; Fe &gt; Cu &gt; Pb and Testes-Ni &gt; Cu &gt; Pb &gt; Zn &gt; Fe. The order of concentration of the metals in the tissues is as follows: iron-blood &gt; liver &gt; testes; zinc-liver &gt; blood &gt; testes; lead-blood &gt; liver &gt; testes; copper-testes &gt; liver &gt; blood; nickel-liver &gt; testes &gt; blood. Activities of the antioxidant enzymes of erythrocytes such as superoxide dismutase, catalase, glutathione S-transferase and glutathione peroxidase increased significantly in a dose-dependent manner with significant elevation in hydrogen peroxide and malondialdehyde levels, whereas glutathione level was not significantly decreased in BLCO-treated animals. Collectively, the results showed that BLCO induces oxidative damage to erythrocytes of rats.</text>
      <sentence>
        <offset>0</offset>
        <text>Tissues distribution of heavy metals and erythrocytes antioxidant status in rats exposed to Nigerian bonny light crude oil.</text>
      </sentence>
      <sentence>
        <offset>124</offset>
        <text>The harmful effects of folkloric uses of Nigerian bonny light crude oil (BLCO) in ailments management may outweigh the expected beneficial effects.</text>
      </sentence>
      <sentence>
        <offset>272</offset>
        <text>We investigated the levels of heavy metal concentrations in the tissues as well as the effect of BLCO on the antioxidant status of erythrocytes of rats after oral exposure to 0, 200 and 800 mg/kg BLCO for 7 days.</text>
      </sentence>
      <sentence>
        <offset>485</offset>
        <text>Analysis of heavy metal concentrations in BLCO showed that Zn &gt; Fe &gt; Pb &gt; Cu &gt; Ni.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zn</infon>
          <location offset="544" length="2"/>
          <text>Zn</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fe</infon>
          <location offset="549" length="2"/>
          <text>Fe</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb</infon>
          <location offset="554" length="2"/>
          <text>Pb</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="559" length="2"/>
          <text>Cu</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ni</infon>
          <location offset="564" length="2"/>
          <text>Ni</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>568</offset>
        <text>The trend of accumulation of the metals in the tissues is blood-Fe &gt; Pb &gt;Zn whereas Cu and Ni levels were not affected; Liver-Ni &gt; Zn &gt; Fe &gt; Cu &gt; Pb and Testes-Ni &gt; Cu &gt; Pb &gt; Zn &gt; Fe. The order of concentration of the metals in the tissues is as follows: iron-blood &gt; liver &gt; testes; zinc-liver &gt; blood &gt; testes; lead-blood &gt; liver &gt; testes; copper-testes &gt; liver &gt; blood; nickel-liver &gt; testes &gt; blood.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fe</infon>
          <location offset="632" length="2"/>
          <text>Fe</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb</infon>
          <location offset="637" length="2"/>
          <text>Pb</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zn</infon>
          <location offset="641" length="2"/>
          <text>Zn</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="652" length="2"/>
          <text>Cu</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ni</infon>
          <location offset="659" length="2"/>
          <text>Ni</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ni</infon>
          <location offset="694" length="2"/>
          <text>Ni</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zn</infon>
          <location offset="699" length="2"/>
          <text>Zn</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fe</infon>
          <location offset="704" length="2"/>
          <text>Fe</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="709" length="2"/>
          <text>Cu</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb</infon>
          <location offset="714" length="2"/>
          <text>Pb</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ni</infon>
          <location offset="728" length="2"/>
          <text>Ni</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cu</infon>
          <location offset="733" length="2"/>
          <text>Cu</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pb</infon>
          <location offset="738" length="2"/>
          <text>Pb</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zn</infon>
          <location offset="743" length="2"/>
          <text>Zn</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fe</infon>
          <location offset="748" length="2"/>
          <text>Fe</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="823" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">zinc</infon>
          <location offset="852" length="4"/>
          <text>zinc</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">copper</infon>
          <location offset="910" length="6"/>
          <text>copper</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nickel</infon>
          <location offset="941" length="6"/>
          <text>nickel</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>972</offset>
        <text>Activities of the antioxidant enzymes of erythrocytes such as superoxide dismutase, catalase, glutathione S-transferase and glutathione peroxidase increased significantly in a dose-dependent manner with significant elevation in hydrogen peroxide and malondialdehyde levels, whereas glutathione level was not significantly decreased in BLCO-treated animals.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">hydrogen peroxide</infon>
          <location offset="1200" length="17"/>
          <text>hydrogen peroxide</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">malondialdehyde</infon>
          <location offset="1222" length="15"/>
          <text>malondialdehyde</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1254" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">superoxide</infon>
          <location offset="1034" length="10"/>
          <text>superoxide</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1066" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">s</infon>
          <location offset="1078" length="1"/>
          <text>S</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glutathione</infon>
          <location offset="1096" length="11"/>
          <text>glutathione</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">superoxide dismutase</infon>
          <location offset="1034" length="20"/>
          <text>superoxide dismutase</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">catalase</infon>
          <location offset="1056" length="8"/>
          <text>catalase</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione s-transferase</infon>
          <location offset="1066" length="25"/>
          <text>glutathione S-transferase</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">glutathione peroxidase</infon>
          <location offset="1096" length="22"/>
          <text>glutathione peroxidase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1329</offset>
        <text>Collectively, the results showed that BLCO induces oxidative damage to erythrocytes of rats.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>19996149</id>
    <passage>
      <offset>0</offset>
      <text>In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.	(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro -2H-pyran-3,4,5-triol (dapagliflozin; BMS-512148) is a potent sodium-glucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes. The preclinical characterization of dapagliflozin, to allow compound selection and prediction of pharmacological and dispositional behavior in the clinic, involved Caco-2 cell permeability studies, cytochrome P450 (P450) inhibition and induction studies, P450 reaction phenotyping, metabolite identification in hepatocytes, and pharmacokinetics in rats, dogs, and monkeys. Dapagliflozin was found to have good permeability across Caco-2 cell membranes. It was found to be a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor. Dapagliflozin was not found to be an inhibitor or an inducer of human P450 enzymes. The in vitro metabolic profiles of dapagliflozin after incubation with hepatocytes from mice, rats, dogs, monkeys, and humans were qualitatively similar. Rat hepatocyte incubations showed the highest turnover, and dapagliflozin was most stable in human hepatocytes. Prominent in vitro metabolic pathways observed were glucuronidation, hydroxylation, and O-deethylation. Pharmacokinetic parameters for dapagliflozin in preclinical species revealed a compound with adequate oral exposure, clearance, and elimination half-life, consistent with the potential for single daily dosing in humans. The pharmacokinetics in humans after a single dose of 50 mg of [(14)C]dapagliflozin showed good exposure, low clearance, adequate half-life, and no metabolites with significant pharmacological activity or toxicological concern.</text>
      <sentence>
        <offset>0</offset>
        <text>In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dapagliflozin</infon>
          <location offset="50" length="13"/>
          <text>dapagliflozin</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bms-512148</infon>
          <location offset="65" length="10"/>
          <text>BMS-512148</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="87" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="94" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sodium-glucose cotransporter type ii</infon>
          <location offset="87" length="36"/>
          <text>sodium-glucose cotransporter type II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T25" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>158</offset>
        <text>(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro -2H-pyran-3,4,5-triol (dapagliflozin; BMS-512148) is a potent sodium-glucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(2s,3r,4r,5s,6r)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro -2h-pyran-3,4,5-triol</infon>
          <location offset="158" length="103"/>
          <text>(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro -2H-pyran-3,4,5-triol</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dapagliflozin</infon>
          <location offset="263" length="13"/>
          <text>dapagliflozin</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">bms-512148</infon>
          <location offset="278" length="10"/>
          <text>BMS-512148</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sodium</infon>
          <location offset="302" length="6"/>
          <text>sodium</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="309" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">sodium-glucose cotransporter type ii</infon>
          <location offset="302" length="36"/>
          <text>sodium-glucose cotransporter type II</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>444</offset>
        <text>The preclinical characterization of dapagliflozin, to allow compound selection and prediction of pharmacological and dispositional behavior in the clinic, involved Caco-2 cell permeability studies, cytochrome P450 (P450) inhibition and induction studies, P450 reaction phenotyping, metabolite identification in hepatocytes, and pharmacokinetics in rats, dogs, and monkeys.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dapagliflozin</infon>
          <location offset="480" length="13"/>
          <text>dapagliflozin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450</infon>
          <location offset="642" length="15"/>
          <text>cytochrome P450</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p450</infon>
          <location offset="659" length="4"/>
          <text>P450</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p450</infon>
          <location offset="699" length="4"/>
          <text>P450</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>817</offset>
        <text>Dapagliflozin was found to have good permeability across Caco-2 cell membranes.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dapagliflozin</infon>
          <location offset="817" length="13"/>
          <text>Dapagliflozin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>897</offset>
        <text>It was found to be a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor.</text>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="932" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="948" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="976" length="4"/>
          <text>P-gp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>992</offset>
        <text>Dapagliflozin was not found to be an inhibitor or an inducer of human P450 enzymes.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dapagliflozin</infon>
          <location offset="992" length="13"/>
          <text>Dapagliflozin</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">human p450</infon>
          <location offset="1056" length="10"/>
          <text>human P450</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1076</offset>
        <text>The in vitro metabolic profiles of dapagliflozin after incubation with hepatocytes from mice, rats, dogs, monkeys, and humans were qualitatively similar.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dapagliflozin</infon>
          <location offset="1111" length="13"/>
          <text>dapagliflozin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1230</offset>
        <text>Rat hepatocyte incubations showed the highest turnover, and dapagliflozin was most stable in human hepatocytes.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dapagliflozin</infon>
          <location offset="1290" length="13"/>
          <text>dapagliflozin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1342</offset>
        <text>Prominent in vitro metabolic pathways observed were glucuronidation, hydroxylation, and O-deethylation.</text>
      </sentence>
      <sentence>
        <offset>1446</offset>
        <text>Pharmacokinetic parameters for dapagliflozin in preclinical species revealed a compound with adequate oral exposure, clearance, and elimination half-life, consistent with the potential for single daily dosing in humans.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dapagliflozin</infon>
          <location offset="1477" length="13"/>
          <text>dapagliflozin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1666</offset>
        <text>The pharmacokinetics in humans after a single dose of 50 mg of [(14)C]dapagliflozin showed good exposure, low clearance, adequate half-life, and no metabolites with significant pharmacological activity or toxicological concern.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(14)c]dapagliflozin</infon>
          <location offset="1729" length="20"/>
          <text>[(14)C]dapagliflozin</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>7816863</id>
    <passage>
      <offset>0</offset>
      <text>Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice.	The effects of several beta-adrenoceptor antagonists on the desipramine-induced increase in aggressive behavior in long-term isolated mice were examined. Desipramine HCl (10 mg/kg, IP) significantly increased the duration of aggressive behavior in isolated mice but did not significantly change the latency to the first attack consistent with our previous reports. Intraperitoneal administration of (+/- )propranolol HCl (2.5-10 mg/kg), a nonselective beta-adrenoceptor antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses. ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it. Moreover, clenbuterol HCl (0.1-0.5 mg/kg, IP), a lipophilic beta 2-adrenoceptor agonist, significantly increased the duration of basal aggressive behavior. Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.</text>
      <sentence>
        <offset>0</offset>
        <text>Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desipramine</infon>
          <location offset="53" length="11"/>
          <text>desipramine</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 1-adrenoceptors</infon>
          <location offset="16" length="20"/>
          <text>beta 1-adrenoceptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>128</offset>
        <text>The effects of several beta-adrenoceptor antagonists on the desipramine-induced increase in aggressive behavior in long-term isolated mice were examined.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desipramine</infon>
          <location offset="188" length="11"/>
          <text>desipramine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="151" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>282</offset>
        <text>Desipramine HCl (10 mg/kg, IP) significantly increased the duration of aggressive behavior in isolated mice but did not significantly change the latency to the first attack consistent with our previous reports.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desipramine hcl</infon>
          <location offset="282" length="15"/>
          <text>Desipramine HCl</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>493</offset>
        <text>Intraperitoneal administration of (+/- )propranolol HCl (2.5-10 mg/kg), a nonselective beta-adrenoceptor antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">(+/- )propranolol hcl</infon>
          <location offset="527" length="21"/>
          <text>(+/- )propranolol HCl</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desipramine</infon>
          <location offset="642" length="11"/>
          <text>desipramine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">beta-adrenoceptor</infon>
          <location offset="580" length="17"/>
          <text>beta-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T4" role="head"/>
          <node refid="T14" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>761</offset>
        <text>ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ici118,551 hcl</infon>
          <location offset="761" length="14"/>
          <text>ICI118,551 HCl</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">metoprolol tartrate</infon>
          <location offset="948" length="19"/>
          <text>metoprolol tartrate</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="808" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 1-adrenoceptor</infon>
          <location offset="998" length="19"/>
          <text>beta 1-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T7" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T8" role="head"/>
          <node refid="T16" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1049</offset>
        <text>Moreover, clenbuterol HCl (0.1-0.5 mg/kg, IP), a lipophilic beta 2-adrenoceptor agonist, significantly increased the duration of basal aggressive behavior.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clenbuterol hcl</infon>
          <location offset="1059" length="15"/>
          <text>clenbuterol HCl</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="1109" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">AGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1205</offset>
        <text>Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">desipramine</infon>
          <location offset="1255" length="11"/>
          <text>desipramine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">yohimbine</infon>
          <location offset="1328" length="9"/>
          <text>yohimbine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha 2-adrenoceptor</infon>
          <location offset="1342" length="20"/>
          <text>alpha 2-adrenoceptor</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">beta 2-adrenoceptor</infon>
          <location offset="1436" length="19"/>
          <text>beta 2-adrenoceptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T2" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23220037</id>
    <passage>
      <offset>0</offset>
      <text>Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells.	P-glycoprotein (P-gp) is an efflux pump belonging to the ATP-binding cassette transporter superfamily expressed in several organs. Considering its potential protective effects, the induction of de novo synthesis of P-gp could be used therapeutically in the treatment of intoxications by its substrates. The herbicide paraquat (PQ) is a P-gp substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote. The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX), a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario. Cytotoxicity was evaluated by the MTT assay and PQ intracellular concentrations were measured by gas chromatography-ion trap-mass spectrometry (GC-IT-MS). Also, the DOX modulatory effect on choline uptake transport system was assessed by measuring the uptake of [³H]-choline. The results show that DOX exerts protective effects against PQ cytotoxicity, preventing the intracellular accumulation of the herbicide. These protective effects were not completely prevented by the incubation with the UIC2 antibody, a specific P-gp inhibitor, suggesting the involvement of alternative protection mechanisms. In fact, DOX also efficiently inhibited the choline transport system that influences PQ cellular uptake. In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing P-gp and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.</text>
      <sentence>
        <offset>0</offset>
        <text>Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="0" length="11"/>
          <text>Doxorubicin</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paraquat</infon>
          <location offset="22" length="8"/>
          <text>paraquat</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>74</offset>
        <text>P-glycoprotein (P-gp) is an efflux pump belonging to the ATP-binding cassette transporter superfamily expressed in several organs.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="131" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-glycoprotein</infon>
          <location offset="74" length="14"/>
          <text>P-glycoprotein</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="90" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">efflux pump</infon>
          <location offset="102" length="11"/>
          <text>efflux pump</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">atp-binding cassette transporter</infon>
          <location offset="131" length="32"/>
          <text>ATP-binding cassette transporter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>205</offset>
        <text>Considering its potential protective effects, the induction of de novo synthesis of P-gp could be used therapeutically in the treatment of intoxications by its substrates.</text>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="289" length="4"/>
          <text>P-gp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>377</offset>
        <text>The herbicide paraquat (PQ) is a P-gp substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">paraquat</infon>
          <location offset="391" length="8"/>
          <text>paraquat</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="410" length="4"/>
          <text>P-gp</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T7" role="head"/>
          <node refid="T23" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>524</offset>
        <text>The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX), a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">doxorubicin</infon>
          <location offset="625" length="11"/>
          <text>doxorubicin</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="638" length="3"/>
          <text>DOX</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="652" length="4"/>
          <text>P-gp</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T9" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>821</offset>
        <text>Cytotoxicity was evaluated by the MTT assay and PQ intracellular concentrations were measured by gas chromatography-ion trap-mass spectrometry (GC-IT-MS).</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mtt</infon>
          <location offset="855" length="3"/>
          <text>MTT</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>976</offset>
        <text>Also, the DOX modulatory effect on choline uptake transport system was assessed by measuring the uptake of [³H]-choline.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[³h]-choline</infon>
          <location offset="1083" length="12"/>
          <text>[³H]-choline</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="986" length="3"/>
          <text>DOX</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline</infon>
          <location offset="1011" length="7"/>
          <text>choline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1097</offset>
        <text>The results show that DOX exerts protective effects against PQ cytotoxicity, preventing the intracellular accumulation of the herbicide.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="1119" length="3"/>
          <text>DOX</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1234</offset>
        <text>These protective effects were not completely prevented by the incubation with the UIC2 antibody, a specific P-gp inhibitor, suggesting the involvement of alternative protection mechanisms.</text>
        <annotation id="T17">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="1342" length="4"/>
          <text>P-gp</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1423</offset>
        <text>In fact, DOX also efficiently inhibited the choline transport system that influences PQ cellular uptake.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="1432" length="3"/>
          <text>DOX</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline</infon>
          <location offset="1467" length="7"/>
          <text>choline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1528</offset>
        <text>In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing P-gp and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dox</infon>
          <location offset="1567" length="3"/>
          <text>DOX</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline</infon>
          <location offset="1666" length="7"/>
          <text>choline</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">p-gp</infon>
          <location offset="1624" length="4"/>
          <text>P-gp</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">choline transporter</infon>
          <location offset="1666" length="19"/>
          <text>choline transporter</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15580557</id>
    <passage>
      <offset>0</offset>
      <text>Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors.	HM74 (GPR109B) and the highly homologous gene, HM74A (GPR109A) code for Gi-G protein-coupled orphan receptors that recently have been discovered to be involved in the metabolic effects of niacin. The B vitamin niacin is an important agent used in the treatment of dyslipidemias, but its use is limited by side effects. The novel role of the adjacent HM74 and HM74A genes in the metabolism of niacin may provide new targets for drug development. Human genetic variations in HM74 and HM74A have been reported but have not been studied in detail. These variations may play a role in the response to agents targeting receptors coded by these genes. Here we show that many of the nonsynonymous SNPs listed in public databases for HM74 and HM74A are artifacts resulting from extensive homology between these two genes. This may be representative of a neglected phenomenon in reporting sequences of highly homologous genes. We provide primer sequences that permit selective amplification of the complete coding regions of HM74 and HM74A. Using these primers, we show that subsequent sequencing of HM74 and HM74A reveals a novel and unique variation in the HM74A gene. Haplotype analysis suggests four SNPs can define the five major haplotypes that lie within a single haplotype block encompassing these two genes.</text>
      <sentence>
        <offset>0</offset>
        <text>Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">niacin</infon>
          <location offset="55" length="6"/>
          <text>niacin</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">human hm74</infon>
          <location offset="14" length="10"/>
          <text>human HM74</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr109b</infon>
          <location offset="26" length="7"/>
          <text>GPR109B</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74</infon>
          <location offset="39" length="4"/>
          <text>HM74</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr109a</infon>
          <location offset="46" length="7"/>
          <text>GPR109A</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">niacin receptors</infon>
          <location offset="55" length="16"/>
          <text>niacin receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>73</offset>
        <text>HM74 (GPR109B) and the highly homologous gene, HM74A (GPR109A) code for Gi-G protein-coupled orphan receptors that recently have been discovered to be involved in the metabolic effects of niacin.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">niacin</infon>
          <location offset="261" length="6"/>
          <text>niacin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74</infon>
          <location offset="73" length="4"/>
          <text>HM74</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74a</infon>
          <location offset="120" length="5"/>
          <text>HM74A</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr109a</infon>
          <location offset="127" length="7"/>
          <text>GPR109A</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gpr109b</infon>
          <location offset="79" length="7"/>
          <text>GPR109B</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gi</infon>
          <location offset="145" length="2"/>
          <text>Gi</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">g protein-coupled orphan receptors</infon>
          <location offset="148" length="34"/>
          <text>G protein-coupled orphan receptors</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>269</offset>
        <text>The B vitamin niacin is an important agent used in the treatment of dyslipidemias, but its use is limited by side effects.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">b vitamin niacin</infon>
          <location offset="273" length="16"/>
          <text>B vitamin niacin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>392</offset>
        <text>The novel role of the adjacent HM74 and HM74A genes in the metabolism of niacin may provide new targets for drug development.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">niacin</infon>
          <location offset="465" length="6"/>
          <text>niacin</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74</infon>
          <location offset="423" length="4"/>
          <text>HM74</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74a</infon>
          <location offset="432" length="5"/>
          <text>HM74A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>518</offset>
        <text>Human genetic variations in HM74 and HM74A have been reported but have not been studied in detail.</text>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74</infon>
          <location offset="546" length="4"/>
          <text>HM74</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74a</infon>
          <location offset="555" length="5"/>
          <text>HM74A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>617</offset>
        <text>These variations may play a role in the response to agents targeting receptors coded by these genes.</text>
      </sentence>
      <sentence>
        <offset>718</offset>
        <text>Here we show that many of the nonsynonymous SNPs listed in public databases for HM74 and HM74A are artifacts resulting from extensive homology between these two genes.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74</infon>
          <location offset="798" length="4"/>
          <text>HM74</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74a</infon>
          <location offset="807" length="5"/>
          <text>HM74A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>886</offset>
        <text>This may be representative of a neglected phenomenon in reporting sequences of highly homologous genes.</text>
      </sentence>
      <sentence>
        <offset>990</offset>
        <text>We provide primer sequences that permit selective amplification of the complete coding regions of HM74 and HM74A.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74</infon>
          <location offset="1088" length="4"/>
          <text>HM74</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74a</infon>
          <location offset="1097" length="5"/>
          <text>HM74A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1104</offset>
        <text>Using these primers, we show that subsequent sequencing of HM74 and HM74A reveals a novel and unique variation in the HM74A gene.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74</infon>
          <location offset="1163" length="4"/>
          <text>HM74</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74a</infon>
          <location offset="1172" length="5"/>
          <text>HM74A</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">hm74a</infon>
          <location offset="1222" length="5"/>
          <text>HM74A</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1234</offset>
        <text>Haplotype analysis suggests four SNPs can define the five major haplotypes that lie within a single haplotype block encompassing these two genes.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>12871155</id>
    <passage>
      <offset>0</offset>
      <text>Recent developments in the synthesis of acetylcholinesterase inhibitors.	The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described. These compounds are tacrine analogues that have been prepared from readily available polyfunctionalized ethyl [6-amino-5-cyano-4H-pyran]-3-carboxylates (9, 10), ethyl [6-amino-5-cyanopyridine]-3-carboxylates (7, 8), 2-amino-3-cyano-4,5-diarylfurans (17-19) and 2-amino-3-cyano-4,5-diphenylthiophene (20) via Friedlander condensation with selected ketones. These compounds are competitive and, in a few cases, non-competitive inhibitors for AChE, the most potent being compound (14), though three-fold less active than tacrine. The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine. Furthermore, the products 12 and 13 are selective and moderate AChE inhibitors.</text>
      <sentence>
        <offset>0</offset>
        <text>Recent developments in the synthesis of acetylcholinesterase inhibitors.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="40" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>73</offset>
        <text>The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pyrano[2,3-b]quinolines</infon>
          <location offset="176" length="23"/>
          <text>pyrano[2,3-b]quinolines</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[1,8]naphthyridines</infon>
          <location offset="208" length="19"/>
          <text>[1,8]naphthyridines</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines</infon>
          <location offset="236" length="58"/>
          <text>4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5h-cyclohepta[e]furo[2,3-b]pyridine</infon>
          <location offset="304" length="75"/>
          <text>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline</infon>
          <location offset="386" length="61"/>
          <text>4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5h-cyclohepta[e]thieno[2,3-b]pyridine</infon>
          <location offset="454" length="77"/>
          <text>4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="99" length="4"/>
          <text>AChE</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">butyrylcholinesterase</infon>
          <location offset="109" length="21"/>
          <text>butyrylcholinesterase</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="77" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">buche</infon>
          <location offset="132" length="5"/>
          <text>BuChE</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T20" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T19" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>552</offset>
        <text>These compounds are tacrine analogues that have been prepared from readily available polyfunctionalized ethyl [6-amino-5-cyano-4H-pyran]-3-carboxylates (9, 10), ethyl [6-amino-5-cyanopyridine]-3-carboxylates (7, 8), 2-amino-3-cyano-4,5-diarylfurans (17-19) and 2-amino-3-cyano-4,5-diphenylthiophene (20) via Friedlander condensation with selected ketones.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tacrine</infon>
          <location offset="572" length="7"/>
          <text>tacrine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethyl [6-amino-5-cyano-4h-pyran]-3-carboxylates</infon>
          <location offset="656" length="47"/>
          <text>ethyl [6-amino-5-cyano-4H-pyran]-3-carboxylates</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethyl [6-amino-5-cyanopyridine]-3-carboxylates</infon>
          <location offset="713" length="46"/>
          <text>ethyl [6-amino-5-cyanopyridine]-3-carboxylates</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-amino-3-cyano-4,5-diarylfurans</infon>
          <location offset="768" length="32"/>
          <text>2-amino-3-cyano-4,5-diarylfurans</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">2-amino-3-cyano-4,5-diphenylthiophene</infon>
          <location offset="813" length="37"/>
          <text>2-amino-3-cyano-4,5-diphenylthiophene</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ketones</infon>
          <location offset="899" length="7"/>
          <text>ketones</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>908</offset>
        <text>These compounds are competitive and, in a few cases, non-competitive inhibitors for AChE, the most potent being compound (14), though three-fold less active than tacrine.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tacrine</infon>
          <location offset="1070" length="7"/>
          <text>tacrine</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="992" length="4"/>
          <text>AChE</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T14" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1079</offset>
        <text>The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tacrine</infon>
          <location offset="1179" length="7"/>
          <text>tacrine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">buche</infon>
          <location offset="1083" length="5"/>
          <text>BuChE</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1188</offset>
        <text>Furthermore, the products 12 and 13 are selective and moderate AChE inhibitors.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="1251" length="4"/>
          <text>AChE</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>19480470</id>
    <passage>
      <offset>0</offset>
      <text>Duloxetine: a review of its use in the treatment of generalized anxiety disorder.	Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effective with regard to improvement from baseline in assessments of anxiety and functional impairment, and numerous other clinical endpoints. Longer-term duloxetine 60-120 mg once daily also demonstrated efficacy in preventing or delaying relapse in responders among patients with GAD. In addition, duloxetine was generally well tolerated, with most adverse events being of mild to moderate severity in patients with GAD in short- and longer-term trials. Additional comparative and pharmacoeconomic studies are required to position duloxetine among other selective serotonin reuptake inhibitors and SNRIs. However, available clinical data, and current treatment guidelines, indicate that duloxetine is an effective first-line treatment option for the management of GAD. Duloxetine is a potent and selective inhibitor of serotonin and noradrenaline transporters, and a weak inhibitor of dopamine transporters. It has a low affinity for neuronal receptors, such as alpha(1)- and alpha(2)-adrenergic, dopamine D(2), histamine H(1), muscarinic, opioid and serotonin receptors, as well as ion channel binding sites and other neurotransmitter transporters, such as choline and GABA transporters. It does not inhibit monoamine oxidase types A or B. The pharmacokinetics of duloxetine in healthy volunteers were dose proportional over the range of 40-120 mg once daily. Steady state was typically reached by day 3 of administration. Duloxetine may be administered without regard to food or time of day. Duloxetine is highly protein bound and is widely distributed throughout tissues. It is rapidly and extensively metabolized in the liver by cytochrome P450 (CYP) 1A2 and 2D6, and its numerous metabolites, which are inactive, are mainly excreted in the urine. The mean elimination half-life of duloxetine is approximately 12 hours. Duloxetine is a substrate for CYP1A2 and CYP2D6 and a moderate inhibitor of CYP2D6. Concomitant use of duloxetine and potent CYP1A2 inhibitors should be avoided and duloxetine should be used with caution in patients receiving drugs that are extensively metabolized by CYP2D6, particularly those with a narrow therapeutic index. Duloxetine was effective in the short-term treatment of patients with primary GAD of at least moderate severity. In four randomized, double-blind, placebo-controlled, multicentre, phase III trials, duloxetine 60-120 mg once daily for 9 or 10 weeks was significantly more effective than placebo with regard to the primary endpoint of mean change in Hamilton Anxiety Rating Scale (HAM-A) total score from baseline to study endpoint. In addition, all other endpoints were generally improved from baseline to a greater extent with duloxetine 60-120 mg once daily than with placebo. Duloxetine also improved patient role functioning (assessed using Sheehan Disability Scale global impairment functioning scores), health-related quality of life and patient well-being compared with placebo. Duloxetine was effective in patients with GAD who were aged &gt;/=65 years. Pooled results of data from the two short-term efficacy trials that also included an active comparator arm showed that the mean change in HAM-A scores with duloxetine relative to placebo were of the same magnitude as those with venlafaxine extended release versus placebo. Duloxetine 60-120 mg once daily was also more effective than placebo in preventing or delaying relapse in responders to duloxetine in a longer-term study. In this study, patients with GAD received duloxetine during a 26-week, open-label, acute treatment phase and responders were then randomized to continue on duloxetine or receive placebo during a 26-week, double-blind, continuation phase. Time to relapse was significantly longer in duloxetine recipients than in placebo recipients. In addition, significantly fewer duloxetine recipients than placebo recipients relapsed during the double-blind phase of the trial and more duloxetine recipients achieved remission. Short- (9-10 weeks) and longer-term (52 weeks) treatment with duloxetine 60-120 mg once daily was generally well tolerated in patients with GAD, with the majority of adverse events being of mild to moderate severity. Nausea, dry mouth, headache, constipation, dizziness and fatigue were among the most common treatment-emergent adverse events. The adverse event profile of duloxetine did not differ with dose or treatment duration. Significantly more patients receiving short-term duloxetine than placebo discontinued treatment because of an adverse event, with nausea being the only event that resulted in significantly more treatment discontinuations in duloxetine recipients than in placebo recipients. Serious adverse events were uncommon with both short- and longer-term duloxetine treatment. Two episodes of attempted suicide and one episode of completed suicide occurred in duloxetine recipients during the 24-week open-label phase of a longer-term trial. No deaths or suicides were reported in any of the short-term trials. Discontinuation-emergent adverse events, most commonly nausea and dizziness, occurred in up to one-third of duloxetine recipients in the short-term trials.</text>
      <sentence>
        <offset>0</offset>
        <text>Duloxetine: a review of its use in the treatment of generalized anxiety disorder.</text>
        <annotation id="T47">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="0" length="10"/>
          <text>Duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>82</offset>
        <text>Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="82" length="10"/>
          <text>Duloxetine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cymbalta(r)</infon>
          <location offset="94" length="11"/>
          <text>Cymbalta(R)</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="119" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noradrenaline</infon>
          <location offset="133" length="13"/>
          <text>noradrenaline</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">norepinephrine</infon>
          <location offset="148" length="14"/>
          <text>norepinephrine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>202</offset>
        <text>It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications.</text>
      </sentence>
      <sentence>
        <offset>304</offset>
        <text>In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effective with regard to improvement from baseline in assessments of anxiety and functional impairment, and numerous other clinical endpoints.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="361" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>540</offset>
        <text>Longer-term duloxetine 60-120 mg once daily also demonstrated efficacy in preventing or delaying relapse in responders among patients with GAD.</text>
        <annotation id="T36">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="552" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>684</offset>
        <text>In addition, duloxetine was generally well tolerated, with most adverse events being of mild to moderate severity in patients with GAD in short- and longer-term trials.</text>
        <annotation id="T43">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="697" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>853</offset>
        <text>Additional comparative and pharmacoeconomic studies are required to position duloxetine among other selective serotonin reuptake inhibitors and SNRIs.</text>
        <annotation id="T45">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="930" length="10"/>
          <text>duloxetine</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="963" length="9"/>
          <text>serotonin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1004</offset>
        <text>However, available clinical data, and current treatment guidelines, indicate that duloxetine is an effective first-line treatment option for the management of GAD.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="1086" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1168</offset>
        <text>Duloxetine is a potent and selective inhibitor of serotonin and noradrenaline transporters, and a weak inhibitor of dopamine transporters.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="1168" length="10"/>
          <text>Duloxetine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="1218" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">noradrenaline</infon>
          <location offset="1232" length="13"/>
          <text>noradrenaline</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1284" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T48">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">serotonin and noradrenaline transporters</infon>
          <location offset="1218" length="40"/>
          <text>serotonin and noradrenaline transporters</text>
        </annotation>
        <annotation id="T49">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">dopamine transporters</infon>
          <location offset="1284" length="21"/>
          <text>dopamine transporters</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1307</offset>
        <text>It has a low affinity for neuronal receptors, such as alpha(1)- and alpha(2)-adrenergic, dopamine D(2), histamine H(1), muscarinic, opioid and serotonin receptors, as well as ion channel binding sites and other neurotransmitter transporters, such as choline and GABA transporters.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">dopamine</infon>
          <location offset="1396" length="8"/>
          <text>dopamine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1411" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">serotonin</infon>
          <location offset="1450" length="9"/>
          <text>serotonin</text>
        </annotation>
        <annotation id="T50">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">neuronal receptors</infon>
          <location offset="1333" length="18"/>
          <text>neuronal receptors</text>
        </annotation>
        <annotation id="T51">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">alpha(1)- and alpha(2)-adrenergic</infon>
          <location offset="1361" length="33"/>
          <text>alpha(1)- and alpha(2)-adrenergic</text>
        </annotation>
        <annotation id="T52">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">dopamine d(2)</infon>
          <location offset="1396" length="13"/>
          <text>dopamine D(2)</text>
        </annotation>
        <annotation id="T53">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h(1)</infon>
          <location offset="1411" length="14"/>
          <text>histamine H(1)</text>
        </annotation>
        <annotation id="T54">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">muscarinic, opioid and serotonin receptors</infon>
          <location offset="1427" length="42"/>
          <text>muscarinic, opioid and serotonin receptors</text>
        </annotation>
        <annotation id="T55">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ion channel</infon>
          <location offset="1482" length="11"/>
          <text>ion channel</text>
        </annotation>
        <annotation id="T56">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">neurotransmitter transporters</infon>
          <location offset="1518" length="29"/>
          <text>neurotransmitter transporters</text>
        </annotation>
        <annotation id="T57">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">choline and gaba transporters</infon>
          <location offset="1557" length="29"/>
          <text>choline and GABA transporters</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1588</offset>
        <text>It does not inhibit monoamine oxidase types A or B.</text>
        <annotation id="T58">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">monoamine oxidase types a or b</infon>
          <location offset="1608" length="30"/>
          <text>monoamine oxidase types A or B</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1640</offset>
        <text>The pharmacokinetics of duloxetine in healthy volunteers were dose proportional over the range of 40-120 mg once daily.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="1664" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1760</offset>
        <text>Steady state was typically reached by day 3 of administration.</text>
      </sentence>
      <sentence>
        <offset>1823</offset>
        <text>Duloxetine may be administered without regard to food or time of day.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="1823" length="10"/>
          <text>Duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1893</offset>
        <text>Duloxetine is highly protein bound and is widely distributed throughout tissues.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="1893" length="10"/>
          <text>Duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1974</offset>
        <text>It is rapidly and extensively metabolized in the liver by cytochrome P450 (CYP) 1A2 and 2D6, and its numerous metabolites, which are inactive, are mainly excreted in the urine.</text>
        <annotation id="T59">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cytochrome p450 (cyp) 1a2 and 2d6</infon>
          <location offset="2032" length="33"/>
          <text>cytochrome P450 (CYP) 1A2 and 2D6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2151</offset>
        <text>The mean elimination half-life of duloxetine is approximately 12 hours.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="2185" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2223</offset>
        <text>Duloxetine is a substrate for CYP1A2 and CYP2D6 and a moderate inhibitor of CYP2D6.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="2223" length="10"/>
          <text>Duloxetine</text>
        </annotation>
        <annotation id="T60">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a2</infon>
          <location offset="2253" length="6"/>
          <text>CYP1A2</text>
        </annotation>
        <annotation id="T61">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="2264" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <annotation id="T62">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="2299" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T15" role="head"/>
          <node refid="T60" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T15" role="head"/>
          <node refid="T61" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T15" role="head"/>
          <node refid="T62" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2307</offset>
        <text>Concomitant use of duloxetine and potent CYP1A2 inhibitors should be avoided and duloxetine should be used with caution in patients receiving drugs that are extensively metabolized by CYP2D6, particularly those with a narrow therapeutic index.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="2326" length="10"/>
          <text>duloxetine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="2388" length="10"/>
          <text>duloxetine</text>
        </annotation>
        <annotation id="T63">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp1a2</infon>
          <location offset="2348" length="6"/>
          <text>CYP1A2</text>
        </annotation>
        <annotation id="T64">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cyp2d6</infon>
          <location offset="2491" length="6"/>
          <text>CYP2D6</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T17" role="head"/>
          <node refid="T64" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>2551</offset>
        <text>Duloxetine was effective in the short-term treatment of patients with primary GAD of at least moderate severity.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="2551" length="10"/>
          <text>Duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2664</offset>
        <text>In four randomized, double-blind, placebo-controlled, multicentre, phase III trials, duloxetine 60-120 mg once daily for 9 or 10 weeks was significantly more effective than placebo with regard to the primary endpoint of mean change in Hamilton Anxiety Rating Scale (HAM-A) total score from baseline to study endpoint.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="2749" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2982</offset>
        <text>In addition, all other endpoints were generally improved from baseline to a greater extent with duloxetine 60-120 mg once daily than with placebo.</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="3078" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3129</offset>
        <text>Duloxetine also improved patient role functioning (assessed using Sheehan Disability Scale global impairment functioning scores), health-related quality of life and patient well-being compared with placebo.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="3129" length="10"/>
          <text>Duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3336</offset>
        <text>Duloxetine was effective in patients with GAD who were aged &gt;/=65 years.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="3336" length="10"/>
          <text>Duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3409</offset>
        <text>Pooled results of data from the two short-term efficacy trials that also included an active comparator arm showed that the mean change in HAM-A scores with duloxetine relative to placebo were of the same magnitude as those with venlafaxine extended release versus placebo.</text>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="3565" length="10"/>
          <text>duloxetine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">venlafaxine</infon>
          <location offset="3637" length="11"/>
          <text>venlafaxine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3682</offset>
        <text>Duloxetine 60-120 mg once daily was also more effective than placebo in preventing or delaying relapse in responders to duloxetine in a longer-term study.</text>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="3682" length="10"/>
          <text>Duloxetine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="3802" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>3837</offset>
        <text>In this study, patients with GAD received duloxetine during a 26-week, open-label, acute treatment phase and responders were then randomized to continue on duloxetine or receive placebo during a 26-week, double-blind, continuation phase.</text>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="3879" length="10"/>
          <text>duloxetine</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="3993" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>4075</offset>
        <text>Time to relapse was significantly longer in duloxetine recipients than in placebo recipients.</text>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="4119" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>4169</offset>
        <text>In addition, significantly fewer duloxetine recipients than placebo recipients relapsed during the double-blind phase of the trial and more duloxetine recipients achieved remission.</text>
        <annotation id="T32">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="4202" length="10"/>
          <text>duloxetine</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="4309" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>4351</offset>
        <text>Short- (9-10 weeks) and longer-term (52 weeks) treatment with duloxetine 60-120 mg once daily was generally well tolerated in patients with GAD, with the majority of adverse events being of mild to moderate severity.</text>
        <annotation id="T34">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="4413" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>4568</offset>
        <text>Nausea, dry mouth, headache, constipation, dizziness and fatigue were among the most common treatment-emergent adverse events.</text>
      </sentence>
      <sentence>
        <offset>4695</offset>
        <text>The adverse event profile of duloxetine did not differ with dose or treatment duration.</text>
        <annotation id="T35">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="4724" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>4783</offset>
        <text>Significantly more patients receiving short-term duloxetine than placebo discontinued treatment because of an adverse event, with nausea being the only event that resulted in significantly more treatment discontinuations in duloxetine recipients than in placebo recipients.</text>
        <annotation id="T37">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="4832" length="10"/>
          <text>duloxetine</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="5007" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>5057</offset>
        <text>Serious adverse events were uncommon with both short- and longer-term duloxetine treatment.</text>
        <annotation id="T39">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="5127" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>5149</offset>
        <text>Two episodes of attempted suicide and one episode of completed suicide occurred in duloxetine recipients during the 24-week open-label phase of a longer-term trial.</text>
        <annotation id="T40">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="5232" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>5314</offset>
        <text>No deaths or suicides were reported in any of the short-term trials.</text>
      </sentence>
      <sentence>
        <offset>5383</offset>
        <text>Discontinuation-emergent adverse events, most commonly nausea and dizziness, occurred in up to one-third of duloxetine recipients in the short-term trials.</text>
        <annotation id="T42">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">duloxetine</infon>
          <location offset="5491" length="10"/>
          <text>duloxetine</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23291630</id>
    <passage>
      <offset>0</offset>
      <text>ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.	Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers. However, concomitant on-target thrombocytopenia caused by BCL-X(L) inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199. This compound inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers.</text>
      <sentence>
        <offset>0</offset>
        <text>ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abt-199</infon>
          <location offset="0" length="7"/>
          <text>ABT-199</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="32" length="5"/>
          <text>BCL-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T17" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>102</offset>
        <text>Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process.</text>
        <annotation id="T8">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">b cell cll/lymphoma 2</infon>
          <location offset="118" length="21"/>
          <text>B cell CLL/lymphoma 2</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="141" length="5"/>
          <text>BCL-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>200</offset>
        <text>This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis.</text>
      </sentence>
      <sentence>
        <offset>370</offset>
        <text>The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">navitoclax</infon>
          <location offset="477" length="10"/>
          <text>navitoclax</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="519" length="5"/>
          <text>BCL-2</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2-like 1</infon>
          <location offset="529" length="12"/>
          <text>BCL-2-like 1</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-x(l)</infon>
          <location offset="543" length="8"/>
          <text>BCL-X(L)</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="596" length="5"/>
          <text>BCL-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T11" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T10" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>635</offset>
        <text>However, concomitant on-target thrombocytopenia caused by BCL-X(L) inhibition limits the efficacy achievable with this agent.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-x(l)</infon>
          <location offset="693" length="8"/>
          <text>BCL-X(L)</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>761</offset>
        <text>Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">navitoclax</infon>
          <location offset="798" length="10"/>
          <text>navitoclax</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abt-199</infon>
          <location offset="887" length="7"/>
          <text>ABT-199</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="860" length="5"/>
          <text>BCL-2</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>896</offset>
        <text>This compound inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets.</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="933" length="5"/>
          <text>BCL-2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>992</offset>
        <text>A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">abt-199</infon>
          <location offset="1009" length="7"/>
          <text>ABT-199</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1117</offset>
        <text>These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1182" length="5"/>
          <text>BCL-2</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bcl-2</infon>
          <location offset="1223" length="5"/>
          <text>BCL-2</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23192339</id>
    <passage>
      <offset>0</offset>
      <text>Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity.	Gastric inhibitory polypeptide (GIP) is an incretin released from enteroendocrine K-cells in response to nutrient ingestion. GIP potentiates glucose-stimulated insulin secretion and induces energy accumulation into adipose tissue, resulting in obesity. Plasma GIP levels are reported to be increased in the obese state. However, the molecular mechanisms of GIP secretion and high fat diet (HFD)-induced GIP hypersecretion remain unclear, primarily due to difficulties in separating K-cells from other intestinal epithelial cells in vivo. In this study, GIP-GFP knock-in mice that enable us to visualize K-cells by enhanced GFP were established. Microarray analysis of isolated K-cells from these mice revealed that transcriptional regulatory factor X6 (Rfx6) is expressed exclusively in K-cells. In vitro experiments using the mouse intestinal cell line STC-1 showed that knockdown of Rfx6 decreased mRNA expression, cellular content, and secretion of GIP. Rfx6 bound to the region in the gip promoter that regulates gip promoter activity, and overexpression of Rfx6 increased GIP mRNA expression. HFD induced obesity and GIP hypersecretion in GIP-GFP heterozygous mice in vivo. Immunohistochemical and flow cytometry analysis showed no significant difference in K-cell number between control fat diet-fed (CFD) and HFD-fed mice. However, GIP content in the upper small intestine and GIP mRNA expression in K-cells were significantly increased in HFD-fed mice compared with those in CFD-fed mice. Furthermore, expression levels of Rfx6 mRNA were increased in K-cells of HFD-fed mice. These results suggest that Rfx6 increases GIP expression and content in K-cells and is involved in GIP hypersecretion in HFD-induced obesity.</text>
      <sentence>
        <offset>0</offset>
        <text>Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity.</text>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">transcriptional regulatory factor x6</infon>
          <location offset="0" length="36"/>
          <text>Transcriptional regulatory factor X6</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="148" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rfx6</infon>
          <location offset="38" length="4"/>
          <text>Rfx6</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gastric inhibitory polypeptide</infon>
          <location offset="54" length="30"/>
          <text>gastric inhibitory polypeptide</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="86" length="3"/>
          <text>GIP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>201</offset>
        <text>Gastric inhibitory polypeptide (GIP) is an incretin released from enteroendocrine K-cells in response to nutrient ingestion.</text>
        <annotation id="T2">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gastric inhibitory polypeptide</infon>
          <location offset="201" length="30"/>
          <text>Gastric inhibitory polypeptide</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="233" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">incretin</infon>
          <location offset="244" length="8"/>
          <text>incretin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>326</offset>
        <text>GIP potentiates glucose-stimulated insulin secretion and induces energy accumulation into adipose tissue, resulting in obesity.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">glucose</infon>
          <location offset="342" length="7"/>
          <text>glucose</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="326" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">insulin</infon>
          <location offset="361" length="7"/>
          <text>insulin</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>454</offset>
        <text>Plasma GIP levels are reported to be increased in the obese state.</text>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="461" length="3"/>
          <text>GIP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>521</offset>
        <text>However, the molecular mechanisms of GIP secretion and high fat diet (HFD)-induced GIP hypersecretion remain unclear, primarily due to difficulties in separating K-cells from other intestinal epithelial cells in vivo.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="558" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="604" length="3"/>
          <text>GIP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>739</offset>
        <text>In this study, GIP-GFP knock-in mice that enable us to visualize K-cells by enhanced GFP were established.</text>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="754" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gfp</infon>
          <location offset="758" length="3"/>
          <text>GFP</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gfp</infon>
          <location offset="824" length="3"/>
          <text>GFP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>846</offset>
        <text>Microarray analysis of isolated K-cells from these mice revealed that transcriptional regulatory factor X6 (Rfx6) is expressed exclusively in K-cells.</text>
        <annotation id="T25">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">transcriptional regulatory factor x6</infon>
          <location offset="916" length="36"/>
          <text>transcriptional regulatory factor X6</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rfx6</infon>
          <location offset="954" length="4"/>
          <text>Rfx6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>997</offset>
        <text>In vitro experiments using the mouse intestinal cell line STC-1 showed that knockdown of Rfx6 decreased mRNA expression, cellular content, and secretion of GIP.</text>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rfx6</infon>
          <location offset="1086" length="4"/>
          <text>Rfx6</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="1153" length="3"/>
          <text>GIP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1158</offset>
        <text>Rfx6 bound to the region in the gip promoter that regulates gip promoter activity, and overexpression of Rfx6 increased GIP mRNA expression.</text>
        <annotation id="T3">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gip promoter</infon>
          <location offset="1218" length="12"/>
          <text>gip promoter</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rfx6</infon>
          <location offset="1263" length="4"/>
          <text>Rfx6</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="1278" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rfx6</infon>
          <location offset="1158" length="4"/>
          <text>Rfx6</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gip promoter</infon>
          <location offset="1190" length="12"/>
          <text>gip promoter</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1299</offset>
        <text>HFD induced obesity and GIP hypersecretion in GIP-GFP heterozygous mice in vivo.</text>
        <annotation id="T6">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="1323" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="1345" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">gfp</infon>
          <location offset="1349" length="3"/>
          <text>GFP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1380</offset>
        <text>Immunohistochemical and flow cytometry analysis showed no significant difference in K-cell number between control fat diet-fed (CFD) and HFD-fed mice.</text>
      </sentence>
      <sentence>
        <offset>1531</offset>
        <text>However, GIP content in the upper small intestine and GIP mRNA expression in K-cells were significantly increased in HFD-fed mice compared with those in CFD-fed mice.</text>
        <annotation id="T10">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="1540" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="1585" length="3"/>
          <text>GIP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1698</offset>
        <text>Furthermore, expression levels of Rfx6 mRNA were increased in K-cells of HFD-fed mice.</text>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rfx6</infon>
          <location offset="1732" length="4"/>
          <text>Rfx6</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1785</offset>
        <text>These results suggest that Rfx6 increases GIP expression and content in K-cells and is involved in GIP hypersecretion in HFD-induced obesity.</text>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">rfx6</infon>
          <location offset="1812" length="4"/>
          <text>Rfx6</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="1827" length="3"/>
          <text>GIP</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">gip</infon>
          <location offset="1884" length="3"/>
          <text>GIP</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23468426</id>
    <passage>
      <offset>0</offset>
      <text>The interaction of isopenicillin N synthase with homologated substrate analogues δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-Xaa characterised by protein crystallography.	Isopenicillin N synthase (IPNS) converts the linear tripeptide δ-(L-α-aminoadipoyl)-L-cysteinyl-D-valine (ACV) into bicyclic isopenicillin N (IPN) in the central step in the biosynthesis of penicillin and cephalosporin antibiotics. Solution-phase incubation experiments have shown that IPNS turns over analogues with a diverse range of side chains in the third (valinyl) position of the substrate, but copes less well with changes in the second (cysteinyl) residue. IPNS thus converts the homologated tripeptides δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-valine (AhCV) and δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-allylglycine (AhCaG) into monocyclic hydroxy-lactam products; this suggests that the additional methylene unit in these substrates induces conformational changes that preclude second ring closure after initial lactam formation. To investigate this and solution-phase results with other tripeptides δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-Xaa, we have crystallised AhCV and δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-S-methylcysteine (AhCmC) with IPNS and solved crystal structures for the resulting complexes. The IPNS:Fe(II):AhCV complex shows diffuse electron density for several regions of the substrate, revealing considerable conformational freedom within the active site. The substrate is more clearly resolved in the IPNS:Fe(II):AhCmC complex, by virtue of thioether coordination to iron. AhCmC occupies two distinct conformations, both distorted relative to the natural substrate ACV, in order to accommodate the extra methylene group in the second residue. Attempts to turn these substrates over within crystalline IPNS using hyperbaric oxygenation give rise to product mixtures.</text>
      <sentence>
        <offset>0</offset>
        <text>The interaction of isopenicillin N synthase with homologated substrate analogues δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-Xaa characterised by protein crystallography.</text>
        <annotation id="T30">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isopenicillin n</infon>
          <location offset="19" length="15"/>
          <text>isopenicillin N</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">δ-(l-α-aminoadipoyl)-l-homocysteinyl-d-xaa</infon>
          <location offset="81" length="42"/>
          <text>δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-Xaa</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">isopenicillin n synthase</infon>
          <location offset="19" length="24"/>
          <text>isopenicillin N synthase</text>
        </annotation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T31" role="head"/>
          <node refid="T40" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>166</offset>
        <text>Isopenicillin N synthase (IPNS) converts the linear tripeptide δ-(L-α-aminoadipoyl)-L-cysteinyl-D-valine (ACV) into bicyclic isopenicillin N (IPN) in the central step in the biosynthesis of penicillin and cephalosporin antibiotics.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isopenicillin n</infon>
          <location offset="166" length="15"/>
          <text>Isopenicillin N</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acv</infon>
          <location offset="272" length="3"/>
          <text>ACV</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">isopenicillin n</infon>
          <location offset="291" length="15"/>
          <text>isopenicillin N</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ipn</infon>
          <location offset="308" length="3"/>
          <text>IPN</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">penicillin</infon>
          <location offset="356" length="10"/>
          <text>penicillin</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cephalosporin</infon>
          <location offset="371" length="13"/>
          <text>cephalosporin</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">δ-(l-α-aminoadipoyl)-l-cysteinyl-d-valine</infon>
          <location offset="229" length="41"/>
          <text>δ-(L-α-aminoadipoyl)-L-cysteinyl-D-valine</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">isopenicillin n synthase</infon>
          <location offset="166" length="24"/>
          <text>Isopenicillin N synthase</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ipns</infon>
          <location offset="192" length="4"/>
          <text>IPNS</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T12" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T16" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T12" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T6" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T16" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T23" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T3" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T15" role="head"/>
          <node refid="T37" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>398</offset>
        <text>Solution-phase incubation experiments have shown that IPNS turns over analogues with a diverse range of side chains in the third (valinyl) position of the substrate, but copes less well with changes in the second (cysteinyl) residue.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">valinyl</infon>
          <location offset="528" length="7"/>
          <text>valinyl</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">cysteinyl</infon>
          <location offset="612" length="9"/>
          <text>cysteinyl</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ipns</infon>
          <location offset="452" length="4"/>
          <text>IPNS</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>632</offset>
        <text>IPNS thus converts the homologated tripeptides δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-valine (AhCV) and δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-allylglycine (AhCaG) into monocyclic hydroxy-lactam products; this suggests that the additional methylene unit in these substrates induces conformational changes that preclude second ring closure after initial lactam formation.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">δ-(l-α-aminoadipoyl)-l-homocysteinyl-d-valine</infon>
          <location offset="679" length="45"/>
          <text>δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-valine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahcv</infon>
          <location offset="726" length="4"/>
          <text>AhCV</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">δ-(l-α-aminoadipoyl)-l-homocysteinyl-d-allylglycine</infon>
          <location offset="736" length="51"/>
          <text>δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-allylglycine</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahcag</infon>
          <location offset="789" length="5"/>
          <text>AhCaG</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">monocyclic hydroxy-lactam</infon>
          <location offset="801" length="25"/>
          <text>monocyclic hydroxy-lactam</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methylene</infon>
          <location offset="871" length="9"/>
          <text>methylene</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">lactam</infon>
          <location offset="985" length="6"/>
          <text>lactam</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ipns</infon>
          <location offset="632" length="4"/>
          <text>IPNS</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T26" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T21" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T19" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T24" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T22" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T20" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">SUBSTRATE</infon>
          <node refid="T25" role="head"/>
          <node refid="T39" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1003</offset>
        <text>To investigate this and solution-phase results with other tripeptides δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-Xaa, we have crystallised AhCV and δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-S-methylcysteine (AhCmC) with IPNS and solved crystal structures for the resulting complexes.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahcmc</infon>
          <location offset="1204" length="5"/>
          <text>AhCmC</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">δ-(l-α-aminoadipoyl)-l-homocysteinyl-d-xaa</infon>
          <location offset="1073" length="42"/>
          <text>δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-Xaa</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahcv</infon>
          <location offset="1138" length="4"/>
          <text>AhCV</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">δ-(l-α-aminoadipoyl)-l-homocysteinyl-d-s-methylcysteine</infon>
          <location offset="1147" length="55"/>
          <text>δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-S-methylcysteine</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ipns</infon>
          <location offset="1216" length="4"/>
          <text>IPNS</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T28" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T29" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1280</offset>
        <text>The IPNS:Fe(II):AhCV complex shows diffuse electron density for several regions of the substrate, revealing considerable conformational freedom within the active site.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fe(ii)</infon>
          <location offset="1289" length="6"/>
          <text>Fe(II)</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahcv</infon>
          <location offset="1296" length="4"/>
          <text>AhCV</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ipns</infon>
          <location offset="1284" length="4"/>
          <text>IPNS</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T4" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1448</offset>
        <text>The substrate is more clearly resolved in the IPNS:Fe(II):AhCmC complex, by virtue of thioether coordination to iron.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fe(ii)</infon>
          <location offset="1499" length="6"/>
          <text>Fe(II)</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahcmc</infon>
          <location offset="1506" length="5"/>
          <text>AhCmC</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">thioether</infon>
          <location offset="1534" length="9"/>
          <text>thioether</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">iron</infon>
          <location offset="1560" length="4"/>
          <text>iron</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ipns</infon>
          <location offset="1494" length="4"/>
          <text>IPNS</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1566</offset>
        <text>AhCmC occupies two distinct conformations, both distorted relative to the natural substrate ACV, in order to accommodate the extra methylene group in the second residue.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ahcmc</infon>
          <location offset="1566" length="5"/>
          <text>AhCmC</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acv</infon>
          <location offset="1658" length="3"/>
          <text>ACV</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">methylene</infon>
          <location offset="1697" length="9"/>
          <text>methylene</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1736</offset>
        <text>Attempts to turn these substrates over within crystalline IPNS using hyperbaric oxygenation give rise to product mixtures.</text>
        <annotation id="T36">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ipns</infon>
          <location offset="1794" length="4"/>
          <text>IPNS</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>15765929</id>
    <passage>
      <offset>0</offset>
      <text>Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients.	Oxidative stress associated with increased presence of neutrophils is an important feature of inflammatory airways diseases like asthma or chronic obstructive pulmonary disease. We studied the in vitro effect of piclamilast (RP73401), a selective phosphodiesterase (PDE)-4 inhibitor, compared to theophylline and prednisolone, on respiratory burst of sputum cells from mild asthmatics and COPD patients. Sputum cells were harvested from mild asthmatics and stable COPD patients and treated with piclamilast, theophylline or prednisolone. Respiratory burst was assessed by luminol-dependent chemoluminescence after stimulation with 10 microM n-formyl-met-leu-phe (FMLP). Piclamilast inhibited FMLP-induced respiratory burst of sputum cells in a concentration-dependent manner (asthma: EC50 approximately 100 nM, max. inhibition: 97.5+/-5% at 100 microM; COPD: EC50 approximately 1 microM, max. inhibition: 70.6+/-4.5% at 100 microM), whereas maximal inhibition observed with theophylline (asthma: max. inhib. 27+/-15%; COPD: 6+/-2%, both p &lt; 0.05 vs. piclamilast) and prednisolone (asthma: 16+/-6%; COPD: 7.8+/-6.2%, both p &lt; 0.05 vs. piclamilast) was weaker. Inhibition by piclamilast was largely reversed through pretreatment of cells with the adenylcyclase inhibitor SQ22536. We concluded that piclamilast, a selective PDE-4 inhibitor, attenuates the respiratory burst of sputum cells from mild asthmatics and COPD patients in vitro. These data underline the potential of PDE-4 inhibition as a novel therapeutic approach to inflammatory airway diseases like asthma or COPD.</text>
      <sentence>
        <offset>0</offset>
        <text>Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients.</text>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piclamilast</infon>
          <location offset="11" length="11"/>
          <text>piclamilast</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphodiesterase-4</infon>
          <location offset="36" length="19"/>
          <text>phosphodiesterase-4</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T26" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>149</offset>
        <text>Oxidative stress associated with increased presence of neutrophils is an important feature of inflammatory airways diseases like asthma or chronic obstructive pulmonary disease.</text>
      </sentence>
      <sentence>
        <offset>327</offset>
        <text>We studied the in vitro effect of piclamilast (RP73401), a selective phosphodiesterase (PDE)-4 inhibitor, compared to theophylline and prednisolone, on respiratory burst of sputum cells from mild asthmatics and COPD patients.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piclamilast</infon>
          <location offset="361" length="11"/>
          <text>piclamilast</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rp73401</infon>
          <location offset="374" length="7"/>
          <text>RP73401</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">theophylline</infon>
          <location offset="445" length="12"/>
          <text>theophylline</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="462" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">phosphodiesterase (pde)-4</infon>
          <location offset="396" length="25"/>
          <text>phosphodiesterase (PDE)-4</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T7" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T24" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>553</offset>
        <text>Sputum cells were harvested from mild asthmatics and stable COPD patients and treated with piclamilast, theophylline or prednisolone.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piclamilast</infon>
          <location offset="644" length="11"/>
          <text>piclamilast</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">theophylline</infon>
          <location offset="657" length="12"/>
          <text>theophylline</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="673" length="12"/>
          <text>prednisolone</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>687</offset>
        <text>Respiratory burst was assessed by luminol-dependent chemoluminescence after stimulation with 10 microM n-formyl-met-leu-phe (FMLP).</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">luminol</infon>
          <location offset="721" length="7"/>
          <text>luminol</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">n-formyl-met-leu-phe</infon>
          <location offset="790" length="20"/>
          <text>n-formyl-met-leu-phe</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fmlp</infon>
          <location offset="812" length="4"/>
          <text>FMLP</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">n-formyl-met-leu-phe</infon>
          <location offset="790" length="20"/>
          <text>n-formyl-met-leu-phe</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>819</offset>
        <text>Piclamilast inhibited FMLP-induced respiratory burst of sputum cells in a concentration-dependent manner (asthma: EC50 approximately 100 nM, max.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piclamilast</infon>
          <location offset="819" length="11"/>
          <text>Piclamilast</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fmlp</infon>
          <location offset="841" length="4"/>
          <text>FMLP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>965</offset>
        <text>inhibition: 97.5+/-5% at 100 microM; COPD: EC50 approximately 1 microM, max.</text>
      </sentence>
      <sentence>
        <offset>1042</offset>
        <text>inhibition: 70.6+/-4.5% at 100 microM), whereas maximal inhibition observed with theophylline (asthma: max. inhib.</text>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">theophylline</infon>
          <location offset="1123" length="12"/>
          <text>theophylline</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1157</offset>
        <text>27+/-15%; COPD: 6+/-2%, both p &lt; 0.05 vs. piclamilast) and prednisolone (asthma: 16+/-6%; COPD: 7.8+/-6.2%, both p &lt; 0.05 vs. piclamilast) was weaker.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piclamilast</infon>
          <location offset="1199" length="11"/>
          <text>piclamilast</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">prednisolone</infon>
          <location offset="1216" length="12"/>
          <text>prednisolone</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piclamilast</infon>
          <location offset="1283" length="11"/>
          <text>piclamilast</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1308</offset>
        <text>Inhibition by piclamilast was largely reversed through pretreatment of cells with the adenylcyclase inhibitor SQ22536.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piclamilast</infon>
          <location offset="1322" length="11"/>
          <text>piclamilast</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sq22536</infon>
          <location offset="1418" length="7"/>
          <text>SQ22536</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">adenylcyclase</infon>
          <location offset="1394" length="13"/>
          <text>adenylcyclase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1427</offset>
        <text>We concluded that piclamilast, a selective PDE-4 inhibitor, attenuates the respiratory burst of sputum cells from mild asthmatics and COPD patients in vitro.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">piclamilast</infon>
          <location offset="1445" length="11"/>
          <text>piclamilast</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pde-4</infon>
          <location offset="1470" length="5"/>
          <text>PDE-4</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1585</offset>
        <text>These data underline the potential of PDE-4 inhibition as a novel therapeutic approach to inflammatory airway diseases like asthma or COPD.</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">pde-4</infon>
          <location offset="1623" length="5"/>
          <text>PDE-4</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>6146346</id>
    <passage>
      <offset>0</offset>
      <text>Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.	The efficacy of astemizole, a new, long acting, oral histamine H1-receptor antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982. Sixty-three patients with a positive skin prick test to grass pollen and current symptoms participated in an 8 week, double-blind, randomized study. Astemizole, 10 mg, was significantly better than placebo in alleviating both nose (P less than 0.05) and eye (P less than 0.01) symptoms despite significantly greater use of the reserve medication, clemastine, by the placebo group (P less than 0.003). There was a lag period of 5 days after initiation of therapy before treatment benefit became manifest. Subdivision of nasal symptoms indicated significant improvement compared to placebo over the 8 weeks for sneezing (P less than 0.05) and runny nose (P less than 0.05) but not blocked nose. The absence of effect on nasal blockage was confirmed by parallel measurement of nasal calibre by body plethysmography. The antihistaminic potency of astemizole was indicated by an 80% inhibition of the histamine induced skin weal response after 8 weeks therapy. A positive correlation was found between serum drug levels and % inhibition of histamine skin weal (r = 0.64, P less than 0.001). Astemizole was free from adverse sedative or anticholinergic effects but did cause a mean increase in weight of 1.3 kg (P less than 0.01) after 8 weeks therapy, not found with placebo.</text>
      <sentence>
        <offset>0</offset>
        <text>Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="0" length="10"/>
          <text>Astemizole</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="110" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="21" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1-receptor</infon>
          <location offset="21" length="21"/>
          <text>histamine H1-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T9" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>182</offset>
        <text>The efficacy of astemizole, a new, long acting, oral histamine H1-receptor antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="198" length="10"/>
          <text>astemizole</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="235" length="9"/>
          <text>histamine</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">histamine h1-receptor</infon>
          <location offset="235" length="21"/>
          <text>histamine H1-receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>390</offset>
        <text>Sixty-three patients with a positive skin prick test to grass pollen and current symptoms participated in an 8 week, double-blind, randomized study.</text>
      </sentence>
      <sentence>
        <offset>539</offset>
        <text>Astemizole, 10 mg, was significantly better than placebo in alleviating both nose (P less than 0.05) and eye (P less than 0.01) symptoms despite significantly greater use of the reserve medication, clemastine, by the placebo group (P less than 0.003).</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="539" length="10"/>
          <text>Astemizole</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">clemastine</infon>
          <location offset="737" length="10"/>
          <text>clemastine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>791</offset>
        <text>There was a lag period of 5 days after initiation of therapy before treatment benefit became manifest.</text>
      </sentence>
      <sentence>
        <offset>894</offset>
        <text>Subdivision of nasal symptoms indicated significant improvement compared to placebo over the 8 weeks for sneezing (P less than 0.05) and runny nose (P less than 0.05) but not blocked nose.</text>
      </sentence>
      <sentence>
        <offset>1083</offset>
        <text>The absence of effect on nasal blockage was confirmed by parallel measurement of nasal calibre by body plethysmography.</text>
      </sentence>
      <sentence>
        <offset>1203</offset>
        <text>The antihistaminic potency of astemizole was indicated by an 80% inhibition of the histamine induced skin weal response after 8 weeks therapy.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="1233" length="10"/>
          <text>astemizole</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1286" length="9"/>
          <text>histamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1346</offset>
        <text>A positive correlation was found between serum drug levels and % inhibition of histamine skin weal (r = 0.64, P less than 0.001).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">histamine</infon>
          <location offset="1425" length="9"/>
          <text>histamine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1476</offset>
        <text>Astemizole was free from adverse sedative or anticholinergic effects but did cause a mean increase in weight of 1.3 kg (P less than 0.01) after 8 weeks therapy, not found with placebo.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">astemizole</infon>
          <location offset="1476" length="10"/>
          <text>Astemizole</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23211364</id>
    <passage>
      <offset>0</offset>
      <text>AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.	Candesartan is an angiotensin II type 1 receptor blocker (ARB) that has been to shown to limit ischemic stroke and improve stroke outcome. In experimental stroke, candesartan induces a proangiogenic effect that is partly attributable to vascular endothelial growth factor. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family that has been reported to have angiogenic effects and play an important role in recovery after stroke. The purpose of this investigation was to determine the role of BDNF in the proangiogenic effect of candesartan in the brain under hypertensive conditions. Accordingly, spontaneously hypertensive rats were treated with candesartan, and brain tissue samples were collected for quantification of BDNF expression. In addition, human cerebromicrovascular endothelial cells were treated with either low-dose (1 ƒM) or high-dose (1 µM) angiotensin II alone or in combination with candesartan (0.16 µM) to assess the effect of candesartan treatment and BDNF involvement in the behavior of endothelial cells. Candesartan significantly increased the expression of BDNF in the SHR (P &lt; 0.05). In addition, candesartan reversed the antiangiogenic effect of the 1-µM dose of AngII (P = 0.0001). The observed effects of candesartan were ablated by neutralizing the effects of BDNF. Treatment with the AT2 antagonist PD-123319 significantly reduced tube-like formation in endothelial cells. AT2 stimulation induced the BDNF expression and migration (P &lt; 0.05). In conclusion, candesartan exerts a proangiogenic effect on brain microvascular endothelial cells treated with angiotensin II. This response is attributable to increased BDNF expression and is mediated through stimulation of the AT2 receptor.</text>
      <sentence>
        <offset>0</offset>
        <text>AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.</text>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at1 receptor</infon>
          <location offset="0" length="12"/>
          <text>AT1 receptor</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bdnf</infon>
          <location offset="55" length="4"/>
          <text>BDNF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>78</offset>
        <text>Candesartan is an angiotensin II type 1 receptor blocker (ARB) that has been to shown to limit ischemic stroke and improve stroke outcome.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="78" length="11"/>
          <text>Candesartan</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii type 1 receptor</infon>
          <location offset="96" length="30"/>
          <text>angiotensin II type 1 receptor</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T21" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>217</offset>
        <text>In experimental stroke, candesartan induces a proangiogenic effect that is partly attributable to vascular endothelial growth factor.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="241" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">vascular endothelial growth factor</infon>
          <location offset="315" length="34"/>
          <text>vascular endothelial growth factor</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>351</offset>
        <text>Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family that has been reported to have angiogenic effects and play an important role in recovery after stroke.</text>
        <annotation id="T23">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">brain-derived neurotrophic factor</infon>
          <location offset="351" length="33"/>
          <text>Brain-derived neurotrophic factor</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bdnf</infon>
          <location offset="386" length="4"/>
          <text>BDNF</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">neurotrophin</infon>
          <location offset="411" length="12"/>
          <text>neurotrophin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>534</offset>
        <text>The purpose of this investigation was to determine the role of BDNF in the proangiogenic effect of candesartan in the brain under hypertensive conditions.</text>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bdnf</infon>
          <location offset="597" length="4"/>
          <text>BDNF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>689</offset>
        <text>Accordingly, spontaneously hypertensive rats were treated with candesartan, and brain tissue samples were collected for quantification of BDNF expression.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="752" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bdnf</infon>
          <location offset="827" length="4"/>
          <text>BDNF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>844</offset>
        <text>In addition, human cerebromicrovascular endothelial cells were treated with either low-dose (1 ƒM) or high-dose (1 µM) angiotensin II alone or in combination with candesartan (0.16 µM) to assess the effect of candesartan treatment and BDNF involvement in the behavior of endothelial cells.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="1007" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="1053" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bdnf</infon>
          <location offset="1079" length="4"/>
          <text>BDNF</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="963" length="14"/>
          <text>angiotensin II</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1134</offset>
        <text>Candesartan significantly increased the expression of BDNF in the SHR (P &lt; 0.05).</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="1134" length="11"/>
          <text>Candesartan</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bdnf</infon>
          <location offset="1188" length="4"/>
          <text>BDNF</text>
        </annotation>
        <relation id="">
          <infon key="type">INDIRECT-UPREGULATOR</infon>
          <node refid="T2" role="head"/>
          <node refid="T12" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1216</offset>
        <text>In addition, candesartan reversed the antiangiogenic effect of the 1-µM dose of AngII (P = 0.0001).</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="1229" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angii</infon>
          <location offset="1296" length="5"/>
          <text>AngII</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1316</offset>
        <text>The observed effects of candesartan were ablated by neutralizing the effects of BDNF.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="1340" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bdnf</infon>
          <location offset="1396" length="4"/>
          <text>BDNF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1402</offset>
        <text>Treatment with the AT2 antagonist PD-123319 significantly reduced tube-like formation in endothelial cells.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">pd-123319</infon>
          <location offset="1436" length="9"/>
          <text>PD-123319</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at2</infon>
          <location offset="1421" length="3"/>
          <text>AT2</text>
        </annotation>
        <relation id="">
          <infon key="type">ANTAGONIST</infon>
          <node refid="T5" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1510</offset>
        <text>AT2 stimulation induced the BDNF expression and migration (P &lt; 0.05).</text>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at2</infon>
          <location offset="1510" length="3"/>
          <text>AT2</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bdnf</infon>
          <location offset="1538" length="4"/>
          <text>BDNF</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1580</offset>
        <text>In conclusion, candesartan exerts a proangiogenic effect on brain microvascular endothelial cells treated with angiotensin II.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">candesartan</infon>
          <location offset="1595" length="11"/>
          <text>candesartan</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">angiotensin ii</infon>
          <location offset="1691" length="14"/>
          <text>angiotensin II</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1707</offset>
        <text>This response is attributable to increased BDNF expression and is mediated through stimulation of the AT2 receptor.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">bdnf</infon>
          <location offset="1750" length="4"/>
          <text>BDNF</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">at2 receptor</infon>
          <location offset="1809" length="12"/>
          <text>AT2 receptor</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23454297</id>
    <passage>
      <offset>0</offset>
      <text>Caffeic acid treatment alters the extracellular adenine nucleotide hydrolysis in platelets and lymphocytes of adult rats.	This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation. Animals were divided into five groups: I (control); II (oil); III (caffeic acid 10mg/kg); IV (caffeic acid 50mg/kg); and V (caffeic acid 100mg/kg). Animals were treated with caffeic acid diluted in oil for 30days. In platelets, caffeic acid decreased the ATP hydrolysis and increased ADP hydrolysis in groups III, IV and V when compared to control (P&lt;0.05). The 5'-nucleotidase activity was decreased, while E-NPP and ADA activities were increased in platelets of rats of groups III, IV and V (P&lt;0.05). Caffeic acid reduced significantly the platelet aggregation in the animals of groups III, IV and V in relation to group I (P&lt;0.05). In lymphocytes, the NTPDase and ADA activities were increased in all groups treated with caffeic acid when compared to control (P&lt;0.05). These findings demonstrated that the enzymes were altered in tissues by caffeic acid and this compound decreased the platelet aggregation suggesting that caffeic acid should be considered a potentially therapeutic agent in disorders related to the purinergic system.</text>
      <sentence>
        <offset>0</offset>
        <text>Caffeic acid treatment alters the extracellular adenine nucleotide hydrolysis in platelets and lymphocytes of adult rats.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="0" length="12"/>
          <text>Caffeic acid</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenine nucleotide</infon>
          <location offset="48" length="18"/>
          <text>adenine nucleotide</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>122</offset>
        <text>This study evaluated the effects of caffeic acid on ectonucleotidase activities such as NTPDase (nucleoside triphosphate diphosphohydrolase), Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase), 5'-nucleotidase and adenosine deaminase (ADA) in platelets and lymphocytes of rats, as well as in the profile of platelet aggregation.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleotide</infon>
          <location offset="274" length="10"/>
          <text>nucleotide</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adenosine</infon>
          <location offset="341" length="9"/>
          <text>adenosine</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="158" length="12"/>
          <text>caffeic acid</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">nucleoside triphosphate</infon>
          <location offset="219" length="23"/>
          <text>nucleoside triphosphate</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ecto-npp (nucleotide pyrophosphatase/phosphodiesterase)</infon>
          <location offset="264" length="55"/>
          <text>Ecto-NPP (nucleotide pyrophosphatase/phosphodiesterase)</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">5'-nucleotidase</infon>
          <location offset="321" length="15"/>
          <text>5'-nucleotidase</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">adenosine deaminase</infon>
          <location offset="341" length="19"/>
          <text>adenosine deaminase</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ada</infon>
          <location offset="362" length="3"/>
          <text>ADA</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ntpdase</infon>
          <location offset="210" length="7"/>
          <text>NTPDase</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">nucleoside triphosphate diphosphohydrolase</infon>
          <location offset="219" length="42"/>
          <text>nucleoside triphosphate diphosphohydrolase</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>456</offset>
        <text>Animals were divided into five groups: I (control); II (oil); III (caffeic acid 10mg/kg); IV (caffeic acid 50mg/kg); and V (caffeic acid 100mg/kg).</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="523" length="12"/>
          <text>caffeic acid</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="550" length="12"/>
          <text>caffeic acid</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="580" length="12"/>
          <text>caffeic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>604</offset>
        <text>Animals were treated with caffeic acid diluted in oil for 30days.</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="630" length="12"/>
          <text>caffeic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>670</offset>
        <text>In platelets, caffeic acid decreased the ATP hydrolysis and increased ADP hydrolysis in groups III, IV and V when compared to control (P&lt;0.05).</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="684" length="12"/>
          <text>caffeic acid</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">atp</infon>
          <location offset="711" length="3"/>
          <text>ATP</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">adp</infon>
          <location offset="740" length="3"/>
          <text>ADP</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>814</offset>
        <text>The 5'-nucleotidase activity was decreased, while E-NPP and ADA activities were increased in platelets of rats of groups III, IV and V (P&lt;0.05).</text>
        <annotation id="T23">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">e-npp</infon>
          <location offset="864" length="5"/>
          <text>E-NPP</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ada</infon>
          <location offset="874" length="3"/>
          <text>ADA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>959</offset>
        <text>Caffeic acid reduced significantly the platelet aggregation in the animals of groups III, IV and V in relation to group I (P&lt;0.05).</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="959" length="12"/>
          <text>Caffeic acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1091</offset>
        <text>In lymphocytes, the NTPDase and ADA activities were increased in all groups treated with caffeic acid when compared to control (P&lt;0.05).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="1180" length="12"/>
          <text>caffeic acid</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ada</infon>
          <location offset="1123" length="3"/>
          <text>ADA</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">ntpdase</infon>
          <location offset="1111" length="7"/>
          <text>NTPDase</text>
        </annotation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T18" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">ACTIVATOR</infon>
          <node refid="T1" role="head"/>
          <node refid="T27" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1228</offset>
        <text>These findings demonstrated that the enzymes were altered in tissues by caffeic acid and this compound decreased the platelet aggregation suggesting that caffeic acid should be considered a potentially therapeutic agent in disorders related to the purinergic system.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="1300" length="12"/>
          <text>caffeic acid</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">caffeic acid</infon>
          <location offset="1382" length="12"/>
          <text>caffeic acid</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>17524933</id>
    <passage>
      <offset>0</offset>
      <text>An assay for the determination of sirolimus levels in the lymphocyte of transplant patients.	UNLABELLED: Both tacrolimus (TAC) and sirolimus (SRL) bind to the same immunophilin FKBP12; however, their mechanisms of action are distinct. SRL inhibits mammalian target of rapamycin (TOR), which is an enzyme critical to the immune function. TOR inhibition blocks the signal that mediates T-cell proliferation by preventing cell-cycle progression from G1 to S phase. Moreover, TOR inhibition results in a decrease in antibody production by blocking B-cell proliferation and maturation into antibody producing cells. The use of SRL has resulted in a decrease in the number of rejection episodes. As with other immunosuppressive agents, SRL can cause dose-related side effects, the most notable of which are hypercholesterolemia, hyperlipidemia, anemia, and thrombocytopenia. Thus, therapeutic drug monitoring to assess efficacy and toxicity has became a necessity. SRL blood levels do not correlate with its bioactivity and are affected by the concomitant use of other immunosuppressive drugs. To determine the bioactivity of SRL we have developed an assay to determine the level of Sirolimus per lymphocyte of transplant patients. The levels were correlated with lymphocyte count. METHODS: Whole blood samples from patients on SRL were collected in Ethylene Diamine Tetra-acetic acid (EDTA) vacutainer tubes. Immediately the lymphocytes from 2 mL of blood were separated using 1.5 mL of Ficoll gradient, by centrifugation for 30 minutes at 2500 RPM. The lymphocytes were washed three times with phosphate-bufferd saline and the pellet suspended in 150 microL of Middle East research institute (MERI) drug extraction solution (Beirut, Lebanon), which was then added to 300 microL of IMx solublizing reagent. The cytoplasmic SRL concentrations in lymphocytes were measured using kits supplied from Abbott diagnostics or by high-performance liquid tomography. A corresponding whole blood sample from each patient was used to measure blood levels. To determine the level per lymphocyte, the value obtained was divided by the number of lymphocytes and expressed as Pg/cell. A pharmacokinetic profile for both blood and lymphocytes was constructed for each patient using data corresponding to predose C(0), 1 hour (C(1)) and 2 hours (C(2)) after the dose. The lymphocyte enumeration for C(0), C(1), and C(2) was performed using the FACS Calibur Flow Cytometer from Becton Dickinson. The average dose was 2.86 +/- 1.27 mg/d with a C(0) = 8.05 +/- 4.24, C(1) = 21.9 +/- 8.9 ng/mL, and C(2) = 23 +/- 0.03 ng/mL. Although there was a significant correlation (P=.0975) between the dose and C(0), there was no correlation between the dose and C(0) level on the lymphocyte count P=.897. However, there was a strong correlation between SRL lymphocyte levels (pg/cell) and the lymphocyte count (r(2)=.6.06). The higher the concentration of the drug the lower the lymphocyte counts. The assay is sensitive to within 0.45 pg/cell, reproducible with a coefficient of variance (CV) of 6.4% within assay and 7.5% for intraassay.</text>
      <sentence>
        <offset>0</offset>
        <text>An assay for the determination of sirolimus levels in the lymphocyte of transplant patients.</text>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sirolimus</infon>
          <location offset="34" length="9"/>
          <text>sirolimus</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>93</offset>
        <text>UNLABELLED: Both tacrolimus (TAC) and sirolimus (SRL) bind to the same immunophilin FKBP12; however, their mechanisms of action are distinct.</text>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tacrolimus</infon>
          <location offset="110" length="10"/>
          <text>tacrolimus</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">tac</infon>
          <location offset="122" length="3"/>
          <text>TAC</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sirolimus</infon>
          <location offset="131" length="9"/>
          <text>sirolimus</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">srl</infon>
          <location offset="142" length="3"/>
          <text>SRL</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">immunophilin fkbp12</infon>
          <location offset="164" length="19"/>
          <text>immunophilin FKBP12</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T8" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T12" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T13" role="head"/>
          <node refid="T22" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>235</offset>
        <text>SRL inhibits mammalian target of rapamycin (TOR), which is an enzyme critical to the immune function.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rapamycin</infon>
          <location offset="268" length="9"/>
          <text>rapamycin</text>
        </annotation>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mammalian target of rapamycin</infon>
          <location offset="248" length="29"/>
          <text>mammalian target of rapamycin</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tor</infon>
          <location offset="279" length="3"/>
          <text>TOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>337</offset>
        <text>TOR inhibition blocks the signal that mediates T-cell proliferation by preventing cell-cycle progression from G1 to S phase.</text>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tor</infon>
          <location offset="337" length="3"/>
          <text>TOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>462</offset>
        <text>Moreover, TOR inhibition results in a decrease in antibody production by blocking B-cell proliferation and maturation into antibody producing cells.</text>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">tor</infon>
          <location offset="472" length="3"/>
          <text>TOR</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>611</offset>
        <text>The use of SRL has resulted in a decrease in the number of rejection episodes.</text>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">srl</infon>
          <location offset="622" length="3"/>
          <text>SRL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>690</offset>
        <text>As with other immunosuppressive agents, SRL can cause dose-related side effects, the most notable of which are hypercholesterolemia, hyperlipidemia, anemia, and thrombocytopenia.</text>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">srl</infon>
          <location offset="730" length="3"/>
          <text>SRL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>869</offset>
        <text>Thus, therapeutic drug monitoring to assess efficacy and toxicity has became a necessity.</text>
      </sentence>
      <sentence>
        <offset>959</offset>
        <text>SRL blood levels do not correlate with its bioactivity and are affected by the concomitant use of other immunosuppressive drugs.</text>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">srl</infon>
          <location offset="959" length="3"/>
          <text>SRL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1088</offset>
        <text>To determine the bioactivity of SRL we have developed an assay to determine the level of Sirolimus per lymphocyte of transplant patients.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">srl</infon>
          <location offset="1120" length="3"/>
          <text>SRL</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">sirolimus</infon>
          <location offset="1177" length="9"/>
          <text>Sirolimus</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1226</offset>
        <text>The levels were correlated with lymphocyte count.</text>
      </sentence>
      <sentence>
        <offset>1276</offset>
        <text>METHODS: Whole blood samples from patients on SRL were collected in Ethylene Diamine Tetra-acetic acid (EDTA) vacutainer tubes.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">srl</infon>
          <location offset="1322" length="3"/>
          <text>SRL</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">ethylene diamine tetra-acetic acid</infon>
          <location offset="1344" length="34"/>
          <text>Ethylene Diamine Tetra-acetic acid</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">edta</infon>
          <location offset="1380" length="4"/>
          <text>EDTA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1404</offset>
        <text>Immediately the lymphocytes from 2 mL of blood were separated using 1.5 mL of Ficoll gradient, by centrifugation for 30 minutes at 2500 RPM.</text>
      </sentence>
      <sentence>
        <offset>1545</offset>
        <text>The lymphocytes were washed three times with phosphate-bufferd saline and the pellet suspended in 150 microL of Middle East research institute (MERI) drug extraction solution (Beirut, Lebanon), which was then added to 300 microL of IMx solublizing reagent.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">phosphate</infon>
          <location offset="1590" length="9"/>
          <text>phosphate</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1802</offset>
        <text>The cytoplasmic SRL concentrations in lymphocytes were measured using kits supplied from Abbott diagnostics or by high-performance liquid tomography.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">srl</infon>
          <location offset="1818" length="3"/>
          <text>SRL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1952</offset>
        <text>A corresponding whole blood sample from each patient was used to measure blood levels.</text>
      </sentence>
      <sentence>
        <offset>2039</offset>
        <text>To determine the level per lymphocyte, the value obtained was divided by the number of lymphocytes and expressed as Pg/cell.</text>
      </sentence>
      <sentence>
        <offset>2164</offset>
        <text>A pharmacokinetic profile for both blood and lymphocytes was constructed for each patient using data corresponding to predose C(0), 1 hour (C(1)) and 2 hours (C(2)) after the dose.</text>
      </sentence>
      <sentence>
        <offset>2345</offset>
        <text>The lymphocyte enumeration for C(0), C(1), and C(2) was performed using the FACS Calibur Flow Cytometer from Becton Dickinson.</text>
      </sentence>
      <sentence>
        <offset>2472</offset>
        <text>The average dose was 2.86 +/- 1.27 mg/d with a C(0) = 8.05 +/- 4.24, C(1) = 21.9 +/- 8.9 ng/mL, and C(2) = 23 +/- 0.03 ng/mL.</text>
      </sentence>
      <sentence>
        <offset>2598</offset>
        <text>Although there was a significant correlation (P=.0975) between the dose and C(0), there was no correlation between the dose and C(0) level on the lymphocyte count P=.897.</text>
      </sentence>
      <sentence>
        <offset>2769</offset>
        <text>However, there was a strong correlation between SRL lymphocyte levels (pg/cell) and the lymphocyte count (r(2)=.6.06).</text>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">srl</infon>
          <location offset="2817" length="3"/>
          <text>SRL</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>2888</offset>
        <text>The higher the concentration of the drug the lower the lymphocyte counts.</text>
      </sentence>
      <sentence>
        <offset>2962</offset>
        <text>The assay is sensitive to within 0.45 pg/cell, reproducible with a coefficient of variance (CV) of 6.4% within assay and 7.5% for intraassay.</text>
      </sentence>
    </passage>
  </document>
  <document>
    <id>16297435</id>
    <passage>
      <offset>0</offset>
      <text>Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission.	The effects of association of cholinergic precursors choline or choline alphoscerate with the cholinesterase inhibitor rivastigmine on acetylcholine levels and [(3)H]hemicholinium-3 binding were assessed in rat frontal cortex, hippocampus and striatum. Acetylcholine immunoreactivity was also evaluated in cerebrocortical cholinergic fibers by immunohistochemistry. Choline alphoscerate or rivastigmine, but not choline increased acetylcholine levels as well as [(3)H]hemicholinium-3 binding used as a marker of high affinity cholinergic transporter. The association of choline alphoscerate with rivastigmine dose-dependently increased both acetylcholine levels and [(3)H]hemicholinium-3 binding. Rivastigmine alone or in association with either choline or choline alphoscerate decreased acetylcholinesterase (AChE), whereas choline or choline alphoscerate alone did not affect AChE activity. Choline alphoscerate or rivastigmine alone or in association, but not choline increased acetylcholine immunoreactivity in nerve fibers supplying cerebral cortex. These data suggest that combination of a suitable precursor of brain acetylcholine such as choline alphoscerate and of a cholinesterase inhibitor may represent an association worthwhile of being further investigated as a cholinergic replacement therapy in pathologies characterized by altered cholinergic neurotransmission.</text>
      <sentence>
        <offset>0</offset>
        <text>Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission.</text>
        <annotation id="T27">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline alphoscerate</infon>
          <location offset="43" length="20"/>
          <text>choline alphoscerate</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rivastigmine</infon>
          <location offset="97" length="12"/>
          <text>rivastigmine</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cholinesterase</infon>
          <location offset="72" length="14"/>
          <text>cholinesterase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T28" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>168</offset>
        <text>The effects of association of cholinergic precursors choline or choline alphoscerate with the cholinesterase inhibitor rivastigmine on acetylcholine levels and [(3)H]hemicholinium-3 binding were assessed in rat frontal cortex, hippocampus and striatum.</text>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rivastigmine</infon>
          <location offset="287" length="12"/>
          <text>rivastigmine</text>
        </annotation>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="303" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(3)h]hemicholinium-3</infon>
          <location offset="328" length="21"/>
          <text>[(3)H]hemicholinium-3</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline</infon>
          <location offset="221" length="7"/>
          <text>choline</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline alphoscerate</infon>
          <location offset="232" length="20"/>
          <text>choline alphoscerate</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cholinesterase</infon>
          <location offset="262" length="14"/>
          <text>cholinesterase</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T3" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>421</offset>
        <text>Acetylcholine immunoreactivity was also evaluated in cerebrocortical cholinergic fibers by immunohistochemistry.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="421" length="13"/>
          <text>Acetylcholine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>534</offset>
        <text>Choline alphoscerate or rivastigmine, but not choline increased acetylcholine levels as well as [(3)H]hemicholinium-3 binding used as a marker of high affinity cholinergic transporter.</text>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline alphoscerate</infon>
          <location offset="534" length="20"/>
          <text>Choline alphoscerate</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rivastigmine</infon>
          <location offset="558" length="12"/>
          <text>rivastigmine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline</infon>
          <location offset="580" length="7"/>
          <text>choline</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="598" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(3)h]hemicholinium-3</infon>
          <location offset="630" length="21"/>
          <text>[(3)H]hemicholinium-3</text>
        </annotation>
        <annotation id="T30">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">cholinergic transporter</infon>
          <location offset="694" length="23"/>
          <text>cholinergic transporter</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T11" role="head"/>
          <node refid="T30" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>719</offset>
        <text>The association of choline alphoscerate with rivastigmine dose-dependently increased both acetylcholine levels and [(3)H]hemicholinium-3 binding.</text>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline alphoscerate</infon>
          <location offset="738" length="20"/>
          <text>choline alphoscerate</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rivastigmine</infon>
          <location offset="764" length="12"/>
          <text>rivastigmine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="809" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">[(3)h]hemicholinium-3</infon>
          <location offset="834" length="21"/>
          <text>[(3)H]hemicholinium-3</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>865</offset>
        <text>Rivastigmine alone or in association with either choline or choline alphoscerate decreased acetylcholinesterase (AChE), whereas choline or choline alphoscerate alone did not affect AChE activity.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rivastigmine</infon>
          <location offset="865" length="12"/>
          <text>Rivastigmine</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline</infon>
          <location offset="914" length="7"/>
          <text>choline</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline alphoscerate</infon>
          <location offset="925" length="20"/>
          <text>choline alphoscerate</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline</infon>
          <location offset="993" length="7"/>
          <text>choline</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline alphoscerate</infon>
          <location offset="1004" length="20"/>
          <text>choline alphoscerate</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">acetylcholinesterase</infon>
          <location offset="956" length="20"/>
          <text>acetylcholinesterase</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="978" length="4"/>
          <text>AChE</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ache</infon>
          <location offset="1046" length="4"/>
          <text>AChE</text>
        </annotation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T18" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T19" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">INHIBITOR</infon>
          <node refid="T20" role="head"/>
          <node refid="T31" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>1061</offset>
        <text>Choline alphoscerate or rivastigmine alone or in association, but not choline increased acetylcholine immunoreactivity in nerve fibers supplying cerebral cortex.</text>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline alphoscerate</infon>
          <location offset="1061" length="20"/>
          <text>Choline alphoscerate</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">rivastigmine</infon>
          <location offset="1085" length="12"/>
          <text>rivastigmine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline</infon>
          <location offset="1131" length="7"/>
          <text>choline</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="1149" length="13"/>
          <text>acetylcholine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1223</offset>
        <text>These data suggest that combination of a suitable precursor of brain acetylcholine such as choline alphoscerate and of a cholinesterase inhibitor may represent an association worthwhile of being further investigated as a cholinergic replacement therapy in pathologies characterized by altered cholinergic neurotransmission.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acetylcholine</infon>
          <location offset="1292" length="13"/>
          <text>acetylcholine</text>
        </annotation>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">choline alphoscerate</infon>
          <location offset="1314" length="20"/>
          <text>choline alphoscerate</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cholinesterase</infon>
          <location offset="1344" length="14"/>
          <text>cholinesterase</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23322164</id>
    <passage>
      <offset>0</offset>
      <text>Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid β-oxidation disorders (mFAODs). It is generally assumed that this plasma acylcarnitine profile reflects the mitochondrial accumulation of acyl-CoAs. The identity of the enzymes and the mitochondrial and plasmalemmal transporters involved in the synthesis and export of these metabolites have remained undefined. We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts. These cell lines, including mock-transduced controls, were loaded with decanoic acid and carnitine, followed by the measurement of the acylcarnitine profile in the extracellular medium. In control fibroblasts, MCAD knockdown markedly increased the production of octanoylcarnitine (3-fold, P&lt;0.01). OCTN2-deficient cell lines also showed extracellular accumulation of octanoylcarnitine (2.8-fold, P&lt;0.01), suggesting that the cellular export of acylcarnitines does not depend on OCTN2. In contrast, in CPT2- and CACT-deficient cells, the accumulation of octanoylcarnitine in the medium did not significantly increase in the MCAD knockdown. Similar results were obtained using pharmacological inhibition of CPT2 in fibroblasts from MCAD-deficient individuals. This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.</text>
      <sentence>
        <offset>0</offset>
        <text>Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.</text>
        <annotation id="T22">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="0" length="9"/>
          <text>Carnitine</text>
        </annotation>
        <annotation id="T23">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitines</infon>
          <location offset="131" length="14"/>
          <text>acylcarnitines</text>
        </annotation>
        <annotation id="T24">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="37" length="9"/>
          <text>carnitine</text>
        </annotation>
        <annotation id="T25">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitine</infon>
          <location offset="47" length="13"/>
          <text>acylcarnitine</text>
        </annotation>
        <annotation id="T46">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">carnitine palmitoyltransferase 2</infon>
          <location offset="0" length="32"/>
          <text>Carnitine palmitoyltransferase 2</text>
        </annotation>
        <annotation id="T47">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">carnitine/acylcarnitine translocase</infon>
          <location offset="37" length="35"/>
          <text>carnitine/acylcarnitine translocase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T23" role="head"/>
          <node refid="T47" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T23" role="head"/>
          <node refid="T46" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>147</offset>
        <text>Acylcarnitines are commonly used in the diagnosis of mitochondrial fatty acid β-oxidation disorders (mFAODs).</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitines</infon>
          <location offset="147" length="14"/>
          <text>Acylcarnitines</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">fatty acid</infon>
          <location offset="214" length="10"/>
          <text>fatty acid</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>257</offset>
        <text>It is generally assumed that this plasma acylcarnitine profile reflects the mitochondrial accumulation of acyl-CoAs.</text>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitine</infon>
          <location offset="298" length="13"/>
          <text>acylcarnitine</text>
        </annotation>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acyl-coas</infon>
          <location offset="363" length="9"/>
          <text>acyl-CoAs</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>374</offset>
        <text>The identity of the enzymes and the mitochondrial and plasmalemmal transporters involved in the synthesis and export of these metabolites have remained undefined.</text>
      </sentence>
      <sentence>
        <offset>537</offset>
        <text>We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.</text>
        <annotation id="T12">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acyl-coa</infon>
          <location offset="607" length="8"/>
          <text>acyl-CoA</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="652" length="9"/>
          <text>carnitine</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="694" length="9"/>
          <text>carnitine</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitine</infon>
          <location offset="704" length="13"/>
          <text>acylcarnitine</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="756" length="9"/>
          <text>carnitine</text>
        </annotation>
        <annotation id="T36">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">medium-chain acyl-coa dehydrogenase</infon>
          <location offset="594" length="35"/>
          <text>medium-chain acyl-CoA dehydrogenase</text>
        </annotation>
        <annotation id="T37">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcad</infon>
          <location offset="631" length="4"/>
          <text>MCAD</text>
        </annotation>
        <annotation id="T38">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">carnitine palmitoyltransferase 2</infon>
          <location offset="652" length="32"/>
          <text>carnitine palmitoyltransferase 2</text>
        </annotation>
        <annotation id="T39">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cpt2</infon>
          <location offset="686" length="4"/>
          <text>CPT2</text>
        </annotation>
        <annotation id="T40">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">carnitine/acylcarnitine translocase</infon>
          <location offset="694" length="35"/>
          <text>carnitine/acylcarnitine translocase</text>
        </annotation>
        <annotation id="T41">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cact</infon>
          <location offset="731" length="4"/>
          <text>CACT</text>
        </annotation>
        <annotation id="T42">
          <infon key="type">GENE-N</infon>
          <infon key="identifier">carnitine transporter</infon>
          <location offset="756" length="21"/>
          <text>carnitine transporter</text>
        </annotation>
        <annotation id="T43">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">octn2</infon>
          <location offset="779" length="5"/>
          <text>OCTN2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>815</offset>
        <text>These cell lines, including mock-transduced controls, were loaded with decanoic acid and carnitine, followed by the measurement of the acylcarnitine profile in the extracellular medium.</text>
        <annotation id="T18">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">decanoic acid</infon>
          <location offset="886" length="13"/>
          <text>decanoic acid</text>
        </annotation>
        <annotation id="T19">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="904" length="9"/>
          <text>carnitine</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitine</infon>
          <location offset="950" length="13"/>
          <text>acylcarnitine</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1001</offset>
        <text>In control fibroblasts, MCAD knockdown markedly increased the production of octanoylcarnitine (3-fold, P&lt;0.01).</text>
        <annotation id="T21">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">octanoylcarnitine</infon>
          <location offset="1077" length="17"/>
          <text>octanoylcarnitine</text>
        </annotation>
        <annotation id="T44">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcad</infon>
          <location offset="1025" length="4"/>
          <text>MCAD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1113</offset>
        <text>OCTN2-deficient cell lines also showed extracellular accumulation of octanoylcarnitine (2.8-fold, P&lt;0.01), suggesting that the cellular export of acylcarnitines does not depend on OCTN2.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">octanoylcarnitine</infon>
          <location offset="1182" length="17"/>
          <text>octanoylcarnitine</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitines</infon>
          <location offset="1259" length="14"/>
          <text>acylcarnitines</text>
        </annotation>
        <annotation id="T26">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">octn2</infon>
          <location offset="1293" length="5"/>
          <text>OCTN2</text>
        </annotation>
        <annotation id="T45">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">octn2</infon>
          <location offset="1113" length="5"/>
          <text>OCTN2</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1300</offset>
        <text>In contrast, in CPT2- and CACT-deficient cells, the accumulation of octanoylcarnitine in the medium did not significantly increase in the MCAD knockdown.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">octanoylcarnitine</infon>
          <location offset="1368" length="17"/>
          <text>octanoylcarnitine</text>
        </annotation>
        <annotation id="T27">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cpt2</infon>
          <location offset="1316" length="4"/>
          <text>CPT2</text>
        </annotation>
        <annotation id="T28">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cact</infon>
          <location offset="1326" length="4"/>
          <text>CACT</text>
        </annotation>
        <annotation id="T29">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcad</infon>
          <location offset="1438" length="4"/>
          <text>MCAD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1454</offset>
        <text>Similar results were obtained using pharmacological inhibition of CPT2 in fibroblasts from MCAD-deficient individuals.</text>
        <annotation id="T30">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cpt2</infon>
          <location offset="1520" length="4"/>
          <text>CPT2</text>
        </annotation>
        <annotation id="T31">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">mcad</infon>
          <location offset="1545" length="4"/>
          <text>MCAD</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1573</offset>
        <text>This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitine</infon>
          <location offset="1633" length="13"/>
          <text>acylcarnitine</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="1819" length="9"/>
          <text>Carnitine</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">carnitine</infon>
          <location offset="1856" length="9"/>
          <text>carnitine</text>
        </annotation>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitine</infon>
          <location offset="1866" length="13"/>
          <text>acylcarnitine</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">acylcarnitines</infon>
          <location offset="1950" length="14"/>
          <text>acylcarnitines</text>
        </annotation>
        <annotation id="T32">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cpt2</infon>
          <location offset="1589" length="4"/>
          <text>CPT2</text>
        </annotation>
        <annotation id="T33">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">cact</infon>
          <location offset="1598" length="4"/>
          <text>CACT</text>
        </annotation>
        <annotation id="T34">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">carnitine palmitoyltransferase 2</infon>
          <location offset="1819" length="32"/>
          <text>Carnitine palmitoyltransferase 2</text>
        </annotation>
        <annotation id="T35">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">carnitine/acylcarnitine translocase</infon>
          <location offset="1856" length="35"/>
          <text>carnitine/acylcarnitine translocase</text>
        </annotation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T34" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T33" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T5" role="head"/>
          <node refid="T32" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">PRODUCT-OF</infon>
          <node refid="T10" role="head"/>
          <node refid="T35" role="tail"/>
        </relation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23625779</id>
    <passage>
      <offset>0</offset>
      <text>Mesoporous Silica Nanoparticles Act as a Self-Adjuvant for Ovalbumin Model Antigen in Mice.	Immunization to the model protein antigen ovalbumin (OVA) is investigated using MCM-41 mesoporous silica nanoparticles as a novel vaccine delivery vehicle and adjuvant system in mice. The effects of amino surface functionalization and adsorption time on OVA adsorption to nanoparticles are assessed. Amino-functionalized MCM-41 (AM-41) shows an effect on the amount of OVA binding, with 2.5-fold increase in binding capacity (72 mg OVA/g AM-41) compared to nonfunctionalized MCM-41 (29 mg OVA/g MCM-41). Immunization studies in mice with a 10 μg dose of OVA adsorbed to AM-41 elicits both antibody and cell-mediated immune responses following three subcutaneous injections. Immunizations at a lower 2 μg dose of OVA adsorbed to AM-41 particles results in an antibody response but not cell-mediated immunity. The level of antibody responses following immunization with nanoformulations containing either 2 μg or 10 μg of OVA are only slightly lower than that in mice which receive 50 μg OVA adjuvanted with QuilA, a crude mixture of saponins extracted from the bark of the Quillaja saponaria Molina tree. This is a significant result, since it demonstrates that AM-41 nanoparticles are self-adjuvanting and elicit immune responses at reduced antigen doses in vivo compared to a conventional delivery system. Importantly, there are no local or systemic negative effects in animals injected with AM-41. Histopathological studies of a range of tissue organs show no changes in histopathology of the animals receiving nanoparticles over a six week period. These results establish the biocompatible MCM-41 silica nanoparticles as a new method for vaccine delivery which incorporates a self-adjuvant effect.</text>
      <sentence>
        <offset>0</offset>
        <text>Mesoporous Silica Nanoparticles Act as a Self-Adjuvant for Ovalbumin Model Antigen in Mice.</text>
        <annotation id="T11">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">silica</infon>
          <location offset="11" length="6"/>
          <text>Silica</text>
        </annotation>
        <annotation id="T22">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ovalbumin</infon>
          <location offset="59" length="9"/>
          <text>Ovalbumin</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>92</offset>
        <text>Immunization to the model protein antigen ovalbumin (OVA) is investigated using MCM-41 mesoporous silica nanoparticles as a novel vaccine delivery vehicle and adjuvant system in mice.</text>
        <annotation id="T9">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mcm-41</infon>
          <location offset="172" length="6"/>
          <text>MCM-41</text>
        </annotation>
        <annotation id="T10">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">silica</infon>
          <location offset="190" length="6"/>
          <text>silica</text>
        </annotation>
        <annotation id="T14">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ovalbumin</infon>
          <location offset="134" length="9"/>
          <text>ovalbumin</text>
        </annotation>
        <annotation id="T17">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="145" length="3"/>
          <text>OVA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>276</offset>
        <text>The effects of amino surface functionalization and adsorption time on OVA adsorption to nanoparticles are assessed.</text>
        <annotation id="T4">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino</infon>
          <location offset="291" length="5"/>
          <text>amino</text>
        </annotation>
        <annotation id="T12">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="346" length="3"/>
          <text>OVA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>392</offset>
        <text>Amino-functionalized MCM-41 (AM-41) shows an effect on the amount of OVA binding, with 2.5-fold increase in binding capacity (72 mg OVA/g AM-41) compared to nonfunctionalized MCM-41 (29 mg OVA/g MCM-41).</text>
        <annotation id="T5">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">amino</infon>
          <location offset="392" length="5"/>
          <text>Amino</text>
        </annotation>
        <annotation id="T6">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mcm-41</infon>
          <location offset="413" length="6"/>
          <text>MCM-41</text>
        </annotation>
        <annotation id="T7">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mcm-41</infon>
          <location offset="567" length="6"/>
          <text>MCM-41</text>
        </annotation>
        <annotation id="T8">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mcm-41</infon>
          <location offset="587" length="6"/>
          <text>MCM-41</text>
        </annotation>
        <annotation id="T13">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="461" length="3"/>
          <text>OVA</text>
        </annotation>
        <annotation id="T15">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="524" length="3"/>
          <text>OVA</text>
        </annotation>
        <annotation id="T16">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="581" length="3"/>
          <text>OVA</text>
        </annotation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T5" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T15" role="tail"/>
        </relation>
        <relation id="">
          <infon key="type">DIRECT-REGULATOR</infon>
          <node refid="T6" role="head"/>
          <node refid="T13" role="tail"/>
        </relation>
      </sentence>
      <sentence>
        <offset>596</offset>
        <text>Immunization studies in mice with a 10 μg dose of OVA adsorbed to AM-41 elicits both antibody and cell-mediated immune responses following three subcutaneous injections.</text>
        <annotation id="T18">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="646" length="3"/>
          <text>OVA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>766</offset>
        <text>Immunizations at a lower 2 μg dose of OVA adsorbed to AM-41 particles results in an antibody response but not cell-mediated immunity.</text>
        <annotation id="T19">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="804" length="3"/>
          <text>OVA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>900</offset>
        <text>The level of antibody responses following immunization with nanoformulations containing either 2 μg or 10 μg of OVA are only slightly lower than that in mice which receive 50 μg OVA adjuvanted with QuilA, a crude mixture of saponins extracted from the bark of the Quillaja saponaria Molina tree.</text>
        <annotation id="T1">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">saponins</infon>
          <location offset="1124" length="8"/>
          <text>saponins</text>
        </annotation>
        <annotation id="T20">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="1012" length="3"/>
          <text>OVA</text>
        </annotation>
        <annotation id="T21">
          <infon key="type">GENE-Y</infon>
          <infon key="identifier">ova</infon>
          <location offset="1078" length="3"/>
          <text>OVA</text>
        </annotation>
      </sentence>
      <sentence>
        <offset>1196</offset>
        <text>This is a significant result, since it demonstrates that AM-41 nanoparticles are self-adjuvanting and elicit immune responses at reduced antigen doses in vivo compared to a conventional delivery system.</text>
      </sentence>
      <sentence>
        <offset>1399</offset>
        <text>Importantly, there are no local or systemic negative effects in animals injected with AM-41.</text>
      </sentence>
      <sentence>
        <offset>1492</offset>
        <text>Histopathological studies of a range of tissue organs show no changes in histopathology of the animals receiving nanoparticles over a six week period.</text>
      </sentence>
      <sentence>
        <offset>1643</offset>
        <text>These results establish the biocompatible MCM-41 silica nanoparticles as a new method for vaccine delivery which incorporates a self-adjuvant effect.</text>
        <annotation id="T2">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">mcm-41</infon>
          <location offset="1685" length="6"/>
          <text>MCM-41</text>
        </annotation>
        <annotation id="T3">
          <infon key="type">CHEMICAL</infon>
          <infon key="identifier">silica</infon>
          <location offset="1692" length="6"/>
          <text>silica</text>
        </annotation>
      </sentence>
    </passage>
  </document>
  <document>
    <id>23497878</id>
    <passage>
      <offset>0</offset>
      <text>The influence of Goishi tea on adipocytokines in obese mice.	This study investigated the influence of Goishi-tea on visceral fat weight in induced obese mice. Mice were divided into two main groups, normal and obesity. 